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903-215 Intramyocardial Bone Marrow Stem Cells 
Transplantation for Non-ischemic Dilated 
Cardiomyopathy: 4 Months Follow-up
Renato A.K. Kalil, Daniele R. Ott, Roberto T. Sant’Anna, Eduardo M. Dias, Solange 
Bordignon, Nance B. Nardi, Iran Castro, Paulo Schvartzman, Paulo R.L. Prates, João 
P.M. Pereira, João Ricardo M. Sant’Anna, Paulo R. Prates, Ivo A. Nesralla, Institute of 
Cardiology of Rio Grande do Sul/FUC, Porto Alegre, RS, Brazil
Background: A study on safety, feasibility and efﬁcacy of transthoracic intramyocardial 
mononuclear autologous bone marrow stem cells transplantation for end-stage non-
ischaemic dilated cardiomyopathy (NIDC) is being conducted. This paper reports 
preliminary results at 4 months follow-up.
Methods: From Dec/04 to Jun/05, 6 patients(pts) (2 fem), age 42.3±14,1 years, NYHA Class 
III/IV and (LVEF)<35% were enrolled. All pts underwent clinical, echocardiographic(ECO) 
and nuclear magnetic ressonance (NMR) assessment. Cells were collected from the iliac 
bone, isolated, washed and suspended, resulting in a mean of 9.6±2.6 x 107 (1.5±0.7% 
CD34+) cells in 5ml saline. These were injected, through 5-6cm thoracotomy at the 5th left 
intercostal space, at 20 points of the free left ventricular wall with a 21F Butterﬂy needle. 
Pts were reviewed at 2 and 4 months of follow-up.
Results: There were no immediate major complications. One pt required placement of 2 
stitches for epicardial bleeding control and other needed lidocaine IV administration for 
persistent ventricular arrhythmia on touching the heart. There was improvement in NYHA 
functional class after 2 and 4 months. The baseline x 2 months x 4 months follow-up 
results were: NYHA Functional Class= IV-2, III-4 to I-5, II-1 and I-3, II-2 pts, respectively. 
Quality of life evaluated by Living with Heart Failure Questionaire (mean±SE)=65.4±7.6 
x 27.0±22.4 x 24.0±23.0 points (p=0.03; p=0.02). ECO: LVEF=26.7±3.9 x 36.0±7.9 x 
31.7±4.7% (p=0.05 and 0.19, respectively); LV short´n fract=13.8±4.7 x 17.9±4.1 x 
15.5±2.5% (p=0.06; p=0.24); end diastolic volume (EDV)=223.6±110.5 x 161.1±51.1 x 
161.9±47.9ml (p=0.12; p=0.137); end systolic volume (ESV)=168.5±99.6 x 106.1±47 x 
111.5±38ml (p=0.07; p=0.12). NMR (baseline x 2 months): LVEF=23.2±16.5 x 30.2±15.6% 
(p=0.04); EDV=415.6±205.9 x 381.2±236.9ml(p=0.14);ESV=339.1±218.4x292.2±232.3
ml(p=0.04);stroke volume=76.2±34.1 x 89±11.7ml (p=0.36)
Conclusions: This study suggests that transthoracic intramyocardial bone marrow stem 
cell transplantation is feasible and safe through a minithoracotomy. Early improvements 
on symptoms, quality of life and LV performance encourage further studies.
903-216 Bone Marrow-Derived Cells Do Not Transdifferentiate 
Into Cardiomyocytes After Myocardial Infarction
Helge Möllmann, Holger M. Nef, Sawa Kostin, Jutta Schaper, Michael Weber, Christian 
W. Hamm, Albrecht Elsässer, Kerckhoff Heart Center, Bad Nauheim, Germany, Max-
Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
Background: The paradigm that cardiac myocytes are non-proliferating and terminally 
differentiated cells has recently been challenged since some studies reported the ability of 
bone marrow derived cells (BMC) to transdifferentiate into cardiomyocytes. However, these 
results were discussed controversially and could not be reproduced by others. We therefore 
examined the contribution of BMC in post myocardial infarction repair mechanisms. 
Methods: Mice were sublethally irradiated and bone marrow from eGFP transgenic mice 
was transplanted. Coronary artery ligation was performed 3 months after engraftment. The 
infarct size was quantiﬁed using magnetic resonance imaging. The hearts were studied 7 
days (n=13) and 21 days (n=12) after myocardial infarction. Immunohistochemical staining 
was performed using titin and connexin 43 antibodies to identify cardiomyocytes, vimentin for 
ﬁbroblasts, vimentin and α-smooth muscle actin for myoﬁbroblasts, α-smooth muscle actin 
for smooth muscle cells, and F4/80 for macrophages. Endothelial cells were stained by BS-1 
and CD31. Additionally, anti-eGFP immunostaining was used to exclude autoﬂuorescence. 
Sections were analyzed using ﬂuorescence microscopy and confocal laser microscopy.
Results: Bone marrow transplantation was successful as FACS analysis showed 84±5% 
eGFP expressing leukocytes. The occlusion typically resulted in infarct sizes of 41±6% 
of the left ventricle. In 25 examined hearts, only 3 eGFP positive cardiomyocytes were 
found. CD45+/eGFP+ inﬂammatory cells were found frequently after 7 days and to a 
lesser degree after 21 days. Numerous BMC derived ﬁbroblasts and myoﬁbroblasts were 
found in the periinfarct and infarct area. BMC contributed sporadically to scar tissue 
neoangiogenesis but not to angiogenesis in the periinfarct region or in the remote zone.
Conclusion: Transdifferentiation of BMC into viable cardiomyocytes is a negligible event 
in the normal repair processes after myocardial damage. Correspondingly, no BMC-
induced neoangiogenesis could be documented. However, scar tissue formation after 
myocardial infarction largely involves BMC-derived cells.
903-217 TGF-β1 Enhances Cardiomyogenic Differentiation 
Potential of Adult Primitive Cells
Ahmed K. Abdel-Latif, Ewa K. Zuba-Surma, Jamie Case, Sumit Tiwari, Greg Hunt, Smita 
Ranjan, Robert J. Vincent, Edward F. Srour, Roberto Bolli, Buddhadeb Dawn, University 
of Louisville, Louisville, KY, Indiana University School of Medicine, Indianapolis, IN
Culture conditions are crucial for lineage commitment of pluripotent stem cells (PSCs) 
and the optimal medium for cardiac differentiation remains to be established. We 
compared the efﬁcacy of four cytokine/growth factor combinations in the induction of 
cardiomyogenic differentiation in murine skeletal muscle (SM)-derived PSCs. Sca1+/
CD45-/c-kit-/Thy-1+ (SM+) and Sca1-/CD45-/c-kit-/Thy-1+ (SM-) cells were differentiated 
in basic medium (BM) or BM supplemented with bFGF, oxytocin (OT), or TGF-β1. The 
expression of cardiac-speciﬁc transcription factors (TFs) and intracellular antigens (IAs) 
was evaluated by confocal microscopy (Fig. 1A). After 28 days of differentiation, BM alone, 
BM+bFGF, BM+OT, and BM+TGF-β1 induced cardiac differentiation in 12.9%, 11.6%, 
9.1%, and 14.9% of cultured SM+ cells, respectively, that expressed cardiac-speciﬁc 
TFs and/or IAs. In cultured SM- cells, BM alone, BM+bFGF, BM+OT, and BM+TGF-β1 
induced cardiac differentiation in 16.6%, 15.8%, 11.8%, and 25.2% cells, respectively. 
Compared with SM+ cells, SM- cells exhibited a relatively higher potential to differentiate 
into cardiomyocytes irrespective of the medium. We conclude that supplementation 
of culture medium with TGF-β1, a growth factor known to modulate cardiac gene 
expression, enhances cardiomyogenic differentiation in SM-derived PSCs. This strategy 
may potentially be utilized to culture and test the cardiomyogenic potential of other adult 
tissue-derived primitive cells.
903-218 Tracking of Intra-Coronary Delivered Mesenchymal 
Stem Cells Using Magnetic Resonance Imaging in a 
Porcine Model of Myocardial Infarction
John J. Graham, Warren D. Foltz, Andrea K. Vaags, Yeusong S. Yang, Jay S. Detsky, 
Margaret R. Hough, Duncan J. Stewart, Graham A. Wright, Alexander J. Dick, 
Sunnybrook & Women’s College Health Sciences Centre, Toronto, ON, Canada, St 
Michael’s Hospital, Toronto, ON, Canada
Background -Optimization of stem cell therapy for myocardial infarction (MI) is 
facilitated using non-invasive imaging in large animal models. We present initial results 
using magnetic resonance imaging (MRI) for cell tracking in porcine myocardium and 
reticuloendothelial system.
Methods -Anterior MI was induced in swine with a 90 minute balloon occlusion of the 
left anterior descending artery (LAD). On day 7 post MI, 2-3 x 106 canine mesenchymal 
stem cells (MSCs) were incubated with Cell Tracker Orange (Molecular Probes) and 
iron-ﬂuorescent microspheres (Bangs Laboratories) and delivered into the LAD in two 
2ml aliquots via an end-hole balloon catheter (Guidant). Spatial patterns of myocardial 
T2*-weighted hypointensity, delayed hyperenhancement and gross ﬂuorescence (Kodak 
Multi-model Imager) were evaluated. An experimental sequence depicted remote cell 
engraftment as a positive contrast.
Results -Hypointense regions characteristic of the cells’ magnetic label were observed 
predominantly in the infarct border rather than within the infarct itself (ﬁg. a, b). Bilateral 
posterior hyperintense signal indicated remote cell sequestration intra-abdominally(ﬁg. 
c). Post-mortem ﬂuorescent imaging displayed concordance of ﬂuorescence and MRI 
hypointensity (ﬁg. d).
Conclusion - MRI visualized intra-coronary infused MSCs, predominantly in the infarct 
border but also intra-abdominally. Further work using autologous cells will evaluate long-
term cell fate and functional beneﬁt.
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903-219 Cardiac SP Cells Have Different Characteristics Distinct 
From Bone Marrow SP Cells
Seung-Cheol Choi, Chi-Youn Park, Ji-Hyun Choi, Jihyun Yoon, Young-Hoon Kim, Wan-Joo 
Shim, Young-Moo Ro, Do-Sun Lim, Korea University Medical Center, Seoul, South Korea
Background: Side population (SP) cells, characterized by their ability to efﬂux Hoechst 
33342, have been identiﬁed with characteristics of stem cells in a number of tissues. 
Recent evidence suggests that the heart possesses cardiac stem cells that are 
clonogenic, self-renewing and multipotent. Here, we demonstrate that cardiac SP cells 
have different characteristics distinct from bone marrow SP cells. Methods: SP cells 
isolated from bone marrow and heart of C57BL/6 (6 to 8-wk-old) mice were analyzed by 
ﬂow cytometry, RT-PCR and real-time RT-PCR. In vitro migration assay was performed 
in the presence or absence of 20 ng/ml HGF, 100 ng/ml SDF-1 and 20 ng/ml VEGF for 
6h. For hematopoietic colony assay, 1 × 104 SP cells prepared from bone marrow or 
heart were cultured in Methocult medium for 14 days. Results: Flow cytometry analysis 
showed that cardiac SP cells are immunophenotypically different from bone marrow 
SP cells in Sca-1 (bone marrow vs. heart = 71.61 ± 11.07% vs. 91.99 ± 1.73%), c-kit 
(27.73 ± 3.87% vs. 9.60 ± 4.05%) and CD45 expression (98.44 ± 1.38% vs. 11.67 ± 
4.83%), respectively. A number of hematopoietic colonies were formed in bone marrow 
SP cells (143.6 ± 4.9, p<0.01), whereas adult heart SP cells only gave rise to less than 
5 colonies. Using dual-chamber migration assays, we determined that bone marrow SP 
cells migrate in response to only SDF-1� (control: 20.6 ± 4.3 vs. HGF: 18.6 ± 1.4 vs. 
SDF-1α: 38.5 ± 8.8, p<0.05 vs. VEGF: 19.2 ± 5.2). However, adult heart SP cells didn’t 
show the migratory response to cytokines. RT-PCR and real-time RT-PCR demonstrated 
that adult heart SP cells expressed cardiac transcription factors such as Nkx2.5, Gata4 
and atrial natriuretic factor whereas bone marrow SP cells strongly expressed angiogenic 
factors such as angiopoietin-1, -2, tie2 and VEGF, and CXCR4 molecule involved in stem 
cell mobilization. Conclusions: These results demonstrate that cardiac SP cells have 
the potential for cardiac differentiation whereas bone marrow SP cells possess more 
committed capacity for neovascularization.
903-220 Impact of Mesenchymal Stem Cell Therapy on Scar 
Composition and Cardiac Regional Function
Luciano C. Amado, Karl H. Schuleri, Anastasios P. Saliaris, Robert Helm, Andrew Boyle, 
Behzad Oskouei, Viriginia Eneboe, Randell G. Young, Joao A.C. Lima, Albert C. Lardo, 
Alan W. Heldman, Joshua M. Hare, Johns Hopkins University School of Medicine and 
Institute for Cell Engineering (ICE), Baltimore, MD, MD
Background: Intramyocardial injection of allogeneic mesenchymal stem cells (MSC) 
improves global cardiac function after myocardial infarction (MI), but the mechanism for 
this effect remains unclear. Here we hypothesized that MSCs stimulate the regeneration 
of contractile myocardium adjacent to evolving MI scars thereby enhancing regional 
systolic function.
Methods: Pigs underwent 60 minute coronary artery occlusion followed by reperfusion, 
and were randomized to receive (n=10) or not receive (n=12) intramyocardial injections 
(Stiletto, Boston Scientiﬁc) of MSCs (200 million, ~15 injections) 3 days post-MI. Serial 
imaging with tagging MRI and contrast-enhanced multi-slice CT (MDCT- Toshiba) was 
performed over 8 weeks to characterize the MI and peri-MI morphology and regional 
function assessed as peak circumferential shortening (peakEcc).
Results: Post-MI peakEcc was similarly depressed in treated and control groups (p<0.05 
vs. normal). In non-treated animals, peakEcc remained persistently depressed during the 
8 weeks study period (from -4.1±0.4 to -4.7±0.6%, respectively day 2 and 8 weeks post-MI, 
p=NS), however MSC treatment restored peakEcc to normal levels in a time-dependent 
manner (from -4.6±0.3 to -10.8±0.6%, p<0.05 vs. non-treated). EF rose in treated (from 
25±1.6 to 42±0.7%, p<0.05) but not in non-treated animals (p=<0.05 vs. non-treated). 
MDCT demonstrated a 50±9% increase (p<0.05) in a rim of subendocardial tissue, not 
seen in non-treated animals. This rim had similar tissue density as viable myocardium in 
the region corresponding to improved function. Histological analysis conﬁrmed that this 
rim contained cardiac myocytes that were smaller than normal (11.6±0.2 vs. 12.6±0.2µm, 
p<0.05), consistent with myocardial regeneration.
Conclusions: Intramyocardial allogeneic MSC therapy stimulates myocardial repair 
over 2 months, enhancing regional tissue viability, systolic function and global chamber 
performance. These data demonstrate the efﬁcacy of cellular cardiomyoplasty and 
highlight the value of large-animal models and non-invasive imaging modalities in 
elucidating mechanisms underlying new myocardial regenerative therapies.
903-221 Adult Mesenchymal Stem Cells From Patients 
With Ischemic Heart Disease Engraft in Ischemic 
Myocardium and Improve Left Ventricular Function in 
NOD/scid Mice
Robert W. Grauss, Paul Steendijk, Elizabeth M. Winter, John van Tuyn, Twan A. de Vries, 
A. van der Laarse, Adriana C. Gittenberger-de Groot, Ernst E. van der Wall, Martin J. 
Schalij, Douwe E. Atsma, Leiden University Medical Center, Leiden, The Netherlands
Background: Until now most studies on stem cell therapy in patients with ischemic heart 
disease (IHD) have used unfractionated mononuclear bone marrow cells (BMCs). Only a 
minority of these cells are stem cells. Recent studies have shown that rodent mesenchymal 
stem cells (MSCs), a subpopulation of BMCs, can differentiate toward the cardiomyocyte 
phenotype in vivo and in vitro. However, not much is known about the in vivo behaviour of 
human MSC (hMSCs) in the ischemic myocardium. Therefore, we investigated whether 
hMSCs from patients with IHD can engraft in the ischemic myocardium and improve left 
ventricular function in an immune-compromised mouse model for myocardial infarction.
Methods:hMSCs were isolated from leftover bone marrow from patients with IHD who 
were enrolled in our clinical stem cell therapy trials. Myocardial infarction (MI) was induced 
in immune-compromised NOD/scid mice by ligation of the LAD. After 10-20 minutes, 
hMSCs labelled with eGFP (2.0 x 105 cells in 20µl, n=6) or vehicle only (control group, 
n=5) were injected into the border zone surrounding the infarct area. Sham operated 
mice were used as baseline (n=5). Hemodynamic studies were performed 2 weeks after 
cell transplantation using a 1.4F conductance catheter to obtain LV pressure -volume 
relations. Mice were subsequently sacriﬁced and processed for (immuno-) histology.
Results: Two weeks after MI eGFP labelled hMSCs could be detected in both the 
infarcted border zone and free wall, and appeared as elongated cells that were 
incorporated between surviving mouse cardiomyocytes. Compared with vehicle injection, 
hMSC transplantation in infarcted myocardium improved LV function as indicated by 
an increased left ventricular maximum dP/dt (6906±1554 versus 3755±1247 mm Hg/
s, P<0.05) and end-systolic pressure (89±13 versus 69±10 mmHg, P<0.05). In sham-
operated mice these values were 10260±2563 mmHg/s and 121±12 mmHg respectively.
Conclusions: Adult hMSCs from patients with IHD engraft in infarcted mouse myocardium, 
and improve left ventricular myocardial function 2 weeks after injection. These results 
suggest that in patients autologous MSCs may be used in stem cell therapy for IHD.
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904-222 Impact of Reduced Glomerular Filtration Rate on 
Outcomes in Patients With ST-Segment Elevation 
Myocardial Infarction Undergoing Fibrinolysis in 
CLARITY-TIMI 28
Shaheeda Ahmed, Marc S. Sabatine, Christopher P. Cannon, Sabina A. Murphy, Eugene 
Braunwald, C. Michael Gibson, The TIMI Study Group, Cardiovascular Division, Brigham 
& Women’s Hospital, Boston, MA
Background: Reduced glomerular ﬁltration rate (GFR) is associated with adverse 
outcomes in patients with cardiovascular (CV) disease. We explored the relationship 
between GFR and clinical outcomes in STEMI patients receiving a pharamacologic 
reperfusion, including clopidogrel.
Methods: Data were available to estimate GFR in 3,252 patients in CLARITY-TIMI 28, 
which randomized patients undergoing ﬁbrinolysis to clopidogrel vs. placebo. The protocol 
mandated a baseline creatinine and excluded patients with a creatinine > 2.5mg/dL. We 
compared outcomes through 30 days between patients with no, mild, and moderate 
reductions in estimated GFR (ml/min/1.73m2) of ≥ 90, 60-89, and < 60 respectively.
Results: Compared to patients with no (n=841) or mildly reduced GFR (n=1897), those 
with moderately reduced GFR (n=514) were older, more often female, and more likely to 
have diabetes, hypertension and be on aspirin (p ≤ 0.001 for all). More severe degrees 
of reduced GFR at baseline were associated with signiﬁcantly more CV events (Figure, 
left) and TIMI major or minor bleeding (Figure, right) (p trend for pooled treatment groups 
<0.0001 and 0.0008 respectively). The relationship between GFR and outcomes was 
similar with clopidogrel and placebo (p interaction=NS for each).
Conclusions: In patients with STEMI, those with reduced GFR have higher rates of 
adverse clinical outcomes. This simple tool identiﬁes high-risk patients in whom further 
research on optimal STEMI therapy is warranted.
904-223 Impact of Age on the Outcome of Fibrinolytic Therapy 
for ST-Segment Elevation Myocardial Infarction: A Meta-
analysis of a Decade of Trials
Shaheeda Ahmed, Elliott M. Antman, Sabina A. Murphy, Robert P. Giugliano, 
Christopher P. Cannon, Harvey White, David A. Morrow, Eugene Braunwald, The TIMI 
Study Group, The TIMI Study Group, Cardiovascular Division, Brigham & Women’s 
Hospital, Boston, MA, Green Lane Cardiovascular Service, Auckland City Hospital, 
Auckland, New Zealand
Background: Fibrinolysis for ST-segment elevation myocardial infarction (STEMI) 
reduces death, but its relative efﬁcacy and risks are age-dependent. We aimed to quantify 
the outcomes of ﬁbrinolysis and antithrombin therapy for STEMI stratiﬁed by age.
Methods: We performed a meta-analysis of 11 published (1992-2001) randomized clinical 
trials of ﬁbrinolysis in STEMI (sample size ≥ 3000, no age limit, no placebo-controlled 
arms) identiﬁed by MEDLINE through June 2005. Event rates and odds ratios (OR) in 
elderly vs. younger patients were calculated for death, intracranial hemorrhage (ICH) and 
stroke (CVA). Elderly patients were > 75 years (GUSTO I, TIMI 9B, GUSTO III, COBALT, 
ASSENT-2, InTIME-II TIMI-17, ASSENT-3, GUSTO V, and HERO-2), except when deﬁned 
as > 65 or >70 years by the study (INJECT and ISIS-3).
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Results: Elderly (n=24 531) vs. younger (n=123 568) patients had higher rates of death, 
ICH, and CVA (Table, top); results were similar in patients ≥ 75 years only (Table, bottom). 
The excess risk among the elderly was substantial (p< 0.001 for all).
Conclusions: Despite established reductions in death with ﬁbrinolysis for STEMI, elderly 
compared with younger patients, have a three to four fold increased risk of death and 
adverse events when treated with ﬁbrinolysis and antithrombin therapy in the modern 
era. These robust estimates of the anticipated rates for death, ICH, and CVA can be 




No. Rate % No. Rate % Odds Ratio (95%CI)
Death 3418/17 362 19.7 5646/ 103 561 5.5 4.37 (4.16-4.58)
ICH 315/22 114 1.4 658/120 001 0.5 2.83 (2.47-3.24)
Total 
Stroke 489/ 14 035 3.5 1177/96 793 1.2 2.92 (2.62-3.25)
Elderly (≥ 75 years 
only) Younger
No. Rate % No. Rate % Odds Ratio (95%CI)
Death 3034/14 948 20.3 5475/99 989 5.5 4.43 (4.22,4.65)
ICH 265/14 945 1.8 587/99 994 0.6 3.04 (2.63,3.52)
Total 
Stroke 471/13 323 3.5 1128/91 495 1.2 2.92 (2.62,3.26)
904-224 Age Related Outcomes in Patients Undergoing Transfer 
for Direct Percutanous Coronary Intervention in ST-
Elevation Myocardial Infarction
Marc C. Newell, Jason T. Henry, Katie M. Menssen, Joseph A. Browning, Christopher 
R. Henry, Barbara T. Unger, David M. Larson, Jay H. Traverse, Ivan J. Chavez, Wes R. 
Pedersen, Timothy D. Henry, Minneapolis Heart Institute Foundation, Minneapolis, MN, 
Ridgeview Medical Center, Waconia, MN
Background: Elderly patients account for the majority of death in STEMI and are 
frequently excluded from reperfusion therapy. Despite this, data regarding outcomes of 
percutaneous coronary intervention (PCI) in STEMI in the elderly is limited, including no 
data regarding transfer of elderly pts with STEMI.
Methods: 732 consecutive STEMI pts presented to (n=158) or were transferred to (n= 
574) Abbott Northwestern Hospital for direct PCI. These pts were divided into age groups 
(<60 (n=335), 60-69 (n=141), 70-79 (n=147), and ≥80 yo (n=109)) and followed for major 
adverse cardiac events (MACE), including death, reinfarction or revascularization, and 
stroke. No pts were excluded, including cardiogenic shock (14%) and out of hospital 
cardiac arrest (11%).
Results: No deaths occurred during transfer in any age group. In hospital, 30 day, and 
1 year mortality in the ≥80 yo age group was signiﬁcantly increased when compared to 
















Mortality (in hosp) 1.5% 2.1% 4.8% 11.9% <0.0001
Mortality (30 d) 1.8% 2.1% 4.8% 15.6% <0.0001
1 year survival 98.2 97.2 91.2 80.7 <0.0001
Reinfarction/
revascularizaiton (30 d) 1.2% 2.2% 1.4% 0.9% 0.81
Stroke (30 d) 0.6% 1.4% 2% 3.7% 0.09
MACE (30 d) 3.6% 5.7% 8.2% 20% <0.0001
Conclusions: Pts are safely transferred for direct PCI regardless of age. Not unexpectedly, 
pts ≥80 yo have increased mortality compared to younger pts, but 35% were non cardiac 
deaths. Despite the increase in mortality in pts ≥80 yo, this data compares favorably to 
previous studies of selected elderly with STEMI and are much lower than published data 
in octogenarians with STEMI. Our data suggest that all STEMI pts should be offered 
transfer for PCI, regardless of age.
904-225 Increased Bleeding Risk in Fibrinolytic Treatment of 
STEMI-Register of Information and Knowledge About 
Swedish Heart Intensive Care Admissions (RIKS-HIA) 
2002-2004
Jonas Oldgren, Johan Lindback, Ulf Stenestrand, Lars Wallentin, Uppsala Clinical 
Research Center, Uppsala, Sweden, University Hospital, Linkoping, Sweden
Background: Fibrinolytic therapy has been standard of care in ST-elevation myocardial 
infarction (STEMI) for several years and this treatment is well-known to be associated 
with risk of severe bleedings. We have analysed bleeding complications in the Register of 
Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA).
Methods and results: Bleeding complications in an unselected cohort of STEMI patients 
was evaluated in data from RIKS-HIA, in which every patient admitted to a coronary care 
unit in 72 hospitals during 2002 through 2004 were recorded. A total of 8999 patients 
who were treated with ﬁbrinolytic therapy were included in the analysis. Higher age, 
ﬁbrinolytic agent other than streptokinase (i.e. alteplas, reteplas, tenecteplas) and pre-
hospital administration of ﬁbrinolytic treatment were identiﬁed as independent predictors 
for bleeding in multivariable analysis. 
Year 2002 2003 2004 p
Number of patients 3763 3107 2129 p
Age (median) 70 69 70 0.34
Gender (females) 34 % 32 % 36 % 0.012
Pre-hospital ﬁbrinolysis 20 % 22 % 28 % <0.001
Bleeding, total 1.6 % 2.5 % 3.3 % <0.001
- lethal or intra-cerebral 0.9 % 1.5 % 1.9 % <0.001
- requiring surgery or transfusion 0.7 % 1.0 % 1.4 %
Conclusion: The use of ﬁbrinolytic treatment in STEMI patients decreases in Sweden, 
as a consequence of an increase in primary PCI. In the RIKS-HIA register, ﬁbrinolysis is 
associated with an increasing risk of major in-hospital bleedings during the last three years. 
Higher age, ﬁbrinolytic agent other than streptokinase and pre-hospital administration of 
ﬁbrinolysis independently predicted bleeding. The present data warrants further cautious 
analyses of bleeding complications in STEMI patients receiving ﬁbrinolysis.
904-226 Impact of Renal Dysfunction and Glucometabolic 
Status on One Year Mortality After Acute Myocardial 
Infarction
Francois Schiele, Marie-France Seronde, Pierre Legalery, Katy Didier-Petit, Nicolas 
Meneveau, Fiona Ecarnot, Jean-Pierre L. Bassand, University Hospital Jean Minjoz, 
Besancon, France
Background: In patients (pts) with acute myocardial infarction (MI), glucometabolic status 
(diabetes or stress hyperglycaemia(SH)) and the presence of chronic renal dysfunction 
(reduction in glomerular ﬁltration rate(GFR)) may modify acute management, thereby 
contributing to increased mortality among these pts. The impact of the glucometabolic 
status and renal dysfunction on one year mortality, taking quality of care into account, is 
poorly documented.
Methods: A prospective, observational study including all pts admitted with acute MI. 
Quality of care was assessed by the rate of use of guidelines-recommended treatment. 
Patients were stratiﬁed according to glucometabolic status (G1 group: no pre-existing 
diagnosis of diabetes or SH, deﬁned as fasting glucose level >=115 mg/dl; G2 group: 
pre-existing diagnosis of diabetes and/or SH); and according to degree of renal failure, 
as deﬁned by the GFR: GFR1>59, GFR2>29 and <60, GFR3<30 ml/min/1.73m². These 
variables were entered into a logistic regression on 1 year mortality to determine their 
independent predictive value.
Results: A total of 724 pts were included, 320 ST elevation MI and 404 non ST elevation 
MI. Normal glucometabolic status (G1) was observed in 395 (54.6%) pts and 329 (45.4%) 
pts composed group G2; 175 (24.2%) had a pre-existing diagnosis of diabetes and 154 
(21.3%) had SH. Based on GFR, 208 (28.7%) had normal renal function (GFR1), 320 
(44.2%) had moderate (GFR2) and 196 (27.1%) severe renal dysfunction. The use of 
guidelines-recommended treatments was similar in groups G1 and G2, but lower in 
groups with impaired renal function. At 1year, mortality was 11.3%; signiﬁcantly lower 
in G1 (24/395, 6.1%) than in G2 (58/329, 17.6%), p<0.001; and signiﬁcantly lower in 
GFR1 (4/208, 2%) than in GFR2 (30/320, 9.4%) or GFR3 (48/196, 24.5%), p<0.001. 
Multivariable regression analysis showed that quality of care, glucometabolic status and 
renal function were independent predictors of 1 year mortality.
Conclusions: In pts with acute MI, glucometabolic status and degree of renal dysfunction 
are predictors of 1 year mortality, even after adjustment on the degree of use of guidelines-
recommended therapies.
904-227 Renal Dysfunction Negates the Beneﬁt of Primary 
Percutaneous Coronary Intervention Over Fibrinolytic 
Therapy in the Treatment of ST Segment Elevation 
Myocardial Infarction
Mark Y. Chan, Wei-Ding Tan, Boon-Lock Chia, Yean-Teng Lim, Huay-Cheem Tan, Jimmy 
Lim, Ling-Ling Sim, Tiong-Cheng Yeo, The Heart Institute, Singapore, Singapore, 
Singapore Cardiac Data Bank, Singapore, Singapore
Background: Several randomized controlled trials have demonstrated better outcomes 
with primary percutaneous coronary intervention (PPCI) over ﬁbrinolytic therapy in the 
treatment of patients with ST segment elevation myocardial infarction (STEMI). There is 
currently little data to show that this beneﬁt extends to pts with renal dysfunction. 
Methods: We studied 1672 pts with STEMI within 12 hours of symptom onset who were 
admitted to 2 major public hospitals in Singapore from 2000-2002. All patients received 
either upfront ﬁbrinolytic or PPCI as determined by the attending cardiologist. Serum 
creatinine was measured on admission and the glomerular ﬁltration rate (GFR) was 
determined using the Modiﬁcation of Diet in Renal Disease equation. The impact of 
reperfusion strategy on 30 day mortality was then determined for pts with GFR≥60 ml 
min-¹ 1.73 m-² (group I) and GFR<60 ml min-¹ 1.73 m-² (group II).
Results: The mean age was 56±12 years (85% male) and mean GFR was 81±30 ml 
min-¹ 1.73 m-². The 30 day mortality for the entire cohort was 9%. After adjusting for 
covariates, PPCI was associated with a signiﬁcantly lower mortality in group I but not 
group II (see table 1).
Conclusions: PPCI was associated with improved 30 day survival in pts with preserved 
renal function (GFR≥60 ml min-¹ 1.73 m-², group I) but not in those with renal dysfunction 
(GFR<60 ml min-¹ 1.73 m-², group II). Randomized trials studying the relative efﬁcacy of 
both reperfusion strategies in patients with renal dysfunction are thus warranted.
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Table 1. Adjusted Odds Ratio of Mortality - PPCI Versus Fibrinolytic 











Adjusted odds ratio of 






I(n=1341) 35 65 4 0.41(0.19-0.89) 0.02
Group 
II(n=331) 44 56 25 0.70(0.31-1.60) 0.40
 
904-228 Impact of Combination Evidence-based Medical 
Therapy on Mortality Following Myocardial Infarction in 
Patients With and Without Renal Dysfunction
Tay Edgar, Chan MarkY, Tan Wei Ding, Sim Ling Ling, Ng Kenneth, Yeo Tiong Cheng, 
National University Hospital, Singapore, Singapore
Background: Antiplatelet agents, beta-blockers, statins and ACE inhibitors have been 
shown to reduce mortality in patients following myocardial infarction (MI). Whether the 
combination of these agents have a similar impact on mortality following MI in patients 
with renal dysfunction is uncertain.
Methods: 5521 patients with MI from 2 public hospitals between January 2000 and 
December 2003 were identiﬁed. Their demographics, comorbidities and in-hospital 
management were collected. Glomerular ﬁltration rate (GFR) was estimated using the 
Modiﬁcation of Diet in Renal Disease equation. Based on discharge medications, the 
patients were divided into those using 0,1,2,3 or 4 medications. The impact of medication 
use on 1 year mortality was then assessed for patients with GFR ≥60ml/min (Group 1) 
and GFR < 60ml/min (Group 2).
Results: Mean age was 63 ± 13 years with 71% males. 35% of patients had reduced 
GFR. Adjusted odds ratio for 1 year mortality in those with reduced GFR, compared to 
those with preserved GFR, was 1.86 (95% CI 1.54-2.25 , p <0.001 ). Compared with 
patients with 0 medication, adjusted odds ratio for 1 year mortality was lower in patients 
with 1,2, 3 and 4 medications in both groups (see table). There was no signiﬁcant 
interaction between the number of medications used and GFR.
Conclusions: Using combination evidence-based medications was independently 
associated with lower 1 year post MI mortality. Similar beneﬁt is seen in patients with and 
without renal dysfunction.















1 0.24 0.12-0.48 <0.001 1 0.35
0.20-
0.62 <0.001
2 0.10 0.05-0.19 <0.001 2 0.13
0.07-
0.22 <0.001
3 0.05 0.03-0.10 <0.001 3 0.08
0.05-
0.15 <0.001
4 0.03 0.02-0.06 <0.001 4 0.06
0.03-
0.11 <0.001
904-229 Impact of Chronic Oral Anticoagulation on Baseline 
Characteristics, Management, and Outcomes of 
Patients With Acute Myocardial Infarction. Data From 
the Rico Survey
Alexandra Oudot, Philippe-Gabriel Steg, Nicolas Danchin, Gilles Dentan, Philippe 
Buffet, Yves Laurent, Pierre Sicard, Luc Janin-Maniﬁcat, Jean-Claude Beer, Marianne 
Zeller, Yves Cottin, on behalf of RICO survey working group, Service de Cardiologie, 
CHU, Dijon, France, Clinique de Fontaine-les-Dijon, Service de Cardiologie, Fontaine-
les-Dijon, France
Background: Patients on chronic oral anticoagulation (OAC) are generally excluded from 
randomized studies; thus, little information is available on their risk proﬁle, management 
and outcomes when admitted for acute myocardial infarction (AMI). In particular, the 
impact of OAC on the use of various antithrombotic therapies is unknown. This analysis 
aimed to explore these factors using data from the population-based RICO regional 
registry of AMI
Methods: All patients from RICO with ST segment elevation AMI were included in this 
analysis. Use of OAC was deﬁned as continuous use in 48h prior to AMI.
Results: Among 2112 STEMI patients enrolled between january 2001 and january 2005, 
93 (4%) patients had received OAC. Patients on OAC were older (76 vs 67 years, p<0.001), 
more likely to have a history of hypertension (65% vs 47%, p=0.001), diabetes (37% vs 
19%, p<0.001), and prior MI (33% vs 11%, p<0.001) than patients without OAC. In addition, 
patients on OAC received less frequently reperfusion therapy (47% vs 69%, P<0.001) and 
underwent fewer recanalization procedures (percutaneous coronary intervention, P=0.001). 
Finally patients on OAC received less frequently antiplatelet (aspirin/thienopyridines)(90% 
vs 96%, P=0.025) and heparins (81% vs 95%, P<0.001)(during the ﬁrst 48 hours) than 
patients without OAC). Patients on OAC experienced a higher incidence of in-hospital 
major adverse events (death, recurrent MI or major bleeding, P=0.005) than patients 
without OAC. Prior use of OAC was an independent predictive factor for heart failure when 
adjusted for age, diabetes, altered creatinine clearance, and lysis, heparin and GpIIbIIIa 
inhibitors (OR=2.04 ; CI 95% : 1.23-3.38 ; P=0.005). Conclusion: In this population-based 
registry, STEMI patients with prior use of OAC represent a sizable group (4% of all STEMI 
patients) and have an overall higher baseline risk proﬁle than patients without OAC. Yet, 
this group received less reperfusion therapies, less aggressive antithrombotic therapies 
and also experienced more frequent adverse outcomes in-hospital than patients without 
OAC. Thus, further studies of this high-risk group are warranted in order to develop speciﬁc 
management strategies.
904-230 Gender and Racial Differences in Invasive Diagnostic 
and Interventional Cardiac Procedures in the 
Management of Acute Myocardial Infarction: 15-Year 
Trends in a Statewide Database
William J. Kostis, Yu-Hsuan Shao, Alan C. Wilson, Nora M. Cosgrove, Ronald S. 
Freudenberger, John B. Kostis, for the MIDAS Study Group, UMDNJ-Robert Wood 
Johnson Medical School, New Brunswick, NJ
Background: Race and gender differences in the rates of invasive procedures following 
acute myocardial infarction (AMI) have been reported. However, little data are available 
on long-term trends of the utilization of these procedures.
Methods: We analyzed the statewide MIDAS data of 247,637 black and white patients 
admitted with a ﬁrst AMI in New Jersey between 1986 and 2002.
Results: The rate of diagnostic cardiac catheterization increased approximately three-fold 
in the years under study (p<0.001) in all race-gender subgroups. It has been highest in 
white men, followed by black men, and lowest, but similar, in black and white women. The 
rate ratio of white women to white men receiving this increased from 63% to 79% by 1998 
and remained stable. Adjusting the rates for age, comorbidities, and AMI complications 
decreased but did not eliminate the differences. The rate ratios for black men to white 
men and black women to white women have remained relatively stable (approximately 
90% and 100%, respectively). The probability of having an intervention following cardiac 
catheterization has increased from 15% to 50%, and is lower in women (47%) than in men 
(55%), and in blacks (45%) than in whites (53%).
 
Conclusions: 1. The rates of cardiac catheterization and intervention following AMI 
are still increasing. Women and blacks have lower rates of cardiac catheterization and 
intervention. 2. Although the utilization rate ratios of women to men have been increasing, 
the ratios for blacks to whites have remained stable.
904-231 An Insight From the National Registry of Myocardial 
Infarction on the Outcome of Elderly Patients with 
Cardiogenic Shock Complicating Acute Myocardial 
Infarction in the Modern Era
Santhosh K.G. Koshy, Eric D. Peterson, Lori S. Parsons, Martha Blaney, William J. 
Rogers, For National Registry of Myocardial Infarction, University of Alabama at 
Birmingham, Birmingham, AL, Duke Clinical Research Center, Durham, NC
Background/Methods: To determine the difference in the in-hospital outcomes in 
‘elderly’(age≥ 75 years) patients (pts) with cardiogenic shock complicating acute 
myocardial infarction (CSAMI) compared to ‘younger’ pts, we evaluated pts enrolled in 
the National Registry of Myocardial Infarction- 4 from 2000-2004. We hypothesized that 
outcomes would be similar in the two groups with the current treatment strategies.
Results: Of a total of 7,161 CSAMI pts (3,035 elderly; mean age 82.1 years and 4,126 
younger; mean age 61.6 years), the elderly more often had history of hypertension, heart 
failure, coronary intervention, stroke, peripheral vascular disease and renal failure, and 
less often received in-hospital treatment with ACE inhibitor, aspirin, beta blocker, statin, 
GP 2b/3a inhibitor, coronary intervention, balloon pump, and CABG (p<0.0001). They also 
had higher in-hospital mortality (OR 1.24; 95% CI 1.22-1.27; p<0.0001) and MACE (major 
adverse cardiac events: in-hospital death, recurrent MI or recurrent ischemia/angina) (OR 
1.61; 95% CI 1.44-1.80; p<0.0001) rates. ST elevation MI, diabetes, prior MI, heart failure 
and angina were independent predictors of MACE, and prior MI, diabetes, stroke and 
heart failure were for in-hospital mortality.






























Conclusion: Patients aged ≥ 75 years presenting with cardiogenic shock complicating AMI 
still have worse outcome than younger patients. They were sicker and less aggressively 
treated. There was incremental increase in death and MACE with advancing age.
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905-232 Reduced Renal Function is Associated With Increased 
Effectiveness of ACE Inhibitor Therapy in Patients With 
Chronic Stable Coronary Disease in the Prevention of 
Events With ACE inhibition (PEACE) Trial
Scott D. Solomon, Madeline M. Rice, Kathleen Jablonksi, Michael Domanski, Bernard 
J. Gersh, Jean L. Rouleau, Marc A. Pfeffer, Eugene Braunwald, Brigham and Women’s 
Hospital, Boston, MA
Background Reduced renal function is associated with increased cardiovascular risk.
Methods We assessed the relation between renal function, outcomes, and inﬂuence 
of ACE inhibition in patients with stable coronary artery disease and preserved systolic 
function enrolled in PEACE. 8290 Patients were randomized to trandolapril (target 
4mg/day) or placebo. Estimated glomerular ﬁltration rate (eGFR) was calculated from 
creatinine available prior to randomization (n=8280) with the 4-point MDRD equation
Results: Mean eGFR was 77.6 ± 19.4, and 16.3% of patients had reduced renal function 
(eGFR < 60 mg/ml/1.73m²). The adjusted risk associated with each 10 unit decrease 
in estimated GFR in the placebo group (HR 1.07; 95% CI, 1.00 - 1.14, p = 0.04)) was 
not observed in the trandolapril group (HR 0.99; 95% CI 0.93 - 1.05, p = 0.72), with a 
signiﬁcant interaction between eGFR and treatment group with respect to cardiovascular 
and all-cause mortality (p = 0.02 for both). Trandolapril was associated with a reduction 
in total mortality in patients with reduced renal function (HR, 0.73; 95% CI, 0.54, 1.00, 
p = 0.05), but not in patients with preserved renal function (HR 0.94; 95% CI 0.78 to 
1.13,p=0.05). 
Conclusions Although trandolapril did not improve survival in the overall PEACE cohort, 
in which mean eGFR was relatively high, trandolapril reduced mortality in patients with 
reduced eGFR. Reduced renal function may identify patients most likely to beneﬁt from 
ACE inhibitor therapy for cardiovascular protection.
905-233 Angiographic Severity of Coronary Artery Disease Is 
Not Related to the Duration of Type-2 Diabetes
Renaud Fressonnet, Philippe Bonnin, Nathalie Kubis, Pascale Massin, Jean-Philippe 
Kevorkian, Bernard I. Levy, Patrick Henry, Lariboisiere Cardiology, Paris, France, 
Lariboisiere Physiology, Paris, France
Background: A relationship between duration of diabetes and the severity of diabetic 
complications is currently supposed in type-2 diabetic patients (T2D). However, this 
relationship has never been clearly investigated for coronary artery disease (CAD). The 
objective of this study was to analyze the angiographic severity of CAD in T2D patients 
suspected of CAD, taking account of the duration of diabetes
Methods: We conducted a prospective study including 86 consecutive T2D referred 
for a ﬁrst coronary angiography excluding acute coronary syndromes. The severity of 
complications were fully screened using the extension of CAD at coronary angiography 
(1, 2 or 3-vessel disease - >50% diameter stenosis) and the modiﬁed Gensini score. 
The severity of retinopathy (fundus examination), neuropathy (electromyography) and 
nephropathy (24h microalbuminuria level) were also screened in this population.
Results: Mean age was 61±10 y.o., 71% were male, mean diabetes duration was 10±9 y 
and 31% were treated with insulin. There was no statistical relationship between duration 
of diabetes and the severity of CAD (extension of CAD: p =0.25 - gensini score: R=0.14, 
p=0.12). In contrast, the severity of microangiopathic complications were strongly related 
to the duration of diabetes (retinopathy: R=0.69 - neuropathy: R=0.70 - nephropathy: 
R=0.43 - all p<0.001). Multivariate analysis taking account of other atherosclerotic 
risk factors cannot explain these results. when the patients were divided into 2 groups 
according to median duration of diabetes: <10y (n=45 - 61±10 y.o., diabetes duration 
4±2y - 13% treated with insulin) or 10y and more (n=41 - 61±10 y.o - diabetes duration 
18±7y - 50% treated with insulin), similar results were found: in the group of patients with 
less than 10 y duration, 47% had 2 or 3-vessel disease vs. 53% in the group with more 
than 10 y duration of diabetes.
Conclusions: In a population of T2D with suspected CAD, there is no clear relationship 
between duration of diabetes and the severity of CAD. Duration of diabetes could be not 
relevant for the risk stratiﬁcation of T2D with suspected CAD.
905-234 Diabetes and Coronary Artery Disease Impose Similar 
Cardiovascular Morbidity and Mortality to Patients With 
End-Stage Renal Disease: A Seven-Year Follow-Up 
Study
Luis Henrique W. Gowdak, Flavio J. de Paula, Luis Estevam Ianhez, Luiz Antonio M. 
Cesar, Eduardo M. Krieger, Jose Antonio F. Ramires, Jose J. G. De Lima, Heart Institute 
(InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil, Renal Transplant 
Unit, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, Brazil
Background: Major cardiovascular events (MACE) in patients (pt) with end-stage renal 
disease (ESRD) may be due to the increased prevalence of coronary artery disease 
(CAD), which, in turn, may be secondary to concomitant cardiovascular risk factors, such 
as diabetes (DM). We investigated the role of diabetes and CAD, alone or in combination, 
on the long-term survival of pt with ESRD.
Methods: 283 pt with ESRD on dialysis (56±8 years-old, 71% men) at high-risk for CAD 
were prospectively enrolled. Coronary angiography was performed in all pt. According 
to the diagnosis of DM or signiﬁcant CAD (stenosis ≥70%), pt were divided in 4 groups: 
G1=DM(no)/CAD(no) (n=111); G2=DM(no)/CAD(yes) (n=61); G3=DM(yes)/CAD(no) 
(n=48); G4=DM(yes)/CAD(yes) (n=63). Median follow-up was 19 months (range=1 to 
90). Kaplan-Meier survival analysis was performed for the composite incidence of fatal/
nonfatal MACE. Cox regression models were used to investigate the association of DM/
CAD and MACE.
Results: There were 78 fatal/nonfatal MACE. Figure 1 shows the Kaplan-Meier curves 
for the survival probability free of MACE. Pt in G1 had the best long-term prognosis 
(P<0.001). The multivariate Cox proportional-hazards model comparing the incidence of 
MACE in pt in G3 (DM=yes/CAD=no) with that of pt in G2 (DM=no/CAD=yes) revealed an 
adjusted hazard ratio of 1.33 (95% conﬁdence interval = 0.58 - 3.46; P=0.51).
 
Conclusions: In pt with ESRD, DM increases cardiovascular morbidity and mortality 
even in the abscence of signiﬁcant CAD.
905-235 Inﬂuence of Severity and Extent of Coronary Artery 
Disease on Long-Term Survival of Patients With and 
Without Diabetes Mellitus: Analysis from the CASS 
Registry
Mandeep Singh, Bernard Gersh, Charanjit Roger, David Hodge, Robert Frye, Mayo 
Clinic, Rochester, MN
Background: Prognostic value of insulin and fasting blood glucose (FBG) in patients with 
diabetes mellitus (DM) and coronary artery disease (CAD) has been debated.
Methods: We compared long-term outcome of 24,958 patients with cardiac angiography 
in the Coronary Artery Surgery Study (CASS) Registry and stratiﬁed them by DM. In DM, 
FBG was divided arbitrarily into quartiles of <100, 100-120, 121-140, and >140mg/dl, and 
use of insulin was noted.
Results: DM had higher prevalence of comorbidities, 3-vessel disease (62.5% vs. 50.4%, 
P<0.001), left main disease (11.9% vs. 10.0%, P=0.006), greater number of segments 
with signiﬁcant CAD, lower EF, and worse mean left ventricular wall motion score. Among 
DM, patients on insulin had worse demographic, and angiogaphic proﬁle with more 
extensive CAD and worse mean EF. 15-year survival was 35% vs. 57% in patients with 
and without DM, P<0.001, In patients with DM, the 15-year survival was 38% in patients 
not, and 23 % in patients on insulin at baseline, P<0.001. Higher FBG in patients with 
DM portended worse long-term prognosis (Fig) Insulin use and higher fasting blood 
glucose at baseline were independent univariate predictors of worse long-term outcome, 
after adjustment fasting blood glucose was still an independent predictor of worse long-
term outcome. Conclusion: Patients with DM had worse angiographic proﬁle, and 
left ventricular function, and long-term outcome. Higher FBG remains an independent 
predictor of worse long-term outcome in DM.
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905-236 Less Revascularization in Diabetic Patients With Silent 
Myocardial Ischemia Results Poor Survival Compared 
to Diabetic Patients With Symptomatic Coronary Artery 
Disease
Eue-Keun Choi, Bon-Kwon Koo, Young-Seok Cho, Hyun-Jai Kang, Woo-Young Chung, 
Tae-Jin Youn, In-Ho Chae, Dong-Joo Choi, Hyo-Soo Kim, Byung-Hee Oh, Young-Bae 
Park, Yun-Shik Choi, Seoul National University Hospital, Seoul, South Korea
Background: There is paucity of information about clinical outcomes of diabetic 
patients with silent myocardial ischemia (SMI). We compared clinical and angiographic 
characteristics, and clinical outcomes between asymptomatic and symptomatic type 2 
diabetic patients (T2DM) with angiographically proven coronary artery disease (CAD).
Methods: Four hundreds thirty-seven consecutive T2DM with CAD were divided into 2 
groups according to the presence of ischemic symptom, and followed for an average 
of 5 years. Seventy asymptomatic T2DM (SMI group) with positive stress test who had 
undergone coronary angiography were compared with 367 symptomatic T2DM (SXCAD 
group) ((acute myocardial infarction (AMI, n=67), unstable angina (UA, n=188), and 
chronic stable angina (CSA, n=112)).
Results: SMI group had longer duration of diabetes, and higher incidence of male, and 
retinopathy compared to symptomatic group. There was no signiﬁcant difference in the 
coronary atherosclerosis severities, which was evaluated by the number of diseased 
vessel and Gensini score. However, SMI group had lower rate of revascularization therapy 
compared to SXCAD group (26.8 vs 62.2%, p<0.001) There was no signiﬁcant difference 
in major adverse cardiac events between 2 groups (5-year event-free survival ASX at 
62%, SXCAD at 69%, p=0.71). However, SMI group had higher cardiovascular mortality 
rate compared to SXCAD group (5-year survival ASX at 66%, SXCAD at 86%, p=0.001) 
Subgroup analysis demonstrated that the survival difference was conﬁned to patients 
with UA or CSA (5-year survival UA at 87%, and CSA at 91%, p<0.05 each compared 
with ASX), and showed no signiﬁcant difference with AMI group (5-year survival at 
73%, p=0.38 compared with ASX). In SMI group, revascularization at the time of index 
angiography was independently associated with improved survival (HR 0.052 [95% CI: 
0.006-0.483] after multivariate adjustment).
Conclusions: We found that SMI group had similar or even higher cardiovascular 
mortality risk compared to symptomatic T2DM with CAD, and infrequent revascularization 
therapy in these patients might be the cause of their poor survival.
905-237 Coronary Angiography Is a Strong Predictor of 
Cardiovascular Events in Patients With End-Stage 
Renal Disease
Luis Henrique W. Gowdak, Flavio J. de Paula, Luiz Antonio M. Cesar, Eulogio Martinez, 
Luis Estevam Ianhez, Jose Antonio F. Ramires, Eduardo M. Krieger, Jose J. G. De Lima, 
Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil, Renal 
Transplant Unit, Hospital das Clinicas, University of Sao Paulo Medical School, Sao 
Paulo, Brazil
Background: Patients (pt) with end-stage renal disease (ESRD) are at high-risk for 
coronary artery disease (CAD), which may relate to major cardiovascular events (MACE). 
Noninvasive tests seem to inadequately identify pt at higher risk for MACE. We investigated 
the value of coronary angiography (CA) as a predictor of MACE in pt with ESRD.
Methods: 281 pt with ESRD on dialysis (56±8 years-old, 70% men) at high-risk for CAD 
were enrolled and underwent CA regardless sypmtoms. Pt were classiﬁed as having 
signiﬁcant 1-, 2- or 3-vessel CAD (stenosis ≥70%), or moderate (MOD) CAD (30%-70% 
stenosis). Follow-up ranged from 1 to 60 months (median=32). Kaplan-Meier survival 
analysis was performed for the composite incidence of fatal/nonfatal MACE according 
to the CA ﬁndings.
Results: Normal CA was found in 118 pt (42%), and MOD CAD in 53 (19%); the number 
of pt with signiﬁcant 1-, 2- or 3-vessel CAD was 46 (16%), 42 (15%), and 22 (8%), 
respectively. Figure 1 shows the Kaplan Meier survival curves. Pt with 3-vessel CAD had 
the lowest event-free survival probability (P=.0012). Clinical variables signiﬁcantly (P<.05) 
associated with CAD ≥70% were diabetes, gender (male), peripheral vascular disease, 
and previous myocardial infarction.
Conclusions: In selected pt with ESRD, the prevalence of CAD detected by CA is high. 
CA clearly identiﬁes pt at the lowest (normal coronary arteries) and highest (3-vessel 
CAD) risk for MACE. Therefore, CA may be an useful tool to better deﬁne the prognosis 
of this high-risk population.
905-238 Pioglitazone Is Superior to Metformin or Glibenclamide 
in Recducing Markers of Cardiovascular Risk in 
Patients With Type-2-diabetes Mellitus
Dietrich Gulba, Hospital Düren, Düren, Germany
Background and aims: The major burden of Type-2-Diabetes (T2D) are atherosclerosis 
and macrovascular complications. Insulin resistance (IR) and its metabolic and 
inﬂammatory consequences are of importance. PPARγ-agonists such as Pioglitazone 
(PIO) ameliorate metabolic control and decrease pro-inﬂammatory cytokine expression. 
These effects have been consistently shown to be independent of glycemic control. 
Studies looking at cardiovascular surrogate markers (CSM) comparing PIO with standard 
oral antidiabetic drugs (OAD) are lacking. We compared PIO, MET and GLIB on CSM in 
a large cohort of patients (n = 1.140) with T2D.
Materials and methods: open, controlled, multicentre, parallel cohort study. The 
cohort included patients with stable coronary artery disease (CAD) and stable OAD 
monotherapy. Combination therapy with either PIO 30 mg qd. (n = 380), MET (mean 
doses 1,900 mg/day, n = 380) or GLIB (mean dose 6.2 mg/day, n = 380) was initiated for 
a mean observation time of 52 + 4 weeks. Primary parameters were the changes of HbA1C 
and high sensitivity C-Reactive Protein (hsCRP). 
Results: 
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*p < 0.001 vs. BL; # p < 0.01 vs. MET and GLIB; ^ p < 0.05 vs. GLIB; ° p < 0.05 vs. BL
During the observation period 78 MACE occurred: 24 PIO, 22 MET and 32 GLIB. There was 
no difference for episodes of heart failure between the three cohorts.Conclusion: Despite a 
comparable reduction in HbA1C levels signiﬁcant differences between treatment arms could 
be observed. Overall, PIO had the most favourable proﬁle of the three agents.
905-239 Renal Function Predicts Presence and Severity of 
Abnormal SPECT Myocardial Perfusion Imaging (MPI)
Eric M. Williams, Timothy J. Kruser, Lisa Nee, Gene Gulliver, Su Min Chang, University 
of Wisconsin, Madison, WI
Background: Chronic kidney disease( CKD) pts have higher cardiovascular events. But 
the relationship between CKD and underlying coronary artery disease (CAD) is not well 
studied.
Objective: We studied whether renal function as measured by creatinine clearance 
(CrCl) reﬂects the presence and severity of CAD as detected by MPI.
Methods:We reviewed the clinical, laboratory and MPI results of 1002 pts (age 65+-10 yrs, 
97 % male, 39 % diabetes (DM)). CrCl was calculated using the modiﬁed MDCD equation. 
CKD deﬁned as CrCl < 60ml/min/1.73 Kg/m2. CrCl not available to the interpreting 
physicians. The extent and severity of MPI were assessed using semi-quantitative visual 
analysis. Moderate to high risk scan( HRS) deﬁned as Sum Stress Score >8.
Result: The prevalence of abnormal MPI ( MPA) and HRS was higher in CKD pts 
compared to pts with CrCl >60. (MPA:260/367 or 70% vs 347/635 or 55% p < 0.001, 
HRS: 26% vs 19% p=0.02) CrCl < 60 was signiﬁcant predictor of MPA(OR 1.85, CI 1.36-
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2.5 p< 0.001) and HRS ( OR 1.6, CI 1.1-2.2 p=0.01) , adjusted for age, gender, ECG and 
risk factors including DM.
607 pts with MPA had lower CrCl compared to 395 pts with normal MPI. (62+-21.vs 68+-
19 p<0.001)
When grouped according to quartiles of CrCl, odds ratio for MPA and HRS are shown 
in table.
Conclusion: Pts with MPA had worse renal function. CKD is associated with a higher 
prevalence and severity of CAD independent of traditional risk factors. These data 
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905-240 The Impact of Reduced Left Ventricular Function on 
Long-Term Outcomes in Diabetes Mellitus Patients With 
Coronary Artery Disease Undergoing Percutaneous 
Coronary Intervention
Kenji Ando, Yoshimitsu Soga, Takashi Yamada, Shinichi Shirai, Koyu Sakai, Keita 
Odashiro, Masahiko Goya, Masashi Iwabuchi, Hiroyoshi Yokoi, Hitoshi Yasumoto, 
Hideyuki Nosaka, Masakiyo Nobuyoshi, Kokura Memorial Hospital, Kitakyushu, Japan
Background: Although reduced LVEF was associated with a poor outcome in patients 
(pts) with coronary artery disease, a few data exist on impact of low LVEF in pts with 
diabetes mellitus (DM) undergoing PCI.
Methods: We analyzed consecutive 9764 consecutive pts underwent PCI for stable 
angina pectoris between Sep. 1981 and July 1998 at our institution. Pts were divided 
into two groups: 2607 pts with DM (DM group) and 7157pts without DM (non-DM group). 
Long-term clinical follow-up data were obtained by a review of the hospital records and 
telephone contacts.
Results: DM group included more LVEF<40% pts than non-DM group (5.8% vs. 4.1%, 
p=0.0002). DM group had similar procedure success rate (90.4% vs.89.8%, p=ns) and 
clinical success rate, deﬁned as procedural success without death/MI/CABG, (88.8% 
vs.88.7%, p=ns) compared to non-DM group during hospital stay. 5-year survival rate 
was signiﬁcantly lower in DM group than non-DM group (83.8% vs. 88.4%, p<0.0001). 
Coexistence of low LVEF was associated with signiﬁcantly lower 5-year survival rates in 
both groups (non-DM group: LVEF>40%, 89.4% vs. LVEF<40%, 66.7%, p<0.0001 DM 
group: LVEF>40%, 85.8% vs. LVEF<40%, 53.3%, p<0.0001) and had a worse impact 
on the outcome in DM group rather than non-DM group (absolute risk increase +32.5% 
vs. +22.7%).
Conclusion: Pts with DM was more often with low LVEF and had a higher long-term 
mortality rate in spite of similar procedure and clinical success rates. Reduced LVEF 
increases the long-term mortality rate of especially DM pts. 
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906-241 How Reliable Are Pre-Hospital and Admission ECGs to 
Predict Recent Coronary Artery Occlusion in Patients 
With Successfully Resuscitated Out-Of-Hospital 
Cardiac Arrest?
Christian Spaulding, Ivan Laurent, Mehran Monchi, Alain Cariou, Olivier Varenne, 
Emmanuel Salengro, Alice Ohanessian, Patrick Sauval, Alain Rozemberg, Philippe 
Allouch, Cedric Gautier, Pierre Carli, Cochin Hospital, Paris 5 Medical School, Rene 
Descartes University, Paris, France
Background: Ischemic heart disease is the main cause of sudden cardiac death (SCD). 
The value of pre-hospital and admission ECG for predicting recent coronary artery 
occlusion in out-of-hospital SCD is debated.
Methods: In cases of successfully resuscitated out-of hospital SCD a standard 12 lead 
ECG was registered immediately after return of spontaneous circulation (ROSC) and 
interpreted by the emergency physician at the scene. A 12 lead ECG registered was also 
recorded immediately after hospital admission. A coronary angiogram was performed at 
admission in all patients.
Results: 185 pts were included in this prospective study (67% male, age 65 ± 14 years). 
The initial arrhythmia was asystole in 7%, ventricular tachycardia in 21% and ventricular 
ﬁbrillation in 72%. Duration from collapse to ROSC was 25min ± 14 min and from ROSC 
to ECG was 6 min ± 1.min respectively. Survivors were admitted 110 ± 36 min after 
the arrest and the coronary angiogram perfomed 35 ± 12 min after admission. A recent 
coronary artery occlusion was found in 93 patients (50%). The ECG data was analyzed 
by multivariate logistic regression to determine whether it could predict the presence of 
recent coronary occlusion on angiography. The presence of a ST-segment elevation on 
the ECG performed immediately after ROSC was associated with positive and negative 
predictive values of 0.65 and 0.76 respectively which increased to 0.68 and 0.79 when 
the admission ECG was used for analysis. 16 patients with no ST-segment elevation were 
found on angiography to have a recent coronary artery occlusion. The presence of risk 
factors or chest pain before arrest did not increase the predictive values.
Conclusion: Acute coronary artery occlusion is frequent in survivors of out-of-hospital 
SCD and is poorly predicted by electrocardiographic ﬁndings. Immediate coronary 
angiogram at admission remains the only reliable diagnostic method in this setting to 
diagnose recent coronary artery occlusion.
906-242 Mild Therapeutic Hypothermia After Cardic Arrest: A 
Nationwide Survey on the Implementation of the ILCOR 
Guidelines in Intensive Care Units
Sebastian Wolfrum, Peter W. Radke, Heribert Schunkert, Volkhard Kurowski, Medical 
Clinic II, University of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
Background: since 2003 the use of mild therapeutic hypothermia (MTH) is recommended 
by the ILCOR in patients after cardiac arrest. Data regarding the implementation of MTH 
guidelines are rare.
Methods: All German hospitals registered for providing ICUs (n=737) were contacted via 
email using a structured evaluation questionnaire.
Results: 38% completed the survey. 201 ICUs (76%) do not use MTH, 23% of those are 
planning to use MTH, 17% do need more information about the method, 20% regard MTH 
as technically too difﬁcult to perform, and 12% claim more trials before MTH becomes a 
standard treatment. 69 ICUs (26%) used MTH in 1251 patients. In 52% of the patients 
cardiac arrest was due to myocardial infarction, where 13% received thrombolytic therapy 
and 87% underwent acute PCI. 59 ICUs (86%) use MTH in patients after out-of-hospital 
resuscitation with observed VF in a routine manner and 67% when other initial rhythms 
were observed. For in-hospital resuscitation numbers are reduced to 73 % and 55%, 
respectively. 22 ICUs (32%) use MTH in patients after cardiac arrest with cardiogenic 
shock whereas 45% regard cardiogenic shock as a contra-indication for MTH. Target 
temperature ranges from 32 to 36°C (31.1± 0.6) and duration of cooling from 14 to 48h 
(23.0 ± 5.3). The majority of centers uses economically priced cold packs (84%) and cold 
infusions (81%) for cooling whereas a minority uses speciﬁc equipment such as cooling 
mattresses (32%) or intravascular cooling devices (16%). Re-warming is carried out with 
a velocity of 0.1 to 1.0 °C/h (0.5±0.3). 67%, 65%, and 48% of the ICU consider infections, 
hypotension, and bleeding as a consequence of hypothermia which is of therapeutic 
relevance in only 25%, 22%, and 10% of the cases, respectively.
Conclusions: MTH can be easily performed in patients after cardiac arrest using low-
cost strategies. Centers which use MTH widely follow the recommendations of the ILCOR 
with respect to indications, timing of cooling, and re-warming. However, similar to a 
recent survey in the US, MTH is signiﬁcantly underused in German ICUs. More efforts 
are needed to promote this therapeutic option and hypothermia should be included into 
future advanced cardiovascular life support protocols.
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906-243 Sudden Cardiac Death in Athletes: Rates of 
Deﬁbrillation
Christine E. Lawless, Rachel Lampert, Brian Olshansky, DuPage Medical Group, 
Chicago, IL, Yale University, New Haven, CT
Background: Unlike the general population, the rates of successful deﬁbrillation from 
sudden cardiac death (SCD) are not known for the athletic population. There is reason to 
suspect that rates may be relatively low, perhaps due to type of underlying heart disease, 
or the intensity of the catecholamine release that occurs during athletics. Methods: To 
determine outcomes of resuscitation from SCD in the athletic population, we conducted 
an anonymous survey by mail to 1069 physicians who specialize in providing medical 
coverage for sporting events. Response rate was 468/1069 (43.8%), with 48/50 states 
represented. Fifteen (3.2%) of the 468 respondents reported 21 episodes of SCD in 
athletes while they were providing event medical coverage. Results: Athletes ranged 
in age from 15 to 74 years: six were ≤ 30 years old and 15 athletes were > 31 years old. 
Sports included: 5 marathon, 3 other running sports, 3 refereeing/ofﬁciating, 2 basketball, 
one badminton, one lacrosse, one softball, one swimming and 4 unreported sports. In 
the athletes over 30 years old, overall deﬁbrillation rate at the scene was 78%, and all 
survived to hospital discharge. In the athletes less than 30 years old, resuscitation tended 
to be prolonged, with 16.7 % (1/6) being deﬁbrillated at the scene. However, an additional 
2 young athletes were resuscitated during transport, for a survival to hospital discharge 
rate of 50% in the younger athlete. Automatic external deﬁbrillators (AEDs) were available 
on-site in 68% of the cases, and overall deﬁbrillation rate with its use was 68.4%. Of the 
athletes in whom return to play information is available, 78% chose to return to either 
the same or a different sport. Conclusions: SCD occurs in athletes of all ages, and 
appears to have higher rates of early successful deﬁbrillation in the athlete over 30 years 
of age. Younger athletes appeared to have very low rates of deﬁbrillation on the scene, 
but prolonged efforts in this group substantially improved their survival. This data is very 
preliminary, but is encouraging.
906-244 Use of Semiautomatic Deﬁbrillators by Minimally 
Trained Lay Persons in Cardiac Emergencies: Is It 
Safe?
Cyrill J. Morger, Raymond Gaillet, Martin von Planta, Hugo Saner, University Hospital 
Bern, Bern, Switzerland
Background: Lay persons get optical and acoustic instructions when using a 
semiautomatic deﬁbrillator (AED). Are these minimally trained teams able to identify a 
cardiac arrest reliably and to operate an AED correctly?
Methods: Since July 2000 in a pilot study in the area of Olten (population of 82’000) lay 
persons (more than 400 ﬁre ﬁghters and samaritans) intervened as ﬁrst responders in 
cardiac emergencies. The training in cardiopulmonary resuscitation (CPR) and use of 
AED lasted 4 hours. The teams are dispatched simultaneously to the ambulances. All 
emergency medical system (EMS) protocols and event registrations of the AEDs between 
January 1st 2001 and December 31 2004 were analyzed and all actions performed by 
the lay persons compared with the evaluations of the professional paramedics and the 
ﬁnal diagnosis.
Results: 801 interventions were included. In 376 patients (47%) the AED was used for 
monitoring or deﬁbrillation. 169 patients (21%) were found in cardiac arrest (42 VF, 15 
PEA, 112 AS). In 130 cases (16%) resuscitation attempts were initiated on site, in 39 
cases (5%) the rescuers abstained from starting CPR. These decisions were assessed 
as appropriate by the later arriving professionals in 36 out of 39 cases. However, 3 of 
these 39 patients were found with PEA. The ﬁrst responders didn’t start CPR because 
of misinterpretation of a visible electrical activity on the AED. All these 3 patients had 
a pacemaker and the later arriving paramedics performed a delayed, unsuccessful 
resuscitation attempt. In contrast to these 3 incorrect assessments, all 42 patients (5%) 
in VF or pulseless VT were deﬁbrillated, 13 successfully. There were no major handling 
errors with negative effects on the patients.
Conclusions: A minimal training of ﬁrst responders during 4 hours allows for a correct 
identiﬁcation of a cardiac arrest in 98% of the interventions. In only 3 cases (2%) with 
PEA the situation was misinterpreted by the lay persons due to ECG-misinterpretation of 
pacemaker activity. These results have to be considered in the organisation of duration 
and contents of early deﬁbrillation courses.
*Study supported by the Swiss Heart foundation and the Olten Heart foundation.
906-245 Cooling Blankets Are Effective for Achieving 
Therapeutic Hypothermia and Improving Survival-to-
discharge Following Cardiac Arrest for Patients With All 
Arrhythmia Types
Creighton Don, Francis Kim, Leonard Cobb, Michael Copass, University of Washington, 
Seattle, WA
Background: Mild therapeutic hypothermia (TH) has been advocated for patients with out-
of-hospital cardiac arrest, as a means of improving survival and neurologic outcomes.
Goal: To evaluate the efﬁcacy of cooling blankets on survival of cardiac arrest patients.
Methods: A retrospective analysis of adults with out-of-hospital cardiac arrest was 
performed on patients presenting between 11/01 and 12/04. Patients with VF, PEA, or 
asystole were included. Exclusion criteria were an admission temperature <30oC and 
death prior to admission to the hospital. Patients admitted between 11/01 and 11/02 were 
not cooled. Patients admitted between 12/02 and 12/04 were cooled to a temperature 
of 32o to 34oC using a cooling blanket. Baseline demographic data was recorded and 
hourly temperatures were gathered for the ﬁrst 24 hours. Survival to hospital discharge 
was noted. A ﬁrst-responder database was used to determine location of the arrest, time 
from arrest to arrival at the hospital, presenting cardiac rhythm, and whether bystander 
CPR was performed.
Results: Of 271 patients presenting with cardiac arrest, 190 underwent TH. Baseline 
characteristics were similar between the two groups with the exception of arrhythmia type. 
The patients receiving active cooling achieved TH for 6.7 hours on average, compared 
to 0.8 hours in the non-cooled group (p<0.000). The actively cooled patients were in the 
therapeutic range for 44% of the ﬁrst 24 hours, compared to 17% among the non-cooled 
patients (p<0.000). There was a trend toward increased survival among patients receiving 
TH (40.5% v. 29.6% p=0.101). Among the patients admitted to the hospital, the univariate 
predictors of survival were VF, witnessed arrest, bystander CPR, arrest in a public place, 
arrival of ﬁrst responders < 4 minutes, and arrival at hospital < 40 minutes, and achieving 
TH for >5 hours. The only factors independently associated with survival were VF, 
witnessed arrest, arrival in hospital < 40 minutes, and achieving TH for > 5 hours.
Discussion: Among patients with out-of-hospital cardiac arrest of all arrhythmia types, 
cooling blankets are an effective means of achieving TH and are associated with an 
improved trend in survival to hospital discharge.
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907-246 Long-Term Safety of Intramyocardial Injection of 
Autologous Bone Marrow Cells for Severe Ischemic 
Heart Disease
Luis Henrique W. Gowdak, Isolmar T. Schettert, Marcos Rienzo, Marcelo L. C. Vieira, 
Carlos Eduardo Rochitte, Cesar J. Grupi, Protasio L. da Luz, Luiz Antonio M. Cesar, 
Jose Eduardo Krieger, Jose Antonio F. Ramires, Sergio A. de Oliveira, Heart Institute 
(InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil
Background: Although adult bone marrow cells (BMC) have been explored therapeutically 
in clinical trials, there is still concerns about the long-term safety of this strategy. We 
investigated the long-tem safety of stem cell therapy in patients (pt) undergoing incomplete 
CABG for severe coronary artery disease (CAD).
Methods: 34 pt (4 women), 61±7 years-old, with limiting angina and 3-vessel CAD, not 
optimal candidates for complete CABG due to the extension of the disease were enrolled. 
Two pt died from acute coronary sydrome during baseline evaluation. BMC were obtained 
immediately prior to surgery, and the lymphomonocytic fraction separated by density 
gradient centrifugation. During surgery, 5mL containing approximately 13±3x107 BMC 
(CD34+=1.30±0.40%) were delivered by multiple injections in non-grafted areas of ischemic 
myocardium. Before (B) and during the ﬁrst year (at 1, 3, 6, and 12 months) after surgery, 
pt underwent laboratory tests, 24-hour ECG monitoring, echocardiogram, and cardiac 
magnetic resonance imaging (MRI). Thereafter, pt were assessed on a clinical basis only.
Results: Follow-up varied from 1 to 39 months (median=15). Injected segments included 
the inferior (n=18), anterior (n=11) and lateral (n=3) walls. Two pt died in-hospital from 
cardiogenic shock. Except for a mild and transient anemia at 1 month after surgery, 
laboratory tests were within normal ranges; during the ﬁrst year, no pt presented complex 
arrhythmias or increased ectopic beats compared to baseline (P=ns), and no structural 
abnormalities were seen either by echo or MRI, including pericardial effusion, ﬁbrosis, 
or growing of non-cardiac tissues. Clinically, there was a reduction in functional class 
of angina from 3.3±0.5 (B) to 1.2±0.5 (12M). After the ﬁrst year, non-fatal complications 
included: non-ST elevation MI (n=1), ST-elevation MI+ventricular arrhythmia (n=1), and 
gastric neoplasia (n=1). Another two pt died from septic shock.
Conclusions: In the long-term, intramyocardial injection of autologous BMC combined 
to CABG appears to be safe. Concerns with arrhythmias, structural abnormalities or 
uncontrolled vascular growth after cell therapy were not conﬁrmed in this safety trial.
907-247 Genomic Association of Graft Failure of the Left Internal 
Thoracic Artery for Myocardial Revascularization
Michael S. Chen, Gang Jia, May M. Luke, Dongming Liu, Eric J. Topol, Bruce W. Lytle, 
Stephen G. Ellis, Cleveland Clinic Foundation, Cleveland, OH, Celera Diagnostics, 
Alameda, CA
Background: In rare cases of failure of the left internal thoracic artery-left anterior 
descending (LITA-LAD) graft after surgery, genetics may play a role. We aimed to 
determine whether LITA-LAD durability is associated with particular single nucleotide 
polymorphisms (SNPs). 
Methods: In the Cleveland Clinic Genebank, blood is obtained during coronary 
angiography (performed for clinical indications). Genotyping analysis of 168 SNPs was 
performed from 150 vascular biology genes in 230 patients with LITA-LAD grafts. Graft 
patency (stenosis < 70% without revascularization) at 5 and 10 years was assessed. 
Primary outcome was association of SNPs with graft patency.
Results: Median age was 63, with 74% male and 36% diabetics. Of 230 subjects, 30 
subjects had a stenotic/occluded graft at 5 years, 11 had a patent LITA-LAD at 5 years 
that was stenotic/occluded at 10 years, and the remainder had a patent LITA-LAD. After 
multivariate analysis, 3 SNPs had a strongly signiﬁcant (p < 0.01) adjusted association 
with LITA-LAD graft failure and 5 SNPs had a strongly signiﬁcant adjusted association 
with graft patency (Table).
Conclusions: We have identiﬁed 3 SNPs associated with a higher rate of LITA-LAD 
failure and 5 SNPs associated with higher LITA-LAD patency. Our results suggest that 
cellular proliferation, inﬂammation, coagulation factors and lipid metabolism all contribute 
to LITA-LAD graft durability. Further studies into mechanisms by which these genetic 
variants may affect graft patency is warranted.
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Gene Function SNP type
F5 Encodes coagulation factor V Missense
VTN Promotes cell adhesion and spreading Missense
MTP Encodes microsomal triglyceride transfer protein Missense
MTHFR Associated with homocysteine metabolism Missense
MMP9 Breakdown of extracellular matrix by degrading collagen Missense
GAB3 Involved with macrophage differentiation Missense
ITGAL
Encodes the integrin alpha L chain which forms the integrin 
lymphocyte function-associated antigen-1 (LFA-1). LFA-1 
plays a central role in leukocyte intercellular adhesion
Missense
IGF1R Binds insulin-like growth factor and can function as an anti-apoptotic agent by enhancing cell survival Missense
907-248 Stem Cell Therapy Increases Myocardial Perfusion 
in Patients Undergoing Incomplete Coronary Artery 
Bypass Surgery
Luis Henrique W. Gowdak, Isolmar T. Schettert, Carlos Eduardo Rochitte, Marcos 
Rienzo, Protasio L. da Luz, Luiz Antonio M. Cesar, Jose Eduardo Krieger, Jose Antonio 
F. Ramires, Sergio A. de Oliveira, Heart Institute (InCor), University of Sao Paulo 
Medical School, Sao Paulo, Brazil
Background: Adult bone marrow cells (BMC) have recently been tested as a novel 
therapeutic strategy for patients (pt) with severe coronary artery disease (CAD). We 
tested the hypothesis that intramyocardial injection of autologous BMC may help increase 
myocardial perfusion in pt undergoing incomplete CABG.
Methods: 21 pt (19 men), 59±7 years old, with limiting angina and 3-vessel CAD, not 
amenable to complete CABG due to the diffuseness of the disease were enrolled. 
BMC were obtained immediately prior to surgery, and the lymphomonocytic fraction 
separated by density gradient centrifugation. During surgery, 5mL containing 13±3x107 
BMC (CD34+ = 1.3±0.4%) were delivered by multiple injections in the ischemic non-
grafted myocardium. Myocardial perfusion (at rest and during pharmacological stress 
with adenosine) was assessed by magnetic resonance imaging (MRI) at baseline and 
1 month after surgery. Each segment was blindly graded as normal (0), or presenting 
mild (1) or severe (2) perfusional defect, thus allowing the determination of an ischemic 
score. The number of affected vessels (stenosis ≥70%) and the number of bypassed 
vessels were recorded. The increase in myocardial perfusion was compared between pt 
with >50% (Group A, n=10) with that of pt with ≤50% (Group B, n=11) of affected vessels 
successfully treated.
Results: Injected myocardial segments included the inferior (n=12), anterior (n=7), and 
lateral (n=2) walls. No complications or deaths occurred. The number of treated vessels 
was signiﬁcantly smaller than the number of affected vessels (2.3±0.8 vs 4.0±1.00, 
respectively; P<.0001), as expected for an incomplete CABG. One month after surgery, 
cardiac MRI showed an overall reduction (%) in the ischemic score of 75.6±3.0 compared 
to baseline (P=.002). There was a similar reduction (%) in the ischemic score of pt in 
Group A (72.5±3.2), compared to pt in Group B (78.1±3.2) (P=.80).
Conclusions: Intramyocardial injection of autologous BMC may help increase myocardial 
perfusion in pt undergoing incomplete CABG, even in those with fewer affected vessels 
successfully “bypassed”. This strategy may be an adjunctive therapy for patients suffering 
from a more advanced (diffuse) CAD.
907-249 Statins, Saphenous Vein Endothelial Function, and 
C-Reactive Protein in Patients With Coronary Artery 
Disease
Aziz U. Momin, Narbeh Melikian, Stephen Wheatcroft, David Grieve, Lindsay John, 
Ahmad El-Gamel, Michael Marrinan, Jatin Desai, Catherine Driver, Roy Sherwood, Ajay 
Shah, Mark Kearney, Guy’s King’s and St Thomas’ School of Medicine, King’s College, 
London, United Kingdom, Kings College Hospital, London, United Kingdom
Background: To investigate the association between C-Reactive Protein (CRP) and 
saphenous vein (SV) endothelial function in patients treated with statins undergoing 
coronary artery bypass surgery.
Methods and Results: 76 patients with optimal LDL cholesterol levels (≤61.8mg/dL) 
secondary to regular treatment with a minimum of simvastatin 40mg were recruited. 
26% of patients had CRP levels in the ‘high risk’ range (>3.0mg/L). Acetylcholine (ACh) 
induced relaxation was assessed ex-vivo in SV rings. There was a negative linear 
correlation between ACh-induced venous relaxation and CRP (r= -0.30, p=0.02), and 
waist circumference (r= -0.21, p=0.03). In a multivariate regression model CRP (p=0.02) 
was the only independent predictor of ACh-induced venous relaxation. In turn correlates of 
CRP were assessed. There was a correlation between CRP and coronary atherosclerotic 
burden (r=0.46, p<0.0001), BMI (r=0.26, p=0.03), glucose (r=0.31, p=0.01) and waist 
circumference (r=0.29, p=0.01). Using multivariate analysis coronary atherosclerotic 
burden (p<0.0001) was the only independent predictor of CRP.
Conclusions: In patients with extensive coronary artery disease, treated with stains to 
achieve optimal LDL-cholesterol levels, a sizable proportion of patients had CRP levels 
within the ‘high risk’ range. CRP was the only independent predictor of impaired SV 
endothelial function in the entire patient group.
 
907-250 Transmyocardial Laser Revascularization Combined 
With Stem Cell Therapy Increases Myocardial Perfusion 
and Functional Capacity in Patients With Refractory 
Angina
Luis Henrique W. Gowdak, Isolmar T. Schettert, Marcos Rienzo, Carlos Eduardo 
Rochitte, Protasio L. da Luz, Luiz Antonio M. Cesar, Luiz Augusto F. Lisboa, Luis Alberto 
O. Dallan, Jose Eduardo Krieger, Jose Antonio F. Ramires, Sergio A. de Oliveira, Heart 
Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil
Background: Transmyocardial laser revascularization (TMLR) is a therapeutic option 
for patients (pt) with severe ischemic heart disease (IHD) not amenable to conventional 
myocardial revascularization, either by CABG or PCI. Recently, cell therapy with 
autologous bone marrow cells (BMC) has been tested in clinical trials for severe IHD. 
We tested the hypothesis that TMLR combined with intramyocardial injection of BMC is 
safe, and may help increase the functional capacity of pt with refractory angina, despite 
maximally tolerated medical therapy.
Methods: 8 pt (7 men), 64±4 years old, with refractory angina for multivessel disease 
and previous myocardial revascularization procedures (CABG/PCI), not candidates for 
another procedure due to the extension of the disease were enrolled. TMLR (8±2 laser 
drills) was performed via a limited thoracotomy using a commercially available CO2 Heart 
Laser System. BMC were obtained immediately prior to surgery, and the lymphomonocytic 
fraction separated by density gradient centrifugation. During surgery, 5mL containing 
approximately 16±2x107 BMC (CD34+=1.7±0.4%) were delivered by multiple injections 
in the ischemic myocardium. Before (B) and 6 months (6M) after the procedure, pt 
underwent clinical evaluation, and myocardial perfusion assessment by cardiac magnetic 
resonance imaging (MRI) during pharmacological stress with adenosine.
Results: Injected segments (n=12) with BMC included the anterior (n=5), lateral (n=4), 
and inferior (n=3) walls. No major complications or deaths occurred during the procedure. 
There was a reduction in the ischemic score as assessed by MRI from 1.56±0.09 (B) to 
0.93±0.10 (6M) (P=.01). Clinically, there was a reduction in functional class of angina from 
3.6±0.2 (B) to 1.4±0.2 (6M) (P<.0001).
Conclusions: In this initial experience, the combined strategy of TMLR plus cell therapy 
appeared to be safe, and may have synergistically acted to reduce myocardial ischemia, 
with clinically relevant improvement in functional capacity. Provided these data are 
conﬁrmed in a larger, randomized, controlled trial with longer follow-up, this strategy could 
be used as a novel therapeutic option for treating pt with refractory angina.
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916-251 Paradoxical Increased Post Ischemic Stroke Mortality 
Among Whites in the Veteran Population:Does Access 
to Care Inﬂuence Outcomes?
Masoor Kamalesh, William Tierney, Indiana University Medical Center, Indianapolis, IN
Background : Excess mortality following ischemic stroke (IS) is higher among blacks. We 
sought to investigate the possibility of access to care leading to racial differences in post 
IS mortality by analyzing IS mortality in large cohort of veteran subjects.
Methods: The Patient Treatment File was used to identify all patients discharged from 
any Veterans hospital between 10/90 and 9/97 with a diagnosis of IS (ICD-9-CM codes 
434, 436) listed as primary discharge diagnosis.Demographic, morbidity and mortality 
data were recorded for each patient. Discharge diagnoses 2 through 10 from the index 
admission were used to identify co-morbidities and construct the Charlson index.
Results: Of 55,094 patients identiﬁed, 34,579 (62.7%) were white (W) and 11,530 
(20.9%) were (B). Charlson index was similar between the groups (53.7 vs 54.7, p=NS). 
One year mortality was higher for W (13.1% vs 12.2%, p=0.009). On multivariate analysis, 
being W was predictive of higher mortality with a hazard ratio of 1.063 (95% CI 1.024-
1.103). From K-M estimates, the estimated probability that W will survive for 1 year or 
more is 0.864 (SE = 0.00188) while blacks is 0.874 (SE = 0.00316). The log-rank test 
showed that W have lower long term survival times than B (p < 0.001).
Conclusion: Despite having similar validated predictors of mortality risk (the Charlson 
index) post IS mortality was lower in B in the veterans affair hospitals. This data sheds 
new light on possible effects of equal access to care in terms of long term prognosis 
after acute IS.
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916-252 Cardiovascular Risk Factors and Events in the Lumbee 
Native Americans of North Carolina
Druenell E. Linton, Duke University Medicial Center, Durham, NC
Background: Native Americans have higher rates of cardiovascular disease (CVD) than 
the general population. The Lumbee Tribe of Robeson County, North Carolina (NC) is the 
second largest tribe east of the Mississippi. We sought to investigate the prevalence of 
CVD risk factors and CVD event rates in Lumbees with coronary artery disease (CAD).
Methods: Patients found to have CAD on cardiac catheterization who self-identiﬁed as 
Native Americans, and who reside in Robeson County of Lumbee tribal areas (determined 
by zip codes), were identiﬁed from the Duke Databank of >130,000 patients undergoing 
cardiac procedures. A randomly selected comparison group of non-Lumbee NC patients 
found to have CAD on cardiac catheterization was also identiﬁed in a 3:1 ratio. Baseline 
characteristics were compared. Adjusted multivariable Cox models were used to compare 
all-cause mortality and individual and composite endpoints of CVD death, myocardial 
infarction (MI) and repeat revascularization.
Results: 920 Lumbees and 2763 non-Lumbees were identiﬁed. Baseline characteristics 
revealed Lumbees presented at a younger age (p<0.0001, median age 60 vs 64 years, 
respectively) and were more often female (p<0.001, 41.7% vs 35.0%). Furthermore, 
Lumbees had a higher prevalence of hypertension (p<0.0001, 70.9% vs 62.5%), 
peripheral vascular disease (p=0.003, 13.9% vs 10.1%), diabetes mellitus (p<0.0001, 
37.6% vs 28.1%), smoking (p=0.02, 62.2% vs 57.5%), prior MI (p<0.0001, 60.6% vs 
49.9%), family history of CAD (p<0.0001, 51.7% vs 38.8%); and higher body mass indices 
(p<0.0001, median 29.0 vs 27.5), prevalence of metabolic syndrome (p=0.006, 45% vs 
39.7%), and rates of three-vessel CAD (p<0.0001, 41.6% vs 33.1%). In adjusted models, 
Lumbees had similar all-cause mortality at nine years of follow-up, but higher rates of 
non-fatal MI (p=0.01) and lower rates of repeat revascularization (p<0.0001) compared 
with non-Lumbees.
Conclusions: Lumbee Native Americans with CAD have a higher burden of CVD risk 
factors, and higher rates of non-fatal MI on follow-up, despite similar all-cause mortality 
and lower rates of repeat revascularization, even after adjustment for risk factors. Further 
studies are warranted.
916-253 Risk Assessment and Stratiﬁcation for Future Cardiac 
Events in Patients Admitted With Acute Coronary 
Syndrome Using a Novel Critical Pathway and Its 
Validation by Framingham Risk Score
Emad F. Aziz, Sripal Bangalore, Dan Musat, Ashraf Fawzy, Raffay Khan, Deborah 
Tormey, Olivier Frankenberger, Eyal Herzog, St. Luke’s-Roosevelt Hospital Center, New 
York City, NY
Background: We have developed a novel pathway for management of patients with 
Acute Coronary Syndrome. The pathway has been designed with the acronym of PAIN 
(Priority Risk-traditionally equivalent to ST-elevation MI, Advanced Risk, Intermediate 
Risk, and Negative/Low Risk), that reﬂects patients most immediate risk stratiﬁcation 
upon admission. Our objective was to compare the patient risk stratiﬁcation upon 
admission using the PAIN pathway to the Framingham Risk Score.
Methods: This is a prospective study conducted at St. Luke’s-Roosevelt Hospital Center in 
New York City. 269 adult patients admitted to the hospital from Sept., 2004, to Feb., 2005, 
with chest pain were enrolled into our chest pain pathway. We risk stratiﬁed all patients 
according to the PAIN pathway and treated them accordingly. Mean risk factors for patients 
in the PAIN pathway arm was compared with the Framingham risk score (FRS). 
Results: The study population consisted of 153 men (56.9 %) with a mean age 56.78 ± 
14.79 years and 116 women (43.1%) with mean age 64.53 ± 16.36 years. On initial risk 
stratiﬁcation using the PAIN pathway, Priority patients had 1.73 traditional risk factors 
vs. the Intermediate patients with 2.9 risk factors, (P<0.001). Using the Framingham risk 
score model, Priority patients had a score of 10.83 (22.24%) vs. Intermediate patients 
with a score of 14.02 (28.78%), P<0.001. In Risk stratifying the patients using the PAIN 
pathway, women had more risk factors than men (2.36 ± 1.91 vs 2.01 ± 1.11), P<0.001, 
which translates to a higher FRS in women compared to men (11.54 ± 7.47 vs 12.83 ± 
10.11), P<0.001. Also Hispanic patients had the highest risk score when compared to 
African-American and Caucasian (2.38 ± 1.36, 2.21 ± 1.24, 1.82 ± 1.39), P<0.001.
Conclusions: In this pilot study; surprisingly patients deﬁned as Intermediate risk 
according to our PAIN pathway had more risk factors which correlates with a higher risk 
for future cardiac events as calculated from the Framingham Risk Score. The patients 
at risk were most likely to be women and Hispanics. This is the population that would 
beneﬁt the most from a more aggressive intervention for risk factor modiﬁcation in order 
to prevent future cardiovascular events.
916-254 The Effects of the Frequency of Exercise-Based Cardiac 
Rehabilitation on Glucose Tolerance and Lipid Levels in 
Patients With Acute Coronary Syndrome
Fumiyoshi Tsunoda, Shinji Koba, Yoshihisa Ban, Yoshinori Fujita, Takashi Katagiri, 
Showa University, Tokyo, Japan
Background: Postprandial hyperglycemia and/or glucose intolerance play important 
roles in progression of coronary heart disease. Recent evidence suggests glucose 
intolerance is common in patients with acute coronary syndrome (ACS) and previously 
undiagnosed diabetes. It remains controversial how exercise-based cardiac rehabilitation 
(CR) can improve abnormal glucose metabolism.
Methods: A 75g-oral glucose tolerance test was performed on 52 ACS patients without 
overt diabetes at discharge and 6 months later. Subjects were classiﬁed into 3 groups: 
normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and preclinical 
diabetes (pDM) according to the criteria of American Diabetes Association. We deﬁned 
improved cases according to the following criteria: NGT at 6 month and/or reduction of 
2-hour glucose concentration at 6 month compared with those at baseline. The data were 
compared among three groups of patients classiﬁed based on the frequency of CR which 
was performed in a supervised exercise regimen using a bicycle ergometer at an intensity 
of anaerobic threshold for 30 minutes: none, low-frequency (34+/-11 times) and high-
frequency of CR (58+/-4 times).
Results: IGT and pDM were found in as many as 56% and 21% at baseline even 
thought their HbA1c level remains in the normal range (5.3±0.5%), while those were 
46% and 12% at 6 month, in respectively. Compared with the baseline, the incidence 
of pDM rose up 36% from 18% in 11 none-CR whereas those of NGT increased 44% 
from 32% in 25 low-frequency group and 44% from 13% in 16 high-frequency group, 
although BMI, fasting glucose, insulin and HbA1c levels were comparable at baseline and 
6 month among three groups. The HDL-cholesterol increased signiﬁcantly in CR group. 
The number of improved cases differed signiﬁcantly among the 3 groups (54%, 80%, and 
94% in none-CR, low-frequency, and high-frequency, in respectively, p<0.05) without any 
changes in insulinogenic index.
Conclusions: These suggest that frequent CR ameliorate not insulin secretion but insulin 
sensitivity and glucose intolerance in patients with ACS, which may lead to beneﬁcial 
effects on the secondary prevention.
916-255 Reappraisal of Conventional Coronary Heart Disease 
Risk Factors using Novel Statistical Approaches: A 
Critical Re-analysis of Framingham Data
Mohammed Yousufuddin, Heather Ratliff, Jeremy Stapleton, Hamid Deleri, Gregory 
Clarke, Gregory Rosencrance, Duolao Wang, West Virginia University-Charleston 
Division, Charleston, WV, London School of Hygiene and Tropical Medicine, London, 
United Kingdom
Background: Studies investigating the relationship between risk factors and coronary 
vascular events (CVE) used conventional analytic methods, which have methodological 
issues of risk factor coding, model selection and uncertainty.
Methods: We used Framingham Heart Study data on Caucasian population aged, 50 to 
79Y on their 11th visit. Using Bayesian model averaging approach (BMA) and alternating 
conditional expectation algorithm (ACEA), we examined the relationship between 
CVE and risk factors: age, sex, systolic (SBP) and diastolic blood pressures (DBP) , 
total cholesterol Chol), number of cigarette smoked per day (CSM), body mass index 
(BMI), glucose intolerance (GLI), and hypertension treatment and compared results with 
conventional analytic methods.
Results: Of 1957 subjects, 493 developed CVE. CVE increases linearly with SBP but 
with age, until 78 years, and with Chol between 6 and 6.8 mmol/l when the risk became 
plateau. Relationship between CSM or BMI and CVE was not linear. When BMA and 
ACEA were compared with conventional statistical method we observed improvements in 
a) predictive performance (7%) of ﬁve of the 9 predictors and b) relationship between risk 
factors (Age, Chol, CSM) and CVE.
Conclusions: Compared with conventional methods, BMA and ACEA statistical 
tools overcome inherent uncertainty of model seclection and chose most appropriate 
transformation and potentially provide improved biological relationship between risk 
factors and CVE.
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916-256 Reduction of Atherothrombosis for Continued Health 
(REACH) Registry Results: 1-Year Cardiovascular 
Event Rates in a Global Contemporary Registry of Over 
68,000 outpatients with Atherothrombosis
P Gabriel Steg, Deepak L. Bhatt, Peter WF Wilson, E Magnus Ohman, Joachim Rother, 
Chiau-Suong Liau, Alan T. Hirsch, Jean-Louis Mas, Shinya Goto, on behalf of the 
REACH Registry Investigators, Hopital Bichat-Claude Bernard, Paris, France
Objectives: Assess contemporary cardiovascular event rates in stable outpatients (pts) 
with or at risk of atherothrombotic disease.
Methods: The REACH Registry, an international, prospective, observational registry, 
recruited more than 68,000 pts at high risk of atherothrombotic events or with established 
atherothrombosis (documented coronary artery [CAD], cerebrovascular [CVD] or 
peripheral arterial disease [PAD]) from 44 countries. One-year follow-up data were 
collected to determine overall real-world risk in this population.
Results: As of August 1st, 85% of pts were followed-up, with visits ongoing. Initial results 
demonstrate relatively high annual event rates in this stable pt population, with the highest 
rates recorded in patients with PAD (Table 1). Overall, 13% of patients experienced a 
major cardiovascular event after 1 year. Patients with established disease (CAD, CVD or 
PAD) had a high incidence of major adverse cardiac events (MACE) ranging from 15% 
to 22% (Table 1). The number of disease locations had a major impact on event rates, 
ranging from 5% in pts with risk factors (RFs) only to 13, 22 and 27% for pts with 1, 2 or 
3 disease locations respectively (p<0.001). Event rates and RFs for recurrences will be 
analyzed and presented by geographic location, pt type, and physician specialty.
Conclusions: In this large, global registry, stable outpatients with atherothrombosis 
experience high annual cardiovascular event rates. Multiple disease locations markedly 
















Cardiovascular death (%) 1.62 0.65 1.91 2.10 2.83
Non-fatal myocardial infarction (%) 1.28 0.77 1.62 1.22 1.62
Non-fatal stroke (%) 1.68 0.78 1.37 3.98 1.75
CV death/myocardial infarction/stroke (%) 4.37 2.07 4.69 6.96 5.83
MACE: CV death/myocardial infarction/stroke/ 
hospitalization for ischemic events (%) * 13.06 5.37 15.37 15.33 22.41
*: TIA, unstable angina, other ischemic arterial event including worsening of PAD
 
916-257 Physical Functioning at Baseline Is a Strong 
Independent Predictor of Long-Term Mortality After 
Myocardial Infarction
Kapil Parakh, Brett D. Thombs, James A. Fauerbach, David E. Bush, Roy C. Ziegelstein, 
Johns Hopkins University School of Medicine, Bayview Medical Center, Baltimore, MD, 
Johns Hopkins University School of Psychiatry, Bayview Medical Center, Baltimore, MD
Background: Physical functioning, as measured by the Short Form-36 (SF-36) Physical 
Composite Score (PCS) is a predictor of mortality in heart failure. The SF-36 has been 
shown to be a valid and reliable measure in patients with acute myocardial infarction (MI), 
but the utility of the PCS in predicting long-term mortality after MI is unknown.
Methods: The PCS was administered to patients admitted with a diagnosis of acute MI 
from July 1995 to December 1996 during their initial hospitalization. A cardiologist blind 
to the PCS evaluated clinical variables using standard criteria. All-cause mortality was 
assessed in July 2005 using the Social Security Death Index and hospital databases. The 
associations of PCS (higher scores = higher function) with traditional risk factors and with 
mortality were tested.
Results: A total of 284 patients were evaluated (57% men, mean age 64.8 ± 12.1 years). 
Hypertension (67%) and hyperlipidemia (62%) were common as were diabetes (36%) 
and prior MI (31%). Angioplasty was done in 10% of patients and 18% underwent bypass 
surgery. Baseline PCS was available in 273 of 284 patients enrolled. Higher PCS was 
seen in younger patients, men, and those with Q-wave MI. Lower PCS was seen in 
patients with hypertension, diabetes, previous MI, higher Killip class, renal insufﬁciency, 
and greater hospital length of stay. There were 32, 96, and 131 deaths at 1, 5, and 8 
years post-MI. Higher PCS was associated with lower mortality in Cox proportional 
hazards models at 1 year [HR=0.95 (0.92-0.97), p<0.01], 5 years [HR=0.96 (0.95-0.98), 
p<0.01], and 8 years [HR=0.97 (0.96-0.99), p<0.01]. This association was independent of 
age, left ventricular ejection fraction, Killip class, depression, living alone, diabetes, and 
treatment (bypass surgery, medications or angioplasty). PCS alone was a good predictor 
of mortality at 1 year, 5 and 8 years (area under receiver-operator curve 0.75, 0.70, 0.68 
respectively).
Conclusions: The Physical Composite Score of the SF-36 obtained during the initial 
hospitalization for acute MI is independently associated with increased long-term 
mortality. Including the SF-36 PCS in clinical assessments may improve risk stratiﬁcation 
in patients with acute MI.
916-258 Global Risk Factors and Treatment Intensity in Elderly 
Patients With Atherosclerosis: The Experience of the 
International REACH Registry
Alan T. Hirsch, Deepak L. Bhatt, Patrick E. McBride, E. Magnus Ohman, Kim A. Eagle, 
Chris P. Cannon, Rob Califf, Ph. Gabriel Steg, on behalf of the REACH Investigators, 
University of Minnesota School of Public Health, Minneapolis, MN, Minneapolis Heart 
Institute Foundation, Minneapolis, MN
Background: The elderly have a high prevalence of atherosclerotic risk factors and high 
ischemic event rates. Nevertheless, risk reduction treatment intensity has not been well 
described in an elderly international population. We hypothesized that risk factors would 
be highly prevalent, but less intensely treated in individuals 65 years or older.
Methods: The REACH (REduction of Atherothrombosis for Continued Health) Registry 
is an international, prospective, registry that recruited 67,888 patients, based on clinical 
disease and risk factors, from 44 countries from December 2003 to July 2004. Baseline 
risk factor, atherosclerotic disease prevalence, & treatment data were available for 43,860 
patients older than 65 years. Data were stratiﬁed by the following age categories: <65 yrs; 
66-75 yrs; 76-85 yrs; >85 yrs.
Results: Elderly patients in the REACH Registry were more likely to be female and 
Caucasian, less likely to be obese or current smokers, and less likely to have diabetes or 
hypercholesterolemia. The elderly were characterized by higher rates of cerebrovascular 
and PAD (but not coronary artery disease) than younger subjects [see data table].
Conclusions: Despite high rates of overt atherosclerosis and risk factors in the elderly, 
and the aging of the world population, use of diabetes, statin, and antiplatelet medications 
was less frequent than in younger patients. These data imply that barriers to use of more 
intensive risk reduction strategies in elderly patients should be identiﬁed.
Risk Factors and Treatment of the REACH Registry Participants Classiﬁed 
by Age
Age <65 years 65-75 years 76-85 years >85 years
N (N=23,959) (N=27,254) (N=14,987) (N=1,688)























Use of at least one diabetes 
medication 41.0% 42.4% 35.2% 26.6%
Use of at least one antihypertensive 90.2% 91.6% 92.2% 92.6%
Use of a statin 73.5% 69.4% 64.8% 53.1%
Use of antiplatelet medication 82.2% 77.7% 75.0% 75.3%
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916-259 Is the Female Advantage Lost Once Patients Have 
Established Atherothrombotic Disease
Kristen Migliaccio-Walle, Jaime Caro, Irina Proskorvosky, Khajak J. Ishak, Caro 
Research, Concord, MA
Background: The impact of atherothrombotic disease on survival in males is well 
documented; less so in females. We compared survival in women to men and the impact 
of additional events on life expectancy.
Methods: Health care records of Saskatchewan residents with coronary artery, 
cerebrovascular or peripheral arterial disease or conditions considered high risk for 
atherothrombotic illness diagnosed between 1990-95 were obtained. Medical history 
was available January 1980 - December 2002 or death. Mortality hazard functions 
were derived with piece-wise parametric regressions; time-dependent Cox proportional 
hazards were used to adjust for covariates; resulting survival curves were integrated to 
compare expected survival in males & females.
Results: Of 81,785 patients, 52.2% were male, mean age 70.9 yrs, 21.2% diabetic, previous 
MI 10.6%, stroke 7.7%, PAD 7.5%, 49.9% hypertensive, 19.6% hypercholesterolemic. 
Mean survival adjusting for all other factors remained consistently higher in women and a 
greater loss was predicted for female patients compared with their male counterparts due 
to further events (Non-Fatal MI, NF stroke, and combinations).
Conclusion: Women retain an advantage even after atherothrombotic is established. 
Prevention of further ischemic events can signiﬁcantly increase life expectancy and the 
impact among women is predicted to be greater for all event patterns. 
Life Expectancy Life-Years Lost
NFMI NFMIx2 NF stroke NFMI+NFST
Male
50 24.4 -8.48 -14.81 -12.21 -17.41
60 17.8 -6.23 -10.98 -8.98 -12.90
70 12.1 -4.20 -7.63 -6.02 -8.74
80 7.6 -2.57 -5.01 -3.67 -5.34
Female
50 27.9 -10.56 -16.12 -14.46 -19.32
60 21.0 -8.20 -12.39 -11.25 -14.90
70 14.8 -5.90 -8.96 -8.11 -10.58
80 9.7 -3.88 -6.14 -5.41 -6.84
 
916-260 National Improvements in the Recognition and 
Treatment of Patients at Increased Coronary Risk: The 
National Health and Nutrition Examination Survey, 1999 
- 2002
Michael W. Cullen, Ronald E. Gangnon, Patrick E. McBride, James H. Stein, Jon G. 
Keevil, University of Wisconsin Medical School, Madison, WI
Background: In 2001, the National Cholesterol Education Program Adult Treatment 
Panel III (ATP III) intensiﬁed the treatment targets for low-density lipoprotein cholesterol 
(LDL-C) and expanded the high-risk group to include individuals with diabetes mellitus 
and other coronary heart disease (CHD) risk equivalent conditions. This study describes 
changes before and after ATP III in the percentages of high-risk individuals (1) at optimal 
LDL-C levels and (2) untreated with LDL-C levels above treatment thresholds.
Methods: Subjects included 3,398 individuals age 20-79 years representing 161 
million Americans in the 1999-2000 National Health and Nutrition Examination Survey 
(NHANES) data set and 3,746 subjects representing 166 million Americans in the 2001-
2002 NHANES data set. CHD risk was determined per ATP III guidelines. Percentages of 
members in the high-risk groups of each NHANES data set were weighted to represent 
population estimates. Comparisons of percentages between the two surveys were based 
on standard errors adjusted for the complex survey design.
Results: High-risk subjects included 13.8% and 14.3% (p = 0.64) of subjects from each 
data set. Of all at high-risk, those with LDL-C < 100 mg/dL increased from 23% to 32% 
(p < 0.01). Those with LDL-C < 100 mg/dL increased from 27% to 41% (p < 0.05) in 
the high-risk subset with CHD and trended from 20% to 26% (p = 0.07) in the high-risk 
subset without CHD. The percentage of all high-risk individuals with LDL-C ≥ 130 mg/dL 
and not taking lipid-lowering medications (untreated) decreased from 36% to 27% (p < 
0.01). The percentage untreated decreased from 25% to 16% (p < 0.05) in the subset with 
CHD and from 44% to 33% (p < 0.01) in those without CHD. Of those with diabetes as 
their only high-risk criterion, the percentage with LDL-C < 100 mg/dL trended from 26% 
to 32% (p = 0.15), and those untreated with LDL-C ≥ 130 mg/dL increased from 38% to 
29% (p = 0.07).
Conclusions: The increased percentage of high-risk Americans at optimal LDL-C 
levels and the decreased percentage of untreated high-risk individuals suggest national 
improvements in the recognition and treatment of patients at increased CHD risk. 
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927-215 Frequency of Angina Pectoris in Patients With Diabetes 
Mellitus Compared to Non-Diabetic Patients: Clarifying 
an Old Myth
Rainer Zbinden, Pascal Meier, Ursula Wenger, Stefan Windecker, Bernhard Meier, 
Christian Seiler, University Hospital Bern, Bern, Switzerland
Background: According to general believe, diabetic patients have less angina pectoris 
during myocardial ischemia than non-diabetic patients (silent ischemia). However, this 
was never investigated systematically under conditions of equal coronary collateral ﬂow 
(CFI).
Methods: 432 patients were included in the study (100 women, 332 men), 108 diabetic 
patients and 324 non-diabetic patients. CFI was assessed invasively using a pressure- or 
Doppler-guide wire. Patients were asked to report any chest pain during a one minute 
coronary balloon occlusion and an intracoronary ECG (i.c. ECG) (derived from the 
guidewire) was recorded simultaneously. Silent ischemia was deﬁned as ST-elevation 
>0.1mV in the i.c. ECG without any chest pain during balloon occlusion. Each diabetic 
patient was matched for gender, age and CFI with three non-diabetic control patients.
Results: The two groups differed signiﬁcantly for high density lipoprotein and triglycerides. 
There was no difference in anti-anginal medication between the two groups.
CFI was identical in the two groups (diabetic patients and non-diabetic patients: 
0.21±0.12). In total, 66 (61%) of the diabetic patients and 216 (67%) of the non-diabetic 
control patients suffered from angina pectoris during the one minute balloon occlusion 
(p=0.34).
88 patients did not have any ST-segment changes in the i.c. ECG during the one minute 
balloon occlusion (24 (22%) diabetic and 64 (20%) non-diabetic patients; p=NS). CFI was 
signiﬁcantly higher in patients without i.c. ECG changes compared to patients with i.c. 
ECG changes (0.34±0.15 vs 0.17±0.08; p<0.0001).
22 (20%) diabetic and 57 (18%) non-diabetic patients had “true” silent ischemia (p=0.50). 
Univariate predictors for the occurrence of silent ischemia were symptoms at entry (e.g. 
dyspnoe/non-speciﬁc symptoms vs typical angina; p<0.0001) and history of a myocardial 
infarction (p=0.01).
Conclusion: Against general believe, diabetic patients do not have less angina pectoris 
during myocardial ischemia under conditions of equal coronary collateral ﬂow. A history of 
myocardial infarction and symptoms at entry are univariate predictors of silent ischemia.
927-216 Better Ventricular Function and Reduced Necrosis After 
Myocardial Ischemia/Reperfusion in Rabbits Treated 
With Ranolazine, an Inhibitor of the Late Sodium 
Current
Sharon L. Hale, Justin A. Leeka, Robert A. Kloner, Good Samaritan Hospital, Los 
Angeles, CA
Background: Ranolazine (Ran) is a selective inhibitor of late sodium current, and via this 
mechanism of action decreases sodium-dependent intracellular calcium overload during 
ischemia and reperfusion. Ran is known to reduce angina, but there is limited information 
on the effects of Ran in acute myocardial infarction. Therefore we tested its effects on LV 
function and infarct size after ischemia/reperfusion in the rabbit heart. 
Methods: Ten min before coronary artery occlusion (CAO), open-chest, anesthetized 
rabbits were randomly assigned to placebo (n=15) or Ran (2 mg/kg bolus plus 60 µg/
kg/min infusion, I.V.,n=15). After 60 min of CAO, hearts were reperfused for 3 hrs. LV 
function was assessed by left ventriculogram and by 2-D echocardiography at the end 
of reperfusion. Hemodynamics were monitored throughout. Necrosis was assessed by 
tetrazolium staining. 
Results: One hr of ischemia caused LV dysfunction associated with necrosis. However, 
at the end of the reperfusion period, rabbits treated with Ran had better global LV ejection 
fraction (0.42 ± 0.02 vs. 0.33 ± 0.02, p < 0.009) and stroke volume (1.04 ± 0.08 ml vs 
0.78 ± 0.07 ml, p< 0.02) compared with placebo treated animals (ventriculography). The 
percent of the LV wall circumference that was akinetic or dyskinetic was signiﬁcantly less 
in the Ran group: 23 ± 3% of the circumference vs. 34 ± 3% in placebo, p< 0.02. Regional 
ejection fraction, assessed by echo, was signiﬁcantly better in the treated group (0.48 
±.03 vs. 0.36± .04, p<0.02). In addition, Ran treatment reduced myocardial necrosis. The 
ischemic risk region was similar in both groups. However infarct size, as a percent of the 
risk region, was signiﬁcantly smaller in the treated group (44 ± 5 vs 57 ± 4% placebo, p< 
0.03). Ran provided these beneﬁts without alterations in hemodynamics. There were no 
differences between groups in heart rate, arterial pressure, LVEDP or maximum positive 
or negative dP/dt. 
Conclusions: The results of this study show that Ran provides protection during acute 
myocardial infarction in this in model of ischemia/reperfusion. Ran treatment led to better 
ejection fraction, stroke volume and less wall motion abnormality after reperfusion, and 
less myocardial necrosis.
ACC_2006_4_Myocardial AA.indd   169 1/4/06   5:13:49 PM



















927-217 The Long Acting Phosphodiesterase-5 Inhibitor 
Tadalaﬁl Reduces Myocardial Infarct Size
Casilde Sesti, Vince Florio, Robert A. Kloner, Heart Institute, Good Samaritan Hospital, 
Los Angeles, CA, Lilly ICOS LLC, Bothell, WA
Background: Patients with erectile dysfunction often have risk factors for coronary artery 
disease. Tadalaﬁl (T), a long-acting inhibitor of phosphodiesterase-5, is used for treatment of 
erectile dysfunction. There is little information regarding the effects of T on hemodynamics 
and no previous information on its effects in the setting of myocardial infarction. The aims 
of this study were to determine the effects of T under non-ischemic conditions, during an 
episode of myocardial ischemia and during ischemia and reperfusion.
Methods: Sprague Dawley rats received T or vehicle (10 mg/kg, by gastric gavage), 
2 hours prior to ﬁrst hemodynamic measures (no ischemia, n=12). A second protocol 
studied T during 30 minutes of myocardial ischemia induced by left coronary artery 
occlusion (n=11). A third protocol studied T’s effect on myocardial infarct size (30 minutes 
coronary occlusion plus 3 hours reperfusion, n=30).
Results: In non-ischemic animals T reduced mean arterial pressure (85 ± 4 mmHg 
control vs 70 ± 4 mmHg T; p=0.025) and had no effect on dP/dt or heart rate. In protocol 
2, during 30 minutes of ischemia, T did not signiﬁcantly affect heart rate, dP/dtmax (6015 ± 
363 mmHg/s control vs 5834 ± 635 mmHg/s T), dP/dt min (-3998 ± 481 mmHg/s control vs -
3276 ± 544 mmHg/s T) and there was a trend towards lower blood pressure in the T group. 
T increased ejection fraction (left ventricular angiography) (54 ± 2 % control vs 64 ± 3 % T; 
p=0.023) and decreased end-systolic volume (0.18 ± 0.02 ml control vs 0.12 ± 0.01 ml T; p 
= 0.011). In protocol 3 T signiﬁcantly reduced myocardial infarct size (triphenyltetrazolium 
chloride) from 54 ± 3 % of the risk zone to 42 ± 2 % of the risk zone (p=0.006), without 
affecting regional myocardial blood ﬂow in the central ischemic area (0.06 ± 0.02 ml/min/g 
control vs 0.05 ± 0.03 ml/min/g T). T decreased mean arterial pressure during occlusion 
(71 ± 4 mmHg control vs 65 ± 3 mmHg T at 30 minutes; p=0.049).
Conclusions: For the ﬁrst time, we show that the long-acting phosphodiesterase-5 
inhibitor, tadalaﬁl, was not only safe in the setting of myocardial infarction, but actually 
cardioprotective. Tadalaﬁl reduced afterload, improved ejection fraction and substantially 
reduced ischemic cell death.
927-218 A Novel Caspase Inhibitor, VX-166, Reduces Myocardial 
Infarction in the Rat
Julie Jones, Deborah A. Dawson, Peter Charlton, Vertex Pharmaceuticals (Europe) Ltd, 
Abingdon, United Kingdom
Background: The caspases, a family of cysteine proteases, are implicated in the 
pathophysiology of acute myocardial infarction (AMI) through their apoptotic and pro-
inﬂammatory actions. Commercially available caspase inhibitors such as zVAD.fmk reduce 
infarct size in animal models of AMI. However, such compounds are not ideally suited to 
clinical use due to their low potency and non-mechanism related toxicity. To address these 
issues we have developed VX-166 - a potent and selective, broad-spectrum irreversible 
inhibitor of the caspase family that inhibits both apoptosis and IL-1β production in vitro 
and has low toxicity in vivo.
Methods: The left anterior descending coronary artery of male Wistar rats was occluded 
for 0.5 h then reperfused for 24 h. VX-166 was administered by continuous intravenous 
infusion started 5 min before reperfusion. It was administered at 0 or 8 mg/kg/h (n=7-8 
per group) in study 1; and at 0, 2, 4 or 8 mg/kg/h (n=4 per group) in study 2. Infarcts were 
compared by Student’s unpaired t-test (study 1) or one-way ANOVA followed by Dunnett’s 
t-test (study 2).
Results: The area at risk did not differ signiﬁcantly (p>0.05) between the control and 
VX-166 groups in either experiment. In study 1, VX-166 signiﬁcantly (p=0.0003) reduced 
infarct size by 44% (infarcts as a percentage of the area at risk were 32.4 ± 2.4 and 18.1 ± 
1.4 for control and VX-166 respectively). In study 2, the 8 mg/kg/h dose again signiﬁcantly 
(p<0.01) reduced infarct, this time by 60%. There was no signiﬁcant reduction in infarct 
at the 2 lower doses of VX-166 (infarcts as a percentage of the area at risk were 33.5 ± 
2.4, 33.8 ± 3.9, 28.2 ± 2.5 and 13.3 ± 1.7 for control and VX-166 at 2, 4 and 8 mg/kg/h 
respectively).
Conclusion: VX-166 signiﬁcantly reduces myocardial infarction when dosed from the 
therapeutically relevant time point of 5 min before reperfusion. These results demonstrate 
the considerable potential of caspase inhibitors such as VX-166 in the treatment of AMI.
927-219 5-Fluorouracil Improves Postinfarct Left Ventricular 
Dysfunction due to Upregulated SDF-1, Mobilized CD34 
Positive Cells and Attenuated Fibrosis
Hiroaki Ushikoshi, Yu Misao, Takamasa Ohno, Yiwen Li, Ngin Cin Khai, Genzou 
Takemura, Shinya Minatoguchi, Takako Fujiwara, Hisayoshi Fujiwara, Gifu University, 
Gifu, Japan, Kyoto Women’s University, Kyoto, Japan
Background: We recently reported that some anticancer drugs improve left ventricular 
(LV) dysfunction following myocardial infarction (MI) in rabbit. However the detailed 
mechanism remains unknown. Here we aimed to elucidate the beneﬁcial effects of 5-
ﬂuorouracil (5FU) using mouse model in vitro and in vivo. 
Methods: (1) In vitro experiments: Primary cultured ventricular cardiomyocytes and 
cardiac ﬁbroblasts were incubated in the presence or absence of 5FU, and cell damage 
and growth were evaluated. (2) In vivo experiments: MI model was created by permanent 
coronary occlusion. On the next day after MI, 5FU (100 mg/kg) or saline (control) 
were injected intraperitoneally. Cardiac function, histological changes and chemokine 
expression were evaluated. For assessment of circulating CD34+ cells, FACS analysis 
was performed after 5FU treatment. 
Results: (1) 5FU inhibited cardiac ﬁbroblast proliferation in a dose-dependent manner, 
however 5FU had no remarkable toxicity on cardiomyocytes in vitro. (2) 5FU increased 
peripheral CD34+ cells (5FU: 30.5 ± 5.5 /µl vs. control (C): 13.2 ± 7.1 /µl, p < 0.05) 
without suppression of white blood cells. 5FU also reduced MI area (5FU: 27.9 ± 4.3% 
vs. C: 38.6 ± 10.6%, p < 0.05) at one week after MI, improved cardiac function (by LVEF; 
5FU: 42.9 ± 6.4% vs. C: 31.3 ± 6.2%, p < 0.01), and decreased heart weight (HW) (by 
HW /body weight; 5FU: 5.96 ± 0.65 vs. C: 7.67 ± 1.03, p < 0.01) at four weeks after MI. 
Histological ﬁndings showed an enhancement of angiogenesis (by capillary density; 5FU: 
15.2 ± 4.5 /High Power Field (HPF) vs. C: 8.7 ± 2.6 / HPF, p < 0.01) at the border area, a 
decreased ﬁbrosis area (5FU: 18.0 ± 5.9% vs. C: 25.7 ± 8.1%, p < 0.05), and decreased 
Ki-67 positive cells in the MI area (5FU: 3.1 ± 1.1 /HPF vs. C: 9.0 ± 3.9 /HPF, p < 0.01). 
Finally, immunoblotting revealed upregulated SDF-1/CXCR4 axis and ANP in the 5FU-
treated hearts. 
Conclusions: Upregulation of SDF-1 and ANP, mobilization of CD34+ cells, acceleration 
of angiogenesis, and attenuation of ﬁbrosis may play important roles in the beneﬁcial 
effects of 5FU after MI. These ﬁndings suggest that 5FU is novel indication for the MI 
heart as well as cancer chemotherapy.
927-220 NECA at Reperfusion Limits Infarction and Inhibits 
Formation of the Mitochondrial Permeability Transition 
Pore by Activating PI3 Kinase, p70S6 Kinase, and GSK-3β
Thomas Krieg, Ina Paul, Karina Förster, Alexander Staudt, Stephan B. Felix, Ernst-
Moritz-Arndt University, Greifswald, Germany
The A1/A2 adenosine agonist 5’-(N-ethylcarboxamido) adenosine (NECA) limits infarction 
when administered at reperfusion. The present study investigated whether PI3 kinase, 
p70S6 kinase, and GSK-3β are involved in this protective effect. Adult rat ventricular 
myocytes were isolated and incubated in tetramethylrhodamine ethyl ester (TMRE, 
100 nM) which causes cells to ﬂuoresce in proportion to their mitochondrial membrane 
potential. A reduction in TMRE ﬂuorescence serves as an indicator of collapse of the 
mitochondrial transmembrane potential, and, therefore, of mitochondrial permeability 
transition pore (mPTP) formation. Cells were subjected to H2O2 (200 µM) which 
induces mPTP as a model for simulated reperfusion. Fluorescence was measured 
every 3 min and membrane potential was considered as irrecoverable collapsed when 
ﬂuorescence reached less than 60% of the starting value. Adding NECA (1 mM) to the 
cells preserved ﬂuorescence intensity, and hence mPTP formation, and prolonged the 
time to ﬂuorescence loss (48.0 ± 3.2 min vs. 29.5 ± 2.2 min in untreated cells, p<0.001). 
Both, the PI3 kinase inhibitor wortmannin (100 nM) and the mTOR/p70S6 kinase inhibitor 
rapamycin (5 nM) abolished this protection (31.3 ± 2.3 min, and 31.3 ± 3.4 min, both 
p<0.005 vs. NECA). The direct GSK-3β inhibitor SB216763 (3 µM) also prolonged the 
time needed for ﬂuorescence loss (49.2 ± 2.1 min, p<0.001 vs. control), and its protection 
could be blocked by the PKC inhibitor chelerythrine (100 nM, 34.4 ± 1.5 min, p=0.002 
vs. SB), but not by either wortmannin, or rapamycin (44.4 ± 2.8 min, and 42.2 ± 2.3 min, 
both p<0.001 vs. control), indicating that GSK-3β is located downstream of p70S6 kinase 
and PI3 kinase, but upstream of PKC for its effect on mPTP. These experiments reveal a 
critical role for PI3 kinase, p70S6 kinase, and GSK-3β in the signaling pathway of NECA’s 
ability to inhibit formation of the mPTP, and hence cardioprotection at reperfusion.
927-221 Inhibition of Serine Protease Activity at Reperfusion 
Reduces Postischemic Injury in a Closed-Chest Model 
of Acute Myocardial Infarction
James G. Reeves, Rong Jiang, James Mykytenko, Laura S. Schmarkey, Ning-Ping 
Wang, Hajime Kin, Amanda J. Zatta, Zhi-Quing Zhao, Robert A. Guyton, Jakob Vinten-
Johansen, Emory University School of Medicine, Atlanta, GA
Background:Aprotinin is a potent inhibitor of serine protease activity used in blood 
conservation. Serine proteases such as tissue factor, factor Xa, elastase and thrombin 
may be involved in the pathogenesis of ischemia-reperfusion injury in part by initiating 
local inﬂammatory responses. This study tested the hypothesis that intravenous aprotinin 
administered during reperfusion (R) attenuates endothelial activation and neutrophil 
accumulation in the area at risk (AAR), and reduces infarct size.
Methods: In anesthetized closed-chest pigs, the proximal LAD was occluded for 75 
minutes using an angioplasty balloon catheter. At 45 minutes of occlusion, pigs were 
randomized to received saline (Vehicle, n=8), Low-Dose Aprotinin (7,000 KIU/kg, n=9), or 
High-Dose Aprotinin (30,000KIU/kg, n=6). All hearts were reperfused for 3 hours.
Results: In vitro IL-8-stimulated neutrophil chemotaxis was reduced by aprotinin in a 
dose-dependent manner. Balloon-induced occlusion reduced subendocardial blood ﬂow 
in the AAR (15 µm microspheres, mL/min/g) from 1.02±0.33 to 0.01±0.01 in Vehicle, 
from 0.80±0.11 to 0.03±0.02 in the Low-Dose Aprotinin group, and from 0.78±0.21 to 
0.02±0.01 in the High-Dose Aprotinin group (P<0.01 vs baseline; no group differences). 
The AAR was comparable among the three groups (Vehicle: 38±2; Low-dose: 34±2; 
High-Dose: 35±2, p=0.3). Low-dose aprotinin did not signiﬁcantly reduce infarct size (TTC 
staining, 42±1%) relative to the Vehicle group (48±4%). In contrast, high-dose Aprotinin 
at reperfusion signiﬁcantly (P<0.05) reduced infarct size (20±5%) by 60% of that in the 
Vehicle group. P-Selectin and vWF expression were signiﬁcantly attenuated in the Low-
dose and High-dose Aprotinin groups compared to Vehicle. Neutrophil accumulation in 
AAR was reduced in the High-dose Aprotinin group as assessed by direct histochemical 
quantiﬁcation of CD18 positive cells (Vehicle: 1350±182 PMNs/slide; Low-dose Aprotinin 
485±235 PMNs/slide; High-dose Aprotinin 120±13 PMNs/slide, P<0.05).
Conclusions: Serine proteases contribute to the pathogenesis of endothelial activation 
and infarct size, which can be attenuated by a serine protease inhibitor at reperfusion.
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928-222 Implications of Passive Cigarette Smoking on the 
Severity and Prognosis of Patients With Acute 
Coronary Syndromes: The Greek Study of ACS (The 
GREECS)
Demosthenes Panagiotakos, Christos Pitsavos, Sophia Arapi, Antonis Antonoulas, 
Yannis Kogias, Yannis Mantas, George Giannopoulos, Christodoulos Stefanadis, First 
Cardiology Clinic, School of Medicine, University of Athens, Athens, Greece
Background: Although smoking increases the risk of a coronary event and accelerates 
the progression of atherosclerotic disease, the implication of passive cigarette smoking 
among non-smokers in the prognosis of patients with acute coronary syndromes (ACS) 
has rarely been investigated.
Methods: From October 2003 to September 2004, 2172 patients from 7 major general 
hospitals in Greece and with a discharge diagnosis of ACS were enrolled into the study. 
Of them, 76% were men (65 ± 11 years old) and 24% were women (72 ± 13 years old). 
Regression analysis and Cox proportional hazard models were applied to evaluate the 
relationships between exposure to environmental tobacco smoke (i.e. passive smoking 
> 30 minutes / day for more than 3 days per week), the severity of the disease (using 
troponin I levels as an bio-index) and the 30-day outcome of cardiovascular events (death 
or hospitalization due to CVD), after adjusting for several potential confounders.
Results: 39% of patients reported non-smokers, and 29% of them reported exposure to 
someone else cigarette smoke at least 30 min per day and 3 days per week. Exposure 
to cigarette smoke was associated with higher Troponin-I levels (beta = 4.23 ± 1.2, p = 
0.03), after controlling for age, sex, and clinical characteristics of the patients. Moreover, 
people exposed to someone else cigarette smoke were 4.6 times more likely to have 
acute myocardial infarction as compared to unstable angina (p < 0.001). Compared to 
non-passive smokers, passive smokers experience 25% higher risk (relative risk = 1.25, 
p = 0.02) of an event during the ﬁrst 30 days after discharge.
Conclusion: Our ﬁndings reveal the association of passive smoking with the severity and 
the prognosis of patients with ACS.
928-223 Natural Catastrophic Events Are Associated With 
Increased Incidence and Severity of Acute Coronary 
Syndromes
Cezar Iliescu, Gregory M. Giesler, Philamon G. Hemstreet, Blaithnead Murtagh, Wing 
Yi Liu, Jaime Gomez, Francisco Fuentes, H. Vernon Anderson, Ali Denktas, Richard 
W. Smalling, University of Texas at Houston/Memorial Hermann Heart and Vascular 
Institute, Houston, TX
Background: On August 29, 2005, Hurricane Katrina struck along the Gulf Coast of the 
United States. The days after the hurricane made landfall, approximately 750 evacuation 
centers were established in at least 18 states to accommodate more than 1 million 
evacuees. The objective of this study is to evaluate the impact of major psychosocial 
stress on the incidence and severity of acute coronary syndromes.
Methods: A total of 1220 patients (from Texas and Louisiana) admitted to a large university 
hospital for chest pain were evaluated. This included patients admitted one month prior 
and one month after the event. We also included those patients admitted during the 
similar time period of 2004. Patients meeting prospectively deﬁned and retrospectively 
validated acute coronary syndrome (ACS) criteria were identiﬁed. Chi-square method 
was used to compare the incidence of unstable angina (UA), NSTEMI and STEMI in each 
of the three-speciﬁed groups.
Results: Compared to the baseline patient population, post-Katrina patients with ACS had 
a higher incidence of NSTEMI 51% vs. 35% (30d prior) and 22% (1yr prior) (p<0.001) and 
STEMI 28% vs. 23% (30d) and 22% (1yr) (p<0.001), while the incidence of UA decreased 
21% vs. 42 % (30d) and 56% (1yr) (p<0.001). We also noted a decrease in admissions for 
stable angina (10%) and atypical chest pain (6%) compared to the prior month.
Conclusions: Psychosocial major stress factors may trigger NSTEMI and STEMI in 
patients with established coronary artery disease. It is imperative to have a disaster relief 
plan as well as personnel readily available to triage and appropriately treat this higher 
risk patient population.
928-224 Drug-Eluting Stent Supported Percutaneous Coronary 
Intervention for Unprotected Left Main Disease
Angela Migliorini, Guia Moschi, Letizia Giurlani, Renato Valenti, Ruben Vergara, Guido 
Parodi, Nazario Carrabba, Emilio V. Dovellini, David Antoniucci, Division of Cardiology, 
Careggi Hospital, Florence, Italy
Background Currently, surgical revascularization is considered the ﬁrst option therapy 
for patients with left main disease (LMD). The results of several studies of percutaneous 
coronary intervention (PCI) for LMD in the pre-drug-eluting stent era, have arised concerns 
on the safety and efﬁcacy of PCI due to the relatively high incidence of restenosis and the 
clinical relevance of recurrent ischemia due to left main restenosis. No data exist about the 
efﬁcacy and safety of drug-eluting stenting of unprotected LMD in unselected patients.
Methods All consecutive patients with unprotected left main disease were considered 
eligible for drug-eluting stent supported PCI. Coronary angiography was required for all 
eligible patients 6 months after the procedure. The surgical risk score (risk of death within 
1 month) was calculated according to the European System for Cardiac Operative Risk 
Evaluation (EuroSCORE) model.
Results One-hundred-one patients with unprotected LMD underwent PCI. The mean 
EuroSCORE was 19 ± 23. The overall 1-month mortality rate was 9.9%. The 1-month 
mortality rate was 50% in patients with acute myocardial infarction (AMI) on presentation, 
and 4.5% in patients without AMI on presentation. The 1-month mortality rate of patients 
with a risk score <13 was 3%, while it was 21% in patients with a risk score > 13. At 6 
months, the mortality rate of the entire cohort of patients increased to 12.8%, and the one 
of the non-AMI patients to 7.8%. Survival rate was 86 ± 4%. Target vessel revascularization 
was performed in 14 patients (16%). The 6-month in-segment restenosis rate was 16%. By 
multivariate analysis the independent predictors of death at 6 months were diabetes mellitus 
(OR 4.55, 95% CI 1.40-14.74 , P = 0.011), left ventricular ejection fraction (OR 0.93, 95%CI 
0.89-0.98, P = 0.010), and Euroscore value (OR 1.03, 95%CI 1.0-1.06, P = 0.024).
Conclusions The results of this study show that PCI is highly feasible also in very high 
risk unprotected left main disease patients, and indirectly suggest that drug-eluting stent 
supported PCI may provide early and mid-term outcomes comparable or superior to 
those expected from coronary artery surgery.
928-225 Mortality Beneﬁt of Drug-Eluting Stent Use in Clinical 
Practice
Robert J. Applegate, Michael A. Kutcher, William C. Little, Matthew T. Sacrinty, Sanjay 
K. Gandhi, Talal T. Baki, Renato M. Santos, Wake Forest University School of Medicine, 
Winston-Salem, NC
Background. In randomized clinical trials, drug-eluting stents (DES) reduce restenosis, 
but not MI or death, possibly due to inclusion of lower risk patients (pts). Whether DES 
have beneﬁts beyond restenosis in clinical practice with higher risk pts is uncertain.
Methods. We assessed clinical outcomes of PCI with bare metal stents (BMS), 4/02-4/05 
(n=1,278) and DES, 4/03-4/05 (n=1,699) at WFU. No pts were excluded from evaluation. 
Simple lesion was deﬁned as single lesion treated with a single <18 mm stent; complex 
lesions included all others. Clinical follow-up was available in 87%; mean 16.3±10.4 months.
Results. Baseline clinical characteristics were similar for BMS and DES pts with overall 
70% ACS, including 29% MI pts. 1.7±0.9 vessels were treated in BMS, and 1.6±0.8 in 
DES, p<0.001. 43% of BMS and 51% of DES lesions were ACC type C lesions, p<0.001. 
Procedural success was 98% BMS and DES, p=NS. At 30 days, clinical outcomes were 
similar for BMS and DES simple or complex lesions. At 1 year in simple lesions, MI and 
mortality were similar; while TVR rates were lower in DES (6.9%) vs. BMS (12.4%), 
p<0.001. By contrast, in complex lesions TVR, MI, and mortality were all signiﬁcantly 
lower in DES compared to BMS (Figure shows survival).
Conclusion. After PCI, DES use reduced mortality compared to BMS in complex but not 
simple lesions. These data suggest that the “real world” use of DES, including higher risk 
patients, may provide a mortality beneﬁt beyond that seen in clinical trials of lower risk 
lesions and patients.
928-226 The Clinical Effectiveness of Clinical Practice 
Guidelines in Managing Acute Coronary Syndromes: A 
10 Year Perspective
James Eldon Calvin, Jr., Clifford J. Kavinsky, Lowell Chang, Rush University Medical 
Center, Chicago, IL
Background: Over the past decade new tests and therapies have proven beneﬁcial in 
the management of unstable angina (UA) and non-ST-segment MI (NSTEMI). Clinical 
Practice Guidelines (CPG’s) were published by the ACC/AHA in 1994 and in 2002 to 
foster clinical dissemination. The purpose of this study was to determine the timeliness 
with which new knowledge was assimilated into clinical practice. Methods: 3,619 patients 
with either UA or NSTEMI were admitted into the CCU of a tertiary care hospital from 
1994 to 2003. Clinical, treatment, and outcome data were recorded on all patients.
Results: Patients aged <65y increased from 45% to 62% over the time span without 
change in male gender (55% to 60%). After the introduction of a troponin assay in 
1998, diagnosis of NSTEMI increased from 25% to 48% (P<.0001). History of coronary 
artery disease (CAD) increased from 17% to 56% over this period (P=0.005). Previous 
MI remained stable but the proportion of patients previously treated with percutaneous 
coronary intervention (PCI) increased from 18% to 33% (P=.037). Aspirin (ASA) 
treatment rose from 54% to 95%, oral beta blocker from 30% to 76% and the proportion 
of low molecular heparin increased from 10% in 1999 to 45% in 2003. Glycoprotein 
2b/3a platelet inhibitors (GP 2b/3a’s) increased steadily since 1998 (P<.0001) but were 
still underutilized (18% in 2003). After the publication of CPG’s in October 2002 and the 
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establishment of a cardiology quality improvement team, unadjusted ACE-Inhibitor use 
increased from 27% in 2002 to 46% (P<.0001), ASA use from 83% to 95% (P<.0001), 
statin use from 16% to 69% (P<.0001) and beta blocker use from 44% to 76% (P<.0001). 
Death, MI or urgent revascularization decreased by 24% (P=.0003) over the decade.
Conclusions: Over the course of 10 years, patient age and the frequency of NSTEMI 
decreased and prevalence of previous PCI increased. With the exception of GP 2b/3a’s 
the publication of CPG’s in 2002 and the establishment of a quality improvement team 
to support their use was associated with increased use of evidence-based medical 
therapies and better outcomes.
928-227 The Changing Characteristics and In-Hospital Mortality 
of Acute Myocardial Infarction in New Jersey 1986-2002
Yu-Hsuan Shao, Alan C. Wilson, Ronald S. Freudenberger, William J. Kostis, Nora M. 
Cosgrove, John B. Kostis, for the MIDAS Study Group, UMDNJ-Robert Wood Johnson 
Medical School, New Brunswick, NJ
Background: In recent years, signiﬁcant changes in the incidence and diagnostic criteria 
for acute myocardial infarction (AMI) have occurred, but little data are available on AMI 
characteristics and outcomes.
Methods: To characterize these trends we examined the statewide MIDAS database of 
247,637 patients admitted with a ﬁrst AMI in New Jersey from 1986 to 2002.
Results: Between 1986 and 1994, the annual incidence (per 1,000) of AMI decreased 
from 2.73 to 2.24 in men and from 1.61 to 1.35 in women. A small further decrease was 
seen in men (to 2.13) and a small increase in women (to 1.47). The median age at ﬁrst 
AMI in women was about 10 years older than men (67 vs. 76 in 2002). The proportion 
of non-Q-wave AMI (NQMI) among all AMI events increased about 3-fold (15.5% to 
51.4% among men and 20.3% to 60.1% among women) . In-hospital mortality decreased 
in both men (12.6% to 6.9%; 5.7 change) and women (20.7% to 11.4%; 9.3 change). 
Median length of stay decreased from 11 to 5 days in men and from 12 to 6 in women. 
30-day mortality decreased by 4.3 (from 13.4% to 9.1%) in men and by 4.6 (from 20.2% 
to 15.6%) in women. Mortality between discharge and 30 days increased 1.1% among 
men and 5.0% among women. This increase persists after adjusting for age, gender, race, 
comorbidity, interventions and length of stay.
Conclusion: The proportion of NQMI has increased and the length of stay has been 
halved. The marked decrease in in-hospital mortality has been partially offset by increased 
mortality in the ﬁrst few weeks after discharge
928-228 Sex-Related Differences in Non-Obstructive Coronary 
Artery Disease Among Patients With Non-ST-Segment 
Elevation Acute Coronary Syndromes: Results From 
the CRUSADE Quality Improvement Initiative
Erika R. Gehrie, Harmony R. Reynolds, Brian H. Neelon, Matthew T. Roe, W. Brian 
Gibler, E. Magnus Ohman, L. Kristin Newby, Eric D. Peterson, Judith S. Hochman, New 
York University School of Medicine, New York, NY, Duke Clinical Research Institute, 
Durham, NC
Background: Women with non-ST-segment elevation acute coronary syndromes (NSTE 
ACS) are more likely than men to have nonobstructive coronary artery disease (CAD) 
on angiography.
Methods: We evaluated sex-related differences in clinical features and outcomes between 
men and women with NSTE ACS who had nonobstructive CAD identiﬁed during coronary 
angiography (January 2001-March 2005) from the CRUSADE Initiative (high-risk NSTE 
ACS patients (pts) with ischemic ST segment changes and/or positive cardiac markers).
Results: Of the 88,303 pts who underwent angiography, only 36% were women; 6,506 
pts (7.4%) had nonobstructive CAD, 57% of whom were women. Approximately 85-87% 
of pts with nonobstructive CAD had positive cardiac biomarkers, but women were more 
likely than men to have signiﬁcantly elevated troponin levels (peak troponin ratio > 3x 
local laboratory upper limit of normal: 64.8% v 59.7% respectively, p=.0004). Outcomes 
such as death (0.6% vs. 0.6%) and cardiogenic shock (0.8% vs. 0.6%) were low among 
women vs. men, respectively. 
Baseline Patient Characteristics
Variable Women Men P-value
ST depression, % 30.5 28.0 0.02
Age, y, median 62.7 55.0 <0.0001
Hypertension, % 67.0 56.0 <0.0001
DM, % 20.7 18.6 0.03
CHF, % 11.5 9.3 0.004
Stroke, % 6.7 4.0 0.0001
Smoking, % 23.0 35.0 0.0001
Prior PCI, % 10.9 16.0 0.0001
Prior MI, % 13.5 16.8 0.0002
CHF = congestive heart failure; DM = diabetes mellitus; MI = myocardial infarction; PCI 
= percutaneous coronary intervention.
Conclusions: A sizable group of high-risk pts with NSTE ACS have nonobstructive 
CAD despite conﬁrmation of ischemia/infarction by ST-segment deviation and/or cardiac 
marker elevation. Sex-related differences in the pathogenesis of ACS are possible in 
these pts (plaque rupture with underestimation of the true burden of CAD by angiography 
and/or endothelial dysfunction and abnormal vasomotor tone) and require further study.
928-229 Management and Prognosis of Non ST-Segment 
Elevation ACS in Very Old Patients. The DESCARTES 
Registry
Hector Bueno, Magda Heras, Alfredo Bardaji, Antonio Fernandez-Ortiz, Helena Marti, 
Jaume Marrugat, Hospital General Universitario “Gregorio Maranon”, Madrid, Spain
The optimal management of very old patients with non ST-segment elevation ACS is not 
well deﬁned.
Methods: DESCARTES recruited 1877 consecutive ACS patients in 45 randomly 
selected Spanish hospitals between April and May, 2002. The clinical characteristics, 
treatment and outcomes of 534 patients >=75 years old (OP) were compared with 1338 
patients of younger age (YP).
Results: OP had higher* rates of risk factors, previous cardiovascular diseases and 
therapies, but beta-blockers and statins. OP showed high-risk features more often than 
YP*: longer chest pain duration, ST depression, and elevated troponin levels. OP presented 
higher rates of AMI (6.9% vs 4.4%, P=.03), heart failure (19% vs 6%*), major hemorrhage 
(4.3% vs 2.1%*) and death (4.3% vs 2.1%*) during hospitalization, but they were treated 
less often with GP IIb/IIIa inhibitors (9% vs 13%, p=.04), ß-blockers (49% vs 68%*). and 
coronary revascularisation (27.6% vs 15%*). Mortality during follow up and results of logistic 
regression analyses (controlling for ECG presentation, troponin elevation, diabetes, and 
previous cardiovascular diseases) are shown in the table. * p<0.01
Conclusions: Despite their higher predicted and actual risk, OP receive less evidence-
based interventions during hospitalisation for ACS. The impact of older age on mortality 
seems to increase with time. Whether a more aggressive hospital management of these 
patients may improve mid-term prognosis needs further investigation.
Mortality according to age group
>= 75 years < 75 years p value Adjusted OR(95%CI)
28-day mortality 6.2% 2.5% <0.0001 1.75 (1.00-3.06)
6-month mortality 15.3% 4.8% <0.0001 2.33 (1.53-3.55)
 
928-230 Short- and Long-Term Prognosis of First Acute ST-
Segment Elevation Myocardial Infarction in Older 
Women. The PPRIMM75 Registry
Hector Bueno, Hugo D. Juan, Manuel Martinez-Selles, Esther Perez-David, Hospital 
General Universitario “Gregorio Maranon”, Madrid, Spain
Background: The inﬂuence of gender on mortality in older patients with AMI is 
controversial.
Methods: To assess the impact of gender on prognosis in older patients with a ﬁrst 
STEMI, the clinical characteristics, outcomes and long-term mortality of 395 consecutive 
older women (W) were compared with those of 380 men (M) with STEMI enrolled in the 
PPRIMM75, a single CCU registry, between 1989 and 2000.
Results: W were older*, had a higher* prevalence of diabetes, hypertension, and 
previous CHF, and lower* of smoking. AMI location, reperfusion rate, and LVEF did not 
differ between sexes. During hospitalisation, W presented higher incidences of CHF (53% 
vs 48%* ), cardiogenic shock (23% vs 16%*), and mechanical complications (14% vs 
7%*). In-hospital mortality was 36% in W and 24% in M*. Multiple logistic regression 
analysis controlling for age, risk factors, Killip class, delay on admission, and reperfusion 
therapy, selected female gender as an independent predictor of early mortality (OR: 1.57; 
95% CI: 1.06 - 2.33, p=0.03). * p <0.01
Median survival time (97% complete FU) was 60 months in M and 50 months in W 
(p=0.006). Cox regression analysis controlling for factors used for hospital mortality 
adjustment did not select female gender as an independent predictor of late mortality 
(hazard ratio 0.89; 95% CI: 0.72 - 1.12)
Conclusions: Older women have a worse short-term prognosis than older men after a 
ﬁrst STEMI. The impact of gender seems to be only clinically relevant at the earlier phase 
of myocardial infarction.
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929-232 Rescue Angioplasty Versus Conservative Treatment 
in Patients with Failed Fibrinolysis- No Late Survival 
Beneﬁt. The Final Analysis of the Middlesbrough 
Early Revascularisation to Limit Infarction (MERLIN) 
Randomised Trial
Babu Kunadian, Andrew GC Sutton, Kunadian Vijayalakshmi, Phil G. Campbell, Richard 
Graham, Dalas J A Price, J. C. Gray, E. D. Grech, A. A. Harcombe, R. H. Smith, J. J. Murphy, 
A. Shyam-Sundar, M. J. Stewart, A. Davies, N. J. Linker, Robert A. Wright, James A. Hall, 
Mark A. de Belder, The James Cook University Hospital, Middlesbrough, United Kingdom
Background: Thirty day and 6 month outcomes in trials comparing rescue angioplasty 
(rPCI) with conservative treatment for failed ﬁbrinolysis complicating ST segment 
elevation myocardial infarction (STEMI) have shown variable results. Whether early rPCI 
confers late (up to 3 years) clinical beneﬁts is not known.
Methods: The MERLIN trial compared rPCI and a conservative strategy in patients with 
failed ﬁbrinolysis complicating STEMI. 30 day and 1 year results have been reported. 
Results to 3 years follow-up are presented. Patients in cardiogenic shock were excluded.
Results: Three year mortality in the rPCI and conservative arms, respectively was 17.6% 
vs.16.9%; p = 0.86; risk difference (RD) -0.76 %; 95% conﬁdence interval (CI) -9.3 to 7.8. 
Death rates were similar (3.9% v 3.3%) between 1 and 3 years follow up. The composite 
end point occurred less often in the rPCI arm (51% v 64.3%; p = 0.02; RD 13.3%; 95% CI 
2.2 to 24.1). There was no signiﬁcant difference in the rate of reinfarction (1.3% vs.3.9%) or 
heart failure (1.3% vs.2.6%) between 1 and 3 year. The incidence of subsequent unplanned 
revascularisation at 3 years was higher in the conservative arm (32.5% v 14.4%; p < 0.01; 
RD 18.1 %; 95% CI 8.7 to 27.3), most of which occurred by 30 days; the rates between 1 
and 3 years was 2.6% in the conservative v 2% in the rPCI arm. There was a trend towards 
fewer strokes in the conservative arm at 3 years (2.6% v 6.5%; p = 0.98; RD -3.9 %; 95% CI 
-9.4 to 0.8), with similar stroke rates (1.3% vs 1.3%) between 1 and 3-year follow-up.
Conclusion: Early rPCI did not confer a late survival advantage at three years, compared 
with those managed more conservatively. The composite end point occurred less often 
in the rPCI arm, mainly because of fewer unplanned revascularisation procedures in 
the early phase of follow up. The highest risk of clinical events in patients with failed 
reperfusion is in the ﬁrst year; beyond 1 year the occurrence of events is low.
929-233 The Efﬁcacy and Safety of Combination Therapy 
Facilitated Angioplasty for ST-Elevation Myocardial 
Infarction: A Meta-analysis of Randomized Clinical 
Trials
Mohamad C. Sinno, Mouaz H. Al-Mallah, Muhammad Arida, Sanjaya Khanal, W. 
Douglas Weaver, Henry Ford Health System, Detroit, MI
Background: Early reperfusion in STEMI is associated with improved outcomes. The use 
of thrombolytic and glycoprotein 2b/3a inhibitors combo prior to percutaneous coronary 
intervention (PCI) in the setting of acute STEMI remains controversial. We reviewed the 
literature and performed a meta-analysis of the efﬁcacy and safety of 2b/3a blockade and 
thrombolytic facilitated PCI in STEMI.
Methods: We performed a literature search and identiﬁed randomized trials comparing the 
use of combination therapy facilitated PCI versus 2b/3a inhibitor alone. Included studies 
were reviewed to determine TIMI III ﬂow at baseline, major bleeding, and 30-day mortality. 
We performed a random-effect model meta-analysis. We quantiﬁed heterogeneity 
between studies with I2. A value > 50% represents substantial heterogeneity.
Results: We identiﬁed 3 clinical trials including 655 patients. 390 patients were pretreated 
with combination therapy and 265 patients had 2b/3a inhibitor facilitated PCI. Combination 
therapy facilitated PCI was associated with increased TIMI III ﬂow upon arrival to the 
catheterization lab (RR 2.11, p<0.00001). There was a statistically signiﬁcant increase 
in major bleeding (RR 2.38, p= 0.007) and a trend toward increased mortality (RR 1.62, 
p=0.44) in the combination therapy group.
Conclusions: Awaiting the results of the ongoing clinical trials, the current cumulative 
evidence does not support the routine use of combination therapy facilitated PCI for the 
treatment of STEMI.
929-234 Rescue Percutaneous Coronary Intervention After 
Failed Fibrinolysis: A Meta-Analysis of Randomized 
Controlled Trials
Taral Patel, Anthony Bavry, Dharam Khumbani, Stephen Ellis, Cleveland Clinic 
Foundation, Cleveland, OH, University of Pennsylvania, Philadelphia, PA
Background: Previous randomized trials have suggested clinical beneﬁt with rescue 
percutaneous coronary intervention (PCI) after failed ﬁbrinolytic therapy. However, the 
results from more recent studies have been conﬂicting. We designed a meta-analysis 
to determine whether rescue PCI improves clinical outcomes compared to conservative 
medical therapy in the setting of early failure of ﬁbrinolysis.
Methods: We searched the MEDLINE database for prospective randomized trials using 
the Medical Subject Heading terms “angioplasty,” “myocardial infarction,” “thrombolytic 
therapy,” and “ﬁbrinolysis.” The inclusion criteria were: (1) a diagnosis of acute ST-elevation 
myocardial infarction initially treated with ﬁbrinolytics, (2) randomization of patients 
who failed ﬁbrinolysis based on clinical or angiographic characteristics to immediate 
PCI versus conservative therapy, and (3) available short term cardiovascular outcome 
data. The primary endpoint was short term mortality, while secondary endpoints were 
thromboembolic stroke and congestive heart failure. The number of events in each arm of 
a trial were tabulated and risk ratios (RR) computed as rescue PCI versus conservative 
therapy. Heterogeneity between the studies was assessed by computing the Q statistic.
Results: We included the following trials for analysis: Belenkie et al, RESCUE, RESCUE 
II, MERLIN, and REACT. To determine heterogeneity, the chi-square value (4 degrees of 
freedom) for the Q statistic from the studies was 4.01 (p = .40). The pooled RR estimate 
for mortality revealed a 36% reduction in death among patients treated with rescue PCI 
(RR = 0.64, 95% CI 0.41 to 0.997, p = .048), while there was a marginally signiﬁcant 28% 
reduction in heart failure (RR = 0.72, 95% CI 0.51 to 1.01, p = .06). Finally, we found a 
marginally signiﬁcant increase in the risk of stroke in the rescue PCI arm (RR = 3.61, 95% 
CI 0.91 to 14.27, p = .07).
Conclusions: A strategy of rescue PCI for early failure of ﬁbrinolytic therapy is associated 
with a signiﬁcant mortality beneﬁt and possibly a reduction in heart failure. This approach 
is tempered by a possible increase in the risk for thromboembolic stroke.
929-235 Rescue Angioplasty versus Conservative Management 
for Failed Thrombolysis in Acute Myocardial Infarction: 
A Meta-Analysis
Babu Kunadian, Kunadian Vijayalakshmi, Joel Dunning, Robert A. Wright, Andrew 
GC Sutton, James A. Hall, Mark A. de Belder, The James Cook University Hospital, 
Middlesbrough, United Kingdom
Background: Individual trials of rescue angioplasty (rPCI) were not powered to detect 
a mortality advantage or difference in the individual end points. We therefore performed 
a meta-analysis of the available 30 day and 6-month outcome results of the randomised 
trials comparing rPCI to conservative management (CM) for failed thrombolysis.
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Methods and results: We identiﬁed 5 clinical trials including 800 patients and mean follow-
up time of 30 days. At 30 days rPCI was associated with a signiﬁcant beneﬁt for reduced 
rates of death (OR, 0.64 [95% CI 0.41 to 1, p = 0.048]), reinfarction (OR, 0.48 [95% CI 0.25 
to 0.94, p = 0.033]) and additional unplanned revascularisation (OR, 0.37 [95% CI 0.22 to 
0.63, p = < 0.01]) and a non-signiﬁcant trend towards reduction in heart failure (OR, 0.72 
[95% CI 0.51 to 1.01, p = 0.06]). RA was associated with more strokes (OR, 3.81 [95% CI 
1.09 to 13.25, p = 0.04]). The combined analysis of the results from the MERLIN and the 
REACT trial showed no mortality beneﬁt at 6 months (OR, 0.68 [95% CI 0.39 to 1.19]).
Conclusion: This meta-analysis suggests that rPCI compared to CM results in reduced 
mortality at 30 days, less reinfarction, and less unplanned intervention, but an increased 
rate of strokes. A reduction in heart failure has not been conclusively established. At 6 
months, the current available information shows no mortality beneﬁt with rPCI. Although it 
is reasonable to offer rPCI to suitable patients, a larger randomized study is required.
929-236 Does Rescue Angioplasty Improve Outcomes?  
A Quantitative Review of Randomized trials
Mónica Masotti, Amadeu Betriu, Rafael Ruiz-Salmerón, Hospital Clínic, Barcelona, Spain
Background: Contrary to primary percutaneous coronary intervention (PCI) the potential 
beneﬁt of rescue PCI in the early hours of acute myocardial infarction (MI) remains 
unclear, as individual studies have yielded controversial results.
We assess whether a policy of routine rescue PCI following failed thrombolysis results in 
better outcomes than conservative treatment.
Methods: We combined data from all control randomized trials (Belenkie, RESCUE 
I, LIMI, PRAGUE I, MERLIN and REACT) comparing rescue PCI with conservative 
management. We focused on hard end-points death and reMI, assessed at 30 days.
Results: Our analysis included a total of 1119 patients; of them, 561 underwent rescue 
PCI while the remaining 558 were managed conservatively. Rescue PCI was performed 
after a mean of 288 minutes after the symptom onset. The 30 day outcomes (rescue PCI 
vs conservative treatment, respectively) were as follows: mortality 8% vs 11% (OR 0.7, 
95% CI 0.46-1.06; p=0.07), reMI 4.9% vs 8.7% (OR 0.54, 95% CI 0.31-0.94; p=0.02), 
and the combined death/reMI 13.4% vs 20.0% (OR 0.61, CI 0.47-0.88; p=0.005). This 
translates into 66 events prevented per 1000 patients treated.
Conclusions: Early rescue PCI following unsuccessful thrombolysis improves outcomes, 
as it signiﬁcantly reduces recurrent MI. Whether this beneﬁt extends to patients treated 
beyond the time window of the randomized trials remains to be established.
929-237 Intracoronary Streptokinase Infusion Just Following 
Primary Percutaneous Coronary Intervention Improves 
Microvascular Perfusion and Integrity in Patients With 
Acute Myocardial Infacrtion
Murat Sezer, Huseyin Oﬂaz, Taner Goren, Irem Okcular, Yilmaz Nisanci, Berrin Umman, 
Ahmet Bilge, Mehmet Meric, Sabahattin Umman, Istanbul University, Istanbul Faculty of 
Medicine, ISTANBUL, Turkey
We hypothesized that intracoronary streptokinase (ICSK) administration just following 
primary percutaneous coronary intervention (PPCI) may improve tissue level perfusion by 
dissolving thrombus (in situ formed or embolized from proximal occlusion) and ﬁbrin at the 
microvascular level in patients with acute myocardial infarction (AMI). For this purpose we 
prospectively investigated effect of ICSK administration just following PPCI on myocardial 
perfusion as determined by objective and quantitative indices.
Methods and patients: Forty-one consecutive patients with AMI undergoing PPCI 
prospectively enrolled. Patients were randomized in ICSK group (n=21) and control group 
(n=20). After completion of PPCI, 250000 U streptokinase administered intracoronarily to 
the infarct related artery in patients who allocated in ICSK group. Coronary ﬂow reserve 
(CFR), index of microvascular resistance (IMR), pressure derived collateral ﬂow index 
(CFIp), coronary wedge pressure [mean (CWPm) and systolic (CWPs) ] were measured 
with using ﬁberoptic pressure - temperature sensor tipped guide wire in infarct related 
artery on day 2. Deceleration time of diastolic velocity (DDT) in the recanalized LAD was 
measured. ST segment resolution (STR), myocardial blush grades (MBG) and corrected 
TIMI frame count (CTFC) were also determined.
IMR was signiﬁcantly lower (16.3 + 5 versus 31.5 + 10, p<0.01) and CFR was signiﬁcantly 
higher (2 + 0.57 versus 1.39 + 0.31, p<0.01) in the ICSK group. CFIp (0.15 + 0.06 versus 
0.23 + 0.8; p=0.004), the mean CWP (10.8 + 5.4 versus 17.1 + 8.1; p= 0.014) and systolic 
CWP (18.2 + 6 versus 34 +11; p<0.001) were signiﬁcantly lower in the ICSK group. DDT 
was signiﬁcantly steeper in the control group (321 + 184 msec. versus 856 + 272 msec; 
p<0.001). Post PCI 60. min. STR was signiﬁcantly better (67.5 + 22 versus 49 + 27, p= 
0.034), MBG 2/3 was signiﬁcantly frequent (72% versus 45%, p=0.017) and CTFC was 
signiﬁcantly faster (22.5 + 5.5 versus 30.1 + 7.7, p<0.01) in ICSK group.
Conclusion: Intracoronary streptokinase administration just following primary PCI 
improves reperfusion at the microvascular level in patients with AMI
929-238 Long Distance Transfer for Direct Percutaneous 
Coronary Intervention: A Facilitated Approach
David M. Larson, Katie M. Menssen, Marc C. Newell, Barbara Tate Unger, Scott W. 
Sharkey, Steven Mulder, Mohammed Hussain, M. Nicholas Burke, Anil K. Poulose, 
Timothy D. Henry, Minneapolis Heart Institute Foundation, Minneapolis, MN, Ridgeview 
Medical Center, Waconia, MN
Background: Primary percutaneous coronary intervention (PCI) is superior for STEMI 
if performed in a timely manner at experienced centers. The beneﬁt of primary PCI 
over ﬁbrinolysis may be lost as distance/time from a PCI center increases. Combining 
reduced dose ﬁbrinolytic prior to transfer results in establishment of earlier reperfusion. 
A facilitated PCI approach may provide equivalent outcomes to primary PCI in patients 
when delays in transfer occur.
Methods: We report clinical outcomes, door to balloon times and pre-procedural TIMI 
ﬂow in STEMI patients who were transferred for facilitated PCI (1/2 dose TNK) to Abbott 
Northwestern Hospital (ANW) from 17 hospitals 60-210 miles away compared to 158 
patients who presented to ANW directly.
Results: From 7/03 to 9/05 210 STEMI patients were transferred to ANW by helicopter 
(96%) or ground ambulance (4%) for facilitated PCI (34 patients with lytic contraindications 
received primary PCI). No patients were excluded including cardiogenic shock (12%), 
cardiac arrest (10%) or mechanical ventilation (7%). Facilitated PCI had longer median 
door to balloon times (117 vs 66 mins, p<0.0001) but also had greater infarct artery 














PCI n=176 43/29 96% 0 0 3.8% 0
ANW n=158 15/16 93% 2.5% 3.8% 6.3% 0
p-value <0.0001 NS NS NS NS NS
Conclusions: Rapid transfer of STEMI patients from distances of 60-210 miles for 
facilitated PCI using a protocol of reduced dose ﬁbrinolytics is safe and feasible with 
equivalent outcomes to those who present to a primary PCI center directly.
929-239 Hospitalization Costs of Tenecteplase-Facilitated 
Angioplasty Versus Thrombolysis-Alone in Acute 
Myocardial Infarction
Michel R. Le May, George A. Wells, Marino Labinaz, Sheila Ryan, Richard F. Davies, 
Michele Turek, University of Ottawa Heart Instsitute, Ottawa, ON, Canada
Background - We have recently shown that compared to tenecteplase- alone, 
tenecteplase-facilitated PCI reduces recurrent ischemic events. Direct costs associated 
with each treatment strategy have not been fully evaluated.
Objectives - We analysed the direct hospital costs of tenecteplase-facilitated PCI 
compared to tenecteplase-alone in patients with ST-elevation myocardial infarction 
(STEMI) randomized in the Combined Angioplasty and Pharmacological Intervention 
versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI) study.
Methods - Between August 2001 and January 2004, we randomly assigned 170 patients 
presenting with features of high-risk STEMI ≤ 6 hours to treatment with tenecteplase-
facilitated PCI (n=86) or to treatment with tenecteplase alone (n=84). Detailed in-hospital 
costs during the initial hospitalization were available for all patients. Exact costs of cardiac 
catheterization, thrombolytic medication, electrocardiography, radiology, nuclear medicine 
and physician billings were obtained. Average costs per patient-day based on known 
institutional ﬁgures for the period of the study were used to calculate costs relating to 
coronary care unit, operating room, recovery room, cardiac surgical unit, step-down unit 
and wards. This study did not allocate overhead administrative costs.
Results - The median cost per patient ($US) for the initial hospitalization was $9,627 
(interquartile range: $8,293 - $11,342) in the facilitated group compared to $8,540 
(interquartile range: $7,313 - $10,711) in the thrombolysis-alone group, p=0.006 by 
Mann-Whitney. The median length of stay was shorter in the facilitated group compared 
to the thrombolysis-alone group, 5.0 (interquartile range: 4.0-7.0) days versus 6.0 days 
(interquartile range:5.5-8.0), (p=0.02). At six months the median cost per patient was 
$9,933 (interquartile range: $8,668 - $11,943) in the facilitated group compared to $9,013 
(interquartile range: $7,566 - $11,378) in the thrombolysis-alone group, p=0.005.
Conclusion - Compared to tenecteplase-alone, tenecteplase-facilitated PCI appears to 
be a cost effective strategy for ST-segment elevation myocardial infarction.
929-240 Time From Symptom Onset to Reperfusion and 
Inﬂuence on Infarct Size in Patients with ST-Elevation 
Myocardial Infarction Reperfused by Prehospital 
Fibrinolysis or Prehospital Initiated Facilitated 
Percutaneous Intervention
Holger Thiele, Mathias Kappl, Enno Boudriot, Gerhard Schuler, University of Leipzig 
- Heart Center, Leipzig, Germany
Background: The time from symptom onset to reperfusion (TSR) has strong effects 
on ﬁnal infarct size (IS) and subsequently on mortality for STEMI patients treated by 
ﬁbrinolysis. In patients reperfused by PCI the IS has been shown to be independent from 
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TSR and the effects on mortality are attenuated. The TSR and effects on IS have not 
been studied for patients treated very early by either prehospital ﬁbrinolysis or prehospital 
initiated facilitated PCI.
Methods: In the Leipzig prehospital ﬁbrinolysis study patients with STEMI were 
randomized to either a prehospital ﬁbrinolytic therapy (n=82) or prehospital initiated 
facilitated PCI (n=82). The TSR was assessed for all patients. Patients were divided into 
the following 3 groups deﬁned by tertiles of the time-to-treatment interval: lower tertile 
(<120 min), middle tertile (120-240 min), and upper tertile (>240-360 min). At 6 months 
follow-up in 134 IS was assessed by MRI.
Results: The TSR had a signiﬁcant inﬂuence on ﬁnal IS for the overall patient population. 
In the lower tertile the IS was 7.7±8.1 % versus 12.1±10.6% in the middle tertile (p=0.04 
versus lower tertile) and 12.7±6.9% in the upper tertile (p=0.03 versus lower tertile). In 
the group of patients treated by prehospital ﬁbrinolysis IS was 10.2±9.8% in the lower, 
15.6±12.6% in the middle, and 12.8±8.5% in the upper tertile (p=0.03). In patients treated 
by prehospital initiated PCI IS was 5.2±4.9% in the lower, 9.1±6.0% in the middle and 
13.3±7.0% in the upper tertile (p=0.01). In patients treated by prehospital ﬁbrinolysis alone 
the ﬁnal IS was greater in the lower (p=0.006) and middle tertile (p=0.03) in comparison 
to facilitated PCI.
Conclusions: The TSR inﬂuences the ﬁnal IS for either prehospital ﬁbrinolysis or 
facilitated PCI. A prehospital initiated facilitated PCI approach is superior to prehospital 
ﬁbrinolysis alone. This underlines the assumed pathophysiological link between early 
restoration of the ﬂow and perfusion in the infarct related artery, which is known as the 
“wavefront phenomenon”.
929-241 Impact of Time to Presentation and Reperfusion 
Modality on the Efﬁcacy of Adenosine During 
Reperfusion Therapy for Acute Myocardial Infarction: 
The AMISTAD-2 Trial
Robert A. Kloner, Raymond J. Gibbons, Allan M. Ross, R. Wayne Alexander, Mervyn 
B. Forman, Gregg W. Stone, Keck Shool of Medicine at the University of Southern 
California, Los Angeles, CA, Heart Institute, Good Samaritan Hospital, Los Angeles, CA
Background and Purpose In the prospective, randomized, multicenter AMISTAD-II trial, 
high dose adenosine reduced infarct size in patients treated with thrombolytic therapy 
or primary percutaneous coronary intervention [PCI]) within 6 hours of anterior acute 
myocardial infarction (MI) symptom onset; however the primary composite clinical endpoint 
of death and heart failure was not different between placebo (17.9%) and adenosine 
(16.3%). Our purpose was to determine whether early treatment with adenosine would 
improve clinical outcomes. 
Methods Patients with acute anterior ST-segment elevation MI were randomized to 
placebo versus adenosine (50 or 70 µg/kg/min) for 3 hours starting within 15 minutes 
of reperfusion therapy (thrombolysis [n = 1234] or PCI [n = 851]). Results were stratiﬁed 
based on median time to treatment (3.2 hours). 
Results 1071 patients received initiation of reperfusion within 3.2 hours of symptom onset 
and in these patients, the primary composite clinical outcome of death, new in-hospital 
congestive heart failure (CHF) or ﬁrst rehospitalization for CHF within six months was 
signiﬁcantly lower in the pooled adenosine (12.1%) versus the placebo group (17.2%; p = 
0.026). Mortality within 6 months was also reduced with adenosine compared to placebo 
(7.4% versus 11.1% respectively, p = 0.0397). The beneﬁt of adenosine was observed 
primarily in patients treated with early (<3.2 hours) thrombolytic therapy in which the 
clinical composite was 14.9% in pooled adenosine patients versus 21.2% in placebo 
patients (p = 0.055). PCI patients (< 3.2 hours) did not demonstrate signiﬁcant beneﬁt 
with adenosine (composite clinical endpoint 7.9% for pooled adenosine versus 11.0% for 
placebo; p = 0.271). Patients reperfused beyond 3.2 hours did not beneﬁt from adenosine 
(composite clinical endpoint 20.7% vs. 18.7% in placebo; p = 0.408). 
Conclusion In a post-hoc analysis of AMISTAD-II, adenosine administered with 
reperfusion therapy within 3.2 hours of symptom onset in anterior MI improved survival 
and freedom from congestive heart failure, primarily in patients treated with thrombolytic 
therapy. Further studies of adenosine as an adjunct to reperfusion are warranted.
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930-242 Predictors of Non-Calciﬁed Plaques of Coronary 
Arteries in 422 Subjects by Multislice Computed 
Tomography Using Logistic Regression Models
Nobusada Funabashi, Miki Asano, Kiyomi Teramoto, Issei Komuro, Chiba University 
Graduate School of Medicine, Chiba, Japan
Background: We detected non calciﬁed plaques (NCP) of coronary arteries using 
multislice CT (MSCT) to determine predictors of NCPs in logistic regression models, and 
to develop novel strategies for the prevention of acute coronary syndrome.
Methods: 422 consecutive subjects (244 males, 17-91 years old) underwent enhanced 
ECG gated MSCT (Light Speed Ultra16) with 0.625 mm slice thickness. The volume data 
were reconstructed at every 10% of the R-to-R interval (0-90%, total 10 phases) to detect 
NCPs. Logistic models for predicting NCPs were constructed using age, sex, coronary risk 
factors (CRFs) (hypertension [HT], diabetes mellitus [DM], hyperlipidemia [HL] smoking 
habits, and obesity), and anginal symptoms or coronary calciﬁed plaque (CP).
Results: NCPs were detected in 174 subjects (132 males, 30-86 years old) whose average 
number of CRFs was 2.4, 63% of whom had HT, 29% DM, 51% HL,62% smoking history, 
37% were obese, and 87% had CP. All were signiﬁcantly higher in subjects with NCPs 
than those without NCPs. The detection ratio of NCP by decade of life showed that even 
in young subjects who were less than 50 years old, the detection ratio ranged from 22 
to 50% in males, but in contrast, only 11 to 14% in females. The predictor variables were 
used in logistic regression models with the incidence of NCPs as the dependent variable. 
Age, male gender, HL and smoking habits (relative risks 1.02, 3.06, 1.60 and 1.72 [95% 
CIs: 1.00-1.04, 1.83-5.13, 1.04-2.47 and 1.05-2.81, respectively]) were associated with 
increased incidence of NCPs. 
Conclusions: In subjects with multiple CRFs, NCPs may be detected in MSCT even in 
young males, but the incidence of NCP is low in subjects without any CRFs or in young 
females. The incidence of NCPs is signiﬁcantly inﬂuenced by the presence of HL and 
smoking. Therefore, control of HL and smoking cessation may be effective strategies for 
the prevention of acute coronary syndrome.
930-243 Association Between Toll-Like Receptors on Circulating 
Monocytes and the Presence and Extent of Coronary 
Artery Disease in Patients With Stable Angina: 
Comparison With High-Sensitivity C-Reactive Protein
Etsuko Mizoguchi, Koji Orihara, Shinichi Hamasaki, Sanemasa Ishida, Tetsuro Kataoka, 
Masakazu Ogawa, Keishi Saihara, Hideki Okui, Tsuyoshi Fukudome, Takuro Shinsato, 
Takahiro Shirasawa, Hitoshi Ichiki, Yutaka Otsuji, Chuwa Tei, Respiratory and Metabolic 
Medicine, Graduate School of Medicine, Kagoshima, Japan
Background: Toll-like receptors (TLRs) mediate the innate immune response triggered 
by pathogen-associated molecular patterns, and atherosclerosis can be considered a 
state of chronic inﬂammation whereby immune system cells accumulate within the intima 
of the arterial wall. Thus, the goal of the present study was to investigate the level of 
TLR1, 2 and 4 expression on CD14+ monocytes obtained from patients with and without 
coronary artery disease as well as assess the high-sensitivity C-reactive protein (hCRP) 
as a marker of inﬂammation in those same patients
Methods and Results: Fifty-three consecutive patients with stable angina were classiﬁed 
into two groups: (1) patients with signiﬁcant coronary artery disease (signiﬁcant CAD 
group, n = 32), on the basis of signiﬁcant stenosis (angiographic diameter >/= 75%) in 
any of the coronary arteries; or (2) patients without signiﬁcant CAD (control group, n = 
21), The expression of TLR1, 2, and 4 on circulating CD14+ monocytes was analyzed by 
ﬂow-cytometry in all patients. TLR2 and TLR4 expression was greater in the signiﬁcant 
CAD group than in the control group (4.79±1.15 vs. 3.86±0.94; p < 0.01, 4.96±1.58 vs. 
3.92±0.93; p < 0.01). Next, patients with the signiﬁcant CAD group were further subdivided 
according to the presence of 1-vessel (n = 11), 2-vessel (n = 11), or 3-vessel (n = 10) 
atherosclerotic coronary artery disease. TLR2 expression was signiﬁcantly higher in the 
3-vessel group than in the control group (5.27±1.28 vs. 3.86±0.94; p < 0.01). No signiﬁcant 
difference existed in TLR2 expression among 1-vessel group (4.45±0.93), 2-vessel 
group(4.69±1.08), and control group. By contrast, there was no signiﬁcant difference in 
high-sensitivity C-reactive protein when comparing the signiﬁcant CAD group and the 
control group. Conclusions: These data suggest that TLR2 and 4 expression correlates 
with the presence of CAD. Moreover, TLR2 expression may be more closely associated 
with the extent of atherosclerotic coronary artery disease when compared with high-
sensitivity C-reactive protein in patients with stable angina.
930-244 Progression of Coronary Artery Stenosis during 6 
Months Was Associated With the Number of Yellow 
Plaques Detected by Baseline Angioscopy
Yosuke Omori, Tomonori Ueda, Sei Komatsu, Oyabu Jota, Kazunori Kashiwase, Atsushi 
Hirayama, Kazuhisa Kodama, Osaka Police Hospital, Osaka, Japan
Background: Plaque rupture and subsequent thrombosis causes the progression of 
coronary artery stenosis. Yellow plaque (YP) detected by coronary angioscopy is regarded 
as a vulnerable plaque. Therefore, we examined if the number of yellow plaques (NYP) 
detected in a coronary artery would be a risk of coronary artery stenosis progression.
Methods: A series of patients (n=57) who received coronary angiography, angioscopy, 
and percutaneous coronary intervention (PCI) were included in this study. Patients were 
divided into 2 groups according to NYP: group-S (NYP<3, n=35) and group-L (NYP>4, 
n=22). On the 6-months follow-up angiography, presence or absence of coronary artery 
stenosis progression at any segment excluding target lesion of PCI was examined.
Results: Background data were not different between group-S and group-L. More 
patients presented progression of coronary artery stenosis in group-L than in group-S 
(50% vs. 8.6%, p=0.0002). Among patients who presented the progression of coronary 
artery stenosis during 6 months, diameter stenosis at baseline and at 6 months was 
25±22% and 69±18%, respectively.
Conclusions: Progression of coronary artery stenosis during 6 months was signiﬁcantly 
associated with the number of yellow plaques in a coronary artery detected by baseline 
angioscopy.
930-245 Impaired Nitric Oxide Mediated Vasodilation in Women 
With Chest Pain and Normal Angiograms
Carmine Pizzi, Olivia Manfrini, Alberico Borghi, GianLuigi Morgagni, Raffaele Bugiardini, 
University Alma Mater, Bologna, Italy
Background: Previous studies in patients with atherosclerosis have shown reduced 
vasodilator response to exogenous sources of nitric oxide (NO). This study sought to 
determine whether NO-mediated vasodilation is abnormal in women presenting with 
typical chest pain despite normal appearing coronary angiograms.
Methods: Sixteen women (mean age 47+6) with chest pain, normal angiograms, and 
reversible myocardial perfusion defects in the anterior wall were considered eligible for 
coronary blood ﬂow (CBF) study (thermodilution technique) during cardiac catheterization. 
Isosorbide dinitrate (5 mg sublingual) was used to evaluate vasodilator response to 
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exogenous NO donor. Verapamil (10 mg intravenously) was administered to distinguish 
impaired NO-mediated vasodilation from general dysfunction of vascular smooth muscle. 
Patients were randomly assigned to isosorbide dinitrate (n=8) or verapamil (n=8). CBF 
and anterior coronary resistance (ACR, mean aortic pressure/CBF ratio) were measured 
at baseline and peak atrial pacing, both off (control) and on drugs. Association of chest 
pain with ST depression was the end point of testing. CBF and ACR data are reported as 
percent changes from baseline to peak pacing.
Results: As compared to control, verapamil caused a consistent increase in CBF (20.0 ± 
3.9% vs 6.0 ± 5.6%, p<0.01) with a concurrent decrease of ACR (-16.0 ± 10.1% vs -7.1 
± 6.8 %, p=0.05). Time to angina increased from 514 ± 96 seconds on control to 649 ± 
103 seconds on verapamil (p=0.03). On the opposite, isosorbide dinitrate lowered CBF 
(from 3.2 ± 1.4% to -14.2 ± 12.0%, p<0.01) and increased ACR (from -6.9 ± 5.9 % to 18.9 
± 11.2%, p<0.01). Angina was achieved after 561 ± 108 seconds on control and 457 ± 
93 seconds on isosorbide dinitrate (P=0.05). Mean aortic pressure decreased both with 
Verapamil (-8.5%) and isosorbide dinitrate (-10.2%) (p=ns).
Conclusions: Coronary vasodilator response to exogenous NO is impaired in women 
with typical chest pain despite normal appearing coronary angiograms. Selective 
impairment of NO-dependent vasodilatation might represent a valuable early diagnostic 
index of angiographically non-visible atherosclerosis.
930-246 Signiﬁcance of Small Dense Low-Density Lipoprotein-
Cholesterol Concentrations in Relation to the Coronary 
Events in Stable Ischemic Heart Disease
Shinji Koba, Fumiyoshi Tsunoda, Yuuya Yokota, Yoshihisa Ban, Takatoshi Sato, Takatoshi 
Sato, Makoto Shoji, Hideki Nishimura, Hiroshi Suzuki, Takashi Katagiri, Showa 
University School of Medicine, Tokyo, Japan
Background: Although elevated plasma low-density lipoprotein-cholesterol (LDL-C) 
concentration is a major risk factor for the development of ischemic heart disease (IHD), 
signiﬁcance of LDL subfractions for predictor of coronary events remains unclear.
Methods: We measured the LDL size by gradient gel electrophoresis and quantiﬁed 
small dense (sd)-LDL-C concentrations by a newly developed rapid assay using heparin-
magnesium precipitation in 201 male and 45 female consecutive CHD patients with stable 
IHD who underwent coronary arteriography. Large LDL-C (L-LDL-C) was estimated by 
subtracting the sd-LDL-C concentration from the LDL-C concentration.
Results: One-hundred-nineteen patients received percutaenous coronary intervention 
(PCI) . The prevalence of PCI was associated with neither the presence of lipid-lowering 
medication (N=115) nor achievement of LDL-C levels less than 100 mg/dL. The sd-LDL-C 
levels were signiﬁcantly higher in patients with PCI than those without PCI, irrespective of 
the presence of lipid-lowering drugs, while L-LDL-C and high-sensitive CRP levels were 
similar between PCI and non-PCI patients. Among 175 patients with LDL-C levels equal or 
more than 100 mg/dL, the sd-LDL-C levels were signiﬁcantly higher (50.6 +/- 2.4 vs 37.4 
+/- 1.8 mg/dL, mean+/-SE), HDL-C levels were signiﬁcantly lower (41.4 +/- 1.4 vs 46.6 +/- 
1.2), and LDL size was signiﬁcantly smaller (25.5 +/- 0.05 vs 25.6 +/- 0.04 nm) in patients 
with PCI than those without PCI, whereas L-LDL-C, glycemic control and high sensitive 
CRP were comparable between PCI and non-PCI group. The sd-LDL-C levels positively 
correlated to the increased Gensini atherosclerosis score among high LDL-C patients. On 
the other hand, all lipid parameters, HbA1c, and high-sensitive CRP did not signiﬁcantly 
differ between PCI and non-PCI group among 71 patients with LDL-C < 100 mg/dL.
Conclusions: The sd-LDL mass plays an important role in the progression of coronary 
atherosclerosis. The sd-LDL-C concentration serves as a predictive marker for the 
development of coronary lesion.
930-247 Comparison of Resting Magnetocardiography With 
Stress Single Photon Emission Computed Tomography 
in Patients With Stable and Unstable Angina
Kirsten Tolstrup, Donnatella Brisinda, Anna M. Meloni, Brian Cheung, Robert J. Siegel, 
Riccardo Fenici, Cedars-Sinai Medical Center, Los Angeles, CA, Catholic University of 
the Sacred Heart, Rome, Italy
Background: Chest pain patients often undergo extensive work up for coronary artery 
disease (CAD) involving stress provocation, injection of medication, contrast, nuclear 
tracer, radiation, or catheterization, which all carry risks. Test results may not be available 
for hours. Resting magnetocardiographic imaging (MCG) is rapid, non invasive and 
without any risk. We examined the performance of rest MCG with stress SPECT imaging 
using coronary angiography as gold standard. 
Methods: Resting MCG was obtained in 37 patients with stable (sa) class I-II (n=20) 
and unstable (usa) class III-IV (n=17) angina. Patients were imaged for 90 seconds (36-
channel MCG) or 6 minutes (9-channel MCG). Results were available immediately. All 
patients had SPECT and coronary angiography for clinical indication. ≥ 50% left main 
stenosis or ≥ 70% major branch vessel stenosis was considered signiﬁcant. 
Results: The mean age was 62.9 years. 65.8% were men. There was a high 
prevalence of CAD risk factors: Hypertension 60.5%; diabetes 26.3 %; smoking 36.1%; 
hypercholesterolemia 78.4%; family history 50.0%, and prior myocardial infarction 57.9%. 
The MCG imaging was signiﬁcantly associated with CAD (p=0.01). The diagnostic value 
of MCG and SPECT for the detection of CAD is shown in the table. 
Conclusions: Resting MCG imaging provides immediate results with very high positive 
predictive value for CAD that exceeds or meets the performance of SPECT but without 
the use of stress provocation, radiation or injection of nuclear tracer.
Diagnostic Value of MCG and SPECT for the Detection of CAD
MCGall MCGusa MCGsa SPECTall
Sens. % 80.6 85.7 76.5 94.1
Spec.% 83.3 66.7 100 33.3
PPV % 96.2 92.3 100 88.9
NPV % 45.5 50.0 42.9 50.0
 
930-248 Apo A1-LDL Complex in Coronary Artery Disease - 
Oxidized Lipoprotein and Inﬂammation
Syunsuke Matsuno, Ken Ogasawara, Shinichi Mashiba, Hideki Hashimot, Kazuo 
Uchida, Tadanori Aizawa, The Cardiovascular Institute, Tokyo, Japan, Teikyo University 
School of Medicine, Tokyo, Japan
Background:Both inﬂammation and oxidation of lipoproteins are mutually dependent and 
have strong relation to the development of atherosclerosis.
Methods:To determine the role of inﬂammation and oxidized lipoproteins in the process 
of coronary artery disease (CAD), we measured serum lipoproteins, C-reactive protein 
(CRP), serum amyloid A (SAA) and Apo A1-LDL complex, which is newly identiﬁed oxidized 
LDL, in consecutive 475 patients who underwent diagnostic coronary angiography. Serum 
levels of the apoA1-LDL complex were measured by newly developed sandwich enzyme-
linked immunosorbant assay method.
Results:The patients consisted of 84 with unstable angina (UA), 258 with stable CAD 
(STA) and 133 without CAD (CON). The values of inﬂammatory markers and Apo A1-LDL 
complex are shown below.
UA (n=84) SAT (n=258) CON (n=140)
CRP (mg/dl) 0.11 (0.064-0.219) 0.086 (0.055-0.18) 0.083 (0.05-0.155)
SAA (µg/ml) 5.6 (2.78-11.65) 5.1 (2.7-9.15) 4.9 (2.85-8.15)
Apo A1-LDL (µg/ml) 44.5 (35.8-51.9) 27.2 (19.7-35.7) 24.1 (18.1-29.1)
The data are expressed as median (25th-75th percentile). By logistic regression analysis, 
only Apo A1-LDL complex was independent and statistically signiﬁcant to predict CAD 
(p=0.002) and to discriminate unstable angina (p<0.001) even after controlling for classical 
risk factors (age, gender, diabetes, hypertension and serum HDL cholesterol level).
Conclusions: The serum level of Apo A1-LDL complex, newly identiﬁed oxidized LDL, 
can be a more sensitive marker of CAD and acute coronary syndrome than CRP.
930-249 Gene Sequence Variations of the CD14 Receptor 
Inﬂuences C-Reactive Protein Levels in Patients With 
Stable Coronary Artery Disease
Celia Ramirez, Dominick J. Angiolillo, Esther Bernardo, Manel Sabate, Ugo Cavallari, 
Elisabetta Trabetti, Pier F. Pignatti, Fernando Alfonso, Antonia Rodriguez de la Pena, 
Marco A. Costa, Theodore A. Bass, Antonio Fernandez-Ortiz, Carlos Macaya, University 
of Florida-Shands Jacksonville, Jacksonville, FL, San Carlos University Hospital, 
Madrid, Spain
Background: The CD14 membrane receptor is a mediator of inﬂammatory reactions. 
A C(-260)T polymorphism in the promoter region of the CD14 receptor gene has 
been associated with monocyte production of pro-inﬂammatory cytokines in patients 
with unstable angina and with the risk of myocardial infarction. Whether the C(-260) T 
polymorphism of the CD14 gene may inﬂuence the inﬂammatory status even in patients 
with stable coronary artery disease is still unknown.
Methods:The CD14 C(-260)T polymorphism was determined in 82 patients with stable 
coronary artery disease. Patients were divided into 3 groups: CC homozygotes, CT 
heterozygotes, and TT homozygotes. As a marker of inﬂammation, high sensitivity C-
reactive protein (hs-CRP) was assessed.
Results: (expressed as median and interquartile range): The genotype distribution was as 
follows: CC (18/82), CT (48/82), and TT (16/82). TT homozygotes had signiﬁcantly higher 
hs-CRP levels (0.49 mg/dL; 0.33-0.79 mg/dL) than carriers of both the CC (0.28 mg/dL; 
0.13-0.46 mg/dL; p<0.05) and CT (0.26 mg/dL; 0.14-0.37 mg/dL; p<0.05) genotypes.
Conclusions: The C(-260)T polymorphism in the promoter region of the CD14 receptor 
gene is associated with a higher degree of systemic inﬂammation in patients with stable 
coronary artery disease. This polymorphism allows to identify across the spectrum of 
manisfestations of coronary artery disease those patients genetically more prone to have 
higher hs-CRP levels and therefore with enhanced cardiovascular risk.
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931-250 Predictors of In-Hospital and Late (More Than 
Three Years) Death of Acute Myocardial Infarction 
Complicated by Cardiogenic Shock
Shinichi Shirai, Kenji Ando, Takashi Yamada, Yoshimitsu Soga, Katsuhiro Kondo, 
Koyu Sakai, Masashi Iwabuchi, Hiroyoshi Yokoi, Hitoshi Yasumoto, Hideyuki Nosaka, 
Masakiyo Nobuyoshi, Kokura Memorial Hospital, Kitakyushu, Japan
(Purpose)Acute Myocardial Infarction (AMI) complicated by cardiogenic shock had a poor 
prognosis even after revascularization therapy.
(inclusion criteria)
1) Systemic Pressure below 90mmHg or inotropic drug use to maintain systolic pressure 
>=90mmHg
2) Support Device was needed to maintain hemodynamic state
3) Without mechanical complication
Emergency revascularization (Percutaneus Coronary Intervention: PCI or Bypass 
surgery: CABG) was performed within 6 hours after admission.
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(Result) From Jan. 1995 to Sep. 2002, of the 2223 AMI patients, 197 patients (age 
70±11, woman 61pts (31%), prior MI 37pts (19%)) with cardiogenic shock were met the 
inclusion criteria. Overall mortality at hospital discharge was 73 pts (37%).Multivariate 
predictors of In-hospital death were Chronic renal failure (CRF)(Cre>1.5mg/dl):(Hazard 
Ratio (HR) 3.414, C.I: 1.553-7.503 , p=0.0022)and Left main trunk disease(LMTD):(HR 
3.885, C.I: 1.781-8.478, p=0.0007). Late death (mean follow-up interval 56±25 months) 
was occurred in 14 pts (Cardiac death(CD) 11 pts, Non-CD 3 pts). Multivariate predictors 
of late death were CRF(Cre>1.5mg/dl):(HR 11.836, C.I: 1.919-73.003 , p=0.0078), Poor 
LV:(HR 23.914, C.I: 4.530-126.233, p=0.0002) and Multi-vessel disease:(HR 4.626, CI: 
1.070-20.003).
(Conclusion) CRF and LMT disease were the predictors of in-hospital death even after 
early revascularization therapy. In the analysis of over three years follow-up, CRF, Poor LV 
and MVD were the predictors of late death.
931-251 Initial Heart Rate and Systolic Blood Pressure Provides 
Important Insights in the Risk-Stratiﬁcation of Age-
related Mortality Among Patients Presenting With 
Cardiogenic Shock and Acute ST-Elevation Myocardial 
Infarction Treated With Fibrinolysis
Rajendra H. Mehta, Robert A. Harrington, Qinghong Yang, Karen S. Pieper, Robert M. 
Califf, Christopher B. Granger, Duke Clinical Research Institute, Durham
Background: Elderly patients (pts) with cardiogenic shock (CS) complicating ST-
elevation myocardial infarction (STEMI) are perceived as a homogeneous group with poor 
survival, despite aggressive treatment. Yet, signiﬁcant heterogeneity exist in this cohort 
making identiﬁcation of elderly with better or worse prognosis helpful to guide aggressive 
therapies. Methods: We evaluated 771 STEMI pts with presenting CS receiving 
ﬁbrinolysis. We categorized pts into 3 age-groups <60 (n=224), 60-<75 (n=360) and >75 
(n=177) years. Results: Death at 30 days occurred in 118 (53%), 214 (59%) and 127 
(72%) of pts aged <60, 60-<75 and >75 years, respectively. Factors associated with death 
(per 10 unit change) on multivariable analysis were age (OR 1.43, 95% CI 1.23-1.66), 
heart rate (HR, OR 1.27, 1.19-1.35) and systolic blood pressure (SBP, OR 0.76, 95% CI 
0.71-0.81) (c index 0.79). Important age, HR, SBP interactions were found suggesting 
that while age was strongly associated with death among pts with HR <100, it was less 
strongly related to death in pts with HR >100 bpm. Furthermore, even elderly with SBP 
>80 had substantial chance of recovery. In contrast, those with SBP<80 mmHg and HR 
>100 bpm had 30-day death rates of >90% even if they were young. Conclusions: Our 
data suggest that presenting HR and SBP offers additional insights into age-related death 
in STEMI pts with CS receiving ﬁbrinolysis that may help physicians particularly while 
treating elderly pts with CS and counseling them about their perceived risks.
 
931-252 Evaluation of Cardiac Arrest During Severe Chronic 
Obstructive Pulmonary Disease (COPD) Exacerbations
Gabriel Sardi, Albert Einstein Medical Center, Philadelphia, PA
Background/objective: Variables reﬂecting heart dysfunction have been implicated in the 
high mortality associated with severe exacerbations of COPD. Cardiac arrest occurring in 
these patients has not been studied. We aimed to determine the demographic and clinical 
characteristics of patients with severe COPD exacerbations who suffered an unexpected 
cardiac arrest in the hospital setting.
Patients/Methods: Patients with the primary diagnosis of COPD exacerbation requiring 
mechanical ventilation who sustained a cardiac arrest between 1994 and 2004 were 
included; 208 medical records were reviewed, and 53 met inclusion criteria. Seventy 
demographic, clinical and laboratory variables were analysed. Patients with history of 
lung cancer, acute coronary syndrome at admission, pre-hospital cardiopulmonary arrest 
and those on comfort care were excluded.
Results: Mean age was 71 years. 57% were female. The mean Apache II score was 19 
points. Mortality rate was 93% (95%CI, 82%-90%). Before the arrest, circulatory collapse 
occurred in 38% of patients (95%CI, 25%-52%), and did not correlate with antecedent 
pneumonia or sepsis. Thirty-two percent of patients had ventricular arrhythmias prior to 
the arrest (95%CI, 20%-46%) and 64% had electrocardiographic changes suggestive 
of acute myocardial ischemia or infarction (95%CI, 46%-74%). Electrocardiographic 
changes were independent of a history of coronary artery disease (CAD), of the presence 
of hypoxia, acidosis and anemia. At the time of arrest, the most common initial rhythm 
was sinus bradycardia, occurring in 42% of patients. Initial survival was 40%, with only 
7% discharged from the hospital.
Conclusions: In patients with severe exacerbations of COPD, electrocardiographic 
changes suggestive of myocardial ischemia or infarction commonly precede cardiac 
arrest. This occurred even in patients without a documented history of CAD. Even though 
our patients had a relatively low APACHE score, their overall survival after cardiac arrest 
was extremely poor.
931-253 Elevated Cardiac Troponin is an Independent Predictor 
of in Hospital Mortality in the Medical Intensive Care 
Unit Patients
Luciano Babuin, Jorge R. Alegria, Bekele Afessa, Allan S. Jaffe, Mayo Clinic, Rochester, MN
Background: Troponin elevations are common in critically ill patients. In some series, 
they appear independent of the severity of disease. Accordingly, we evaluated the impact 
of troponin elevations in patients admitted to Medical Intensive Care Unit for non-cardiac 
reasons. We speciﬁcally tested their ability to independently predict hospital mortality 
after adjustment for severity of illness as measured by the APACHE (Acute Physiology, 
Age and Chronic Health Evaluation) III prognostic system which is a well validated robust 
predictor of in hospital mortality.
Methods: We examined the APACHE III database and cardiac troponin T (cTnT) levels of 
1662 patients consecutively admitted to the MICU at the Mayo Medical Center, Rochester, 
MN, between August 2000 and December 2001. Admission cTnT > 0.01 ng/mL were 
considered elevated. Chi square test, t-Tests (or Wilcoxon tests) and logistic regression 
were used for statistical analysis. The logistic regression model included observed 
hospital mortality as a dependent variable and admission cTnT elevation and APACHE 
III predicted hospital mortality rates as independent variables. Odds ratio (OR) and 95% 
conﬁdence interval (CI) were calculated.
Results: Troponin was measured in 929 (56%) of 1662 patients. Patients whose 
troponin was measured were older (mean = 67±15 vs 54±20, p<0.0001) and had a 
higher APACHE III score (mean = 63±29 vs 50±31, p<0.0001). Predicted in hospital 
mortality calculated by the APACHE III method was 22.8% in patients with troponin 
measurements and 15.2% in those without (p<0.0001). The observed mortality of 
patients with and without troponin measurements was 22.9% and 14.7%, respectively 
(p<0.0001). Troponin elevations occurred in 168 of 213 non-survivors (78.8%) and 402 
of 716 survivors (56.1%) (p<0.0001). Troponin elevation was an independent predictor of 
hospital mortality (OR=2.91, 95%CI=2.04-4.22, p<0.0001) even after adjustment for the 
APACHE III predicted mortality (adjusted OR= 1.8, 95%CI=1.23-2.81, p=0.0035).
Conclusions: Admission troponin elevations are independent predictors of hospital 
mortality even after correction for the severity of disease.
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932-254 Evaluation of Robotic Coronary Surgery by 
Intraoperative Angiography in Combination With 
Postoperative Multislice Computer Tomography
Guy Friedrich, Nicos Bonaros, Thomas Schachner, Guenther Laufer, Otmar Pachinger, 
Gudrun Feuchtner, Johannes Bonatti, University Hospital, Innsbruck, Austria
Background: Robotically assisted coronary artery surgery, in particular total endoscopic 
coronary bypass surgery (TECAB), is an innovative minimal invasive procedure requiring 
proof of immediate and short term patency of grafts to compete with conventional bypass 
surgery or percutaneous coronary interventions.
Methods: In 53 patients after robotic coronary surgery (31 arrested heart TECAB, 20 
via sternotomy robotically assisted anastomoses, 2 beating heart TECAB) intraoperative 
coronary angiography was performed with a mobile C-arm (OEC 9800, GE Healthcare). 
Within 3 months after surgery, all patients underwent 16 row ECG gated Multislice 
Computer Tomographic Angiography (MSCTA, Sensation 16, Siemens Medical Systems, 
Erlangen) and invasive coronary angiographic follow up.
Results: 51/53 bypass grafts could be visualized by intraoperative coronary angiography. 
Spasm of target vessels and/or bypass grafts (reversible after intraluminal nitroglycerine 
application) could be observed in 40%. In 6 patients (11%) immediate surgical revision 
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due to stenotic - occluded target vessel segments or anastomotic bleeding was required. 
No angiography related complications occurred. Follow up MSCTA and correlation to 
invasive catheterization showed patent grafts in all patients investigated. MSCTA image 
quality of proximal bypass anastomoses was judged excellent, scanning quality of distal 
anastomoses was of lower quality, but still sufﬁcient to judge patency.
Conclusions: The combination of intraoperative angiography and follow up MSCTA 
allows safe and high quality evaluation of immediate and short term outcome in innovative 
robotic coronary surgery.
932-255 Radial Artery Patency in CABG and Factors Affecting 
Long Term Outcome
Talal T. Baki, Ali Al-Housseini, Robert J. Applegate, Sanjay K. Gandhi, Michael A. 
Kutcher, Renato M. Santos, David C. Sane, Matthew T. Sacrinty, William C. Little, Wake 
Forest University School of Medicine, Winston-Salem, NC
Background:  Superior long term patency of LIMA over saphenous vein grafts (SVG) has 
generated interest in the use of alternative arterial conduits. Little is known about rates of 
and factors affecting long term patency of radial artery grafts (RAG).
Methods: We reviewed outcomes of patients who underwent CABG at WFU with the use of 
a RAG and subsequent cardiac catheterization. Graft stenosis rates by type of conduit were 
compared. Baseline characteristics and cardiac catheterization data were analyzed.
Results: From January 1998 till June 2004, 184 patients with a total of 482 grafts (194 
RAG, 169 LIMA, 110 SVG, and 9 RIMA) were identiﬁed. The mean time from CABG to 
angiography was 2 years. There were signiﬁcant differences in stenosis rates between 
conduit types (see table). Subgroup analysis in patients with both RAG’s and SVG’s 
revealed a probability of stenosis of 28.6% in RAG’s and 14.5% in SVG’s (p = 0.02) 
with an OR of 2.35 (95% C.I.: 1.17-4.73). Total occlusion of RAG was signiﬁcantly higher 
than SVG (21.6% vs 8.2%, p=0.0023). Factors associated with signiﬁcantly higher RAG 
stenosis were African-American patients (OR of 3.37, 95% C.I. = 1.06-10.73), native 
target artery stenosis < 70% (OR of 3.33, 95% C.I. = 1.56-7.14), and radial Y-graft off the 
LIMA (OR of 1.55, 95% C.I.: 1.02-2.34).
Conclusions: The RAG is inferior to LIMA and SVG for long term graft patency. The 
outcomes in RAG were particularly worse in African-American patients, native target 
artery stenosis < 70%, and in radial Y-graft off the LIMA.
932-256 Novel Intra-Operative Fluorescence Imaging System 
for On-Site Assessment of Off-Pump Coronary Artery 
Bypass Graft
Katsuhisa Waseda, Takao Hasegawa, Yoshihisa Shimada, Junya Ako, Fumiaki Ikeno, 
Paul G. Yock, Yasuhiro Honda, Peter J. Fitzgerald, Masao Takahashi, Stanford University, 
Stanford, CA, Hiratsuka Kyosai Hospital, Hiratsuka, Japan
Background: The aim of this study was to evaluate a novel intraoperative ﬂuorescence 
imaging (IFI) system, using the ﬂuorescence of indocyanine green (ICG) excited by 
infrared light, in real-time assessment of off-pump coronary artery bypass graft (CABG) 
surgery.
Method: A total of 379 grafts in 129 patients with off-pump CABG were intraoperatively 
assessed with IFI and Doppler transit-time ﬂowmetry (TTFM). Postoperative angiography 
was performed 13.5±6.3 days after surgery. The grafts were divided into 3 groups, based 
on the heartbeats required for ICG washout: good-ﬂow (≤15 beats), fair-ﬂow (>15 beats), 
and no-ﬂow groups.
Results: Initial IFI assessment revealed 178 grafts as good-ﬂow, 198 as fair-ﬂow, and 
3 as no-ﬂow. Immediately after IFI, 5 grafts of fair-ﬂow and 2 grafts of no-ﬂow were 
revised and ended as good-ﬂow. Compared to fair-ﬂow, good-ﬂow was associated with 
a higher preoperative ejection fraction (66±14% vs. 58±17%, p<0.05), internal mamary 
artery grafts (52% vs. 31%, p<0.001) and anterior lesion location (42% vs. 27%, p<0.05). 
TTFM showed varying degrees of graft ﬂow (range: 2 to 161 ml/min) with no signiﬁcant 
difference between good and fair-ﬂow groups. Postoperative angiography veriﬁed graft 
patency as 97% in patients with at least fair-ﬂow by IFI.
Conclusions: The new IFI system enables on-site assessment of graft patency, providing 
both morphologic and functional information. This unique technique may help reduce 
procedure-related, early graft failures.
932-257 Impact of Early Clopidogrel Use on Angiographic and 
Clinical Outcomes Following Coronary Artery Bypass 
Surgery: Findings from PREVENT IV
John H. Alexander, Peter B. Berger, Gail Haﬂey, Abhinav Goyal, Eric D. Peterson, 
Robert A. Harrington, T. Bruce Ferguson, Randal K. Wolf, Michael J. Mack, Nicholas 
Kouchoukos, Robert M. Califf, C. Michael Gibson, for the PREVENT IV Investigators, 
Duke University Medical Center, Durham, NC, PERFUSE Angiographic Core 
Laboratory, Harvard, Boston, MA
Background: Dual antiplatelet therapy (aspirin and a ADP antagonist) is beneﬁcial post 
PCI and ACS. Dual antiplatelet therapy is increasingly being given early after coronary 
artery bypass (CABG), although little is known about its efﬁcacy.
Methods: PREVENT IV was a randomized, placebo-controlled trial of edifoligide in 3014 
patients undergoing CABG at 107 US sites. One-year angiographic and MACE (death, 
MI, or revascularization) follow-up is complete in 1920 (80% of the planned angiographic 
cohort) and 2996 (99.4%) of enrolled patients. Post-operative antiplatelet therapy was left 
to physician discretion. We compared angiographic and clinical outcomes among patients 
taking and not taking clopidogrel at 30 days.
Results: At 30-days, 634 (21%) patients were taking clopidogrel and 2327 (79%) were 
not. Aspirin use was similar in patients taking and not taking clopidogrel (90% vs 92%). 
Of those on clopidogrel at 30 days, 56% remained on clopidogrel at 1 year. Clopidogrel 
users were of similar age (63 vs 64 yrs), had similar rates of diabetes (38% vs 39%), 
had more peripheral (15% vs 11%, p=0.03) and cerebrovascular disease (17% vs 11%, 
p<0.001), more prior MI (46% vs 41%, p=0.01), less prior atrial ﬁbrillation (3.8% vs 7.6%, 
p=0.001), longer surgery duration (240 vs 229 min, p=0.001), and more off-pump surgery 
(33% vs 18%, p<0.001) than patients not taking clopidogrel. Angiographic vein graft 
failure (≥75%) was more common in clopidogrel users (30.3% vs 23.8%, p<0.001) even 
after adjusting for differences in signiﬁcant predictors of graft failure (target artery quality, 
length of surgery, endoscopic vein harvest, >1 distal anastomosis/graft, and weight) (OR 
1.32, 95% CI 1.09-1.60, p=0.005). Clopidogrel users also had more MACE before (10.1% 
vs 6.3%, p<0.001) and after adjusting for differences in signiﬁcant predictors of MACE 
(age, gender, heart failure, atrial ﬁbrillation, and smoking) (HR 1.61, 95% CI 1.20-2.18, 
p=0.002).
Conclusions: Although observational, these data do not support a beneﬁcial effect 
of dual antiplatelet therapy following CABG. An adequately powered, randomized trial 
is needed before widespread adoption of dual antiplatelet therapy following CABG is 
recommended.
932-258 Impact of Perioperative Myocardial Infarction on 
Angiographic and Clinical Outcomes Following 
Coronary Artery Bypass Surgery: Findings From 
PREVENT IV
James M. Yau, John H. Alexander, Gail Haﬂey, Kenneth W. Mahaffey, Michael J. Mack, 
Nicholas T. Kouchoukos, Abinav Goyal, Eric D. Peterson, C. Michael Gibson, Robert M. 
Califf, Robert A. Harrington, T. Bruce Ferguson, for the PREVENT IV Investigators, Duke 
University Medical Center, Durham, NC
Background: Myocardial necrosis after CABG is associated with postoperative 
morbidity and mortality; however, the contemporary frequency, predictors, and clinical 
consequences of periop MI remain poorly understood.
Methods: PREVENT IV was a randomized, placebo-controlled trial of edifoligide in 3014 
patients undergoing CABG at 107 US sites. One-year angiographic and MACE (death, 
postop MI, or revascularization) follow-up is complete in 1920 (80% of the angiographic 
cohort) and 2996 (99.4%) patients. Periop MI was deﬁned as CK-MB elevated >10x the 
upper limit of normal or >5x the upper limit of normal with new 30ms Q-waves within 24 
hrs of surgery. We compared angiographic and clinical outcomes of patients with and 
without periop MI.
Results: Periop MI occurred in 294 (9.8%) of patients. Patients with periop MI were similar 
in age and had similar rates of diabetes, hyperlipidemia, peripheral and cerebrovascular 
disease, prior MI, and heart failure but longer surgery duration (250 vs 230 min, p<0.001) 
and more on-pump surgery (83% vs 78%, p=0.048) than those without periop MI. ICU 
stay was longer in patient with periop MI (26 vs 29 hrs, p<0.001). Periop MI patients had 
similar inhospital use of ASA, ACE inhibitors, and beta blockers, more use of clopidogrel, 
heparin, diureics, digoxin, inotropes, and amiodarone, and less use of statins than those 
without periop MI. Vein graft failure (>75%) was more common in patients with periop MI 
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(35.8% vs 24.2%, p<0.001) even after adjusting for differences in signiﬁcant predictors 
of graft failure (target artery quality, length of surgery, endoscopic vein harvest, >1 
distal anastomosis/graft, and weight) (OR 1.56, 95% CI 1.22-2.00, p<0.001). Patients 
with periop MI had more MACE before (14.3% vs 7.8%, p<0.001) and after adjusting for 
differences in signiﬁcant predictors of MACE (age, gender, heart failure, atrial ﬁbrillation, 
and smoking) (HR 1.87, 95% CI 1.34-2.62, p<0.001).
Conclusions: In contemporary clinical practice, perioperative MI is frequent and 
associated with longer surgery duration and on-pump CABG. Patients with periop MI have 
substantially worse long-term outcomes. Further research is needed into the prevention 
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949-215 CD44 Critically Regulates Healing of Myocardial Infarcts
Peter Huebener, Pawel Zymek, Marcin Bujak, Tareq Abou-Khamis, Thorsten Leucker, 
Guofeng Ren, Geeta Thakker, Mark L. Entman, Nikolaos G. Frangogiannis, Baylor 
College of Medicine, Houston, TX
Background: CD44 is a transmembrane adhesion molecule with a role in inﬂammatory 
processes mediated in part through interactions with hyaluronan. CD44 modulates 
leukocyte trafﬁcking, promotes resolution of inﬂammation through removal of dead 
cells and debris, and regulates ﬁbroblast behavior. We hypothesized that CD44 may be 
important in post-infarction cardiac repair and left ventricular remodeling by modulating 
inﬂammation and ﬁbrous tissue deposition.
Methods: We studied the inﬂammatory response, ﬁbrous tissue deposition and 
remodeling in CD44 -/- and WT mice using a model of reperfused infarction. We also 
examined CD44 expression by isolated mouse cardiac ﬁbroblasts.
Results: WT animals showed marked upregulation of CD44 mRNA expression after 6h 
of reperfusion. CD44 was expressed on inﬁltrating leukocytes, and wound myoﬁbroblasts 
in the infarcted myocardium. CD44 -/- animals showed enhanced expression of pro-
inﬂammatory cytokines (TNF-α, IL-1β, IL-6) and increased neutrophil (p<0.05) and 
macrophage (p<0.05) inﬁltration during the early stages of reperfusion when compared 
to their WT littermates. During the proliferative phase of healing, ﬁbroblast inﬁltration 
was diminished in CD44-/- animals (p<0.05) and the amount of collagen in the scar 
was signiﬁcantly reduced (p<0.05). In CD44 -/- mice, decreased collagen content was 
associated with enhanced adverse remodeling (LVEDV -/-: 47.5 ± 15.7 vs WT: 34.8 ± 
4.1 mm³, p=0.06), whereas infarct size was similar in both groups. In vitro experiments 
demonstrated that TNF-α and bFGF markedly induced CD44 mRNA synthesis by isolated 
cardiac ﬁbroblasts.
Conclusions: CD44 critically regulates inﬂammation and ﬁbrous tissue deposition in 
healing infarcts. CD44 gene disruption results in enhanced inﬂammation, possibly through 
defective clearance of hyaluronan fragments and debris from the infarcted myocardium. 
In addition, CD44 deﬁciency decreases ﬁbroblast inﬁltration in the infarct, probably by 
disrupting cellular interactions with newly deposited hyaluronan-based matrix. These 
defects enhance adverse remodeling.
949-216 Persistent Reductions in Flow and Function After 
Revascularization of Swine With Hibernating 
Myocardium
Michael D. Banas, Herbert Young, James A. Fallavollita, John M. Canty, Jr., University at 
Buffalo, Buffalo, NY, WNY VA Medical Center, Buffalo, NY
Background. The time course of functional recovery of hibernating myocardium is 
controversial and it is unclear whether regional reductions in resting ﬂow and systolic wall 
thickening (WT) completely normalize after revascularization.
Methods. We chronically instrumented 6 pigs with silastic LAD stenoses (1.5 mm). After 
3 months, reductions in resting LAD ﬂow (0.7 ± 0.1 vs. 1.1 ± 0.1 ml/min/g, p<0.05) and 
WT (3.8 ± .3 vs. 7.5 ± .7 mm, p<0.05) indicative of hibernating myocardium, were present. 
Revascularization was accomplished via PCI with measurements of ﬂow (microspheres) 
and function (echo WT) evaluated for up to 1 month.
Results. Immediately after PCI, vasodilated ﬂow normalized (LAD 5.8 ± 0.8 vs. 6.0 ± 
1.0 ml/min/g) but resting ﬂow remained reduced (LAD 0.8 ± 0.1 vs. 1.2 ± 0.1 ml/min/g, 
p<0.05). LAD WT (Figure) increased over the subsequent week but remained signiﬁcantly 
depressed as late as 1 month. Although there was no restenosis, resting ﬂow continued 
to be reduced (LAD ﬂow 1.2 ± 0.1 vs. 1.5 ± 0.1 ml/min/g in remote, p<0.05). TTC staining 
demonstrated no infarction.
Conclusions: 1.) There is no immediate improvement in function in hibernating 
myocardium, 2.) Late functional recovery falls short of complete normalization in the 
absence of infarction and 3.) Relative reductions in resting ﬂow persist in the absence 
of restenosis or infarction. Thus, intrinsic adaptive responses that downregulate 
regional energy demand and function do not completely normalize 1 month after 
revascularization.
 
949-217 Erythropoietin Receptor and Anti-Apoptotic Effect 
of Erythropoietin on Anoxia/Reoxygenation Injury in 
Endothelial Cells
B. Daan Westenbrink, Jan Veerbeek, Erik Lipsic, Peter van der Meer, Rob H. Henning, 
Wiek H. van Gilst, University Medical Centre Groningen, Groningen, The Netherlands
Background: Recently expression of the erythropoietin receptor (EPOR) was discovered 
on endothelial cells. Therefore, we hypothesized that erythropoietin (EPO) might protect 
the endothelium against ischemia reperfusion injury.
Methods: Bovine arterial endothelial cells (BAEC) were subjected to increasing time of 
anoxia (100% N2, 5-60 min). The EPOR was quantiﬁed by Western blot and visualized by 
confocal microscopy. Activation of EPOR signaling pathways was quantiﬁed by Western 
Blot. To study the effects of EPO on apoptosis, BAEC were subjected to 24-hour anoxia 
followed by 6-hour reoxygenation. EPO (10 IU/ml) was administered 24 hours before 
anoxia, at the start of anoxia and at the start of reoxygenation. Apoptosis was evaluated 
by measuring the activity of caspase-3.
Results: Anoxia gradually induced up to a two-fold increase in protein levels of EPOR 
(ﬁgure 1a,b). EPO treatment during anoxia or reoxygenation resulted in signiﬁcant 
reduction of apoptosis, independent of timing. (ﬁg 1c). This was associated with activation 
of STAT-5, Akt-1.
Conclusions: EPOR expression in endothelial cells is upregulated during anoxia. EPO 
treatment attenuates apoptosis in endothelial cells by activating STAT-5, Akt-1 and MAPK. 
This property might be important during myocardial ischemia reperfusion injury. 
949-218 Thyroid Hormone Receptors α1 and β1 Are 
Downregulated in the Post-infarcted Rat Heart: 
Consequences on the Response to Ischaemia-
reperfusion
Costas Pantos, Iordanis Mourouzis, Theodosios Saranteas, George Charitsis, Ioannis 
Paizis, Christina Tesseromatis, Dennis V. Cokkinos, University of Athens, Athens, 
Greece, Onassis Cardiac Surgery Center, Athens, Greece
Background: This study investigated whether thyroid hormone (TH) signalling is altered 
during cardial remodelling after myocardial infarction (MI) and the possible consequences 
on function and response to ischaemia/reperfusion (I/R). 
Methods: Wistar rats were subjected to left coronary artery ligation (AMI), or sham 
operation (SHAM). After 8 weeks, hearts from AMI and SHAM rats were perfused in 
Langendorff mode and subjected to 20 min of zero-ﬂow global I and 45 min of R; AMI(I/R), 
n=7 and SHAM(I/R), n=7. Recovery of function was expressed as % of the initial value of 
left ventricular developed pressure (LVDP%). Left ventricular end-diastolic pressure was 
measured at 45 min of R (LVEDP45 in mmHg). Expression of TH responsive genes, i.e. 
Na+/H+ exchanger (NHE), SR Ca2+-ATPase (SERCA), PKCε and TH receptors α1 and 
β1 (TRα1, TRβ1) were determined by western blotting in SHAM hearts and in the non-
infarcted myocardium of AMI hearts.
Results: Hemodynamic data are shown in Table.
T3 and T4 plasma levels were not altered. TRα1 and TRβ1 were 1.3 and 1.8 fold lower 
in AMI than in SHAM hearts, p<0.05. SERCA and NHE1 expression was 2.1 and 1.8 
fold lower in AMI than in SHAM, p<0.05. PKCε was 1.3 fold higher in AMI compared to 
SHAM, p<0.05.
Conclusions: A hypothyroid like phenotype occurs after MI and may account for 
suppressed cardiac function but increased tolerance to I/R providing endogenous 
protection to the post-infarct myocardium.
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LVDP LDH release LVDP% LVEDP45
AMI-I/R 83.6 (7.9) 256 (102) 79.8 (4.3)% 20.3 (3.2)
SHAM-I/R 125.4 (4.9)* 656 (71) * 53.6 (6.1)%* 50.6 (4.8)*
 
949-219 Thyroid Hormone Protects the Heart Against Ischaemia-
Reperfusion Injury Through a Redox Regulated Survival 
Signaling
Costas Pantos, Vassiliki Malliopoulou, Iordanis Mourouzis, Anastasia Thempeyioti, 
Ioannis Paizis, Christodoulos Xinaris, Antonis Dimopoulos, Demosthenes D. Cokkinos, 
Dennis V. Cokkinos, Onassis Cardiac Surgery Center, Athens, Greece
Background: Accumulating evidence shows that long term pretreatment with thyroxine 
protects the heart in a similar pattern as ischaemic preconditioning. The present study 
investigated whether this response involves a redox regulated survival signaling.
Methods: L-thyroxine (T4) (25 µg/100g/day s.c.) was administered to Wistar rats for 
2 weeks (THYR, n=5), while normal animals served as controls (NORM, n=5). NORM 
and THYR isolated hearts were perfused in Langendorff mode and subjected to 20 min 
of zero-ﬂow global ischaemia (I) followed by 45 min of reperfusion (R), NORM-I/R, n=8 
THYR-I/R n=8. Postischaemic recovery of left ventricular developed pressure at 45 min of 
R was expressed as % of the initial value (LVDP%). The expression of the redox regulated 
heat shock proteins such as HSP27 and HSP70 were assessed by western blotting. Basal 
myocardial malondialdehyde (MDA) levels (µmol/g left ventricular weight) were measured 
as an index of oxidative stress.
Results: Basal MDA levels were 41.2 (2.1) µmol/g in THYR hearts as compared to 28.9 
(1.9) in NORM hearts, p<0.05. Baseline total HSP27 and phospho-HSP27 levels were 
increased in THYR hearts, 1.5 and 1.6 fold respectively as compared to NORM, p<0.05. 
In addition, HSP70 expression was increased 1.8 fold in THYR vs NORM hearts, p<0.05. 
Baseline LVDP was 121.4 (4.9) for NORM-I/R and 133.4 (4.7) for THYR-I/R, p>0.05. In 
response to I/R, LVDP% was 62.4 (4.2) for THYR-I/R vs 45.8 (5.5) for NORM-I/R, p<0.05.
Conclusions: Thyroid hormone protects the heart against I/R injury possibly by up-
regulating redox dependent survival signalling resulting in increased myocardial HSP70 
and HSP27 levels.
949-220 Bay 11-7082, an Inhibitor of NF-κB, Improves Post-
Ischemic Ventricular Dysfunction in Rats
Yong Sook Kim, Youngkeun Ahn, Soo Yeon Joo, Jong Eun Park, Moon Hwa Hong, 
Jeong Ha Kim, Young Joon Hong, Kye Hun Kim, Il Seok Sohn, Hyung Wook Park, Ju 
Han Kim, Weon Kim, Myung Ho Jeong, Jeong Gwan Cho, Jong Chun Park, Jung Chaee 
Kang, Chonnam National University Hospital, Gwangju, South Korea
Background: Nuclear factor kappa-B (NF-κB) is a transcription factor responsible for rapid 
responses to cytokines, oxidative stress, and ischemia-reperfusion (I/R) in several tissues. 
However, it is controversial whether NF-κB activation during I/R is cardioprotective or not.
Methods: We investigated the efﬁcacy of BAY 11-7082, an inhibitor of NF-κB, in a 
neonatal cardiomyocyte (CM) and rat myocardial I/R model. I/R was induced by ligation of 
left anterior descending coronary artery (LAD) for 30 min followed by release. Saline (S) 
or BAY 11-7082 (130 µg/kg) were given intraperitoneally 15 min after LAD ligation.
Results: BAY 11-7082 inhibited phosphorylation of IκBα and nuclear translodation of 
NF-κB p65 induced by TNF-α (10 ng/mL) in cultured CMs. TNF-α induced production 
of interleukin-8 and vascular cell adhesion molecule-1 from cultured CMs was reduced 
signiﬁcantly by BAY 11-7082. Infarct size was reduced in BAY 11-7082 treated rats (%MI; 
23.1±5.5 % vs. 10.3±6.8 %, p=0.031, n=8 in each group) after 24h I/R. BAY 11-7082 
preserved shortening fraction ratio (20.4±5.3 % vs. 31.0±5.4 %, p=0.001, n=8 in each 
group) and ejection fraction (46.2±10.0 % vs. 63.7±7.9 %, p=0.001, n=8 in each group) in 
four weeks after I/R. The number of apoptotic cardiac myocytes were lower in BAY treated 
I/R rats (76.5±21.2 % of control, p=0.042, n=8 in each group).
Conclusions: This study suggests that the inhibition of NF-κB could provide an effective 
approach to attenuate myocardial I/R injury in acute and improve ventricular function in 
chronic term.
949-221 Intracoronary Mesenchymal Stem Cell or Endothelial 
Progenitor Cell Transfer Post Myocardial Infarction 
Prevents Negative Remodeling but Fails to Enhance 
Global Functional Recovery
Christophe L. Dubois, Daisy Thijs, Glenn Marsboom, Helène Depelteau, Peter Liu, 
Witold Streb, Lertlak Chaothawee, Frederik Maes, Marc Swinnen, Hilde Gillijns, Marijke 
Pellens, Desiré Collen, Frans Van de Werf, Stefan Janssens, University Hospital 
Gasthuisberg, Leuven, Belgium
Background: Cardiac transfer of stem cells may improve myocardial performance 
following acute myocardial infarction (AMI) but comparative studies with distinct cell 
populations in a relevant preclinical model are scarce.
Methods: In a blinded, randomized, sham-controlled study, transfer of allogeneic porcine 
LentiGFP-infected mesenchymal stem cells (MSC, n=8, 10.35±2.57x10E6 cells), autologous 
endothelial progenitor cells (EPC, n=6, 39.03±20.63x10E6 cells) or sham injection (Con, n=5) 
was performed in the infarct related artery 1 week after AMI induced by 90 minutes balloon 
occlusion of the circumﬂex artery. Left ventricular (LV) function was analyzed invasively 
(dP/dtmax/min) and using magnetic resonance imaging by determination of ejection fraction at 
the time of MSC/EPC/sham delivery and before sacriﬁce at 7 weeks. LV remodeling was 
evaluated by serial measurements of end-diastolic and end-systolic volumes. Infarct size was 
quantiﬁed as the late enhancement volume after gadolinium contrast injection.
Results: Plasticity of cultured MSC was conﬁrmed using adipogenic and osteogenic 
differentiation protocols. EPC phenotype was documented using ﬂow cytometry (99% 
CD31+, 1.6%CD45+), acetylated LDL uptake and tube formation on matrigels. Changes 
in LV dP/dtmax/min from 1 to 7 weeks were not signiﬁcantly different between groups. Global 
LV ejection fraction was reduced 1week after AMI at 39±9, 36±10 and 42±12% in MSC, 
EPC, and Con, respectively, and did not increase signiﬁcantly over time. In contrast, LV 
end-diastolic volume increased from 1 to 7 weeks in Con (+99±54 %) but not in MSC or 
EPC (+15±40% and +15±44%, P=0.068 by Kruskal Wallis). Infarct volume decreased 
over time by 36±18% in MSC, versus 58±18% and 34±15% in EPC and Con (P=0.10). 
Conclusion: Selective targeting of areas of myocardial necrosis by MSC or EPC transfer 
limits maladaptive ventricular remodeling but is not associated with improved global 
functional recovery. These data suggest that MSC or EPC transfer does not mediate 
cardiomyogenesis but may beneﬁcially affect LV remodeling via paracrine matrix-
modulating or angiogenic effects.
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950-215 Unrecognized Myocardial Infarction: The Association 
With Cardiopulmonary Symptoms and Mortality is 
Mediated Via Echocardiographic Abnormalities of 
Global Dysfunction Instead of Regional Dysfunction. 
The Olmsted County Heart Function Study
Khawaja A. Ammar, Richard J. Rodeheffer, Mayo Clinic, Rochester, MN
Background: There are very few data describing the association of ECG based 
unrecognized myocardial infarction (UMI) with non-anginal cardiopulmonary symptoms 
(NACS), echocardiographic abnormalities and mortality in the community
Methods: We studied 2,042 Olmsted County residents, randomly selected, age ≥45 
years, by a survey questionnaire for NACS, echocardiogram for structural abnormalities 
and a 5-year follow-up for all-cause mortality. UMI (n=81) were diagnosed if ECG-MI 
criteria were met without the history of a documented recognized myocardial infarction.
Results: In UMI vs. No MI controls the prevalence (%) of dyspnea on exertion (49 vs. 
29), orthopnea (6 vs. 4), palpitations (20 vs. 15) and history of ﬂuid overload (6 vs. 1) 
was signiﬁcantly higher (p<0.05). The associations of exertional dyspnea and history of 
ﬂuid overload with UMI were independent of age, sex and pulmonary disease, but had a 
signiﬁcant reduction in their magnitude after adjusting for global dysfunction (diastolic or 
systolic dysfunction). All the four NACS were associated with increased risk of mortality 
(hazard ratios ranging from 2.3 to 9.1; p<0.0001), which was meaningfully attenuated by 
adjusting for ECG-UMI status. Global ventricular dysfunction had a more signiﬁcant impact 
on this association than regional ventricular dysfunction (wall motion abnormalities).
Conclusions: The increased risk of mortality associated with NACS is at least in part 
mediated via ECG-UMI. Structural abnormalities of global dysfunction play a greater role 
in mediating this risk than regional dysfunction, challenging the current clinical practice 
of calling an ECG-MI false positive in symptomatic adults in the absence of wall motion 
abnormalities.
950-216 Early Electromechanical Changes Following Acute 
Coronary Artery Microembolization
Carlos L. del Rio, Patrick I. McConnell, Bradley D. Clymer, Roger Dzwonczyk, George E. 
Billman, Robert E. Michler, Michael B. Howie, The Ohio University, Columbus, OH
Background: Coronary microembolization is a common pathological ﬁnding in sudden 
cardiac death (SCD) cases. However, studies assessing the impact of microembolization 
on myocardial electrical inhomogeneities and electrotonic uncoupling, two established 
substrates of SCD, are lacking.
Methods: Adult sheep were chronically instrumented for myocardial electrical impedance 
(MEI), hemodynamics and left ventricular (LV) functional measurements. We compared 
the early changes in LV function and MEI during acute occlusion (N=5, CAO) and 
percutaneous microembolization (N=7, CME) of the left circumﬂex coronary artery 
(LCXa).
Results: After CAO and CME, systolic segment shortening decreased signiﬁcantly 
from baseline (CAO: 15.1±3.1%, CME: 10.9±1.5%) reaching 3.9±0.7% and 1.6±0.7% 
(respectively, at 30s). Both insults signiﬁcantly increased the MEI of the LCXa distribution 
(see ﬁgure); however CME resulted in a faster (p<0.05) progression (CAO: 2.5±0.6%, vs. 
CME: 7.0±0.8% at 30s).
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Conclusion: Coronary microembolization resulted in sudden MEI changes reﬂecting 
electrotonic uncoupling, a known substrate for malignant arrhythmias and SCD.
950-217 Abnormal Myocardial Transmural Shear Strains Persist 
During Evolution From Acute Ischemia to Infarction
Tom C. Nguyen, Frank Langer, Allen Cheng, Filiberto Rodriguez, George T. Daughters, 
Neil B. Ingels, Jr., D. Craig Miller, Stanford University School of Medicine, Stanford, CA, 
Palo Alto Medical Foundation Research Institute, Palo Alto, CA
Background: Altered cardiac strains adjacent to an acutely ischemic region after 70 
seconds of mid-circumﬂex occlusion were recently demonstrated. Such alterations could 
trigger the deleterious LV remodeling cycle. Whether these abnormal strains persist 
during evolution to acute infarction, however, remains unknown. We tested the hypothesis 
that shear strain perturbations immediately following ischemia persisted after 1 hour.
Methods: 15 sheep had 2 triads of radiopaque bead columns inserted into the anterior-basal 
and midlateral LV wall, with additional markers silhouetting the LV. One week later, animals 
underwent ligation of a obtuse marginal (OM) coronary artery; 4-D marker coordinates 
were obtained both before and 1 hour after OM occlusion. Fractional area shortening (FAS) 
as well as cardiac systolic shear strains were quantiﬁed in the circumferential-longitudinal 
(ECL), longitudinal-radial (ELR), and circumferential-radial (ECR) planes.
Results: Acute infarction increased EDV (150±66 to 162±76ml), ESV (115±54 to 123±60ml) 
and EDP (15±6 to 22±7ml), all p<0.007. Posterolateral-equatorial and posterolateral-
apical FAS decreased, while posteroseptal-basal and anterolateral-basal FAS increased 
(all p<0.02), a contraction pattern noticeably different than prior acute ischemia studies. 
Subepicardial and midwall ECR shear strain increased adjacent to the infarct (0.03±0.04 
vs. 0.06±0.03, 0.04±0.04 vs. 0.08±0.03, respectively [both p<0.03]), similar to the previous 
ﬁnding after acute ischemia. Moreover, in a LV region remote from the infarcted myocardium, 
anterior-basal midwall and subendocardial radial (ERR) strain increased (0.21±0.07 vs. 
0.33±0.10, 0.31±0.15 vs. 0.54±0.21, respectively [both p<0.02]).
Conclusions: Increased shear strain (ECR) adjacent to acutely ischemic myocardium 
(presumably before molecular injury and repair processes could be established) persisted 
out to 1 hour post MI, after the onset of presumably irreversible myocyte injury. Shear 
strains were also markedly perturbed remote from the infarction. The persistence of 
abnormal shear strains adjacent to the infarct could serve as a catalyst for post-infarct 
cellular remodeling.
950-218 Alimentary Lipemia Enhances Procoagulatory Effects 
of Inﬂammation in Patients With a History of Acute 
Myocardial Infarction Complicated by Ventricular 
Fibrillation
Thorsten Kaelsch, Elif Elmas, Xuan Duc Nguyen, Harald Klueter, Tim Sueselbeck, 
Martin Borggrefe, Carl-Erik Dempﬂe, University Hospital Mannheim, Mannheim, 
Germany, Institute of Transfusion Medicine and Immunology, Mannheim, Germany
Background: Acute myocardial infarction, often occurring postprandially, can be 
complicated by ventricular ﬁbrillation. The role of acute alimentary lipemia and 
inﬂammation in the occurrence of ventricular arrhythmias in acute myocardial infarction 
have not been described yet.
Methods and Results: Before and two hours after consumption of a fatty meal, 
whole blood samples of 27 patients with a history of acute myocardial infarction were 
incubated with lipopolysaccharide (LPS). In 10 patients, acute myocardial infarction was 
complicated by ventricular ﬁbrillation (VF), in 17 patients myocardial infarction occurred 
without ventricular ﬁbrillation. CD40-ligand and CD62P expression on platelets, tissue-
factor binding on monocytes and platelet-monocyte aggregates were measured with ﬂow 
cytometry. Soluble CD40-ligand plasma levels were measured with an ELISA.
Alimentary lipemia had no signiﬁcant effect on platelet-monocyte aggregates and on 
tissue factor expression on monocytes in both patient groups. LPS stimulation before 
the meal showed a non-signiﬁcant increase in platelet-monocyte aggregates and tissue 
factor on monocytes in both patient groups. LPS stimulation in acute alimentary lipemia 
signiﬁcantly increased platelet-monocyte aggregates in patients with VF but not in 
patients without VF. Tissue factor expression on monocytes was signiﬁcantly increased 
in both patient groups. Alimentary lipemia and LPS challenge had no signiﬁcant effects 
on CD62P and CD40L expression on platelets. Acute alimentary lipemia signiﬁcantly 
decreased plasma levels of sCD40L, leading to a signiﬁcantly lower level of sCD40L in 
patients with a history of VF compared to patients without VF
Conclusions: Alimentary lipemia enhances procoagulatory effects of inﬂammatory 
stimulation in patients with a history of acute myocardial infarction complicated by 
ventricular ﬁbrillation. These observations might reveal a mechanism for an increased 
risk of postprandial ventricular ﬁbrillation in acute coronary syndromes.
950-219 Cardiospeciﬁcity of the 3rd Generation Cardiac Troponin 
T Assay After a 216 km Ultra-Endurance Marathon Run 
in the Death Valley
Susanne Korff, H. J. Roth, R. M. Leithäuser, H. Doppelmayr, M. Doppelmayr, H. Finkernagel, 
S. P. von Duvillard, R. Beneke, Hugo A. Katus, Evangelos Giannitsis, University of 
Heidelberg, Heidelberg, Germany, Laboratory Dr. Limbach, Heidelberg, Germany
Background. The reasons for the appearance of cardiac-speciﬁc troponin after strenuous 
exercise are unclear. The aim of the present study was to evaluate the cardiospeciﬁcity of 
the 3rd generation cardiac troponin T (cTnT) assay after an ultra-endurance race of 216 
km at extreme environmental conditions in the Death Valley. 
Methods. We measured serially cTnT, CK, CK-MB (mass and activity), Myoglobin and NT-
pro BNP in 10 well-trained athletes before, during and after the Badwater ultramarathon 
race under extreme heat. 
Results. 9 of 10 participants ﬁnished the race within a preset time of 60 hours. Postrace 
values of biochemical markers CK, CK-MB (mass and activity), Myoglobin and NT-
proBNP were signiﬁcantly increased compared to baseline (p<0,05). CK-MB activity 
increased from median 12 U/L to 72 U/L and CK increased from median 36 U/L to 3,570 
U/L respectively. Pre-race median Myoglobin was 27 µg/l compared to 530 µg/L after the 
run. NT-pro BNP increased from 16.8 ng/L to 308 ng/L. One runner developed signiﬁcant 
exercise-induced rhabdomyolysis with spontaneous recovery. cTnT values remained 
below the 99th percentile in all athletes including the runner who developed signiﬁcant 
rhabdomyolysis (peak CK 27,951 U/L). 
Conclusions. Strenuous endurance exercise, even under extreme environmental 
conditions, does not result in structural myocardial damage in well-trained ultraendurance 
athletes. We found no crossreactivity between cTnT and CK, neither in exercise-induced 
skeletal muscle trauma nor after rhabdomyolysis underscoring the excellent analytical 
performance of 3rd generation cTnT assay.
950-220 Intracoronary Infusion of Gd3+ Into the Ischemic 
Region Does not Suppress Phase Ib Ventricular 
Arrhythmias After Coronary Occlusion in Swine
Jose A. Barrabes, David Garcia-Dorado, Luis Agullo, Antonio Rodriguez-Sinovas, Ferran 
Padilla, Lourdes Trobo, Jordi Soler-Soler, Hospital Vall d’Hebron, Barcelona, Spain
Background: Increased mechanical tension in the ischemic region during acute coronary 
occlusion might favor the occurrence of phase Ib ventricular arrhythmias. We aimed to 
investigate whether intracoronary administration of Gd3+, a stretch-activated channel 
blocker, into the ischemic zone reduces the incidence of these arrhythmias.
Methods: In thiopental-anesthetized, open-chest pigs, the left anterior descending 
coronary artery (LAD) was ligated for 45 or 48 min. Phosphate-free, HEPES-buffered 
saline bubbled with 100% N2 was infused into the ischemic region for 4 min, starting 5 min 
(series A, n = 16) or 20 min (series B, n = 16) after coronary occlusion, at a rate doubling 
the baseline blood ﬂow. Animals were blindly allocated to receive 40 µM Gd3+ or only the 
buffer during the 2 ﬁnal minutes of the infusion. Regional myocardial segment length was 
monitored by means of ultrasonic crystals.
Results: There were not signiﬁcant intergroup differences with respect to hemodynamic 
variables, plasma K+ levels or size of the ischemic region. A mild myocardial edema, of 
similar magnitude among the groups, was present in the ischemic region at the end of the 
experiment. In none of the series was the number of phase Ib premature ventricular beats 
reduced by Gd3+ (46 ± 20 in controls vs. 91 ± 37 in treated animals in series A and 19 ± 7 vs. 
22 ± 13, respectively, in series B, both P = NS). The occurrence of ventricular tachycardia 
or ﬁbrillation during the Ib phase was closely related to the magnitude of early ischemic 
expansion of the LAD region (15 min after coronary occlusion, enddiastolic length was 
121.3 ± 2.6% of the baseline value in animals with phase Ib ventricular tachyarrhythmias 
and 112.6 ± 1.5% in those without, P = 0.005) but was also not prevented by Gd3+.
Conclusions: These results argue against a major role of stretch-activated channels 
located inside the area at risk in the genesis of phase Ib ischemic ventricular arrhythmias. 
In view of the close association between early ischemic expansion and malignant 
arrhythmias, the contribution of stretch-activated channels in the border zone deserves 
further investigation.
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951-222 Recurrent Ischemia Detected by Continuous 
Electrocardiogram Recording After Percutaneous 
Coronary Intervention for Non-ST-Elevation Acute 
Coronary Syndromes
Benjamin M. Scirica, C. Michael Gibson, Sabina A. Murphy, David A. Morrow, Ajay 
Kirtane, Polly Fish, Carolyn H. McCabe, Peter H. Stone, Brigham and Women’s Hospital, 
Boston, MA
Background: The importance of recurrent (RI)ischemia after PCI is not clearly deﬁned. 
Continuous ECG (CECG) monitoring improves the sensitivity for detecting RI. Methods: 
The PROTECT-TIMI 30 trial randomized 841 pts undergoing PCI for NSTEACS to 
eptiﬁbatide/heparin or bivalirudin. CECG monitoring began immediately after PCI and 
lasted for ≥48hrs. RI was deﬁned as ST dev ≥1.0mm lasting ≥1 min. Myocardial infarction 
(MI) post PCI was deﬁned as CKMB ≥3ULN if the pre-PCI level was normal, or, in pts 
with elevated levels, a ≥50% increase over prior value and documentation that CKMB 
was falling. Results: RI was detected on CECG in 98 pts (11.6%) after PCI for a total of 
270 episodes (median duration of 23min). Pts with a periprodedural MI were more likely 
to experience RI (16.3 v 5.8%, p<0.001). Furthermore, pts with impaired tissue perfusion 
(TIMI Myocardial Perfusion Grade 0-2) after PCI were more likely to experience RI, 
although there was no difference in the rates of subsequent ischemia according to post-
PCI TIMI Flow Grade (TFG) or corrected TIMI Frame Count.(Figure) There was a trend 
towards less RI in pts assigned to eptiﬁbatide/heparin compared to bivalirudin. (Figure) 
Pts with RI had a greater increase from baseline of CKMB (1.2 v.0.3 ng/dl, p=0.007) and 
sCD40L (0.3 v. -0.4ng/ml, p=0.014). Conclusion: In this high-risk population of NSTEACS 
pts, a peri-procedural MI and impaired myocardial perfusion, but not epicardial ﬂow, were 
associated with increased rates of recurrent ischemia as detected on CECG.
951-223 Resting Magnetocardiography Detects Ischemia 
With High Accuracy in Patients With Acute Coronary 
Syndrome
Kirsten Tolstrup, Sean Rashti, Brian Cheung, Donnatella Brisinda, Anna M. Meloni, 
Robert J. Siegel, Riccardo Fenici, Cedars-Sinai Medical Center, Los Angeles, CA, 
Catholic University of the Sacred Heart, Rome, Italy
Background: Early diagnosis of ischemia is complicated by the poor sensitivity of 
standard tests (ECG and troponin) and contraindication for stress testing in unstable 
angina patients. Magnetocardiographic (MCG) imaging is a new technology developed 
for the rapid, non-invasive, non-stress detection of ventricular repolarization abnormalities 
at rest.
Methods: 51 acute coronary syndrome patients from the telemetry unit and 33 normal 
controls were studied utilizing a 9-channel CMI Magnetocardiograph in an unshielded 
location in the cardiac noninvasive laboratory. Scan time was 6 minutes and results 
were available immediately. The MCG data were processed and interpreted utilizing 
an automated MCG analysis program. All patients were chest pain free at the time of 
scanning.
Results: The mean age was 60.2 ± 14.4 years (range 32 - 86) and 68.6% were men. 
Most had normal ECG (74.5%) and normal troponin I (83.3%). Ischemia determined 
by positive troponin I, positive stress echo or nuclear testing, and/or positive coronary 
angiogram (70% occlusion) were demonstrated in 54.9%. The MCG detected ischemia 
with high accuracy (p<0.0001) and high diagnostic value: Sensitivity 89.3%, speciﬁcity 
85.7%, positive and negative predictive value of 75.8% and 94.1%, respectively. In 
the subgroup with negative troponin I and ECG, the sensitivity, speciﬁcity, positive and 
negative predictive values were 84.6%, 92.2%, 73.3%, and 95.9%.
Conclusions: Resting magnetocardiographic imaging is a rapid, no risk scan for the 
early and accurate detection of ischemia in a high risk patient population.
951-224 Index of Microcirculatory Resistance: A Novel Measure 
for Predicting Myocardial Damage in Patients with 
Acute Myocardial Infarction
Maulik G. Shah, Jennifer Tremmel, Todd Brinton, Andrew Wilson, Ingela Schnittger, 
David P. Lee, Alan C. Yeung, William F. Fearon, Stanford University School of Medicine, 
Stanford, CA
Background: Studies suggest that the status of the coronary microvasculature in 
patients with acute myocardial infarction (AMI) is important in determining outcomes. 
Current techniques for evaluating the microvasculature in the cardiac catheterization 
laboratory have limitations. We compared a novel coronary pressure wire-derived 
Index of Microcirculatory Resistance (IMR) to standard techniques for evaluating the 
microvasculature in AMI patients.
Methods: After 17 patients with ST-elevation AMI underwent primary stenting, the 
resting mean transit time (Tmn) of injected room temperature saline was measured in 
the culprit vessel via a validated thermodilution technique using a coronary pressure 
sensor/thermistor-tipped wire. After inducing maximal hyperemia, the hyperemic Tmn and 
the mean distal pressure were measured. Because Tmn is inversely proportional to ﬂow, 
coronary ﬂow reserve (CFR) was deﬁned as resting Tmn / hyperemic Tmn and IMR as distal 
pressure x Tmn during hyperemia. IMR was compared to CFR, TIMI Myocardial Perfusion 
Grade, corrected TIMI Frame Count, ST segment resolution, peak creatinine kinase (CK), 
and 3 month echocardiographic left ventricular ejection fraction.
Results: At the end of the procedure all patients had TIMI grade 3 ﬂow except two with 
grade 2. IMR correlated signiﬁcantly with peak CK (R=0.61, p<0.01), while CFR, TIMI 
Myocardial Perfusion Grade, corrected TIMI Frame Count, and ST segment resolution 
did not. IMR correlated signiﬁcantly with corrected TIMI Frame Count (R=0.70, p=0.002) 
and TIMI Myocardial Perfusion Grade (R=-0.49, p=0.05), but not with CFR or ST segment 
resolution. IMR was the strongest predictor of left ventricular ejection fraction at 3 month 
follow-up (R=-0.46, p=0.13). Patients in whom the IMR was >25 had a signiﬁcantly greater 
peak CK (2960 ±1656 vs. 1040 ±269, p=0.01) and a lower 3 month left ventricular ejection 
fraction (50 ±11 vs. 62 ±2%, p=0.059).
Conclusions: IMR is a relatively simple, wire-based index that can be measured at the 
time of primary stenting in patients with AMI. IMR is a better indicator of microvascular 
function and predictor of myocardial damage than current techniques for evaluating the 
microvasculature.
951-225 Clinical Feasibility of Quantitative Color-mapping of 
Shear Stress for Predicting Coronary Plaque Rupture 
Site With Use of Three-Dimensional Intravascular 
Ultrasound Imaging
Yusaku Fukumoto, Takafumi Hiro, Takashi Fujii, Hiroko Kanou, Kaori Kodama, Genta 
Hashimoto, Jutaro Yamada, Takayuki Okamura, Masunori Matsuzaki, Yamaguchi 
University Graduate School of Medcine, Ube, Japan
Background: Coronary plaque rupture with subsequent thrombus formation is the 
most important mechanism leading to acute coronary syndrome ( ACS ). Various local 
determinants of plaque vulnerability have been documented. However, reliable predictor 
is still not clariﬁed yet. We previously reported that most plaque rupture site is related to 
the site of shear stress concentration (J Am Coll Cardiol 2005). We recently developed a 
method to quantitate the degree of stress concentration from the 3D shear stress mapping 
of intravascular ultrasound ( IVUS ) imaging. This study investigated the feasibility of this 
index for predicting plaque rupture site.
Methods: Twenty ACS patients with a distinct plaque rupture in longitudinal intravascular 
ultrasound ( L-IVUS ) images of 40MHz were selected. A total of 36 L-IVUS images 
with 10 degree span were obtained to reconstruct mesh polygons of lumen contour. The 
shear stress for each polygon was calculated and colorized by using computational ﬂuid 
simulation software of ﬁnite element analysis. The degree of shear stress concentration of 
ROI was calculated by the ratio between the maximum and the minimum values of shear 
stress with referring the three-dimensional graphic representations. The ROI size was 
determined by the vessel size and the lesion length.
Results: Plaque rupture was observed at the proximal portion of plaque hills in 65% 
(13/20), and at the top of the hills in 35% (7/20). The site of plaque rupture was associated 
with the site of shear stress concentration in 80% of the cases. The index representing the 
degree of shear stress concentration showed a mean value of 8.1±2.8. This index of more 
than 7.0 had a sensitivity of 85% for predicting plaque rupture.
Conclusions: The quantiﬁcation of shear stress concentration might be useful for 
accurately predicting future rupture point of coronary atherosclerotic plaques.
951-226 Clinical Impact of Collateral Circulation on 30-Day 
Mortality for Acute Myocardial Infarction Complicating 
Heart Failure
Daisaku Nakatani, Hiroshi Sato, Yasuhiko Sakata, Hiroya Mizuno, Masahiko Shimizu, 
Shinichiro Suna, Shinsuke Nanto, Yukihiro Koretsune, Masatsugu Hori, Osaka University 
Graduate School of Medicine, Suita, Japan
Background: It has been reported that presence of collateral circulation (Coll) in the 
setting of acute myocardial infarction (AMI) is associated with favorable outcomes. 
Mortality remains high in the percutanous coronary intervention (PCI) era in AMI patients 
complicating heart failure (HF) deﬁned as Killip class II or more, but not so high in AMI 
patients without heart failure. We hypothesized that the Coll is more beneﬁcial in patients 
with HF than those without it. Methods: We studied 3,824 patients who underwent PCI 
within 24 hours after the symptom onset and examined the clinical impact of Coll on 
30-day mortality in patients with AMI by the presence and absence of HF. Results: The 
prevalence of HF was 17.6%. The 30-day mortality was higher in patients with HF than 
those without it (20.6% vs. 1.6%, P<0.001). The 30-day mortality was lower in patients with 
Coll than those without it among both the patients without HF (0.7% vs. 2.0%, P=0.005) 
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and with HF (13.6% vs. 23.9%, P=0.002) by univariate analysis. After adjustment for 
baseline characteristics, Coll was independently associated with a decreased risk of 
30-day mortality in patients with HF (hazard ratio [HR]; 0.443, 95% CI: 0.243-0.811, 
P=0.008), but not in patients without HF (HR; 0.589, 95% CI: 0.233-1.489, P=0.263). 
Peak value of creatinine kinase was relatively low and similar between the presence and 
absence of Coll in patients without HF (2767±2169 vs. 2906±2609, P=0.113), but was 
lower in the presence of Coll group compared with the absence of Coll group in patients 
with HF (4528±5768 vs. 6270±8651, P=0.005). Conclusion: In patients with AMI treated 
by PCI, collateral circulation has a beneﬁcial effect on 30-day mortality not in Killip class I 
but in Killip class II or more, probably through protecting jeopardized myocardium.
951-227 Malondialdehyde-modiﬁed LDL(MDA-LDL) Is a Novel 
Marker as Instability of Coronary Plaque: Angioscopic 
Analysis
Kenichiro Tajika, Beni Ogawa, Daisuke Murakami, Kenichi Tokuyama, Shigenobu Inami, 
Kouji Seimiya, Masamichi Takano, Takayoshi Ohba, Norihiko Ohno, Atsunobu Nomura, 
Satoshi Okumura, Kentaro Okamatsu, Kyouichi Mizuno, Nippon Medical School Chiba 
Hokusoh, Chiba, Japan
Background: Oxidative LDL plays an important role for the initiation and progression 
of atherosclerosis. Recently, it was reported that the plasma level of MDA-LDL but, 
not oxidized LDL was higher in patients with acute coronary syndrome (ACS) than in 
those without ACS. Yellow plaques diagnosed by coronary angioscopy are thought to be 
vulnerable plaques. However, there is no direct evidence that MDA-LDL is correlated with 
vulnerable plaque. Therefore, we investigated the relationship between MDA-LDL and 
plaque morphology using angioscopy.
Methods: The plasma levels of MDA-LDL were measured in 28 patients with coronary 
artery disease (ACS 8, non-ACS 20). Plaque color of culprit lesion was classiﬁed either 
yellow or white.
Results: Nine patients had yellow plaque (yellow plaque group), remaining white (white 
plaque group). ACS patients were 6 in yellow, 2 in white plaque group. Levels of MDA-LDL 
and lipid proﬁles, indicating plasma level of TC, TG, HDL-C, and LDL-C in both groups 
were compared. There were similar lipid proﬁles in both groups. The plasma level of 
MDA-LDL was signiﬁcantly higher in patients with yellow plaque than in those with white 
(106.5±51.0 U/l versus 67.3±20.7 U/l, p<0.005).
Conclusions:This study showed that MDA-LDL level is a novel marker for instability of 
coronary plaque.
951-228 Limitation of Angiography to Identify the Culprit Lesion 
in Acute Myocardial Infarction With Total Occlusion: 
Utility of Thermal Wire to Identify Culprit Lesion by 
Intravascular Ultrasound
Takuro Takumi, Souki Lee, Kouichi Toyonaga, Hachiro Obata, Keisuke Kusumoto, 
Daisuke Kanda, Hitoshi Toda, Shuichi Hamasaki, Yutaka Otsuji, Chuwa Tei, Kogoshima 
City Hospital, Kagoshima, Japan, Kagoshima University School, Kagoshima, Japan
Background: Acute myocardial infarction (AMI) results from plaque rupture and 
subsequent thrombosis. Therefore, it can be difﬁcult to identify the plaque rupture site by 
angiography in patients with total coronary occlusion, due to the subsequent thrombosis 
with development to the proximal region. We hypothesized 1) that the site of total occlusion 
by angiography is often proximal to the culprit lesion by intravascular ultrasound (IVUS) 
and 2) that site of maximal vessel wall temperature by thermal wire coincides with the 
culprit lesion by IVUS.
Methods: In 30 consecutive patients with a ﬁrst anterior AMI in the acute phase before 
coronary intervention, occlusive or most stenotic site by angiography, the site with 
maximal vessel wall temperature by a pressure-temperature sensor-tipped guidewire, 
and the culprit lesion with ruptured or soft plaque by IVUS were evaluated.
Results: (1) Twelve of the 30 patients had LAD reperfusion and the other 18 had LAD occlusion 
on the angiography. (2) While the distance between the most stenotic lesion by angiography 
and the lesion with maximal vessel wall temperature by thermal wire was negligible (1.8+1.3 
mm) in patients with reperfusion, occluded lesion by angiography was signiﬁcantly more 
proximal compared to the maximal temperature lesion (8.4+2.5 mm, p<0.001) in those with 
total occlusion. (3) In 10 of the 18 patients with total occlusion, culprit lesion was identiﬁed by 
IVUS, which showed same location to maximal temperature lesion.
Conclusions: The data suggest that angiographic evaluation of the culprit lesion is of 
limited utility, while thermal wire enables accurate localization of the lesion in patients with 
AMI and total coronary occlusion.
951-229 Impact of Elevated Troponin T level at Admission on the 
Non-Culprit Plaque Progression in Clinical Unstable 
Angina Pectoris: A Volumetric Intravascular Ultrasound 
Analysis
Hideto Yano, Kiyoshi Hibi, Kazuo Kimura, Naoki Nozawa, Hiroyuki Ozaki, Ikuyoshi 
Kusama, Masami Kosuge, Toshiaki Ebina, Tatsuya Nakachi, Noriaki Iwahashi, Jun 
Okuda, Kengo Tsukahara, Masahiko Kanna, Satoshi Umemura, Yokohama City 
University Medical Center, Yokohama, Japan
Background: The relationship between coronary atherosclerosis progression rates and 
clinical events has been previously established. Recent reports have shown that elevated 
cardiac troponin T (cTnT) levels predict the risk of long-term adverse outcomes even after 
successful coronary revascularization in the patients (pts) with acute coronary syndrome. 
The aim of this intravascular ultrasound (IVUS) study was to investigate the association 
between cTnT level and coronary plaque progression of non-culprit intermediate lesion in 
clinical unstable angina pectoris (UAP).
Methods: IVUS interrogation was performed in 51 pts with UAP who underwent troponin 
T analysis at admission. All pts underwent percutaneous coronary intervention (PCI) to 
culprit lesions. IVUS ﬁndings for non-culprit intermediate plaque were analyzed at acute 
phase and at 6-momth follow up. The target plaque had to be a minor lesion and had to be 
at least 10 mm apart from any PCI site. Volumes were calculated by means of Simpson’s 
rule. The percent plaque volume changes (%∆PV), the percent lumen volume changes 
(%∆LV), and the percent vessel volume changes (%∆VV) were calculated. Positive cTnT 
was deﬁned as serum cTnT level ≥0.1ng/ml.
Results: cTnT was positive in 23 pts (group cTnT) and negative in 28 pts (group non-
cTnT). Pts characteristics, medications including statins (55 vs 61%, p=0.6), and LDL 
cholesterol levels at follow up (96 vs 105mg/dl, p=0.5) were similar between the groups. 
High sensitive C-reactive protein (hsCRP) levels on admission were higher in group cTnT 
than in group non-cTnT (0.67 vs 0.15mg/dl, p=0.03). %∆VV tended to be larger in group 
cTnT (2.8 vs -1.1%, p=0.1), whereas %∆LV was similar (1.7 vs 2.4%, p=0.9). %∆PV 
was signiﬁcantly larger in group cTnT than in group non-cTnT (5.2 vs -4.8%, p=0.007). 
By multivariate analysis, positive cTnT was independently associated with larger %∆PV 
(p=0.01), whereas hsCRP levels showed no association (p=0.3).
Conclusions: In patients with UAP, positive cTnT at admission was associated with 
accelerated progression of atherosclerosis independent of systemic inﬂammation. Our 
results may partly explain worse long-term outcomes in patients with positive cTnT.
951-230 Echo-attenuation in the Target Lesion Before 
Perutaneous Coronary Intervention and Incidence of 
Angiographic Slow Flow
Kiyoshi Hibi, Tomoaki Shimizu, Hiroyuki Ozaki, Ikuyoshi Kusama, Hideto Yano, Masami 
Kosuge, Kengo Tukahara, Masahiko Kanna, Yoshio Tahara, Naoki Nozawa, Kazuo 
Kimura, Satoshi Umemura, Yokohama City University Medical Center, Yokohama, Japan, 
Yokohama City University School of Medicine, Yokohama, Japan
Background: Catheter-based intervention in coronary arteries carries a risk of reduced 
antegrade ﬂow (slow ﬂow) resulting in myocardial necrosis. Therefore, accurately 
identifying lesions at high risk of slow ﬂow is of crucial importance. The aim of this 
intravascular ultrasound study was to investigate the impact of echo attenuation in the 
target lesion before PCI on the incidence of angiographic slow ﬂow during PCI.
Methods and Resurts: A total of 407 patients with acute coronary syndrome and 
95 patients with stable angina pectoris who underwent IVUS interrogation before 
PCI were included in this analysis. Slow ﬂow was deﬁned as severe reduction of ﬂow 
grade (corrected TIMI frame counts get more than twice compared with baseline) after 
ballooning or stenting. Echo-attenuation was deﬁned as absence of echo reﬂection 
without signiﬁcant calciﬁcation in the target lesion. Slow ﬂow occurred in 28 (6%) patients. 
Average vessel area at the reference sites of patients who showed slow ﬂow was larger 
than those without slow ﬂow (17 vs. 15mm2, p=0.02). Echo-attenuation subtending 3 
to 4 quadrants was observed in 160 (32%) patients and those subtending 2 quadrants 
was in 66 (13%). Twenty seven out of 28 patients (96%) who showed slow ﬂow had 
the target lesion with echo-attenuation subtending 3 to 4 quadrants. Patients with echo-
attenuation subtending 3 to 4 quadrants were divided into 3 groups. Patients with longer 
echo-attenuation (≥7mm) with larger reference vessel area (≥15mm2)(n=24) had higher 
rate of slow ﬂow compared with those who had either longer attenuation (≥7mm) or larger 
reference vessel area (≥15mm2)(n=61) and those with shorter echo-attenuation (<7mm) 
with smaller reference vessel area (<15mm2) (n=75) (58 vs 18 vs 3%, p<0.0001). Echo-
attenuation was frequently observed in culprit lesion of acute coronary syndrome than 
those in stable angina pectoris (48 vs. 34%, p=0.01), resulting in the increased rate of 
slow ﬂow in the patients with acute coronary syndrome (7 vs. 1%, p=0.04).
Conclusions: Large vessels with long echo-attenuation subtending 3 to 4 quadrants in 
the target lesion are at extremely high risk for severe slow ﬂow during PCI.
951-231 Comparison between Culprit and Nonculprit Lesions 
in Patients with Multiple Plaque Ruptures and Acute 
Coronary Syndrome
Kentaro Okamatsu, Shigenobu Inami, Shinya Yokoyama, Masamichi Takano, Koji 
Seimiya, Takayoshi Ohba, Fumiyuki Ishibashi, Noritake Hata, Kyoichi Mizuno, Nippon 
Medical School, Chiba Hokusoh Hospital, Chiba, Japan
Background: Although the concept of multifocal plaque rupture has already been 
established, the difference between a plaque rupture remaining clinically silent and a 
plaque rupture causing Acute Coronary Syndrome (ACS) in the same patient remains 
to be elucidated. We examined whether the local lesion characteristics could enable us 
to distinguish culprit ruptured plaques from nonculprit ruptured plaques, using coronary 
angioscopy.
Methods: We analyzed 30 plaque ruptures in 14 consecutive patients with their ﬁrst 
occurrence of ACS who had both culprit and nonculprit ruptured plaques. We compared 
the pre-interventional angiographic ﬁndings (the severity of stenosis, the location of the 
ruptured plaques, the complexity, and thrombus) and the pre-interventional angioscopic 
ﬁndings (the yellow color grade, the amount of thrombus, the severity of complexity, the 
type of thrombus, and the type of complexity) between the culprit and nonculprit ruptured 
plaques.
Results: Univariate logistic regression analyses indicated that the intensive yellow 
color (odds ratio, 20.0; 95% CI, 2.04 to 196.42; P = 0.010) and the large amount of 
thrombus detected with angioscopy (odds ratio, 55.0; 95% CI, 5.02 to 602.29; P = 0.001) 
correlate with the culprit lesions. A multivariate logistic regression analysis showed the 
two parameters to not be statistically signiﬁcant. However, there was a good correlation 
between the yellow intensity and the amount of thrombus (r=0.74; P<0.0001).
Conclusions: The local factors for distinguishing culprit ruptured plaques from nonculprit 
ruptured plaques were the yellow color intensity of the plaque and the amount of coronary 
thrombus. The grade of yellow plaque color might therefore be a predictor of the degree 
of thrombosis following a plaque rupture.
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952-232 Randomized Trial of Sirolimus- Versus Paclitaxel-
Eluting Stents for the Treatment of Acute ST-Elevation 
Myocardial Infarction
Jae-Hwan Lee, Hyun-Sook Kim, Seung-Whan Lee, Jae-Hyeong Park, Si-Wan Choi, Jin-Ok 
Jeong, Jai Kun Chae, Jae-Ki Ko, In-Whan Seong, Chungnam National University Hospital, 
Daejeon, South Korea, Chonbuk National University Hospital, Jeonju, South Korea
Background: It is uncertain that which of commercially available two DESs, paclitaxel-
eluting stent (PES) and sirolimus-eluting stents (SES), is more effective for the treatment 
of STEMI. This study was designed to determine the safety and efﬁcacy of two kinds of 
DESs for these lesions.
Methods: From Jan 2004 to 2005, 232 consecutive patients underwent primary 
angioplasty for the treatment of STEMI. Among them, 15 patients were excluded and 217 
patients were randomly assigned to PES (Group I, n=108) or SES (Group II, n=109). Six 
month angiographic restenosis and incidence of MACE were assessed.
Results: The baseline clinical and angiographic characteristics were similar between 2 
groups. During the 10 months of clinical follow-up, 14 patients were died (9 in group I 
and 5 in group II). There were 2 acute stent thrombosis in group I and one subacute 
stent thrombosis in group II. Six-month angiographic follow-up was performed in 80% 
of patients. Group II showed higher angiographic in-segment restenosis (16% vs. 4%, 
P=0.04) and higher in segment late loss (0.35±0.69mm vs. 0.05±0.42mm, P<0.001) than 
group II. The TLR rate was 4% (6 patients in group I, and 3 in group II, p=0.25). 10-month 
MACE were signiﬁcantly higher in group I than group II (92±3% vs. 82±4%, p=0.04).
Conclusions: DESs implantation demonstrated safe and favorable clinical outcomes in 
unselected STEMI patients. SES was more effective in preventing neointimal hyperplasia 
and angiographic restenosis compared with PES.
Group I(n=108) Group II(n=109) P-value
Reference diameter, mm 2.93±0.41 2.91±0.42 0.46
Lesion length, mm 21.0±8.2 21.2±11.8 0.90
In segment postprocedural MLD, mm 2.88±0.42 2.81±0.41 0.29
In segment follow-up MLD 2.22±0.79 2.36±0.60 0.21
In-stent late loss, mm 0.46±0.74 0.17±0.53 0.005
In segment late loss, mm 0.35±0.69 0.05±0.42 0.001
 
952-233 First Human Experience with Intracoronary Red Light 
Irradiation for the Treatment of High Risk Non-Culprit 
Atheromatic Plaques
Konstantinos Toutouzas, Nicholas Kipshidze, Maria Drakopoulou, Eleftherios Tsiamis, 
Virginia Markou, Elli Stefanadi, John Karabelas, Panagiotis Angelopoulos, Christodoulos 
Stefanadis, Lenox Hill Hospital, CARDIOLOGY, NY, First Department Of Cardiology, 
Athens, Greece
Background: Intraluminal low-power red laser light (LPRLL) irradiation has been used 
for the prevention of restenosis after percutaneous coronary intervention. Except from 
the antiproliferative properties of LPRLL recent studies have shown that also enhances 
reendothelialization by promoting nitric oxide production. We hypothesized that by LPRLL 
irradiation of high risk plaques, as detected by coronary thermography, stabilization of 
these plaques may occur.
Methods. We included patients with ≥2 angiographically signiﬁcant lesions at different 
vessels. Culprit lesions were identiﬁed in all patients by a combination of ECG, wall 
motion abnormalities, scintigraphic perfusion defects, and/or coronary angiogram. The 
non-culprit lesions were intermediate producing 50-75% stenosis. In non-culprit lesions 
coronary thermography was performed by a dedicated thermography catheter (Epiphany, 
Medispes S.W., ZUG, Switzerland). The temperature difference (DΤ) was assigned as 
the difference between the atherosclerotic plaque and the proximal vessel wall. If DΤ was 
>0.05OC irradiation with LPRLL was performed. Low power red light was transmitted from 
a diode laser (650 nm) at an energy level of 10 mW. The system uses the CL Illuminator 
cold red laser light balloon catheters At the end of LPRLL irradiation repeat temperature 
measurement was performed.
Results. We included 11 patients in the study with 11 non-culprit lesions. The percentage 
of stenosis was 67±12%. Temperature measurement in the non-culprit lesions and 
application of LPRLL irradiation was performed without any complication. The mean 
DT at baseline was 0.09±0.08 oC. Immediately after LPRLL irradiation DT was reduced 
to 0.05±0.04 oC (p<0.02). In all patients there were no major adverse cardiac events at 
30 days. Four month clinical, angiographic, IVUS and thermography follow-up will be 
available at the time of presentation.
Conclusions. In this ﬁrst application of LPRLL for the treatment of high risk plaques, as 
recognized by coronary thermography, the immediate results were promising. Further 
studies are required to evaluate this method for the treatment of high risk plaques.
952-234 Similar Mortality After Prehospital Thrombolysis or 
Primary PCI in Patients With ST-Elevation Myocardial 
Infarction Diagnosed in the Prehospital Phase. Results 
of PREMIR
Uwe Zeymer, Ulrich Tebbe, Hans-Richard Arntz, Jörg Friedrich, Burckhard Dirks, Klaus 
Ellinger, Harald Genzwürker, Lutz Nibbe, Jochen Senges, Herzzentrum Ludwigshafen, 
Ludwigshafen, Germany
Background: There is ongoing debate about the comparative value of prehospital 
ﬁbrinolysis and primary PCI in patients with STEMI. Therefore we analysed the inhospital 
outcomes of patients with STEMI diagnosed already in the prehospital phase in a large 
nationwide regis-try.
Methods: In PREMIR consecutive patients with STEMI < 24 hours diagnosed by 12-
lead ECG were prospectively included and treatments during the prehospital and 
inhospital phase, as well as outcomes were evaluated. A total of 2450 pts were included 
in 63 ambulance systems in Germany between 02/03 and 12/04. For this analyses we 
compared patients without the need for prehospital cardiopulmonary resucitation treated 
with prehospital ﬁbrinolysis (n=506) or primary PCI (n=943).
Results: Patients treated with primary PCI were older (65 versus 63 years), more women 
(28.8% versus 24%), had more often a bundle branch block (5.3% versus 1.6%), systolic 
blood pressure was lower in the lysis patients. The time interval between symptom 
onset and 12-lead ECG was longer in the PCI group (120 mins versus 75 mins). While 
ﬁbrinolysis was started within 10 mins after the ECG, it lasted 90 min until the arrival in 
the cath-lab. (table).
Conclusion: In this prospective registry with STEMI diagnosed already in the prehospital 
phase by 12-lead ECG prehospital ﬁbrinolysis and early primary PCI were comparable 






Death 5.5 % 4.4 % 0.3
Reinfarction 5.3 % 4.7 % 0.6
Cardiogenic shock 9.4 % 8.0 % 0.4
Stroke 1.6 % 1.3 % 0.5
Major bleeding 1.9 % 1.5 % 0.6
 
952-235 Primary Percutaneous Coronary Intervention for Acute 
Myocardial Infarction in Women Versus Men 1995-2004
James M. Fitts, Theodore M. Silver, Michael J. Hearne, Thomas J. Ryan, Jr., John F. 
Robb, Mirle A. Kellett, Jr., Thomas P. Wharton, William Phillips, Winthrop D. Piper, David 
J. Malenka, Dartmouth-Hitchcock Medical Center, Lebanon, NH, Northern New England 
Cardiovascular Disease Study Group, Lebanon, NH
Background: Mortality with ﬁbrinolysis for MI in women is higher than in men. PCI is 
now the standard treatment for MI. We hypothesized that with PCI, MI mortality would be 
similar for women and men.
Methods: From our northern New England PCI Registry, we searched for emergency PCI 
as the primary treatment for MI from 1995-2004, excluding prior CABG, prior ﬁbrinolysis, 
shock. Adjusted odds ratios for women’s v men’s in-hospital outcomes were calculated 
by logistic regression. 
Results: Between 1995 and 2004, 2,828 patients underwent PCI as the primary 
treatment of MI - 793 (28%) were women. Compared to men, women were signiﬁcantly 
older (41 v 18% >70), had more diabetes (20 v 16%), vascular disease (12 v 8%), 
pulmonary disease (13 v 7%) and heart failure (11 v 8%) but a similar prevalence of 
multivessel CAD (31.2 v 32.8%). The LAD was the infarct vessel in 38.6% of women 
and 38.6% of men. Angiographic success was similar (women 96.3% v men 96.5%). In-
hospital rates of death, stroke, and vascular were higher in women (Table). An analysis 
of recent experience (2001-2004) found no signiﬁcant difference in mortality (OR 1.39, 
95%CI 0.77-2.52) or stroke (OR 2.18, 95%CI 0.69-6.92) for women v men but vascular 
complications remained more common in women (OR 3.27, 95%CI 2.21-4.82).
Conclusions: Over the last decade, primary PCI to treat acute MI has been associated 
with a higher rate of adverse events in women than men. Recent experience suggests that 
mortality and stroke rates for women are becoming more comparable to those in men.


















Death 5.30% 2.20% 1.70 1.05 2.73 0.029
Emergency CABG 1.01% 1.45% 0.67 0.29 1.55 0.351
Stroke 1.39% 0.45% 3.13 1.24 7.92 0.016
Vascular 
Complications 10.82% 2.46% 3.14 2.28 4.31 0.001
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952-236 Routine Percutaneous Coronary Intervention in Elderly 
Patients With Cardiogenic Shock Complicating Acute 
Myocardial Infarction
Angela Migliorini, Guia Moschi, Renato Valenti, Guido Parodi, Emilio V. Dovellini, 
Piergiovanni Buonamici, Nazario Carrabba, David Antoniucci, Division of Cardiology, 
Careggi Hospital, Florence, Italy
Background Age is a strong predictor of cardiogenic shock (CS) and death in patients 
with acute myocardial infarction (AMI). Few data exist on the impact of a routine early 
percutaneous revascularization strategy in elderly patients with CS complicating AMI. The 
aim of this study is the assessment of feasibility and effectiveness of a routine emergency 
PCI strategy in elderly patients (> 75 years old) with AMI complicated by CS due to 
predominant ventricular failure.
Methods We performed an analysis of age-related differences in outcome in 280 
consecutive patients with AMI complicated by CS who underwent primary PCI between 
January 1995 and September 2004 who were included in a single center prospective 
registry of primary PCI for AMI. The following clinical events were considered: death 
from any cause, reinfarction, and repeat target vessel revascularization within 1 month, 
6 months, and 1 year of initial revascularization. The contribution of clinical, angiographic 
and procedural variables to the clinical outcome was evaluated with forward stepwise 
multivariate Cox regression analysis.
Result Out of the 280 patients with CS, 104 (37%) were aged > 75 years. The mean age 
of the elderly group was 81 + 5 years, and half of patients were aged > 80 years. Most 
patients had PCI within 6 hours from symptom onset (92%). PCI success rate was lower 
in the elderly group than in the younger patient group (92% vs 97%, p = 0.062). The 6-
month mortality rate was 56% in the elderly group and 26% in the younger patient group 
(p < 0.001). At multivariate analysis, the variables independently related to the risk of 
death in elderly group were age (HR 1.07, 95% CI 1.02-1.12, P = 0.005) and PCI failure 
(HR 4.01, 95% CI 1.53-10.51, P = 0.005).
Conclusion A strategy of routine emergency PCI in elderly patients with CS complicating 
AMI is highly feasible. Among elderly patients, age remains a strong predictor of mortality. 
However, outcome after successful PCI is better than previously reported and the 
apparent beneﬁt of emergency PCI in elderly with AMI complicated by CS, as revealed 
in our study, strongly support the use of a routine emergency PCI strategy in this high 
risk subset of patients.
952-237 Adjunctive Use of the Rinspiration System for Fluidic 
Thrombectomy During Primary Angioplasty: The 
Rinspiration International Registy
Marco De Carlo, Bernardo Cortese, John G. Webb, Eberhard Grube, Jaap N. 
Hamburger, Anna S. Petronio, Mitchell W. Krucoff, University of Pisa, Pisa, Italy, St. 
Paul’s Hospital, Vancouver, Canada
Background: Effective reperfusion of the ischemic myocardium is a primary objective of 
the interventional treatment of Acute Myocardial Infarction (AMI). Recent trials of distal 
protection and thrombectomy devices (EMERALD and AiMI) have not generated positive 
results. We investigated a new thrombectomy device, the Rinspiration System (Kerberos 
Proximal Solutions Inc, Cupertino, CA), which simultaneously rinses the vessel with a 
turbulent ﬂow of heparinized saline and aspirates through a 6F-compatible mono-rail 
catheter.
Methods: The Rinspiration Registry enrolled 101 patients, 46 in Italy, 33 in Canada, and 
22 in Germany. The primary inclusion criteria are: 2mm ST elevation in 2 contiguous 
leads, and presentation within 12 hours from symptom onset. Use of a distal protection 
ﬁlter (FilterWire EZ, Boston Scientiﬁc, Santa Clara, CA) was allowed at physician 
discretion. The primary endpoint was ≥ 50% ST segment elevation resolution (STR) at 
60 minutes post-procedure and was assessed by independent 24-hour Holter Monitor 
Core Lab. Secondary end points include ﬁnal TIMI ﬂow, Blush and 30-day major adverse 
cardiac events.
Results: Mean patient age was 61±11 years, with 14% diabetes. Mean symptom onset-
to-needle time was 288±210 minutes, and AMI location was anterior in 47% of patients. 
A baseline TIMI 0/1 ﬂow was observed in 61%. Rinspiration was successfully delivered at 
target site in 97% of cases (98 out of 101), with a ﬁnal TIMI 3 ﬂow in 81% and Blush >2 
in 65% of patients. STR ≥50% and >70% at 60 minutes was achieved in 96% and 79% 
of patients, respectively. No device-related complications were observed. Three major 
adverse cardiac events (3%) occurred at 30 days.
Conclusions: Use of the Rinspiration System is safe and feasible as an adjunctive 
treatment during primary angioplasty. The excellent STR data compare favorably with 
previous trial results using different devices for thrombus management, indicating a 
potential clinical beneﬁt that should be conﬁrmed in a randomized trial.
952-238 Strong Impact of Mechanical Coronary Intervention on 
Cardiac Rupture After Acute Myocardial Infarction: The 
Kochi Acute Myocardial Infarction (KAMI) Study
Shinjirou Tamura, Jun Takata, Kazuya Kawai, Naohisa Hamashige, Naoki Nishimura, 
Takane Owaki, Takashi Furuno, Kiyoshi Nishino, Toshikazu Yabe, Masafumi Akisawa, 
Atsuo Ishimoto, Hiromi Seo, Tetsurou Sugiura, Yoshinori Doi, KAMI Study Group, Kochi 
Medical School, Kochi, Japan
Background: Mechanical coronary intervention (PCI) may prevent cardiac rupture after 
acute myocardial infarction(AMI).
Methods: 2293 patients (1563 men, 730 women, 68±12 yrs) with AMI were registered 
since 1992 to 2003.
Results: (1)Cardiac rupture occurred in 60 patients(2.6%; 21 men, 39 wemen, 75±8 
yrs);47 free wall ruptures, 13 ventricular septal perforations. (2)Nine patients had 
prehospital rupture. Fifty-one patients had in-hospital rupture ;early rupture(n=28), late 
rupture(n=16), unknown (n=7). (3)Incidence of rupture in patients treated with PCI was 
signiﬁcantly lower than those with thrombolysis and conservative therapy (0.9%, 2.7%, 
2.5%, p=0.018). Both early and late rupture decreased with PCI(p<0.01). (4) Incidence of 
early rupture tended to increase with thrombolysis.
Conclusions: PCI has strong impact on the prevention of cardiac rupture. Thrombolysis 
may have a risk to increase early rupture.
 
952-239 Unprotected Left Main Bifurcation Lesion: Impact of 
Drug-Eluting Stents (Cypher)
Samin K. Sharma, Prakash Krishnan, Mary-Beth Duffy, Angelica M. Mares, Madhu 
S. Prattipati, Bradley Brown, Michael C. Kim, Persis Bhandari, Pedro R. Moreno, 
Annapoorna S. Kini, Mount Sinai Medical Center/ Cardiovascular Institute, New York, NY
Background: Percutaneous coronary interventions (PCI) of unprotected left main coronary 
artery (ULMCA) lesions can safely be done. The ULMCA lesions involving distal bifurcations 
have been associated with relatively high restenosis rate and cardiac events at follow-up. 
The impact of drug-eluting stents (DES) has not been reported in this lesion type.
Methods and Results: We analyzed all ULMCA bifurcation lesions treated utilizing DES 
(CypherTM), from May 2003 to December 2004 (n = 50), and compared to bare metal 
stents (BMS) treated lesions, from January 2002 to April 2003 (n = 27) at Mount Sinai 
Hospital. There was signiﬁcantly lower mortality and target lesion revascularization (TLR) 
at 1 year in the DES vs. BMS group (Table). Multivariate predictors of TLR were: diabetes 
mellitus (OR 4.2; 95% CI 2.4-7.6), use of DES (OR 0.42; 95% CI 0.24-0.78) and SKS 
technique (OR 0.22; 95% CI 0.12-0.38).
Conclusions: Therefore, DES used by simultaneous kissing stent technique is associated 
with signiﬁcant lower restenosis rates in the treatment of ULMCA bifurcation lesions. 
The observed lower 1-year mortality in the DES group was perhaps mediated by lower 





Age (years) 72 ± 12 74 ± 18 NS
Unstable angina (%) 48 52 NS
Myocardial infarction (%) 22 26 NS
LVEF (%) 41 ± 14 33 ± 12 0.02
Lesion length (mm) 8 ± 3 8 ± 4 NS
Reference vessel size (mm) 4.01 ± 0.24 3.96 ± 0.34 NS
MLD pre (mm) 0.84 ± 0.12 0.86 ± 0.22 NS
MLD post (mm) 4.10 ± 0.22 3.88 ± 0.21 <0.01
Rotablator (%) 57.0 30.0 0.01
“T”-stenting technique (%) 55.5 12.0 <0.01
“SKS” technique (%) 33.3 82.0 <0.01
30-day MACE (%) 7.4 4.0 NS
Angiographic follow-up (%) 88.7 90.0 NS
Angiographic restenosis (%) 40.7 13.3 0.01
TLR (%) 29.6 8.0 0.01
MI at follow-up (%) 7.4 4.0 0.24
Death at follow-up (%) 15.0 4.0 0.03
“SKS” = Simultaneous Kissing Stents
952-240 The Impact of the Thrombus Aspiration on the Final TIMI 
Flow in Patients with ST-Elevation Myocardial Infarction 
(STEMI)
Ken Kozuma, Nobuaki Suzuki, Kengo Tanabe, Yuji Ikari, Masami Sakurada, Takaaki 
Isshiki, Teikyo University Hospital, Tokyo, Japan
Background: Few studies have demonstrated the efﬁcacy of thrombus aspiration therapy 
in primary PCI for STEMI.
Methods: VAMPIRE study was designed to investigate the efﬁcacy of thrombus aspiration 
for STEMI patients using a thrombectomy catheter (TVAC™ system, 7Fr) in a randomized 
fashion. From the total of 368 patients enrolled in the VAMPIRE study, 260 patients were 
analyzed until now. One hundred thirty ﬁve patients were treated with thrombectomy 
(TVAC group) and 125 patients were non-TVAC group. 205 patients were treated with 
PCI before 6 hours from the onset (Early group) and 65 patients were treated between 6 
hours and 24 hours (Late group).
Results: Between TVAC and Non-TVAC group, and Early and Late group, clinical 
and angiographic demographics had no difference. Post procedural TIMI ﬂow was 
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demonstrated in Table. Higher incidence of TIMI-3 ﬂow post-procedure was obtained in 
Late group, comparing to Early group. Blush grade 2 or 3 was signiﬁcantly higher in TVAC 
group than non-TVAC group (81 vs. 64%, p<0.001). No difference was observed in major 
adverse cardiac event at 1 month between the 2 groups (1.1% vs. 1.8%, p=NS).
Conclusions: Thrombus aspiration therapy for STEMI may be effective in achieving TIMI-
3 ﬂow in primary PCI, especially for the cases of late reperfusion (>6 hours from the 
onset). Further long-term study is warranted to demonstrate the clinical efﬁcacy of the 
plaque aspiration therapy. 
952-241 Protection of Distal Embolization in High-Risk Patients 
With Acute ST-Segment Elevation Myocardial Infarction
Fernando Cura, Alejandro Garcia Escudero, Liliana Grinfeld, Daniel Berrocal, Oscar 
Mendiz, Marcelo Trivi, Juan Fernandez, Ruben Piraino, Miguel Riccitelli, Miguel Ballarino, 
Mitchel Krucoff, Jorge Baccaro, Anibal Daamonte, Jorge Belardi, on behalf of the 
PREMIAR Investigators, Instituto Cardiovascular Buenos Aires, Buenos Aires, Argentina
Background: Distal embolization may reduce myocardial reperfusion after primary 
percutaneous coronary intervention (PCI). Nonetheless, results of previous trials 
assessing the role of distal protection during primary PCI have been controversial. The 
PREMIAR trial (Protection of distal EMbolization In patients with Acute myocaRdial 
Infarction), performed at 20 sites in 3 countries, was designed to enroll 140 subjects in 
order to evaluate the role of SpideRX Distal Protection Device, ev3, during PCI in a high-
risk group of patients with ST-segment elevation myocardial infarction (STEMI).
Methods: This trial prospectively randomized patients within 12 hours after onset of STEMI 
at high-embolic risk (including only baseline TIMI 0-2 ﬂow) to undergo PCI with or without 
SpideRX Device. The primary endpoint was the ST-segment resolution by continuous 
Holter monitoring measured at 60 minutes after PCI. Secondary endpoints included: core 
laboratory analysis of TIMI frame count, distal embolization and myocardial blush; ejection 
fraction by cardiac ultrasound; and major adverse cardiac events at 30 days.
Results: Baseline characteristics were comparable between arms. The SpideRX device 
was successfully positioned in 96% of patients without complications.
Conclusions: A randomized multicenter trial has been performed to provide information 
of the safety and efﬁcacy of the SpideRX Distal Protection Device in primary PCI among 







Anterior wall 53% 59%
Killip B-C 23% 19%
Prophilactic use of IIb/IIIa 23% 21%
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953-242 Ethnic Differences in the Effect of Polymorphisms in 
the Renin-Angiotensin System on Recurrent Cardiac 
Events in Post-Myocardial Infarction Patients
Ilan Goldenberg, Arthur J. Moss, Wojciech Zareba, Daniel Ryan, Shirley W. Eberly, Scott 
McNitt, University of Rochester Medical Center, Rochester, NY
Background: Ethnic differences in the renin-angiorensin system (RAS) may affect 
cardiovascular risk.
Methods: The angiotensin-converting enzyme insertion/deletion (ACE-I/D), 
angiotensinogen (AGT) M235T, and angiotensin receptor (AGTR1) 1166A->C 
polymorphisms were genotyped in a cohort of 916, black (n=145) and white (n=771), 
post-myocardial infarction (MI) patients. The risk of recurrent cardiac events (cardiac 
death, non-fatal MI, or unstable angina) was prospectively investigated during an average 
follow-up of 28 months.
Results: The black:white adjusted odds ratios for the AGTM235T and ACE-I/D 
polymorphisms were 8.19 (p <0.001) and 1.98 (p = 0.005), respectively. During follow-up, 
the rate of recurrent cardiac events was similar in black (28%) and white (26%) patients 
(p = 0.49). In multivariate analysis, the AGTM235T polymorphism was signiﬁcantly 
associated with increased risk of recurrent cardiac events among black (HR = 4.57, 
p=0.04) but not white (HR = 0.88, p = 0.70) patients, with signiﬁcant race-related effect (p-
value for the difference = 0.04). Kaplan-Meier probabilities of recurrent cardiac events by 
race in patients with the AGTM235T polymorphism are shown in the Figure. The ACE-I/D 
and AGTR1 polymorphisms were not associated with increased risk of recurrent cardiac 
events among either black or white patients.
Conclusions: The AGT M235T polymorphism is associated with a signiﬁcantly increased 
risk of recurrent cardiac events among black, but not white, post-MI patients.
953-243 Gender Differences in Non-ST-Elevation Acute Coronary 
Syndromes
Carlos T. Aguiar, Jorge S. Ferreira, Investigators of the Portuguese Registry of ACS, 
Hospital Santa Cruz, Carnaxide, Portugal
Purpose: Characterise the impact of gender on clinical proﬁle, value of risk markers, 
hospital management, and outcome in patients (P) with non-ST-elevation acute coronary 
syndromes (NSTE-ACS).
Methods: We reviewed 7170 NSTE-ACS P included in a national registry. Study endpoint 
was in-hospital death or myocardial infarction (MI). Elective revascularisation (Revasc) 
was PCI/CABG during hospitalization, with clinical stability in the past ≥24 hrs.
Results: Women (W) (33% of P) were older, more often diabetic or hypertensive, less 
often smoked or had previous MI, PCI or CABG. W were on more cardiac medications 
before admission, and more often presented with heart failure and ST-depression. W were 
less likely to receive beta-blockers, statins, and GP 2b/3a inhibitors, and more likely ACE 
inhibitors. Angiography and intervention rates were lower in W. In-hospital death/MI rate 
was 5.5% in W and 4.7% in M, but this difference was not signiﬁcant after multivariable 
adjustment. Tn elevation was an independent predictor of outcome, regardless of gender, 
but ST-depression was an independent predictor only in M. TIMI risk score >3 was 
signiﬁcantly more predictive of outcome in M than W. The prognostic impact of elective 
Revasc was similar among W and M.
Conclusions: W and M with NSTE-ACS have similar short-term prognosis and seem to 
beneﬁt similarly from elective Revasc. Risk stratiﬁcation tools currently used for guiding 
management of NSTE-ACS P have better performance in M. Novel risk markers are 
needed for W.
Interaction between gender and prognostic value of risk markers and Revasc
Frequency OR (95% CI) for In-hospital death/MI Interaction test
Tn Elevation W: 74%M: 72%
W: 3.03 (1.73-5.32)
M: 2.25 (1.56-3.26) P=0.386
ST-Depression W: 44%M: 37%
W: 1.51 (1.05-2.18)
M: 2.33 (1.75-3.09) P=0.068
TIMI risk score above 3 W: 36%M: 29%
W: 1.67 (1.15-2.41)
M: 2.71 (2.04-3.61) P=0.040
Elective Revasc W: 19%M: 27%
W: 0.52 (0.21-1.28)
M: 0.41 (0.22-0.74) P=0.661
 
953-244 Living Alone and Atypical Clinical Presentation Are 
Associated With Higher Mortality in Patients With all 
Components of the Acute Coronary Syndrome
Kirsten M. Nielsen, Anders Foldspang, Mogens L. Larsen, Ole Faergeman, Aarhus 
Sygehus University Hospital, Aarhus, Denmark
Background: Most prognostic studies of the acute coronary syndrome (ACS) are 
performed among highly selected patients included in clinical trials. We aimed to stratify 
risk of death during the year following hospitalisation for ﬁrst episode of unstable angina 
or myocardial infarction (ACS) in unselected patients based on clinical and socioeconomic 
information.
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Methods: A cohort study of 138,290 persons aged 30-69 residing in the Municipality 
of Aarhus, Denmark. From April 1, 2000 to March 31, 2002, a total of 1839 consecutive 
patients belonging to the cohort were admitted to the two coronary care units covering the 
area. First episode of ACS was conﬁrmed in 457 patients, of whom 450 survived 72 hours 
after admission and were followed for 365 days as concerns mortality. Data on mortality, 
social, clinical and biochemical ﬁndings were acquired by linkage of Danish population 
registers and from hospital charts. The data set was complete with no missing data.
Results: Crude case-fatality proportion during the year following ﬁrst episode of ACS was 
9.8% in unselected patients. By logistic regression controlling for age and sex, positive 
predictors of mortality were single living, Q waves, right bundle branch block, tachycardia 
and diabetes. Negative predictors were chest pain, ST-elevation and treatments within 72 
hours of admission with angioplasty or thrombolysis. As indicated by the area under the 
Receiver operator characteristics curve, the predictive validity of the model was 92.0% 
and 88.8% for 30 and 365 days mortality, respectively.
Conclusions: Mortality is still high among unselected patients with ACS. Patients 
living alone or patients with non-ST-elevation myocardial infarction and atypical clinical 
presentations were found to have the poorest prognosis.
953-245 Effect of Nadir Hemoglobin During Hospital Course 
on the Long-Term Risk of Heart Failure and Death in 
Survivors of Acute Myocardial Infarction
Doron Aronson, Mahmoud Suleiman, Yoram Agmon, Miry Blich, Michael Kapeliovich, 
Rafael Beyar, Walter Markiewicz, Haim Hammerman, Rambam Medical Center, Haifa, 
Israel
Background: Anemia on admission is associated with short-term mortality in patients 
(pts) with acute myocardial infarction (AMI). Anemia can develop or worsen during hospital 
course, but the long-term impact of changes in hemoglobin (Hb) levels is not known.
Methods: We prospectively studied 1084 pts with AMI who survived the acute event. Cox 
models were used to evaluate the relationship between baseline, nadir, and discharge Hb 
and the primary endpoints of mortality and readmission for heart failure (HF).
Results: During a median follow up of 28 months (12 to 48), 138 pts died and 130 were 
admitted for HF. Nadir Hb during hospital course was a stronger predictor of outcome than 
baseline or discharge Hb. In a Cox model adjusting for clinical variables and predischarge 
ejection fraction, there was an inverse independent association between nadir Hb and 
mortality: Adjusted HRs of pts with nadir Hb in the 3rd, 2nd and 1st quartiles, compared with 
pts in the 4th, were 1.0 [95% CI, 0.5 to 2.1], 1.9 [95% CI, 1.0-3.9], and 3.0 [95% CI, 1.5 to 
5.7], respectively (Ptrend < 0.0001; Figure). Compared with pts in the 4th nadir Hb quartile, 
the adjusted HRs for HF were: 3rd quartile, 0.9 [95% CI, 0.5 to 1.8]; 2nd quartile, 1.5 [95% 
CI, 0.8 to 2.7]; and 1st quartile, 1.8 [95% CI, 1.1 to 3.4], respectively (Ptrend = 0.007).
Conclusions: Nadir Hb during hospital course is a predictor of long-term mortality and 
HF in survivors of AMI and provides prognostic information beyond conventional risk 
factors and left ventricular systolic function.
 
953-246 Long-Term Prognosis of Patients With Isolate 
Myocardial Bridge
Vinicius D. Vaz, Fausto Feres, Alexandre Abizaid, Luis F. Tanajura, Rodolfo Staico, Luis 
A. Mattos, Galo Maldonado, Sergio Braga, Amanda Sousa, J Eduardo Sousa, Instituto 
Dante Pazzanese de Cardiologia, São Paulo, Brazil
Background: Myocardial bridges (MB) have been considered usually as a benign 
condition. However, several complications have been consistently reported (sudden 
death, myocardial infarction).
Purpose: Evaluate the long-term outcomes of patients with isolated myocardial bridge 
and identify angiographic and clinical predictors of cardiac events.
Methods: 24859 non-consecutive coronary angiogram reports, performed between 
1996 and 2004, were reviewed. Patients with other concomitant cardiac diseases were 
excluded. Follow-up was carried out by telephone and completed with medical interviews. 
Cardiac death and anterior myocardial infarction (MACE) were evaluated.
Results: From the total of 255 (1.02%) MB reported, 185 (0.74%) were conﬁrmed 
as isolated MB, but just 172 were available for this investigation. Mean follow-up was 
4.17±2.4 years, mean age was 48.7±14 years and 70% were men. Mean reference 
diameter was 2.52±0.5mm, minimum luminal diameter 1.36±0.5mm, diameter stenosis 
46.2±18% and MB length 13.5±4.7mm. There were 9 (5.2%) cardiac events during the 
follow-up (3 deaths and 7 myocardial infarction). Cox proportional cumulative survival rate 
free of MACE at means of covariates was 95.4%
Univatiate Predictors of MACE HR 95% CI p value
Aspirin Usage 0.37 0.1-1.27 0.03
Angina 2.3 1.31-3.89 0.02
Nitrates Usage 5.4 1.99-14.8 0.01
Diameter Stenosis 12.6 0.56-24.63 0.04
Multivariate Predictors of MACE
Aspirin Usage 0.16 0.03-0.86 0.03
Nitrates Usage 8.59 1.50-49.10 0.01
Conclusion: In this cohort, the long-term prognosis of patients with isolated MB was not 




Markers of Outcome After 
Revascularization
Monday, March 13, 2006, 9:00 a.m.-12:30 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 10:00 a.m.-11:00 a.m.
954-247 Anemia Predicts Long-Term Mortality and 
Cardiovascular Events in Japanese Patients 
Undergoing Elective Revascularization: From the 
Coronary Revascularization Demonstrating Outcome 
Study in Kyoto (CREDO-kyoto)
Yoshisumi Haruna, Yutaka Furukawa, Ryoji Taniguchi, Natsuhiko Ehara, Satoshi 
Shizuta, Hirokazu Mitsuoka, Akira Miura, Hajime Kotoura, Masaki Aota, Hiroshi Kato, 
Eiichi Matsuyama, Mamoru Takahashi, Takafumi Tabata, Izumi Miki, Yukiko Imai, Satoshi 
Teramukai, Masanori Fukushima, Toru Kita, Takeshi Kimura, for the CREDO-Kyoto 
Investigators, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background: Recent reports have shown anemia is an independent risk factor for one-
year prognosis after percutaneous coronary intervention (PCI). Impact of anemia on long-
term prognosis after revascularization still remains to be clariﬁed.
Methods: 5,996 patients who underwent ﬁrst elective PCI or coronary artery bypass 
surgery during 2000-2002 have been enrolled in CREDO-Kyoto registry from 31 
institutions. After excluding patients with end stage renal disease on hemodialysis, 
malignant disease, or in-hospital death, 5,539 patients were analyzed. The lowest quartile 
of hemoglobin level (male; Hb<12.8 mg/dl, female; Hb<11.3 mg/dl) was deﬁned as 
anemic. The efﬁcacy of anemia in assessing cardiovascular morality, all cause mortality 
and combined hard end points (cardiovascular death, myocardial infarction, cerebral 
vascular disease) was compared with standard coronary risk factors by uni-variate 
analysis from Kaplan-Meier models (p<0.05, log rank test) and multi-variate analysis from 
Cox regression analysis (p<0.05).
Results: At baseline, anemic patients had more frequent cardiovascular comorbidities 
such as old myocardial infarction (not anemic vs. anemic; 22.4% vs. 31.7%), history of 
heart failure (11.6% vs. 23.6%), peripheral artery disease (9.1% vs. 17.3%), aortic disease 
(3.3% vs. 6.6%), and prior cerebral vascular disease (13.6% vs. 21.4%). During follow 
up (30±14 months), 219(4.1%) death and 348(6.5%) hard end points occurred. Kaplan-
Meier models indicated signiﬁcantly higher cardiovascular mortality (1.5% vs. 4.9% at 36 
month), all cause mortality (3.0% vs. 10.7% at 36 month) and combined events (6.4% vs. 
11.7% at 36 month) in anemic patients. After adjustment for other potential risk factors, 
anemia was identiﬁed as an independent predictor of long-term cardiovascular mortality 
(risk ratio (RR) 2.16, 95% conﬁdence interval (CI) 1.28-3.66), all cause mortality (RR 
2.83, 95% CI 1.97-4.09) and combined hard end points (RR 1.40, 95% CI 1.04-1.87) in 
Cox regression analysis.
Conclusions: Anemia is an independent predictor of long-term mortality and hard end 
points in patients undergoing initial elective revascularization in a Japanese cohort.
954-248 Predictors of Target Lesion Revascularization and 
Target Vessel Revascularization After Implantation 
of Sirolimus- Eluting Stent: Pooled Analysis From 6 
Randomized Trials and Registries
Susheel Kodali, Roxana Mehran, Abdolreza Agahtehrani, Tayo Addo, Yingbo Na, 
George Dangas, Neil Goyal, Eugenia Nikolsky, Giora Weisz, Warren Sherman, 
Alexandra J. Lansky, Leroy Rabbani, Gregg W. Stone, Jeffrey W. Moses, Martin B. Leon, 
Columbia University Medical Center, New York, NY, The Cardiovascular Research 
Foundation, New York, NY
Background: Determinants of clinical restenosis in pts undergoing PCI using drug-eluting 
stents are not studied enough. To determine predictors of target lesion revascularization 
(TLR) and target vessel revascularization (TVR) after implantation of sirolimus eluting 
stent (SES), pooled data from four randomized trials (RAVEL, SIRIUS, E-SIRIUS, C-
SIRIUS) and two prospective registries (DIRECT, SVELTE) were analyzed.
Methods: A total of 2,088 pts treated with SES were included into analysis. Univariate 
and multivariate predictors of TLR and TVR were identiﬁed.
Results: Rates of TLR and TVR in the included trials were 4.7% and 6.9%, respectively. 
Pts with TLR (TLR+) compared to pts without TLR, had higher prevalence of diabetes 
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(41.8% vs. 25.6%), longer lesions (18.4 mm vs. 14.8 mm), smaller reference vessel 
diameters (RVD) [2.43mm vs. 2.59mm] and higher proportion of ACC/AHA type C lesions 
(32.8% vs. 23.5%) [P-values <0.05 to 0.001]. Procedural data revealed longer total stent 
lengths (41.7 mm vs. 28.9 mm) and more stents per lesion (2.12 vs. 1.54) in TLR+ pts 
(both P<0.001). Independent predictors of TLR in pts treated with SES are presented in 
the Table. For TVR, multivariate predictors were the same plus ostial lesion location.
Conclusions: Pts in whom SES fail are more likely diabetic, have smaller vessels and 
have longer, more complex lesions. The multivariate predictors for both TLR and TVR 
include diabetes, lesion length, RVD and number of stents implanted.
Table: Multivariate Predictors of TLR in SES
 
Multivariate Predictors Hazard Ratio[95% C.I.] p value
Lesion length 1.04 [1.01, 1.06] 0.0019
Diabetes 1.96 [1.28, 3.02] 0.0022
Double Diseased Native Coronary Arteries >50% Stenosed 1.76 [1.14, 2.71] 0.0102
Pre-procedure RVD 0.48 [0.30, 0.76] 0.0019
Number of Stent implanted 1.44 [1.15, 1.79] 0.0014
 
954-249 Do the Traditional Risk Factors of Vessel Size, Lesion 
Length and Diabetes Mellitus Predict Restenosis With 
TAXUS Stents? Insights From a TAXUS Meta-Analysis
Gregg W. Stone, Stephen G. Ellis, Jeffrey J. Popma, David A. Cox, James Hermiller, Louis 
Cannon, J. Tift Mann, Roxana Mehran, Joerg Koglin, Mary E. Russell, Columbia University 
Medical Center, New York, NY, Cardiovascular Research Foundation, New York, NY
Background. The 3 most widely accepted risk factors for restenosis after bare metal 
stent (BMS) implantation are reference vessel diameter (RVD), lesion length (LL), and 
diabetes mellitus (DM). Whether these variables still predict restenosis after TAXUS 
paclitaxel-eluting stent (PES) implantation is unknown.
Methods. In TAXUS IV and V, 2470 pts were randomized to PES (n=1239) or BMS 
(n=1231). 9mo angiographic FU was obtained in 1547 of 1888 planned pts (82%). The 
univariate and multivariate predictors of 9mo in-segment angiographic binary restenosis 
(ABR) and 1yr target lesion revasc (TLR) were determined from 18 baseline variables.
Results. DM was present in 674 (27.3%) pts, mean RVD was 2.72 ± 0.52 mm (median 
2.70 mm), mean LL was 15.17 ± 8.01 mm (median 13.0 mm). The univariate relationships 
between these variables and restenosis appear in the Table. By multivariate analysis, in 
the BMS arm smaller RVD (OR=3.03, p<0.0001), longer LL (OR=1.06, p<0.0001) and 
DM (OR=1.38, p=0.06) were independent predictors of 9mo ABR, whereas smaller RVD 
(HR=2.13, p<0.0001) and longer LL (HR=1.03, p=0.0004) predicted 1yr TLR. In the PES 
arm, smaller RVD and longer LL were independent predictors of 9mo ABR (OR=3.85 and 
1.03, p<0.0001 and =0.005 respectively) and 1yr TLR (HR=2.44 and 1.03, p<0.0001 and 
=0.015 respectively).
Conclusions. Small RVD and long LL remain strong predictors of clinical and 
angiographic restenosis after PES implantation, whereas DM may no longer be a risk 
factor for restenosis with the TAXUS stent.
 
1yr TLR 9mo ABR
PES BMS PES BMS
Diabetes - 7.0% 15.7% 15.1% 29.1%
Diabetes + 9.2% 20.4% 14.3% 37.3%
P 0.16 0.045 0.83 0.035
RVD <median 10.9% 21.2% 21.9% 41.4%
RVD ≥median 4.5% 12.4% 7.9% 21.2%
P <0.0001 <0.0001 <0.0001 <0.0001
LL <median 7.0% 15.0% 13.8% 25.1%
LL ≥median 8.3% 18.9% 15.8% 36.9%
P 0.33 0.056 0.48 0.0006
 
954-250 Relationship Between Late Loss, Diameter Stenosis 
and Target Lesion Revascularization After Stent 
Implantation: An Examination of Surrogate Endpoints 
From a Pooled Analysis of Eight Large Randomized 
DES Trials
Stuart Pocock, Gregg W. Stone, Martin Fahy, Roxana Mehran, Alexandra J. Lansky, Eugenia 
Nikolsky, Jeffrey W. Moses, Martin B. Leon, Jeffrey J. Popma, London School of Hygiene 
and Tropical Medicine, London, United Kingdom, Columbia University Medical Ce, NY
Background: Drug eluting stents (DES) have decreased cardiac events signiﬁcantly such 
that subsequent trials examining equivalency to the current approved DES are limited 
due to large sample sizes required to demonstrate safety and efﬁcacy. While clinical and 
angiographic surrogates have been used in past, choice of the best surrogate in DES 
trials is controversial.
Methods: Data for 4,069 pts in 8 randomised DES trials (TAXUS IV and V, SIRIUS, 
E-SIRIUS, C-SIRIUS, RAVEL, DELIVER and REALITY) were pooled to explore 
associations between in-stent and analysis-segment late loss (LL) and percent diameter 
stenosis (%DS) and target lesion revascularisation (TLR). Surrogacy was evaluated 
using examination of treatment differences between mean LL and %DS, ROC curves 
(c-statistic), Prentice criterion, and Hughes criterion.
Results. See graphs. The treatment differences in mean LL and mean %DS were equally 
strong and consistent across trials. LL and %DS also had very strong associations with 
risk of TLR (c-statistics > 0.9) [strongest for analysis segment]. A curvilinear relationship 
was present between late loss and TLR which accurately predicted clinical restenosis for 
the 8 trials. LL and %DS each fully explained observed treatment differences in TLR in 
each trial, meeting both Prentice and Hughes criteria.
Conclusions. Both analysis segment LL and %DS are valid and highly correlated 
surrogates for TLR. Their use as primary endpoint in future trials rather than TLR could 
reduce trial size by 70%.
954-251 Impact of Renal Insufﬁciency on the Long-Term 
Outcomes Following Percutaneous Coronary 
Intervention With Sirolimus-Eluting Stents
Gaku Nakazawa, Kengo Tanabe, Jiro Aoki, Yasutomo Higashikuni, Hirosada Yamamoto, 
Yoshinobu Onuma, Hiroyoshi Nakajima, Kazuhiro Hara, Mitsui Memorial Hospital, Tokyo, 
Japan
Background: Sirolimus-eluting stents (SES) have been demonstrated to reduce 
restenosis. However, there have been few studies evaluating the relationship between 
renal insufﬁciency and the outcome following SES implantation.
Methods: We evaluated consecutive 146 patients (180 lesions) who underwent 
percutaneous coronary intervention (PCI) with SES from August 1, 2004 to November 
30, 2004. These patients were divided into 3 groups; Group 1 consisted of patients with 
creatinine clearance >= 60 (n = 93), Group 2; patients with creatinine clearance < 60 (n 
= 38), Group 3; patients on dialysis (n = 15). Angiographic follow-up was performed at 
8 months.
Results: Clinical follow-up was obtained in all patients and angiographic follow-up at 8 
months was obtained in 134 patients (91.8%). Baseline patient and lesion characteristics 
were comparable among the 3 groups except for hyperlipidemia. Major adverse cardiac 
events (MACE; cardiac death, myocardial infarction, target lesion revascularization) at 8 
months were reported in 5 patients (5.5%) in Group 1, 6 patients (15.8%) in Group 2 and 
4 patients (26.7%) in Group 3 (p = 0.018), respectively. Late lumen loss at 8 months was 
signiﬁcantly different among the 3 groups (Group 1; 0.13 ± 0.48 mm, Group 2; 0.29 ± 0.63 
mm, Group 3; 0.72 ± 0.92 mm, p = 0.0004).
Conclusions: Neointimal growth following SES implantation is more pronounced in 














Reference diameter, mm 2.53 ± 0.60 2.43 ± 0.51 2.54 ± 0.63 n.s
Minimal lumen diameter, mm 0.78 ± 0.46 0.67 ± 0.42 0.79 ± 0.41 n.s
Lesion length, mm 14.36 ± 10.29 19.03 ± 15.21 15.39 ± 8.82 n.s
Post stenting
Minimal lumen diameter, mm 2.43 ± 0.47 2.24 ± 0.48 2.40 ± 0.40 n.s
8 months follow up
Minimal lumen diameter, mm 2.30 ± 0.58 1.96 ± 0.61 1.68 ± 0.89 <0.0001
Late loss, mm 0.13 ± 0.48 0.29 ± 0.63 0.72 ± 0.92 0.0004
 
954-252 Myocardial Positive Preejection Velocity Accurately 
Detects Presence of Viable Myocardium and Predicts 
Recovery of Left Ventricular Function After Surgical 
Revascularization
Martin Penicka, Petr Tousek, Otto Lang, Juraj Madaric, Karel Medilek, Libor Lisa, 
Bernard De Bruyne, Jozef Bartunek, Third Medical School Charles University and 
University Hospital Kralovske Vinohrady, Prague, Czech Republic, Cardiovascular 
Center, OLV Hospital, Aalst, Belgium
Background: We aimed to assess the accuracy of the tissue Doppler imaging (TDI)-
derived myocardial positive preejection velocity (+Vic) ﬁrst, to detect myocardial viability 
deﬁned by dobutamine stress echocardiography (DSE), ﬂuorine-18 ﬂuorodeoxyglucose 
PET and delayed contrast-enhanced MRI, and second, to predict recovery of left 
ventricular contractile function after CABG in patients with chronic ischemic dysfunction.
Methods: +Vic in dysfunctional segments was recorded in 54 patients treated medically 
and 65 patients undergoing CABG (age 67 ± 9y; 81% males, ejection fraction 30±6%). 
Patients treated medically underwent DSE, PET and MRI within 5 days after TDI.
Results: A good agreement was observed between +Vic and detection of viable 
myocardium at DSE, PET and MRI (�=0.76). In CABG patients, the presence +Vic in ≥ 
5 dysfunctional segments had the highest accuracy (88% and 76%) to identify patients 
with ≥5% and ≥10% increase, respectively, in ejection fraction between baseline and 6-
month echocardiogram. During follow-up (median, 333±172 days), 6 cardiac deaths and 
7 hospitalizations occurred in 24 patients with <5+Vic, while only 4 hospitalizations in 39 
patients with ≥5+Vic (Figure).
Conclusions: This study demonstrated strong relationship between the extent of 
TDI-derived +Vic in dysfunctional segments, extent of viable myocardium at reference 
techniques and LV contractile function recovery after CABG. The data also suggested the 
prognostic value of +Vic after CABG.
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954-253 Intravascular Ultrasound Predictors and Their Cut-off 
Values for Angiographic Restenosis After Sirolimus-
Eluting Stent Implantation
Myeong-Ki Hong, Cheol Whan Lee, Young-Hak Kim, Bong-Ki Lee, Duk-Woo Park, Duk-
Hyun Kang, Sang-Sig Cheong, Jae-Kwan Song, Jae-Joong Kim, Seong-Wook Park, 
Seung-Jung Park, Asan Medical Center, Seoul, South Korea
Background: We evaluated the clinical, angiographic, procedural, and intravascular 
ultrasound (IVUS) predictors of angiographic restenosis after sirolimus-eluting stent (SES) 
implantation. Methods: SES implantation was successfully performed in 550 patients 
with 670 native coronary lesions. Six-month follow-up angiography was performed in 449 
patients (81.6%) with 543 lesions (81.1%). Clinical, angiographic, procedural, and IVUS 
predictors of restenosis were determined.
Results: The overall angiographic restenosis rate was 3.9% (21/543). Using multivariate 
logistic regression analysis, the only independent predictors of angiographic restenosis 
were the IVUS stent area (odds ratio=0.584, 95% CI 0.385-0.885, p=0.011) and IVUS-
measured stent length (odds ratio=1.028, 95% CI 1.002-1.055, p=0.038). The IVUS stent 
area and IVUS-measured total stent length that best separated restenosis from non-
restenosis were 5.5mm2 and 40mm, respectively. Lesions with stent area <5.5mm2 and 
stent length >40mm had the highest rate of angiographic restenosis [17.7% (11/62)], 
compared to other groups (Table).
Conclusions: Independent predictors of angiographic restenosis after SES implantation 
were the IVUS stent area and IVUS-measured total stent length. The angiographic 
restenosis rate was highest in lesions with stent area <5.5mm2 and stent length >40mm.
Table. Angiographic restenosis rate according to post-intervention IVUS stent cross-
sectional area (CSA) and total stent length
Stent length Stent CSA 
<5.5 (mm2) >5.5 (mm2) p
<40 (mm) 3/127 (2.4%) 1/284 (0.4%) 0.090
>40 (mm) 11/62 (17.7%) 6/70 (8.6%) 0.116
p <0.001 <0.001
 
954-254 The Impact of Changes in Insulin Resistance After PCI 
on Lumen Narrowing
Mikihito Toda, Kenji Wagatsuma, Junichi Yamazaki, Toho University Omori Medical 
Center, Tokyo, Japan
Background: Metabolic Syndrome is of note as a risk factor closely associated with the 
onset and progression of arteriosclerosis.Deﬁned by the prevalence of components such 
as abnormal glucose tolerance and hyperlipidemia,the established view is that insulin 
resistance is at its core.Objective: We observed the changes in lumen narrowing over time 
at late follow up after PCI to study differences with changes in insulin resistance.
Methods: Subjects were 158 non-diabetic patients who underwent PCI for ischemic 
heart disease, were controlled for coronary risk factors at the time of the PCI procedure, 
and were able to undergo late follow-up study. HOMA-R (fasting blood glucose x fasting 
insulin/405) at the time of PCI was used as the insulin resistance index. The patients were 
divided into the insulin resistant group (H group) and the insulin sensitive group (L group), 
and those showing improvement of HOMA-R were classiﬁed the D group, and those with 
worsening were the U group. Within the D group, patients were sub-classiﬁed into those 
using medication to improve insulin (DA group), those under dietary therapy (DB group) 
and the DA + D B (DC group), for comparative studies. MLD and RD were measured by 
QCA immediately after, at 2 months, and at 6 months after the procedure, late loss was 
calculated, and the differences between the groups were studied.
Results: Changes in MLD in the H group were 2.91±0.48, 2.02±0.59 and 1.70±0.46, 
and in the L group were 2.99±0.51, 2.48±0.55 and 2.12±0.43, with a signiﬁcantly larger 
late loss in the H group compared to the L group ( P<0.05). The MLD at late follow-up 
was signiﬁcantly smaller in the U group (1.68mm) compared to the D group (2.18mm) 
(P<0.05). There was no signiﬁcant difference in late loss between the DA and DB 
groups, but a tendency for less late loss was seen in the DC group.Conclusion: Insulin 
resistance may promote the narrowing of the stent lumen, suggesting the necessity of 
strict management of not only pharmacologic therapy but also dietary therapy from the 
time of the PCI procedure, during the post-procedural course, and up to the late follow-
up period.
954-255 Two-Year Intravascular Ultrasound Follow-Up After 
Implantation of Non-Polymeric Paclitaxel-Coated 
Stents: A Serial Volumetric Intravascular Ultrasound 
Analysis From the Asian Paclitaxel-Eluting Stent 
Clinical Trial (ASPECT)
Duk-Woo Park, Myeong-Ki Hong, Young-Hoon Jeong, Eui-Seock Hwang, Se-Whan Lee, 
Bong-Ki Lee, Young-Hak Kim, Ki Hoon Han, Cheol Whan Lee, Jae-Joong Kim, Seong-
Wook Park, Seung-Jung Park, Asan Medical Center, University of Ulsan College of 
Medicine, Seoul, South Korea
BACKGROUND: The aim of the present study was to use serial volumetric intravascular 
ultrasound (IVUS) analysis to evaluate the long-term efﬁcacy of a paclitaxel coating on 
in-stent intimal hyperplasia (IH) 2 years after stent implantation.
METHODS: Patients were randomized to placebo (bare metal stents) or one of two 
doses of paclitaxel (low dose, 1.28 µg/mm2; high dose, 3.10 µg/mm2). Complete post-
stent implantation, 6-month and 2-year follow-up IVUS were available in 53 patients (17 
patients in placebo, 17 in low dose and 19 in high dose).
RESULTS: Baseline characteristics were similar between the three groups. At 6-month 
follow-up, there was a stepwise reduction in IH accumulation within the stented segment 
(23±18 mm3 in placebo, 14±11 mm3 in low dose, and 10±12 mm3 in high dose, p<0.017). 
But, at 2-year follow-up, no difference existed in IH accumulation between 3 groups (25±19 
mm3 in placebo, 18±10 mm3 in low dose, and 23±14 mm3 in high dose, p=0.4). Increase of 
IH volume between 6-month vs. 2-year follow-up was signiﬁcantly greater in the high dose 
patients compared to placebo and low-dose patients (13±14 mm3 in high dose vs. 1±13 
mm3 in placebo, p=0.019 and 4±7 mm3 in low dose, p=0.074). With increasing dose, there 
was no signiﬁcant change in the reference segments after 2 years.
CONCLUSIONS: Despite the suppression of IH after non-polymeric paclitaxel-coated 
stents compared with bare stents at 6-month follow-up, a “late catch-up” IH growth was 
found in the high dose patients at 2-year follow-up.
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955-256 Inﬂuence of Number of Vessels Disease in Prognosis 
and Therapeutic Results in Chronic Coronary Artery 
Disease After Medical, Bypass Surgery or Angioplasty: 
3-Years Follow-Up of the Mass I I Study
Neuza Lopes, Aécio FT Góis, Luiz AM Cesar, Jorge Borges, Sergio A. Oliveira, Whady 
Hueb, José AF Ramires, Heart Institute(InCor), São Paulo, Brazil
Background: Chronic coronary disease with preserved ventricular function usually has 
a good prognosis. It is not known whether the number of vessels involved has impact 
on therapeutic results accordingly to different modalities of treatment. We analyzed the 
inﬂuence of number of vessels diseased in prognosis in this subset of patients after 
medical, bypass surgery or angioplasty
Methods: we have evaluated 825 individuals enrolled in MASS registry, a randomized 
study to compare treatments for single or multivessel CAD with preserved left ventricular 
function, prospectively followed during 3 years. The incidence of the composite end-point 
of cardiac death, myocardial infarction and refractory angina was compared in three 
groups: single vessel disease (SVD n =214), two vessel disease (2VD n = 253) and three 
vessel disease (3VD n =358). Survival curves were calculated with the Kaplan-Meier 
method and evaluated with the log-rank statistic.
Results: most baseline characteristics were similar among groups, except age (younger in 
SVD and older in 3VD, p<0.001). There were no statistical differences in composite end-
point in three years among groups independently of kind of treatment, however, there was 
a higher mortality rate in 3VD (p<0.001). When we stratiﬁed our analysis for each treatment 
option, bypass surgery was associated with a lower number of composite end-point in all 
groups (SVD p<0.001, 2VD p<0.002, 3VD p<0.001). In multivariate analysis, we found 
higher mortality risk in 3VD comparing to SVD (p<0.012, HR 13.18, 95%CI 1.7-97).
Conclusion: Three vessel disease was associated with worse prognosis comparing to 
single or two vessel disease in patients with chronic coronary disease and preserved 
ventricular function at 3 year follow-up. In addition, bypass surgery is the best therapeutic 
option, independently of number of vessel diseased in this subset of patients.
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955-257 Impact of Admission Serum Glucose Level on In-
Hospital Outcomes Following Coronary Artery Bypass 
Grafting Surgery
Dale Clayton, Syed Ali Imran, Bandar Al-Sheri, Alison Rowe, Karen Buth, Ehud Ur, 
Thomas Ransom, Imtiaz Syed Ali, Dalhousie University, Halifax, NS, Canada
Background: Elevated admission serum glucose (SG) level is known to predict adverse 
outcomes in patients with acute myocardial infarction (MI) and those undergoing 
percutaneous coronary intervention. The impact of admission SG level on outcomes in 
coronary artery bypass grafting (CABG) surgery is unknown. We sought to determine 
whether elevated admission SG level is associated with increased in-hospital mortality 
(IHM) and/or major morbidity following CABG.
Methods: Patients undergoing isolated CABG between Jan 2001 and Dec 2003 at a 
single centre were identiﬁed (n=1330). Admission SG was deﬁned as the ﬁrst recorded 
glucose level between the period of pre-operative assessment clinic visit and the time of 
surgery. A cut-off value of admission SG < or ≥ 9.2mmol/L was chosen to divide patients 
into two groups [Group A (SG<9.2mmol/L) and Group B (SG≥9.2mmol/L)] based upon 
the 75th percentile of SG distribution in the entire study population. A logistic regression 
model was generated to determine the impact of admission glucose ≥9.2mmol/L on a 
composite outcome deﬁned as any one or more of IHM, stroke, MI, sepsis, deep sternal 
wound infection, renal failure, requirement for postoperative inotropes, and prolonged 
(>24hrs) ventilation.
Results: Of the 1330 patients, 992 (74.6%) had admission SG<9.2mmol/L (Group A) 
and 338 (25.4%) had admission SG≥9.2mmol/L (Group B). Group B patients were more 
likely to be diabetic (p<0.0001), have preoperative renal failure (p<0.02), an ejection 
fraction<40% (p<0.0001), suffered an MI<7days of surgery (p=0.01), have a history of 
heart failure (p<0.0001), and undergo urgent CABG (p<0.04). Univariate analysis revealed 
no difference in IHM between Group A (2.1%) and Group B (3.0%), p=0.37; however, the 
composite outcome was more likely to occur in Group B (43.2%) vs. Group A (27.2%), 
p=0.0001. After adjustment, admission SG≥9.2mmol/L remained a strong independent 
predictor of the composite outcome, odds ratio=1.71, 95% conﬁdence interval=1.26-2.31, 
p=0.0005, model receiver operating characteristic=0.79
Conclusions: Admission SG≥9.2mmol/L is independently associated with the occurrence 
of major morbidity following isolated CABG.
955-258 Antiplatelet Treatment with P2Y12 Receptor Antagonist 
Decreases Blood Loss in a Canine CABG Model with 
Cardiopulmonary Bypass
Christopher S. Crean, Arthur P. Bode, You-Su Sun, Wiley Nifong, Matt Cowlen, 
Stephanie Anderson, Ward Peterson, Jose L. Boyer, Inspire Pharmaceuticals, Inc, 
Durham, NC, East Carolina University, Greenville, NC
Background: Postoperative bleeding after cardiac surgery with cardiopulmonary bypass 
(CPB) is associated with alterations in the hemostatic system likely as a result of platelet 
activation during surgery and CPB.
Methods: This study’s primary objective was to evaluate the effect of treatment with INS50589, 
a reversible, short half-life, P2Y12 receptor antagonist, on postoperative blood loss and platelet 
function in a canine model of CPB with or without CABG. Canines were continuously infused 
with placebo (N=7) or INS50589 at 1 mg/kg/h (N=6) just prior to sternectomy through the end 
of CPB and evaluated through a 4-hour post-operative period.
Results: Ex vivo platelet aggregation stimulated by 20µM ADP in placebo-treated animals 
was reduced by ca. 50% during CPB and remained reduced after CPB by approximately 
15-30%. Platelet aggregation in INS50589-treated animals was completely inhibited 
during CPB and fully reestablished within 90 minutes after discontinuation of infusion to 
the end of the 4 h postoperative observation period. This protection of platelet function by 
INS50589 resulted in a signiﬁcant decrease in postoperative blood loss when compared 
with placebo-treated animals (459±97 vs. 684±128 mL blood volume). In addition, 3 of the 
placebo-treated animals required a blood transfusion during the post-operative period in 
order to maintain a hematocrit value of > 20% necessary for survival during the post-CPB 
observation period. In contrast, no postoperative blood transfusions were necessary in 
the animals treated with INS50589. The patency of the bypassed artery was maintained 
in both treatment groups.
Conclusions: In conclusion, the data support our hypothesis that inhibition of platelet 
activation with a P2Y12 receptor antagonist during extracorporeal circulation alleviates 
the platelet dysfunction observed after cardiac surgery with CPB and conﬁrms the 
central role of the platelet ADP receptor in hemostasis. The pharmacological activity and 
pharmacokinetic properties of INS50589 should prove useful in the prevention of the 
bleeding diathesis observed in humans after cardiac surgery with CPB.
955-259 Does Platelet Hyperactivity Exist After Off-Pump 
Compared to On-Pump Coronary Artery Bypass 
Surgery?
Frantisek Bednar, Tomas Vanek, Pavel Osmancik, Heidi Mocikova, Martin Jares, Zbynek 
Straka, Petr Widimsky, Cardiocenter, Kralovske Vinohrady University Hospital, Clinic of 
Cardiac Surgery, Prague, Czech Republic, Third Medical School of Charles University, 
Prague, Czech Republic
Background: Hypercoagulability after off-pump coronary artery bypass grafting (CABG) 
as a one of possible cause of early graft failure is currently often discussed. We assessed 
platelet activity after off-pump and on-pump CABG surgery.Methods: Ten off-pump and 
twelve on-pump surgeries were performed in a prospective randomized study. Blood 
samples were drawn before surgery, immediately postoperatively, on days 1,2, 5 and day 
30 after surgery. Platelet activity was determined by membrane expression of platelet 
antigen CD41 (part of GpIIb/IIIa integrin), CD42 (von Wilebrand factor receptor) and CD 
62P (P-selectin) by ﬂow cytometry as mean ﬂuorescence intensity (CD41, 42b) or % of 
positive cells (CD62P). Platelet aggregability was measured by arachidonic acid (ARA)-
aggregometry .Results: Baseline characteristics and intraoperative variables were 
comparable in both group, except for surgery duration and grafts count. Post-operative 
membrane antigen expression was signiﬁcantly and transiently increased in off-pump and 
decreased in on-pump CABG compared with preoperative values. Maximum difference 
of antigen expression in the off-pump was observed for CD41 on day 5 (11.9+1.0 vs. 
11.2+0.8, p<0.05), for CD42 on day 1 (12.4+1.5 vs. 11.7+1.2, p=n.s.) and on day 2 for 
CD62P (2.16+2.3 vs. 0.9+0.3, p<0.05). In the on-pump, maximum diference was on day 
5 for all measured antigens (CD41: 11.0+0.7 vs. 11.7+0.9, p<0.05; CD42b: 11.5+1.3 vs. 
13.6 +1.0, p<0.05; CD62P: 1.2+0.3 vs. 1.2+0.9, p=n.s.). No changes to preoperative 
values were evident in both group on day 30. Platelet ARA-aggregation was signiﬁcantly 
decreased immediately after operation and on day 1 in both groups (-70%,p< 0,05) and the 
decrease was sustained until day 30. However, there was a surprisingly transient increase 
of ARA agregation on day 2, particularly in off-pump, compared with day 1.Conclusions: 
The platelet hyperactivity determined by membrane expression of platelet antigen seems 
to be present in early post-operative period in off-pump, but not in on-pump CABG 
surgery. Standard antiplatelet therapy with aspirin seems to be insufﬁcient in early post-
operative period especially in off-pump CABG surgery.
955-260 Impact of Mitral Valve Anuloplasty Combined with 
Revascularization in Patients with Functional Ischemic 
Mitral Regurgitation
Tomislav Mihaljevic, Masami Takagaki, Jeevanantham Rajeswaran, Michael S. Lauer, 
Buu-Khanh Lam, A. Marc Gillinov, Eugene H. Blackstone, The Cleveland Clinic 
Foundation, Cleveland, OH
Background: This study was undertaken to determine if concurrent mitral valve 
anuloplasty is of beneﬁt in patients with moderate to severe (3+/4+) functional ischemic 
mitral regurgitation (MR) undergoing coronary artery bypass grafting (CABG).
Methods: From 1991 to 2003, 390 patients with moderate to severe ischemic MR 
had CABG with (n=290) or without (n=100) concurrent mitral valve anuloplasty. These 
groups were propensity matched using demographics, extent of coronary artery disease, 
echocardiographic ﬁndings, and quantitative electrocardiography. Outcomes compared 
were time-related survival, echocardiographic severity of MR, and New York Heart 
Association (NYHA) class, the latter two using longitudinal mixed model analysis.
Results: 1-, 5-, and 10-year survival was 88%, 75%, and 47% in the CABG alone group 
and 92%, 74%, and 39% in the CABG+mitral valve anuloplasty group (P=.6). Increased 
risk of death was associated with echocardiographic ﬁndings of severe lateral wall motion 
abnormalities (P=.05), ST-segment elevation in lateral leads (P=.0002), and higher 
QRS complex voltage sum (P=.003). Patients who had CABG alone were more likely 
to have moderate to severe postoperative MR (77% at 1 year) than patients who had 
CABG+mitral valve anuloplasty (34% at 1 year, P<.0001). Substantial improvement in 
NYHA class occurred postoperatively in both groups (P<.001) and remained constant 
over time; further, presence of severe postoperative symptoms (NYHA III/IV) was similar 
in both groups (23% in CABG+mitral anuloplasty group vs 25% in CABG alone group over 
the ﬁrst 5 postoperative years, P=.3).
Conclusions: Although coronary revascularization with concomitant mitral valve 
anuloplasty reduces postoperative MR, it does not improve functional status or survival 
in patients with severe functional ischemic MR when compared to CABG alone. This 
corroborates the idea that mitral anuloplasty in this setting, without addressing the 
fundamental ventricular pathology, is insufﬁcient to improve clinical outcomes.
ORAL CONTRIBUTIONS
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814-3 Paracrine Effects of Endothelial Progenitor Cells on 
Acutely Infarcted Myocardium
Hyuj-jai Cho, Namho Lee, Tina Thorne, Jin-ok Jeong, Masaaki Ii, Ji Yoon Lee, Andrea 
Wecker, Mejeong Lee, Juyong Lee, Young-sup Yoon, St. Elizabeth’s Medical Center, 
Tufts University School of Medicine, Boston, MA
Background: Recently paracrine effects have been emerged as an additional mechanism 
to explain therapeutic effects of adult stem/progenitor cells. In this study, we investigated 
the kinds and the source of paracrine factors modulated after myocardial injection of 
EPCs.
Methods and Results: Immediately after creation of MI in mice, mice received 5x105 
mouse EPCs, 5x105 mouse endothelial cells (EC), or PBS (n=10, each) into peri-infarct 
area. In EPC group, we observed higher capillary density, higher proliferation rate, and 
lower apoptosis in peri-infarct area, and functional improvement. Real-time RT-PCR at 2 
weeks revealed that mRNA expression levels of the following cytokines were signiﬁcantly 
increased in the EPC group compared to control groups: VEGF (1.7 fold, P<0.01), bFGF 
(1.9, P<0.05), VEGFR2 (2.3, P<0.05), Ang-1 (2.0, P <0.05), Ang-2 (4.4, P<0.05), e-NOS 
(2.4, P<0.01), PLGF (1.9, P<0.05), PDGF (2.2, P<0.05), HGF (2.0, P<0.05), SDF-1� 
(1.5, P<0.01) and IGF-1 (4.5, P<0.01). To determine whether these upregulated cytokines 
were derived from injected donor cells or recipient animals, we used a xenotransplantation 
approach. We injected 5x105 human EPCs into nude mice in an identical fashion (n=10). 
Human- and mouse-speciﬁc probes were designed for the above listed factors individually 
to detect the source of upregulated cytokines. More than 80% of increased mRNA 
expression of each factor was attributed to mouse cells. To investigate the contribution 
of bone marrow (BM)-derived cells to such upregulation, we induced MI in GFP-bone 
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marrow transplanted wild-type (WT) mice and injected EPC, EC or PBS (n=5, each). 
Signiﬁcantly higher number of incorporated GFP (+) cells was observed in the EPC group 
compared to the EC and PBS group (127±16 vs. 17± 4, 15±3/HPF, P<0.01).
Conclusions: This study demonstrated that intramyocardial injection of EPCs induced 
sustained upregulation of multiple paracrine factors in infarcted myocardium, which can 
facilitate regeneration of infarcted myocardium. Also the data suggests that the sustained 
paracrine effects after EPCs transplantation may be derived from recipient origin, both 
proper myocardial cells and mobilized BM cells into the myocardium.
11:15 a.m.
814-4 Mesenchymal Stem Cells Improve Cardiac Function 
in a Rat Model of Myocardial Infarction Through a 
Mechanism Independent of Increasing Muscle Mass or 
Limiting Myocardial Infarct Size
Wangde Dai, Loren E. Wold, Sharon L. Hale, Robert A. Kloner, Heart Institute, Good 
Samaritan Hospital, Los Angeles, CA
Background: Some studies report that injection of bone marrow-derived mesenchymal 
stem cells (MSC) into a myocardial infarction (MI) can reduce MI size, increase muscle 
mass, and enhance cardiac function. Whether MSC can beneﬁt function independent of a 
mechanism involving MI size or muscle mass is unknown.
Methods and Results: We injected 2×106 MSC or saline (S) into one week old MIs in 
rats(n=12 in each group). At 4 weeks we observed an improvement in left ventricular 
(LV) function in MSC group with an increased ejection fraction (EF) of 12.9% compared 
to S group (p=0.0027), and an increased stroke volume of 18.9% compared to S 
group (p=0.032); yet the size of the scar expressed as an area was similar in both S 
(5.36±0.54mm2) and MSC group (6.08±0.48mm2, p=0.33); and was similar when 
expressed as a circumference in S (12.5±0.55mm) and MSC group (13.45±0.58mm, 
p=0.22). Scar thickness did not differ between the S group (0.45±0.04mm) and MSC group 
(0.48±0.02mm, p=0.54). The noninfarcted LV area was similar in the S (14.1±0.71mm2) 
and MSC group (13.9±1.02mm2, p=0.87); the noninfarcted LV circumference was also 
similar in the S (14.4±0.75mm) and MSC group (13.76±0.62mm, p=0.52). There was 
no hypertrophy of the noninfarcted tissue. Infarct size and stroke volume histograms are 
shown on the graphs below.
Conclusions: MSC improved function at 4 weeks after transplantation into a MI through 
a mechanism independent of reducing MI size or increasing cardiac muscle mass, 
implicating a paracrine or other unknown mechanism.
11:30 a.m.
814-5 Hypoxia-Induced Differential Expression of 
Angiogenesis Genes by Umbilical Cord Blood-derived 
CD34+/CD133+ Progenitor Cells
Mohamed A. Gaballa, Ludmilla Khailova, Steven Goldman, Haung Thai, David Harris, 
University of Arizona Sarver Heart Center, Tucson, AZ
Background: Umbilical cord blood (UCB) is an emerging source of stem cells for 
treatment of various diseases because it contains primitive hematopoeitic stem cells. 
The combination of CD34 and CD133 cell markers is typically used to enrich for 
these hematopoeitic stem cells in the UCB. Several recent studies demonstrate that 
transplantation of umbilical cord blood-derived progenitor cells improved cardiac function 
after myocardial infarction mainly by inducing vasculogenesis. However, it is still unclear 
whether the improvement in cardiac function is primarily due to the incorporation of the 
transplanted cells into the heart vasculature or secondary due to the angiogenic factors 
released by these cells. Since these cells are typically transplanted into ischemic heart, 
they are subjected to hypoxia due to the lack of oxygen in the infarcted region. Methods: 
To identify the hypoxia-induced genes, and possibly the factors released by these cells 
in the infarcted myocardium, we compared the gene expression of fresh isolated CD34 
CD133 cells incubated in culture for 24 hrs under normal conditions to those cells 
exposed to hypoxia. We used cDNA microarray for angiogenesis. Results: Out of the 128 
angiogensis genes examined, only 8 growth factors are differentially expressed (greater 
than 2 fold difference) due to hypoxia, namely angiopoiten1/2, CSF, PDGFa/b, EGFb, 
EGFR3, TFGb, VEGFb, and VG5Q; and nine inﬂammatory genes, IL-1b, IL-6, MMP2/9, 
Ephrin A1/A2/A3, neurophilin1, urokinase, and thrombopondin1, VE-Cadherin, CD31, 
and chemokine (C-X-C motif) ligands. Conclusions: UCB-progenitor cells differentially 
express a limited number of angiogenic genes when subjected to hypoxia.
11:45 a.m.
814-6 Therapeutic Potential of Human Unrestricted Somatic 
Stem Cells Isolated from Placental Cord Blood for 
Concurrent Cardiomyogenesis and Vasculogenesis 
With Functional Regenerative Recovery Post 
Myocardial Infarction
Hiroto Iwasaki, Atsuhiko Kawamoto, Christina Willwerth, Andreas Muhs, Toshihiko 
Shibata, Akira Oyamada, Saeko Hayashi, Kazuyo Sadamoto, Miki Horii, Shigefumi 
Suehiro, Stephan Wnendt, Takayuki Asahara, Kobe Institute of Biomedical Research 
and Innovation / RIKEN Center for Developmental Biology, kobe, Japan, Osaka City 
University Graduate School of Medicine, Osaka, Japan
Background: In 2004, Koegler et al have successfully identiﬁed CD34-negative, CD45-
negative, pluripotent stem cells by cultivating human cord blood mononuclear cells, termed 
unrestricted somatic stem cells (USSCs). However, multi-lineage developmental capacity 
of USSCs, especially into cardiomyocytes (CMCs) and smooth muscle cells (SMCs) in 
vivo, still needs further investigation. Functional contribution of USSC transplantation in 
acute myocardial infarction (MI) has also never been evaluated.
Methods: PBS, 1x106 human ﬁbroblasts (Fb), 1x105 USSCs (Lo) or 1x106 USSCs (Hi) 
were intramyocardially transplanted 20 min after ligating LAD of nude rats (n=9 in each 
group). Histological and functional outcomes were compared among the groups.
Results: Differentiation of the transplanted USSCs into human CMCs and SMCs in rat 
infarcted myocardium at day 28 was conﬁrmed by double immunostaining for cardiac 
troponin-I and human nuclear antigen (HNA) and that for smooth muscle actin and human 
leukocyte antigen-ABC. Differentiation of USSCs into human endothelial cells was also 
detected in the infarct area by double immunostaining for vWF and HNA. Necropsy 
examination at day 28 disclosed dose-dependent augmentation of capillary density by 
isolectin B4 staining (Hi, 492.4±25.0; Lo, 420.9±11.2; Fb, 274.8±36.2; PBS, 319.3±25.6 
/mm2, P<0.05) and dose-dependent inhibition of left ventricular (LV) ﬁbrosis area (Hi, 
14.8±1.0; Lo, 19.6 ±0.8; Fb, 33.2±1.4; PBS, 31.5±1.2%. P<0.05). Functional assessment 
by echocardiography and a micro-tip conductance catheter (Millar) at day 28 revealed 
dose-dependent preservation of LV function by USSC transplantation [(1) +dP/dt: Hi, 
11496±309; Lo, 9384±292; Fb, 7067±205; PBS, 7262±160 mmHg/sec, P<0.01, (2) -dP/
dt: Hi, -6700±142; Lo, -4990±302; Fb, -4211±183 PBS, -4186±192 mmHg/sec, P<0.01, 
(3) Millar LVEF: Hi, 67.9±2.8; Lo, 55.1±2.8; Fb, 44.0±2.0; PBS, 38.7±2.4 %, P<0.01, (4) 
Regional wall motion score: Hi, 21.0±0.19; Lo, 23.5±0.5; Fb, 26.1±0.4; PBS, 26.7±0.3 
%. P<0.01].
Conclusion: USSC transplantation may have signiﬁcant and dose-dependent potential for 
concurrent cardiomyogenesis and vasculogenesis with functional recovery from acute MI.
Noon
814-7 Collagen Implantation as an Internal Support to Prevent 
Eccentric Hypertrophy and Preserve Cardiac Function 
After Myocardial Infarction in Rats
Wangde Dai, Loren E. Wold, Joan S. Dow, Robert A. Kloner, Heart Institute, Good 
Samaritam Hospital, Los Angeles, CA
Purpose: It is hypothesized that following acute myocardial infarction, lengthening of 
the noninfarcted myocardium (eccentric hypertrophy) can impair cardiac function. We 
investigated whether stabilization of an infarct scar with direct collagen injection can 
prevent eccentric hypertrophy in the noninfarcted tissue and preserve cardiac function in 
a rat myocardial infarction model.
Methods: Collagen or saline (100 µl) were directly injected into the scar area at 1 week 
after ligation of the proximal left coronary artery in Fischer rats (n=11 each group). Six 
weeks later, left ventricular (LV) function was assessed by angiograms, and the hearts 
were processed for histology to measure the infarcted and noninfarcted LV area.
Results: At 6 weeks after treatment, the noninfarcted LV area was signiﬁcantly smaller in 
the collagen-treated group (13.2 ± 0.5 mm2) compared to the saline-treated group (15.2 ± 
0.7 mm2, p=0.036). The circumference of the noninfarcted myocardium was signiﬁcantly 
shorter in the collagen-treated group (13.2 ± 0.6 mm) than in the saline-treated group 
(15.3 ± 0.8 mm, p=0.046). Thickness of the noninfarcted wall did not differ between 
groups at 1.35 ± 0.03mm (collagen-treated group) and 1.26 ± 0.07mm (saline-treated 
group, p=0.23). As expected, scars treated with collagen injection demonstrated a greater 
area (8.3 ± 0.5 mm2) than scars treated with saline only (5.6 ± 0.6 mm2, p=0.0016) due 
in part to an increased thickness of the treated scar area by 63.4%. LV angiography 
demonstrated that cardiac function was signiﬁcantly improved in the collagen treated 
group. LV ejection fraction in the collagen-treated group (48.4±1.8%) was signiﬁcantly 
greater than that in the saline-treated group (40.7±1.0%, p=0.002). 
Conclusion: This study shows for the ﬁrst time that collagen implantation within the 
infarcted area reduced eccentric hypertrophy of the noninfarcted wall, and preserved 
cardiac function after myocardial infarction. Thus collagen implantation may provide a 
novel approach to limit the development of eccentric (length-wise) hypertrophy of the 
noninfarcted myocardium after myocardial infarction.
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814-8 Aging Impairs the Beneﬁcial Effects of Intravenous 
Infusion of Mesenchymal Stem Cells on Post- 
Myocardial Infarction Remodeling
Stephanie Lehrke, Daniel J. Durand, Ramesh Mazhari, Jeffrey M. Zimmet, Djahida 
Bedja, Roberto M. Saraiva, Jin-Qiang Kuang, Randell Young, Bradley J. Martin, Kathleen 
L. Gabrielson, Randal Mills, Joshua M. Hare, Johns Hopkins University School of 
Medicine, Baltimore, MD, Osiris Therapeutics, Baltimore, MD
Background: Recent ﬁndings suggest that the favorable effect of cellular cardiomyoplasty 
on post-myocardial infarction (MI) remodeling is attributable to an enhancement of 
endogenous cardiac repair mechanisms. Since the capacity of these repair mechanisms 
diminishes with age, we hypothesized that post-MI infusion of mesenchymal stem cells 
(MSCs) would be effective in preventing post-MI remodeling in young, but not in old rats.
Methods: MI was induced by permanent left coronary artery ligation in young (6-
7 month) and old (18-22 month) Wistar rats. Rats were randomized to i.v. infusion of 
allogeneic mesenchymal stem cells (4-5×106) or saline 48 hours after MI. MSCs were 
made to express enhanced green ﬂuorescent protein (eGFP). Rats underwent serial 
echocardiography for 4 weeks.
Results: Pre-MI 2-D ejection fraction (EF) was 97± 0.4% in young vs 98±0.6 % in old rats. 
At day 2 post-MI, EF was reduced to 55.8± 5.7% (young control, n=9), 61.9± 26% (young 
MSC, n=11), 78.6±2.2% (old control, n=10) and 75.2±3.7% (old MSC, n=10), suggesting 
comparable initial myocardial damage within each age group. While EF continued to 
decline in young control animals (EF 51.4± 7.5% at week 4), MSC therapy prevented 
the deterioration of cardiac function among young animals and led to an increase of EF 
to 67.3± 5.4% at week 4 (p= 0.002 vs. control by 2-way ANOVA). This favorable effect of 
MSC therapy on cardiac function was completely absent among old animals (EF at week 
4: 72.1± 4% old control vs. 64.8± 6.5% old MCS). Furthermore, among young rats MSC 
therapy mitigated the time-dependent increase in left ventricular end-diastolic dimensions 
(p= 0.006 by 2-way ANOVA), but did not prevent cardiac enlargement in old rats. Infarct 
size at week 4 was comparable among age and treatment groups. No eGFP expressing 
cells were present in the myocardium at 4 weeks post-MI.
Conclusions: We here conﬁrm the efﬁcacy of intravenous MSC infusion to ameliorate 
post-MI remodeling in young rats and present the novel ﬁnding that this effect is 
dramatically reduced with aging. While the exact mechanisms warrant further research, 
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815-3 A Prehospital Diagnostic Strategy Reduces Time to 
Treatment and Mortality in Real Life Patients With ST-
Elevation Myocardial Infarction Treated With Primary 
Percutaneous Coronary Intervention
Erik Björklund, Ulf Stenestrand, Johan Lindbäck, Leif Svensson, Lars Wallentin, Bertil 
Lindahl, Department of Cardiology, Uppsala, Sweden
Background: There are sparse data on the inﬂuence on time to treatment and 
subsequent mortality with a prehospital diagnostic strategy in patients treated with 
primary percutaneous coronary intervention (PCI). We therefore evaluated time delays 
and outcome in a large cohort of real world patients with ST-elevation myocardial infarction 
treated with primary PCI according to a prehospital electrocardiogram (ECG) or not
Methods: Prospective cohort study using data from the Swedish Register of Cardiac 
Intensive Care on consecutive patients admitted to the coronary care units of 66 Swedish 
hospitals in 2002-2004. Ambulance transported patients younger than age 80 years, 
with the ﬁrst diagnosis of acute myocardial infarction during the registration period, with 
ST-elevation on the admission ECG, treated with primary PCI and with information on 
symptom duration were included. Out of eligible 2017 patients, 911 had a prehospital 
ECG transmitted to the nearest hospital using telemedicine. Mortality data were obtained 
from the Swedish National Cause of death register.
Results: Patients with (n=911) compared to without (n=1106) a prehospital ECG were 
older, otherwise there were no differences in baseline characteristics. The median time 
to treatment was 165 (25th-75th percentile,114-260) and 220 (25th-75th percentile, 140-
354) (p<0.001) minutes according to prehospital ECG or not. There was no difference 
in median time from symptom onset to ambulance arrival in a subgroup of the patients 
with or without prehospital ECG (69 vs. 70 minutes, p=0.17). 30-day mortality was 
2.4% vs. 3.6% (p=0.12) in patients with and without prehospital ECG. In multivariable 
analyses, after adjusting for risk factors at baseline, a prehospital diagnostic strategy was 
associated with lower 30-day mortality (OR 0.57; 95% CI, 0.32-0.99).
Conclusions: Time from symptom onset to primary PCI is reduced by almost one hour 
and the adjusted 30-day mortality is reduced with a prehospital diagnostic strategy in 
this registry study.
A diagnostic strategy with prehospital ECG is important even when treatment is restricted 
to primary PCI.
11:15 a.m.
815-4 Does Hospital PTCA Volume Inﬂuence Mortality and 
Complication Rates in the Era of PTCA With Systematic 
Stenting? Results of the Greater Paris Area PTCA 
Registry
Marie-Claude Morice, Christian Spaulding, Bernard Lancelin, Simon El Haddad, 
Eric Lepage, Sophie Bataille, Xavier Mourange, Jean-Pierre Tresca, Mehran Monchi, 
Sandrine Fosse, Nikita de Vernejoul, Institut Cardiovasculaire Paris-Sud, Massy, France, 
Cochin Hospital, Paris 5 Medical School, Rene Descartes University, Paris, France
Background : In acute myocardial infarction (AMI), primary percutaneous transluminal 
angioplasty (PTCA) is the preferred option when it can be performed less than 90 minutes 
after the ﬁrst medical contact. Because of limited access to high PTCA volume centers 
in some countries, it has been suggested that PTCA could be performed in low-volume 
centers on AMI patients. Little data exist on the validity of this strategy in modern era 
PTCA.
Methods : The Greater Paris area comprises 11 million inhabitants and accounts for 18% 
of the French population. In 2001, the hospital agency of the Greater Paris area set up a 
registry of all PTCAs. Data from 2001 and 2002 was analyzed. Hospitals performing < 400 
PTCAs per year were classiﬁed as low-volume.
Results : A total of 37,848 angioplasty procedures performed in 44 centers located 
in the Paris area were recorded in the registry during 2001 and 2002; 24% were 
performed in centers with less than 400 procedures per year. By multivariate analysis, 
in-hospital mortality predictors were age, female gender, annual PTCA hospital volume 
and emergency procedures. Interactions warranted a case control analysis (propensity 
score) comparing centers performing < 400 PTCAs/year and > 400 PTCAs/year. Mortality 
rates were signiﬁcantly different in the sub-group of emergency procedures: 6.75% in 
high vs 8.54% in low-volume centers, p=0.028. No difference was noted between low 
and high-volume centers in the subgroup of non-emergency procedures (0.62% vs 
0.62%, p=0.99). The same analysis found a statistically signiﬁcant reduced rate of in-
hospital complications in patients admitted to high-volume centers (overall population: 
3.01% vs 4.01%, p = 0.0027, non-emergency procedures: 8.79% vs 11.01%, p = 0.0092, 
emergency procedures: 1.43% vs 1.95%, p=0.026)
Conclusion: These data demonstrate that in the era of modern stenting, a clear 
inverse relationship exists between hospital PTCA volume and in-hospital mortality after 
emergency procedures in patients with AMI < 24 hours, cardiogenic shock or OHCA. 
Tolerance of low-volume thresholds for angioplasty centers with the purpose of providing 
primary PTCA in AMI should not be recommended, even in underserved areas
11:30 a.m.
815-5 Field Triage Directly to the Catheter Laboratory Safely 
Reduce Time to Reperfusion and Infarct Size in Patients 
With ST-Elevation Myocardial Infarction
Steen Carstensen, Greg Nelson, Peter Hansen, Lewis Macken, Steve Irons, Michael 
Flynn, Pramesh Kovoor, Soon Yeng Soo Hoo, Michael Ward, Helge Rasmussen, Royal 
North Shore Hospital, Sydney, Australia, New South Wales Ambulance, Sydney, Australia
Background: Delays in delivery of primary percutaneus coronary intervention (PCI) to 
patients with ST-elevation myocardial infarction (STEMI) should be minimized in order 
to obtain the optimal outcome. This rationale is primarily based on data from clinical 
registries demonstrating that mortality increases with treatment delay, however, it remains 
to be shown that reducing treatment delay conveys the expected beneﬁt in outcome. We 
tested the hypothesis that bypassing emergency departments (ED) through ﬁeld triage 
of STEMI patients directly to the catheter laboratory on a 24/7 basis is safe and reduces 
time to reperfusion and infarct size.
Methods: Random assignment of patients with suspected AMI to either ﬁeld triage or 
assessment and triage at the closest ED in an area where primary PCI was the preferred 
reperfusion strategy. One third of the ambulances servicing a regional heart centre and 
4 district hospitals in the Sydney metropolitan area (population 890,000) were equipped 
with 12-lead ECG recording and transmitting capability and patients with ST-elevation in 
the ﬁeld ECG were tele-triaged by emergency doctors directly to the catheter laboratory at 
the heart centre while all other patients, including those attended by ordinary ambulances, 
were taken to the closest ED for triage.
Results: In the 18 months study period 551 ﬁeld ECGs were recorded and 101 patients 
(18%) with STEMI were triaged from the ﬁeld directly to the catheter laboratory while 
203 STEMI patients presented to the EDs by ambulance. Median symptom onset to 
reperfusion time was 148 (IQR: 119-228) and 248 (IQR: 177-349) minutes in the two 
groups respectively (p<0.0001). In the 140 patients presenting within 120 minutes of 
symptom onset maximal levels of Troponin-T (3.3 (IQR: 1.8-6.3) versus 5.4 (IQR: 2.2-8.3) 
µg/L, p<0.02) and Creatin Kinase (973 (IQR: 520-2038) versus 1681 (IQR: 916-2866) 
U/L, p<0.01) were lower in the ﬁeld triaged group compared with those triaged at EDs. No 
patient in the ﬁeld triage group died at the scene or during transport.
Conclusions: Field triage of STEMI patients directly to a catheter laboratory is feasible, 
safe, reduces time to reperfusion and reduces infarct size compared with triage at EDs.
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815-6 A Randomized Trial Comparing Primary PCI With 
or Without On-Site Surgery for Acute Myocardial 
Infarction in the Netherlands: From Randomization to 
Clinical Practice
Victor A. Umans, Hans O. Peels, Raymond Hautvast, Hans de Swart, Medical Center 
Alkmaar, Alkmaar, The Netherlands
Background: One approach to expedite AMI treatment is to improve the accessibility 
of primary PCI by increasing the number PCI centers. We describe the results of a 
randomized trial comparing primary PCI with or without on-site surgery.
Methods: This trial compared off-site with on-site PCI in AMI pts. The primary endpoint of 
this study is angiographic success without adverse events
Results: In the randomized trial, 173 pts presenting with an acute ST elevation MI were 
treated by off-site (84) or onsite (89)PCI. The mean door-to-balloon time was 73 min but 
33 min less (p<0.01) in the off-site clinic. 35% had an anterior infarct, mean CKmb was 
190U/l. Stenting was performed in 93%. 
30-days Death re-MI em CABG re-PTCA
Off-site PCI 2% 0 0 0
On-site PCI 7% 4% 0 0
Following this trial, all primary PCI’s were performed without onsite surgery (case load 
180/yr). Of these, 436 pts (50% men, mean age 65yrs) 35% had an anterior MI: 4% were 
in Killip class IV. Mean ST deviation and CK-MB were 17±10mm and 186±1550 U/l. On 
angiography, 44% had multivessel disease and 71%had TIMI 0/1 ﬂow. The median door-
to-balloon time was 57 min. TIMI-3 ﬂow was achieved in 90%. 30-days clinical follow-up 
are: death 0%, CABG 0%, reMI 0.9%,rePCI 0.9%.
Conclusion: This randomized study shows the safety and effectiveness of off-site 
primary PCI in a regional infarct center with a reduction of 33 min in door-to-balloon time. 
Emergency surgery was not needed. Our experience led to new Dutch PCI guidelines 
permitting primary and elective PCI in clinics without surgery with at least 3 operators and 
an annual volume load of 450 procedures.
Noon
815-7 Lower Mortality With Paramedics Interpreting the 
Electrocardiogram Coupled to Primary Percutaneous 
Angioplasty for ST-Segment Elevation Myocardial 
Infarction
Michel R. Le May, Richard Dionne, Justin Maloney, Marino Labinaz, John Trickett, Irene 
Whatpool, Michel Ruest, Sheila Ryan, Derek Y F So, Andrew Ha, Ian Stiell, Richard F. 
Davies, University of Ottawa Heart Institute, Ottawa, ON, Canada
BACKGROUND: Most trials reporting on pre-hospital management of ST-elevation 
myocardial infarction (STEMI) had a physician accompanying the mobile unit or the ECG 
was transmitted to a physician at the base hospital. We sought to determine if advanced 
care paramedics (ACPs) could effectively establish the presence of (STEMI) on the 
pre-hospital electrocardiogram (ECG), and contribute to strategies that shorten time to 
reperfusion and improve clinical outcomes.
METHODS: After training, ACPs began to independently triage patients with chest pain, 
and transport those with STEMI directly to a designated centre for primary percutaneous 
coronary intervention (PCI), bypassing the city’s emergency rooms. For comparison with 
the patients referred by the ACPs, we used a control group of 226 consecutive patients 
presenting with STEMI that were brought in by ambulance to the city’s hospital emergency 
rooms between July 2001 and January 2004.
RESULTS: Between July 2004 and June 2005 inclusive, the ACPs referred 108 
consecutive patients for PCI with a conﬁrmed diagnosis of STEMI. Primary PCI was 
performed in 94.4% of patients in the ACP referred group vs. 9.3% of patients in the 
control group, p<0.0001. None of the patients referred by the ACPs received thrombolytic 
therapy while the majority of patients (80.1%) in the control group received thrombolytic 
therapy as the initial reperfusion therapy, p<0.0001. The median door-to-balloon time was 
63 minutes in patients referred by the ACPs compared to 125 minutes in the patients 
referred for primary PCI in the control group, p<0.0001. The median door-to-needle time 
was 41 minutes for patients treated with thrombolytic therapy in the control group. In-
hospital mortality was lower in patients referred by the ACPs, 1.9%, compared to that 
recorded in the entire control group, 8.9%, p=0.017.
CONCLUSION: Our study demonstrates that with appropriate training, paramedics can 
accurately diagnose STEMI on a 12- lead ECG and independently triage patients for 
primary PCI. This multidisciplinary regional strategy shortened door-to-balloon times and 
yielded signiﬁcantly lower mortality.
12:15 p.m.
815-8 Achieving Rapid Myocardial Infarction Reperfusion 
With Percutaneous Coronary Intervention Remains a 
Challenge, Especially in Women, Elderly, and Minorities: 
Results From American Heart Association Get With the 
Guidelines
Vincent J. Bufalino, Eric D. Peterson, Leslie J. Lantz, Midwest Heart Foundation, 
Lombard, IL, Duke Clinical Research Institute, Durham, NC
Background: The speed of reperfusion [door to balloon time (DTB)] is a well established 
performance metric for patients with ST elevation myocardial infarction (STEMI). While 
ideally DTB times should be <90 minutes, it is unclear how consistently this is achieved in 
community practice, particularly in women, elderly, and minorities.
Methods: We used the American Heart Association Get With The Guidelines (GWTG) 
database to study DTB times at 191 participating United States sites from July 2001 to 
September 2005. Eligible patients included those with STEMI or Left Bundle Branch Block 
having primary percutaneous coronary intervention (PCI) within 24 hours of myocardial 
infarction admission. Mean DTB time and % compliance with goal (PCI w/in 90 min) 
were assessed overall, overtime, and among patient subgroups. Generalized estimating 
equations (GEE) were used to assess log-transformed continuous trends and disparities 
in care based on race, gender, and age.
Results: Over study period, 4234 STEMI patients received primary PCI (76.7% 
Caucasian, 62.8% under age 65, and 72.8% male). The overall mean DTB time was 
157 minutes (25th-75th range: 72, 140). Only 42% of cases had DTB < 90 minutes. Mean 
DTB time improved over study period, from 163 minutes to 117 minutes by the 8th quarter 
(P=.0051). The % achieving DTB <90 minutes also improved from 40.7% to 54.5% p 
value= .0082 . Relative to their peers, women (176 vs. 150, p <0.003), those aged >65 
years (174 vs. 149, p<0.001), and minorities (156 vs. 171, p=.1384) had longer mean 
DTB times. The time trend for disparities based on age is marginally signiﬁcant, indicating 
that the difference in DTB time between younger and older patients is decreasing over 
time (p<.05).
Conclusion: While the speed of PCI reperfusion for STEMI is improving, it is still well 
below the optimum level. DTB times are particularly delayed in women, elderly, and 
minority populations. These results demonstrate the need for ongoing involvement in 
national quality improvement initiatives such as GWTG.
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971-215 Pregnancy-associated Plasma Protein A: An Instant 
Rising Biomarker in Patients With ST-Elevation 
Myocardial Infarction
Christian J. Terkelsen, Claus Oxvig, Bjarne L. Nørgaard, Jens F. Lassen, Leif Thuesen, 
Erling Falk, Torsten T. Nielsen, Henning R. Andersen, Department of cardiology B, 
Skejby University Hospital, Aarhus, Denmark, Department of Molecular and Structural 
Biology, University of Aarhus, Aarhus, Denmark
Background: In patients with Acute Myocardial Infarction (AMI) traditional biomarkers are 
not detectable until at a time when irreversible myocardial damage may have occurred. An 
instant rising biomarker would be ideal for diagnostic and therapeutic purposes. Markers 
of plaque instability, such as Pregnancy-Associated Plasma Protein A (PAPP-A), may 
be detectable even before occlusion of coronary epicardial vessels occurs. The present 
study evaluated the acute course of PAPP-A compared with traditional biomarkers, in 
patients with ST-Elevation Myocardial Infarction (STEMI).
Methods: The study population comprised 87 STEMI-patients who were treated with 
acute angioplasty. The ﬁrst plasma sample was drawn before or immediately following 
acute angiography. Additional samples were drawn during the ﬁrst 5 days of admission. 
Exact time of plasma sampling was registered. Samples were evaluated for the level of 
PAPP-A, Troponin-T (TnT), N-terminal-pro-Brain-Natriuretic Peptide (Nt-pro-BNP), and 
high-sensitive C-Reactive Protein (hsCRP).
Results: Raised levels of PAPP-A were detectable in 95% of samples drawn within three 
hours of symptom onset, but only in 17% of samples drawn from six to 12 hours following 
onset of symptoms. Median [IQR] time from symptom onset to peak-level of PAPP-A, TnT, 
Nt-pro-BNP and hsCRP was 4.7 [3.0-10.4], 15.8 [10.0-25.2], 28.8 [11.1-42.4] and 56.8 
[40.8-74.2] hours, P<0.0001.
Discussion: The instant rise and abrupt normalization of PAPP-A may be explained 
by stabilization of disrupted plaques during coronary intervention. Pre-interventional 
treatment with high-dose heparin in STEMI-patients, however, may contribute to the high 
levels of PAPP-A observed, because cellular adhesion of PAPP-A is dependent on a 
heparan binding site. Future studies should establish whether the “plaque stabilization 
by angioplasty” or “heparin-induced PAPP-A detachment” theory is correct, and further 
evaluate the diagnostic and therapeutic value of PAPP-A in patients with AMI.
Conclusions: PAPP-A is detectable in the earliest hours following onset of symptoms 
in patients with STEMI, but it is unsettled whether early rise in PAPP-A is restricted to 
heparinized patients.
971-216 Linkage Analyses of Markers of Inﬂammation: The 
Genetic Epidemiology Network of Arteriopathy 
(GENOA) Study
Dali L. Feng, Mariza de Andrade, Stephen T. Turner, Eric Boerwinkle, Thomas H. Mosley, 
Jr., Sharon LR Kardia, Iftikhar J. Kullo, Mayo Clinic, Rochester, MN
Background: C-reactive protein (CRP) and ﬁbrinogen are correlated markers of 
inﬂammation and cardiovascular risk. Although polymorphisms in CRP and ﬁbrinogen 
genes have been shown to modify their plasma levels, genes at remote loci that may 
regulate their levels are largely unknown. We performed univariate and bivariate linkage 
analyses to identify genetic regions that may inﬂuence the individual traits and exert 
pleiotropic effects on both traits. Methods: Subjects (n = 2323) belonged to the GENOA 
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study, a community-based study of hypertensive sibships and included 1317 African 
Americans (AA) (mean age 63.0±9.5 years) and 1006 non-Hispanic whites (NHW) 
(mean age 60.3±9.9 years). CRP was measured by a highly sensitive immunoassay 
and ﬁbrinogen by the Clauss method. Genotyping was performed at 366 microsatellite 
marker loci spaced approximately 10 cM apart across the 22 autosomes. Univariate 
and bivariate linkage analyses were performed using a variance components approach. 
Results: Moderate heritability (h2) was noted for CRP (0.37 in AA, 0.37 in NHW) and 
ﬁbrinogen (0.48 in AA, 0.28 in NHW). Signiﬁcant genotypic correlations between CRP 
and ﬁbrinogen were present in NHW (0.40) and in AA (0.39). Univariate linkage analysis 
demonstrated either tentative or suggestive evidence of linkage (deﬁned as multipoint 
LOD score 1.3-2.0 and 2.1-3.0 respectively) for CRP on chromosome (ch) 9 in AA and 
on ch 1 and 10 for NHW; for ﬁbrinogen on ch 1, 2, 6, 10, 12, and 17 in AA and on ch 2 
in NHW with the maximum LOD score of 2.14 for ﬁbrinogen on ch 2 in AA (55.5 cM, P = 
0.0009). Bivariate linkage analysis suggested evidence of genetic regions with pleiotropic 
effects on both traits (LOD score > 2.0) on ch 2 and 12 in AA and on ch 21 in NHW; with 
the maximum LOD score of 3.44 on ch 12 in AA (152.1 cM, P = 0.0003). Conclusions: 
CRP and ﬁbrinogen levels are heritable traits that are genetically correlated in AA and 
NHW hypertensive sibships. Univariate and bivariate linkage analyses identiﬁed several 
chromosomal regions that may harbor genes inﬂuencing CRP and ﬁbrinogen levels as 
well as regions that may have pleiotropic effects on the two traits.
971-217 Soluble Tumour Necrosis Factor-related Apoptosis 
Inducing Ligand is Low Early in the Presentation of 
Acute Coronary Syndromes and Is Inversely Correlated 
With C-Reactive Protein and Troponin T
Victoria Watt, Kausik K. Ray, Sheila E. Francis, Moira K. Whyte, David C. Crossman, 
University of Shefﬁeld, Shefﬁeld, United Kingdom
Background: Tumour necrosis factor-related apoptosis inducing ligand (TRAIL) is a 
member of the TNF ligand superfamily. TRAIL is a pro-apoptotic cytokine, expressed on 
inﬂammatory cells, notably T cells, and is present in stable and unstable atherosclerotic 
plaques. We assessed the potential role of soluble TRAIL (sTRAIL) in the pathogenesis of 
acute coronary syndromes (ACS).
Methods: Plasma was collected from patients with stable coronary artery disease (CAD) 
before angiography (n=76), & patients with ACS (Braunwald Class IIIB) 24 hrs after 
admission (n=62), at 48 hrs & pre-discharge. sTRAIL was measured using a sandwich 
ELISA. CRP & Troponin T (cTnT) were also measured & correlations with TRAIL 
assessed.
Results: In the ACS group at 24 hrs, sTRAIL was signiﬁcantly lower vs patients with stable 
CAD (p<0.001, see Fig 1) and was then seen to increase at 48 hrs and pre-discharge 
(p<0.001, Fig 1). sTRAIL was inversely correlated with CRP (R=-0. 45, p<0.001; R=-
0.48, p<0.001; R= -0.49, p<0.05) at all time points. Among patients with a positive cTnT, 
sTRAIL was lower at 24 hrs (57.3 vs 83.3 pg/ml, p<0.001) & at 48 hrs (69.3 vs 95.7 
pg/ml, p<0.01).
Conclusion: sTRAIL is signiﬁcantly lower during the ﬁrst 24 hrs of ACS vs stable CAD, but 
levels steadily increase as the ACS resolves. This initial low level may reﬂect sequestration 
of TRAIL or reduced release mechanisms. The inverse correlations between sTRAIL & 
known markers of atherothrombotic risk may support a mechanistic role for TRAIL in the 
pathogenesis of ACS.
971-218 Electrocardiographic Unrecognized Myocardial 
Infarction Is Associated With Increased Mortality 
Independent of Regional Wall Motion Abnormalities on 
Echocardiogram
Khawaja A. Ammar, Richard J. Rodeheffer, Mayo Clinic, Rochester, MN
Background: Unrecognized Myocardial Infarction (UMI), diagnosed by a surveillance 
ECG, is associated with increased mortality similar to that of recognized myocardial 
infarction. The impact of echocardiographic abnormalities associated with UMI on 
mortality has not been evaluated.
Methods: A population based random sample of 2,042 Olmsted County residents, age 
>45 years, were studied. Main exposure measures included UMI (n=81; diagnosed if 
ECG-MI criteria were met without the history of a documented myocardial infarction), No 
MI (n = 1847; diagnosed if both ECG and chart abstraction were negative for the evidence 
of myocardial infarction) and echocardiographic abnormalities (RWMA, diastolic and 
systolic dysfunction, left atrial and ventricular enlargement). The main outcome measure 
was 5 year all-cause mortality.
Results: ECG-UMI was associated with an increased risk of all-cause mortality as 
compared to No MI controls [hazard ratio (HR) 3.7, 95% CI 2.00, 6.22; p<0.001]. This 
association persisted after adjustment for age, sex, smoking, diabetes and hypertension, 
although it was reduced in magnitude (HR 1.82; 95% CI 0.97, 3.14; p = 0.05). ECG-UMI 
subjects with any echo abnormality (n=52) had a higher risk of mortality (HR 4.22; 95% CI 
2.05,7.75; p<0.001). Exclusion of subjects with RWMA did not attenuate this relationship. 
The highest risk was seen in UMI subjects with left atrial enlargement (HR 7.96;p<0.001), 
left ventricular enlargement (HR 6.08;p<0.01), systolic dysfunction (HR 5.12; p=0.03), 
diastolic dysfunction (HR 4.81;p<0.01) and RWMA (HR 2.39;p=0.45) in the descending 
order. ECG-UMI subjects without any echo abnormality were not associated with an 
increased risk of mortality (HR 0.99;p = 0.99).
Conclusions: Multiple echocardiographic abnormalities signifying global ventricular 
dysfunction due to post MI remodelling are signiﬁcant modiﬁers of the increased 
mortality associated with ECG-UMI. These data challenge the current clinical practice of 
declaring an ECG-MI false positive in the absence of regional wall motion abnormalities 
on a conﬁrmatory echocardiogram and suggest attention to other echocardiographic 
abnormalities signifying global dysfunction.
971-219 Mitral Annular Dilatation; Is It Active or Passive? A 
Cardiac MRI Study
Robert W. Biederman, Ketheswaram Caruppannan, Ronald B. Williams, June Yamrozik, 
Geetha Rayarao, Vikas K. Rathi, Tarun Tewatia, Diane A. Vido, Mark Doyle, Allegheny 
General Hospital, Pittsburgh, PA
Introduction Explanations offered for the etiology of LV annular dilatation include many 
active processes reﬂecting remodeling of adjacent myocardium. However, passive 
mechanisms have not been considered. Cardiac MRI (CMR) delayed hyperenhancement 
(DHE) post-contrast techniques describe LV histopathology including infarct, inﬁltrative 
and inﬂammatory perturbations and may also be sensitive to non-myocardial pathology.
Hypothesis We hypothesize that DHE may detect occult LV annular and/or mitral valvar 
enhancement in post MI patients.
Methods Forty patients; 32 s/p MI (12 F, 9 acute, 23 chronic) underwent CMR (1.5T CV/i 
GE) with 0.2mmol/kg of Magnevist (Berlex NJ). Notation of presence or absence of a DHE 
pattern involving the mitral annulus and/or valve was made. Patients were speciﬁcally 
excluded if the MI pattern involved basal myocardium to avoid confounding signal etiology. 
Non MI patients (8) referred for contrast CMR served as controls.
Results All post-MI patients demonstrated an area of infarct by functional analysis, 
conﬁrmed by DHE. Additional DHE was present involving the mitral annulus in 17/32 
(53%) and in 28/32 (89%) the mitral valve (Fig A). No controls demonstrated any degree 
of annular or valvar enhancement (Fig B).
Conclusion CMR DHE depicts focal annular and/or valvar enhancement in a signiﬁcant 
number of post MI patients, suggesting a passive as yet, unknown reactive process that 
may portend, if not potentiate LV annular dilatation and mitral leaﬂet pathology.
 
971-220 Effect of CKMB Elevation After Successful PCI on One-
Year Mortality
Ramin Ebrahimi, Michael Lincoff, Jahandar Saleh, Nitin Wadhani, Behzad 
Daneshpanahi, Edward J. Toggart, Kathy Wolski, Eric Topol, UCLA/GLAVA, Los 
Angeles, CA, Cleveland Clinic, cleveland, OH
Background: Percuatenous Coronary Intervention (PCI) is a very effective and common 
treatment for symptomatic Coronary Artery Disease (CAD). Creatine Kinase-MB (CKMB) 
elevation may be noted in a large percentage of patients undergoing PCI. The effect of 
this cardiac enzyme elevation on one year mortality after successful PCI has not been 
well studied and continues to be subject of much debate. The purpose of this study is to 
evaluate the effect of various levels of CKMB elevation above normal limit on one year 
mortality after successful PCI. This is the largest analysis of its kind based on a single 
prospective randomized double blind trial.
Methods: REPLACE 2 was a double blind prospective randomized trial in patients 
undergoing PCI that compared different regimens of antiplatelet/antithrombotic therapies. 
Patients were divided into not successful PCI (residual stenosis>50%, ﬁnal TIMI ﬂow<3, 
or unable to cross or dilate) or successful PCI (all others). Patients were divided in to three 
groups based on CKMB elevation. CKMB <1, 1-3, >3 times upper limits of normal (ULN).
Results: Of the 6002 patients 4902 had successful PCI and CKMB determination. The three 
groups did not differ signiﬁcantly in terms of their baseline characteristics. 1234/4902 (25.2%) 
had CKMB >1 X ULN, 357/4902 (7.2%) had CKMB >3 X ULN. One year ortality was 67/3668 
ACC_2006_4_Myocardial AA.indd   194 1/4/06   5:14:03 PM




(1.8%), 20/877 (2.28%), and 12/345 (3.36%) in the <1, 1-3, >3 XULN groups respectively. 
The Mantel-Haenszel Chi-Square analysis reveled statistically signiﬁcant trend for increased 
mortality based on graded increase in CKMB despite successful PCI, p= 0.046.
Conclusions: Based on the results of this analysis, rated increase in CKMB after successful 
PCI results in statistically signiﬁcant trend in graded increase in mortality at one year.
971-221 Abnormal Radial Strain in Both Infarcted and 
Remote Myocardial Regions Following Ischemia 
and Reperfusion in Rats Assessed by 2D Strain 
Echocardiography
Raymond Q. Migrino, Xiaoguang Zhu, Ming Zhao, Medical College of Wisconsin, 
Milwaukee, WI
Background: Strain, reﬂecting intrinsic myocardial mechanics,may be more sensitive 
than segmental thickening (ST) in assessing myocardial dysfunction. We compared 
endsystolic radial strain (RS) and ST following ischemia and reperfusion (I/R) in infarcted 
(I), periinfarct (PI) and remote (R)myocardial segments using novel tissue tracking 2D 
strain echo (2DSE). 
Methods:The proximal LAD was ligated in 7 male Sprague-Dawley rats for 30 min followed 
by 60 min reperfusion. Open chest 2DSE was done at baseline, and following ischemia and 
reperfusion using GE Vivid 7 echo and 13 MHz transducer. The mid LV in short axis was 
divided into 6 standard segments. RS was measured using Q analysis software (General 
Electric). ST(systolic-diastolic thickness/diastolic thicknessx100) was measured. After 
sacriﬁce, triphenyl tetrazolium staining identiﬁed infarcted myocardial segments. Segments 
1-2 and occasionally 3 were infarcted and comprised the I group (n=17). Segments adjacent 
to I were designated as PI (n=14), the rest were designated as R (n=11). 
Results: See ﬁgure. 
Conclusions:1. There is reduced RS in I, PI and even remote regions signifying myocardial 
dysfunction following I/R. 2. This dysfunction was not detectable in PI and R regions following 
reperfusion by conventional ST analysis. 3. 2DSE may be more sensitive for detecting 
ischemic dysfunction than ST. 4. The mechanism underlying myocardial dysfunction following 
I/R even in remote, uninvolved segments is unclear and need to be further studied.
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972-222 The Efﬁcacy and Safety of Fondaparinux Versus 
Enoxaparin in Non-ST Elevation ACS: Impact of Renal 
Dysfunction (OASIS 5)
Keith A. A. Fox, J. P. Bassand, L. Wallentin, S. Mehta, P. Theroux, L. Piegas, V. Valentin, 
T. Moccetti, S. Chrolavicius, S. Yusuf, Keith A. A. Fox, Edinburgh, United Kingdom, 
University of Edinburgh, Edinburgh, United Kingdom
Background. Renal dysfunction in ACS independently predicts in-hospital death and late 
mortality. Renal excretion of anti-thrombins may inﬂuence this hazard and bleeding risk.
Methods. In OASIS 5 (n=20,078) we tested whether the reductions in major bleeding 
with fondaparinux (fonda) at 9 days (overall: 4.0% vs 2.1%, enoxaparin (enox) vs fonda, 
HR 0.53, 95% CI 0.45 - 0.62, P<0.0001) and the impact on mortality at 6 months, were 
inﬂuenced by renal dysfunction.
Results. Overall, death rates at 9 days (0.97%, 1.28%, 1.65%, 3.12%) and major bleeding 
(2.7%, 2.5%, 2.4%, 4.8%) increased with respective quartiles of creatinine. But, the 
hazard ratio for bleeding was consistently lower with fonda (0.54, 0.56, 0.54, 0.48, p value 
<0.01 for each). Death rates were substantially higher for the highest quartile of creatinine 
(>1.19 mg/dL). This quartile was associated with the largest increase in bleeding, and 
signiﬁcantly higher late mortality (11.4 vs 9.5%, p<0.02) with enox compared to fonda 
(11.4 vs 9.5%, p<0.02). Similar ﬁndings were observed for the composite of death/MI/
refractory ischemia (19.2 vs 16.8%, p<0.02) for creatinine >106mmol/L (or 1.19 mg.dL).
Conclusion. Rates of bleeding were markedly inﬂuenced by elevated baseline creatinine 
for both anti-thrombins. However the rates were consistently and signiﬁcantly lower with 
fondaparinux. Higher mortality and higher bleeding risks for enox comapared to fonda 
were was most evident in the highest quartile of renal dysfunction.* p<0.023
Creatinine Death (6 months) Major Bleeding (9 days)
mmol/L mg/dL Enoxaparin Fondaparinux Enoxaparin Fondaparinux
<77 <0.87 4.48 3.44 4.8 3.4
77-<88 0.87-<0.99 3.96 4.73 4.9 3.4
88-<106 0.99-<1.19 5.64 5.17 4.4 3.7
>106 >1.19 11.38* 9.53* 8.2 5.5
972-223 Enhanced Expression of Natriuretic Peptide Receptors 
in Accumulated Neutrophils and Macrophages at the 
Sites of Coronary Unstable Plaques in Acute Coronary 
Syndromes
Kei Yunoki, Takahiko Naruko, Akira Itoh, Kazuo Haze, Nobuyuki Shirai, Hajime 
Yamashita, Shoichi Ehara, Chizuko Kitabayashi, Takehisa Suekane, Yoshimi Sugama, 
Yoshihiro Ikura, Masahiko Ohsawa, Makiko Ueda, Osaka City General Hospital, Osaka, 
Japan, Osaka City University Graduate School of Medicine, Osaka, Japan
Background : Despite natriuretic peptides and its speciﬁc receptors are instrumental 
in relaxation and growth inhibition of vascular smooth muscle cells (SMCs), the role of 
natriuretic peptide receptors (NPRs) in unstable atherosclerotic lesions has not received 
much attention. Recently we have demonstrated that neutrophils play a role in mediating 
destabilization of atherosclerotic plaques (Circulation 106: 2894-2900, 2002). Previously 
in vitro studies have shown that natriuretic peptides regulated the chemotaxis and priming 
of neutrophils. To elucidate the role of NPRs in coronary plaque destabilization, we 
immunohistochemically studied the presence of NPRs in coronary atherectomy specimens 
obtained from patients with stable angina (SAP) and unstable angina pectoris (UAP). 
Methods: Atherectomy specimens were obtained from patients with SAP (n=21) and 
UAP (n=21). Immunohistochemical staining of the specimens was carried out using 
antibodies against SMCs, endothelial cells, macrophages, neutrophils, and NPRs. For 
the identiﬁcation of cell types which stain positive for NPRs, immunodouble staining was 
also performed. 
Results: The percentage of NPR-A and NPR-B positive cells in patients with UAP was 
signiﬁcantly higher than in patients with SAP (NPR-A: P<0.0001; NPR-B: P<0.0001). 
However, there was no signiﬁcant difference in the percentage of NPR-C positive cells 
in the two groups. Immunodouble staining revealed that the vast majority of NPR-A and 
NPR-B positive cells were neutrophils and macrophages. On the other hand, the majority 
of NPR-C positive cells were either macrophages or SMCs. 
Conclusions: These results suggest that enhanced expression of NPR-A and NPR-B 
relates to plaque instability in human coronary atherosclerotic lesions.
972-224 Bleeding Complications Predict Major Cardiovascular 
Outcomes in Non ST-Elevation Acute Coronary 
Syndromes: Results From the OASIS - 5 Trial
Andrzej Budaj, John Eikelboom, Lars Wallentin, Shamir Mehta, Denis Xavier, Alexander 
Parkhomenko, Rizwan Afzal, Susan Chrolavicius, Salim Yusuf, for the OASIS-5 
Investigators, Grochowski Hospital, Postgraduate Medical School, Warsaw, Poland, 
McMaster University, Hamilton Health Sciences, Hamilton, ON, Canada
Background: Anticoagulant therapies in ACS reduce ischemic events but are associated 
with an increased risk of bleeding. In the OASIS 5 trial, efﬁcacy between fondaparinux 
and enoxaparin were similar at 9 days but major, minor, and total bleeding was reduced 
by fondaparinux by about 50%. The aim of this analysis was to evaluate the relationship 
between bleeding and late major cardiovascular events.
Methods: 20,078 patients with NSTE ACS, were randomly assigned to enoxaparin or 
fondaparinux. The relation between major bleeding and death, MI, and stroke at 30 days 
and 6 months was evaluated using a Cox proportional hazard model.
Results: Fondaparinux compared with enoxaparin reduced both major bleeding 
(2.1% versus 4.0%, HR 0.53, p<0.0001), and minor bleeding (1.1 vs 3.1%, HR 0.35, 
p<0.0001).
Bleeding was strongly associated with death, MI, and stroke, both unadjusted, and after 
adjustment that included baseline characteristics, propensity for bleeding and bleeding 
as a time dependent variable (table). There was no signiﬁcant interaction between the 
randomized treatments and bleeding related to these outcomes. Adjusted hazard ratios 
for death, MI, and stroke in patients experiencing a major or minor bleeding:
Conclusions: Major and minor bleeding complications in patients treated with 
anticoagulants are strong independent predictors of death, MI, and stroke. Future 
treatment strategies need to focus on lowering the risk of bleeding in order to maintain 
any gains from reduction in thrombotic events.
30 days 180 days
Major Bleeding
Death 5.06 (4.59-5.62) 3.16 (2.92-3.44)
MI 5.01 (4.56-5.57) 2.99 (2.75-3.28)
Stroke 4.77 (3.95-6.00) 3.30 (2.82-3.97)
Minor Bleeding
Death 2.42 (2.03-2.97) 1.76 (1.31-2.37)
MI 1.48 (1.28-1.78) 1.29 (1.15-1.48)
Stroke 1.54 (1.06-2.67) 1.48 (0.76-2.89)
ACC_2006_4_Myocardial AA.indd   195 1/4/06   5:14:03 PM



















972-225 Oxidative Stress Within the Coronary Circulation Is 
Associated With Reduction in Endothelium-Dependent 
Coronary Vasodilation in Patients With Acute Coronary 
Syndromes.
Lavinia Forte, Pasquale Pignatelli, Francesco Violi, Giovanni Cimmino, Francesco 
Loffredo, Raffaella Scaraﬁle, Rosangela Cocchia, Elvira Renzullo, Raffaele Calabro’, 
Paolo Golino, Second University of Naples, Naples, Italy, Clinica Medica I, University of 
Rome “La Sapienza”, Rome, Italy
Background: Acute coronary syndromes (ACS) are associated with an increased oxidative 
stress. However, little is known about the site of oxidant production and whether this increased 
oxidative stress might affect endothelium-dependent coronary vasodilation (EDCV). Thus, we 
aimed at assessing whether oxidative stress is increased within the coronary circulation of 
patients with ACS and whether this phenomenon is associated with a reduced EDCV.
Methods: Nitrate/nitrite, an index of NO production, and 8-hydroxy-2’-deoxyguanosine 
(8-OHdG), an index of oxidant generation, were measured in plasma samples obtained 
from the aorta (Ao) and the coronary sinus (CS) of 13 patients with ACS undergoing 
PTCA. EDCV, (coronary ﬂow velocity at baseline/intracoronary acetylcholine 10-6 M), was 
measured after stent implantation with a Doppler guidewire. Results: NO was signiﬁcantly 
reduced in plasma samples obtained from the CS, as compared to those collected from 
the Ao, 9.9±1.7 vs 14.0±1.1 µmol/L, respectively, p<0.001, while 8-OHdG was signiﬁcantly 
increased in the CS as compared to Ao, 1.9±0.4 vs 0.6±0.1 ng/ml, respectively, p<0.001, 
reﬂecting an increased oxidative stress in the coronary circulation. Interestingly, 8-OHdG 
levels correlated with the impairment of coronary endothelial function (Figure).
Conclusions: An increased oxidant stress occurs within the coronary circulation 
of patients with ACS; this phenomenon is associated with an impairment of coronary 
endothelial function.
972-226 Myeloperoxidase May Contribute to the No-reﬂow 
Phenomenon in Patients With Acute Myocardial 
Infarction
Hiroshi Funayama, Norifumi Kubo, Takanori Yasu, Masanobu Kawakami, San-e 
Ishikawa, Muneyasu Saito, Jichi Medical School, Omiya Medical Center, Saitama, Japan
Background: The no-reﬂow phenomenon is a deteriorating factor for prognosis of 
acute myocardial infarction (AMI). Leukocyte enzymes may be involved in developing 
the no-reﬂow phenomenon. We determined the association of myeloperoxidase (MPO), 
a leukocyte enzyme, with the no-reﬂow phenomenon in the patients with AMI after 
percutaneous coronary inetervention (PCI).
Methods: We enrolled 50 patients with AMI whose infarct-related coronary arteries were rescued 
by a thrombectomy device. Blood samples were collected from the infarct-related coronary artery 
(CA), the ascending aorta (Ao) and the peripheral vein (PV). MPO and elastase were measured 
by ELISA. No-reﬂow was deﬁned as postprocedural TIMI grade 0, 1, or 2 in the absence of a 
mechanical obstruction on the ﬁnal angiogram. Antergrade blood ﬂow in the infarct-related 
coronary artery and myocardial perfusion were evaluated according to the corrected TIMI frame 
counts (cTFC) and the myocardial blush gread (MBG).
Results: Plasma MPO level was 244.6+/-15.7 ng/ml (mean+/-SE) in CA, a value signiﬁcantly 
greater than that of 163.0+/-13.5 and 220.5+/-13.9 ng/ml in PV and Ao (p<0.0005). Plasma 
elastase level was 124.5+/-11.0 ng/ml (mean+/-SE) in CA, a value signiﬁcantly greater than 
that of 98.6+/-7.6 and 100.2+/-11.2 pg/ml in PV and Ao (p<0.05). No-reﬂow was found in 
10 patients (20%). The levels of MPO in CA were signiﬁcantly greater in the patients with 
no-reﬂow than those without no-reﬂow (p<0.05). In contrast, there was no difference in the 
levels of elasatse between the two groups of patients. Plasma MPO levels in CA positively 
correlated with the cTFC(r=0.441, p<0.005). Also, plasma MPO levels were signiﬁcantly 
higher in the patients with MBG 0-2 than those with MBG 3 (p<0.05).
Conclusions: The present ﬁndings indicate that regional MPO levels in the culprit 
coronary artery may contribute to the no-reﬂow phenomenon in the patients with AMI.
972-227 Concurrent Evaluation of Novel Cardiac Biomarkers in 
ACS: Myelopyroxidase, sCD40L, C-reactive Protein and 
Risk of Death or Recurrent Ischemia in TACTICS-TIMI 18
David A. Morrow, Marc S. Sabatine, Christopher P. Cannon, Sabina A. Murphy, Marie-
Luise Brennan, Stanley L. Hazen, Eugene Braunwald, TIMI Study Group, Brigham & 
Women’s Hospital, Boston, MA, Cleveland Clinic Foundation, Cleveland, OH
Multimarker strategies combining pathobiologically distinct cardiac biomarkers enhances risk 
assessment in patients with ACS. Comparative evaluation of newer markers is necessary to 
guide their integration into a strategy using established markers such as BNP and cTnI.
METHODS: We measured plasma levels of myelopyroxidase (MPO), soluble CD40 ligand 
(sCD40L), and C-reactive protein (CRP) in 1509 pts with non-ST elevation ACS treated 
with tiroﬁban and randomized to early invasive vs. conservative management in the 
TACTICS-TIMI 18 trial. MPO and sCD40L were dichotomized at the median. CRP >10 
mg/L was considered elevated.
RESULTS: Pts with elevated baseline MPO (>888 pM) were at signiﬁcantly higher risk of 
death, MI or rehospitalization for ACS at 30 days (9.5 vs. 4.8%, p=0.0003). In contrast, 
no difference was observed for those with higher sCD40L (>938 pg/ml, 7.7 vs 6.4%, p = 
0.32) or CRP (7.0 vs 7.1, p = 0.9). MPO remained associated with death and recurrent 
ischemic events after adjustment for age, ST-deviation, baseline troponin I, CRP and 
sCD40L (Adj HR 1.9; 95% CI 1.06 - 3.45). This association was attenuated at 180 days 
(Adj HR 1.3; 0.87 - 1.97). Stratiﬁcation of pts using baseline MPO, BNP and cTnI identiﬁed 
a nearly 4-fold gradient of risk for death or ischemic events (Figure).
CONCLUSIONS: MPO adds to a multimarker approach for short-term risk assessment 
using BNP, and cTnI in patients with non-ST elevation ACS. sCD40L was not associated 
with risk in this population treated with a GPIIb/IIIa antagonist.
972-228 Cardiac Expression of Placental Growth Factor 
Stimulates Peripheral Mobilization of CD34+ Progenitor 
Cells in Patients with Myocardial Infarction
Hajime Iwama, Shiro Uemura, Noriyuki Naya, Keiichi Imagawa, Yasuhiro Takemoto, 
Kenji Onoue, Satoshi Okayama, Satoshi Somekawa, Yukiji Takeda, Hiroyuki Kawata, 
Manabu Horii, Hiromitsu Yamamoto, Tamio Nakajima, Yoshihiko Saito, Nara Medical 
University, Kashihara, Nara, Japan
Background: Placental growth factor (PlGF), a member of vascular endothelial cell 
growth factor family, seems to be involved in wound healing processes after tissue injury. 
However, clinical signiﬁcance of PlGF in myocardial infarction (MI) has not been elucidated. 
We investigated the role of PlGF on the peripheral mobilization of bone marrow derived 
progenitor cells, as well as on the long-term left ventricular function after acute MI.
Methods: 57 patients with acute MI were enrolled. Blood samples were collected 
from peripheral vein, coronary artery, and coronary sinus. Plasma levels of PlGF were 
measured by ELISA method. Circulating progenitor cells were quantiﬁed by ﬂow cytometry 
as CD45lowCD34+CD133+.
Results: Transcardiac gradient of PlGF was signiﬁcantly higher after coronary 
reperfusion than before reperfusion (14.1±10.6 vs. 0.0±1.1pg/ml p<0.01), indicating 
cardiac production and release of PlGF from acute infarct heart. Circulating progenitor 
cells signiﬁcantly increased on the 7th hospital day compared to admission (10.5±1.4 vs. 
20.4±4.0 /107 CD45, p<0.05). PlGF did not correlate with total WBC count, but positively 
correlated with both peak monocyte count and the increase of circulating PCs count. 
Moreover, PlGF positively correlated with improvement of LVEF (R=0.39, p<0.01) and 
LVESVI (R=0.36, p<0.01) at 6-month study. Multiple regression analysis revealed that 
PlGF was the strongest independent predictor for the restoration of LV function.
Conclusions: Cardiac expression of PlGF plays an important role on wound healing 
processes by stimulating peripheral mobilization of PCs, and might have contributed to 
the improvement of cardiac function in chronic phase of MI.
972-229 The Impact of Several Inﬂammatory Indices on The 
Long-Term Cardiovascular Mortality in Patients With 
Acute Coronary Syndromes
Michael N. Zairis, Konstantinos Mainas, Nikolaos Tellis, Prodromos Temperekidis, 
Charalampos Papoulis, Leandros Stefanatos, Panagiotis Marietis, Charalampos 
Apostolatos, Denis Xenos, Alexander Kardoulas, Evdokia Adamopoulou, Stefanos G. 
Foussas, Tzanio Hospital, Piraeus, Greece
Background-Although an increased level of high-sensitivity C-reactive protein (hs-
CRP), ﬁbrinogen (Fb), serum amyloid A (SAA) and white blood cells count (WBC) 
upon admission have been associated with an adverse long-term prognosis in patients 
with acute coronary syndromes, whether each of these inﬂammatory indices has 
an independent prognostic value when all applied in the same cohort has not been 
thoroughly evaluated. We investigated the possible independent prognostic value of these 
inﬂammatory indices in the BIAS (Biochemical Indices and outcome in Acute coronary 
Syndromes) study. Methods-The BIAS study was designed to evaluate prospectively 
the impact of several biochemical indices including hs-CRP, Fb, SAA and WBC on the 
long-term cardiovascular mortality in patients who hospitalised due to either ST elevation 
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myocardial infarction (STEMI) or non-ST elevation acute coronary syndromes (NSTACS). 
For the purpose of this study 934 consecutive pts with STEMI (458 pts) and NSTACS 
(476) who admitted in the ﬁrst 12 and 24 hrs of index pain respectively, were recruited. 
Cardiovascular mortality at 5 year was the primary study endpoint. Results-By 5-year 
the incidence of primary endpoint was 23.1% and 21.4% in pts with STEMI and NSTACS 
respectively. By univariate Cox regression analysis high levels of hs-CRP, Fb, SAA 
and WBC were signiﬁcantly related with the primary endpoint in pts with either STEMI 
(p<0.001; p<0.001; p=0.004 and p<0.001 for hs-CRP, Fb, SAA and WBC respectively) 
or NSTACS (p<0.001; p=0.008; p=0.002 and p<0.001 for hs-CRP, Fb, SAA and WBC 
respectively). However by multivariate analysis, only high hs-CRP and WBC levels but 
not Fb and SAA were the inﬂammatory indices which independently associated with the 
5-year outcome in both STEMI (p<0.001; p=0.8;p=0.4 and p<0.001 for hs-CRP, Fb, SAA 
and WBC respectively) and NSTACS (p<0.001; p=0.6; p=0.3 and p<0.001 for hs-CRP, Fb, 
SAA and WBC respectively).
Conclusions-The results of the BIAS study suggest that high levels of hs-CRP, and WBC 
but not Fb and SAA upon admission are the inﬂammatory indices which independently 
related to long term mortality in patients with either STEMI or NSTACS.
972-230 Adverse Impact of Bleeding in Patients With Acute 
Coronary Syndromes
John W. Eikelboom, Shamir R. Mehta, Sonia Anand, Changchun Xie, Keith Fox, Salim 
Yusuf, McMaster University, Hamilton, ON, Canada
Background: The use of multiple antithrombotic drugs and aggressive invasive strategies 
has increased the risk of major bleeding in acute coronary syndrome (ACS) patients. It is 
not known whether bleeding is associated with long term adverse clinical outcomes.
Methods: We examined the association between bleeding, its severity, and death in the 
OASIS Registry and OASIS-2 and CURE trials.
Results: The analyses included 34,126 patients with ACS of whom 783 (2.3%) developed 
major bleeding. Patients with major bleeding were older; more often had diabetes or a 
history of stroke; had a lower blood pressure and higher serum creatinine; more often had 
ST segment changes on the presenting ECG; and had a signiﬁcantly higher incidence of 
death at 30 days (12.8% vs. 2.5%, P<0.0001) and between 30 days and 6 months (4.6% 
vs. 2.9%, P=0.002). Using a COX proportional hazards model that adjusted for baseline 
characteristics and propensity for major bleeding, major bleeding was strongly associated 
with an increased hazard of death at 30 days (hazard ratio [HR] 5.37; 95% CI: 3.97-7.26, 
P<0.0001) but there was a much weaker association between 30 days and 6 months (HR 
1.54; 95% CI: 1.01-2.36, P = 0.047). The association was consistent across subgroups 
and there was a higher hazard of death in those with more severe degrees of bleeding 
(P for trend 0.0009).
Conclusions: In ACS patients without persistent ST elevation there is a strong, consistent, 
temporal, and dose related association between major bleeding and death. This evidence 
for a causal association should prompt consideration of strategies to decrease the risk of 
bleeding while preventing ischemic events in patients with ACS.
972-231 Diabetes Mellitus Subjects Have Immune System 
Alterations Similar to That of Patients With Unstable 
Angina: A Clue to Explain Their High Cardiovascular 
Risk?
Salvatore Brugaletta, Simona Giubilato, Dario Pitocco, Michela Narducci, Valeria 
Colafrancesco, Giovanni Ghirlanda, Luigi Marzio Biasucci, Giovanna Liuzzo, Filippo 
Crea, Institute of Cardiology Catholic University, Rome, Italy, Institute of Internal 
Medicina Catholic University, Rome, Italy
Background: Inﬂammation contributes to the pathogenesis of acute coronary syndromes 
(ACS). Type 2 diabetes mellitus (T2DM) is associated with low-grade inﬂammation and 
increased risk of ACS. Unusual T-lymphocytes, CD4+CD28null cells, indicating aging in the 
immune system, have been recently found in the peripheral blood and in the coronary 
plaques of ACS. As these cells can induce pro-inﬂammatory pathways, we hypothesized 
that CD4+CD28null cell expansion might be involved in the immune system disorders 
associated with T2DM.
Methods: Peripheral blood T cells from 47 patients with T2DM without clinical evidence 
of ischemic heart disease were analyzed for the distribution of T cell subsets by ﬂow 
cytometry, and compared with 45 age- and sex-matched healthy subjects (H), and 
110 patients with unstable angina (UA). High sensitivity C-reactive protein (CRP) was 
also measured. UA patients were sub-grouped according to the presence (26 patients, 
UADM+) or absence (84 patients, UADM-) of clinical T2DM.
Results: No differences were found in lymphocyte count and total CD4+ cell frequency. 
CD4+CD28null cell frequency (median, range) was signiﬁcantly higher in T2DM (5.3, 0.2-
22.5%) than in H (0.7, 0.1-3.8%; P<0.001). UADM+ showed the highest CD28null cell 
frequency (13.3, 0.11-48.0%) as compared with UADM- (4.0, 0.2-35.0%; P=0.011), 
T2DM (P=0.013) and H (P<0.001). CRP measurement gave similar results. Notably, 
no difference was found in CD28null cell frequency between T2DM and the overall UA 
population (4.9, 0.1-48.0%; P=0.26). Regression analysis (including age, body mass 
index [BMI], glycemic control as indicated by glycosylated hemoglobin A1c [HbA1c], 
HDL-cholesterol, triglicerides, CRP, and insulin therapy) was performed in T2DM patients 
to identify the variables associated with CD28null cell expansion. CD28null cell frequency 
was directely associated with HbA1c (r=4.5, P=0.004) and inversely with HDL-cholesterol 
(r=-3.63, P=0.011).
Conclusions: Senescent T-lymphocytes with functional activities predisposing to 
vascular injury are expanded in T2DM, are associated with poor glycemic control, and 
might conceivable contribute to the increased cardiovascular risk of diabetes.
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973-232 The MITRA-Score: A New Score for the Quality of 
Care in Patients With Acute ST Elevation Myocardial 
Infarction
Uwe Zeymer, Claus Jünger, Anselm Gitt, Jochen Senges, Herzzentrum Ludwigshafen, 
Ludwigshafen, Germany
Background: A variety of scores have been proposed to estimate the risk of patients with 
STEMI. So far there are no scores to evaluate the quality of care provided by hospitals in 
these patients. Therefore our aim was to propose a hospital score which might allow to 
estimate the quality of the individual hospital treating patients with STEMI.
Methods: We used the database of the MITRA-Plus registry to look for parameters 
which were related to outcome. These were related to structure (availibility of a cath-
lab with interventional capacities), organisation (short time to reperfusion intervals, high 
rate of reperfusion therapies, high rate of reperfusion therapies during off-hours) and 
implementation of guideline adherent therapies (acutely and at discharge). Each parameter 
was than counted as one point for a total of 6 possible points. Hospitals were divided into 
three groups: low (0-2 points), medium (3-4 points) and high (5-6 points) MITRA score.
Results: Inhospital mortality and major adverse cardiovascular and cerebral events 
(MACCE) were signiﬁcantly associated with the MITRA score, being 6%, 5% and 4% (p 
=0.0013) and 13%, 9% and 6% in the three groups, respectively. The hospital MACCE 
rate in relation to the TIMI risk score of the patients is shown in the table.
Conclusion: The MITRA score provides an easy tool for estimating the quality of the 
hospital treating patients with STEMI. Even after adjusting for the baseline risk of the 
patients these score is closely linked to clinical outcome.
In-hospital MACC related to TIMI risk score of the patients and MITRA 








0-3 7.7 % 5.0 % 3.0 %
TIMI risk score
4-6 14.3 % 11.7 % 6.8 %
TIMI risk score
>6 26.3 % 14.4 % 11.5 %
 
973-233 R Wave Frontal Plane Right Axis Deviation on the 
Admission Electrocardiogram in Patients With Acute 
Myocardial Infarction: A Strong Independent Predictor 
of Increased Mortality Both In-Hospital and in Early 
Follow-up
Mircea Petrina, Fadi Saab, Jianming Fang, Alan D. Goldberg, Kim A. Eagle, University of 
Michigan Cardiovascular Center, Ann Arbor, MI
Background: Pre-thrombolythics era studies on right axis deviation (RAD) established it 
as a potential risk factor for death after acute myocardial infarction (AMI). This association 
has not been described in the modern revascularization era.
Methods: We studied 1,314 patients admitted with AMI to the University of Michigan 
between 01/99-05/04 to assess the incidence of RAD (+90° to +180°) on the index ECG 
and its correlation with demographics, comorbidities, management, and outcome. RAD 
and non-RAD patients were compared using chi-square test for binary and Students’ t-
test for continuous variables. A multivariate logistic regression model was used to assess 
if RAD was an independent predictor of mortality.
Results (see table): Eighty (6.1%) patients had RAD; when compared to non-RAD, they 
had similar presentation features and comorbidities, but lower frequencies of HTN and 
prior angina. RAD patients received lower rates of coronary angiography, angioplasty 
and evidence-based medicine (beta-blockers and statins). After correction for potential 
confounding factors, RAD remained an independent predictor of in-hospital (OR 3.9; 1.6-
9.5 95%CI) and six-month (OR 3.2; 1.6-6.2 95%CI) mortality (follow-up rate 94.4%).
Conclusions: Despite similar comorbidities and presentation, patients with RAD in the 
setting of AMI have worse short and long-term outcome. The striking mortality difference 
argues for a more intensive approach including revascularization and maximized 
evidence-based therapy.
Baseline Characteristics, Therapy and Outcomes
Variable RAD (N=80) Non-RAD (N=1,234) p-value
Age (mean/SD) 63.6 (16.7) 65.2 (13.9) N/S
Female gender 25 (31.3%) 442 (35.8) N/S
HTN 45 (56.9%) 845 (68.7%) 0.0293
Prior Angina 21 (26.2%) 461 (37.6%) 0.0410
Killip Classes II-IV 14 (17.5%) 168 (15.1%) N/S
PCI 28 (35%) 571 (46.2%) 0.0498
CABG 11 (13.7%) 110 (8.9%) N/S
In-hospital death 11 (13.7%) 49 (3.9%) <0.0001
Six-month death 19 (26.7%) 132 (11.8%) 0.0003
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973-234 The Deleterious Impact of Blood Transfusion on 
Mortality in Patients With ST-Elevation Myocardial 
Infarction
Vivek Rajagopal, Michael S. Lauer, Amy Hsu, Eugene Blackstone, Hitinder S. Gurm, 
Eric J. Topol, Cleveland Clinic Foundation, Cleveland, OH
Background: The role of transfusion in patients after myocardial infarction remains 
controversial. Whereas some data suggest harm with transfusion, other data suggest 
beneﬁt, particularly for patients with recent ST-elevation myocardial infarction.
Methods: We evaluated death at 30 days for 4073 patients with ST-elevation myocardial 
infarction enrolled in the GUSTO-IIb trial, according to whether they had been transfused. 
We also performed a multivariate logistic regression adjusting for differences in baseline 
characteristics and for propensity to receive a transfusion.
Results: This cohort contained 363 patients who received a transfusion and 3,710 
patients who did not. Patients who received a transfusion were older (68 vs. 62 yrs old, 
P<0.01), more likely to be female, and more likely to have a history of diabetes, smoking, 
chronic renal insufﬁciency, and peripheral vascular disease. Death at 30 days was 13% 
for transfused patients compared to 5% for non-transfused patients (P<0.01). After 
adjusting for baseline characteristics and propensity score for transfusion, transfusion 
was still associated with higher mortality (HR 3.6, 95% CI 2.5-5.2, P<0.001).
Conclusions: These data suggest that blood transfusion is associated with increased 
mortality in patients with ST-elevation myocardial infarction. This study and others suggest 
that the common practice of blood transfusion after myocardial infarction is harmful, and 
prospective, randomized trials are warranted. 
973-235 Do All Patients With ST-Segment Elevation Myocardial 
Infarction Beneﬁt From Invasive Treatment? The Simple 
Risk-Score Derived From PL-ACS Registry
Marek Gierlotka, Mariusz Gasior, Lech Polonski, Zbigniew Kalarus, Tadeusz Zebik, 
Grzegorz Opolski, Marian Zembala, Michal Tendera, Silesian Centre for Heart Diseases, 
Zabrze, Poland, Medical University of Silesia, Katowice, Poland
Background. Patients (pts) with acute myocardial infarction with ST-segment elevation 
(STEMI) present with a wide spectrum of risk for death. The aims were: (1) to develop the 
risk score, and (2) to assess the relationship between the developed risk score and the 
30-day all-cause mortality of STEMI pts treated either with invasively or not.
Methods. We used the 12-month data from a prospective, population-based registry 
of ACS (N = 14581 pts) conducted in Silesia region of Poland. 5066 pts (34.7%) were 
hospitalized due to STEMI. The development of the risk score was based on variables 
available at the ﬁrst medical contact.
Results. Of 5066 pts with STEMI (mean 30-day mortality - 13.0%), 55.6% had early 
coronary angiography performed with lower 30-day mortality than non-invasively treated 
pts (5.6% vs. 22.2%, p<0.0001). The logistic model performance was 0.85. The risk score 
variables were selected as follows (points): age 65-74y (1); age >=75y (2); female sex (1); 
pulmonary edema at admission (1); cardiogenic shock at admission (2); anterior infarction 
(1). The performance of the risk score was 0.83 (0.80 in non-invasive, and 0.81 in invasive 














0 468 4.1% 1032 1.2% 2.9 (1.2-4.3) 71.4 (42.3-85.8)
1 610 8.0% 1022 2.5% 5.5 (3.3-7.4) 68.3 (49.8-80.1)
2 593 21.9% 501 8.8% 13.1 (9.0-16.7) 59.9 (45.1-71.0)
3 385 35.8% 218 17.9% 18.0 (10.7-24.3) 50.1 (32.3-63.7)
4 163 73.0% 58 46.6% 26.5 (11.9-40.3) 36.2 (17.2-52.6)
>=5 57 87.7% 14 85.7% 2.0 (-10.6-25.1) 2.3 (-12.4-27.2)
Conclusions. Invasive treatment of STEMI is beneﬁcial along wide spectrum of the initial 
risk, except for extremely high risk patients. The developed risk score predicts not only 
the outcome but also the absolute and relative beneﬁt of invasive treatment of STEMI 
patients.
973-236 Insights Into the Change in Brain Natriuretic Peptide 
After ST-Elevation Myocardial Infarction: Why Should it 
Be Better Than Baseline Brain Natriuretic Peptide?
Justin A. Ezekowitz, Pierre Theroux, Robert C. Welsh, Iqbal Bata, John Webb, Paul W. 
Armstrong, University of Alberta, Edmonton, AB, Canada
Background: Whereas baseline N-terminal brain natriuretic peptide (NTBNP) is useful in the 
prognosis of acute ST-elevation myocardial infarction (STEMI), it is unclear what relationship 
exists between serial NTBNP, time to treatment, reperfusion success and prognosis.
Methods: We prospectively deﬁned a NTBNP analysis in the WEST (Which Early 
Reperfusion StraTegy) trial which enrolled 304 acute STEMI patients < 6 hrs from 
symptom onset. NTBNP (pg/ml) was measured at pre-treatment (n=258), 72 to 96 hrs 
(n=247) and 30 days (n=221). ∆NTBNP is the 72 hr value minus the baseline NTBNP. 
Reperfusion success was measured by ST-segment resolution (STR, <30%, 30 to 70%, 
≥70%) at 180 mins, and infarct size by peak CKMB during the ﬁrst 24 hrs and QRS 
score at discharge (QRSd). The primary endpoint was a 30 day composite of mortality, 
reinfarction, ischemia, CHF, shock and ventricular arrhythmia. Data are medians with 
interquartile range, and appropriate non-parametric methods were used for analysis.
Results: Median NTBNP was 87 (39-316) at baseline, 864 (338-1857) at 72 hrs and 585 
(264-1212) at 30 days. Time to treatment was weakly correlated with baseline NTBNP 
(r=0.19, p=0.002), ∆NTBNP (r=0.061, p=0.37), and 30 day NTBNP (r=0.14, p=0.04). 
Importantly, STR was inversely correlated with ∆NTBNP (r=-0.23, p=0.002), and 30 day 
NTBNP (30 day NTBNP 1016, 828 and 397 for <30%, 30-70%, ≥70% STR respectively, 
p<0.001). Infarct size was correlated with ∆NTBNP by both CKMB (r=0.41, p<0.001) and 
QRSd (r=0.31, p<0.001); the 30 day NTBNP was similar for CKMB (r=0.48, p<0.001) 
and QRSd (30 day NTBNP 437, 568 and 775 for QRSd of <=1, 2-4, and >4; p=0.003). 
Although baseline NTBNP was associated with an increased 30 day composite endpoint 
(Q1 19%, Q2 20%, Q3 15%, Q4 38%, p=0.03 for trend), the ∆NTBNP (Q1 16%, Q2 18%, 
Q3 19%, Q4 37%, p=0.009 for trend) had a stronger relationship to outcomes.
Conclusions: ∆NTBNP predicts short-term adverse cardiac events and is superior to 
baseline NTBNP in predicting these outcomes in the ﬁrst 30 days after STEMI. This superiority 
likely relates in part to incorporating the variability in NTBNP at presentation as well as the 
integration of key surrogate measures of STEMI such as reperfusion and infarct size.
973-237 Long-term Mortality Reasons and Predictors in Primary 
Coronary Angioplasty Population
Jaroslaw Zalewski, Andrzej Machnik, Michal Cul, Monika Durak, Tadeusz Przewlocki, 
Krzysztof Zmudka, Institute of Cardiology, Jagiellonian University, Krakow, Poland
Background: The aim of the present study was to determine a long-term mortality 
reasons and predictors in patients with ST-segment elevation myocardial infarction 
(STEMI) treated with primary coronary angioplasty (PCI).
Methods: Our population consisted of 2322 consecutive patients (pts, 567 female, aged 
58.6±10.7) undergoing PCI for STEMI between January 2001 and June 2004. During 
a median follow-up time of 30 months (10-52 months), death, recurrent myocardial 
infarction (ReMI) and heart failure (HF) requiring hospitalization were recorded.
Results: The mortality rate and reasons of death are presented in the ﬁgure. At 1 year, 
Killip class 3/4 on admission (OR 36.4; 95% CI 13.6-97.4; p<0.001), ischemic time of 
>6 hours (OR 3.0; 95% CI 1.0-8.4; p=0.01), anterior wall infarction (OR 2.9; 95% CI 1.2-
7.2; p=0.02), left ventricular ejection fraction (LVEF) of <45% (OR 2.7; 95% CI 1.0-7.3; 
p=0.025) and incomplete myocardial perfusion (TMPG<3) after PCI (OR 4.1; 95% CI 1.1-
8.6; p=0.008) were independent mortality predictors. At the end of a follow-up, the age of 
>75 (RR 3.5; 95% CI 1.4-7.4; p<0.001) and multivessel coronary disease (RR 2.6; 95% 
CI 0.9-5.2; p=0.007) were independent mortality predictors.
Conclusion: During the ﬁrst year, the mortality rate in PCI population depended on LV 
function as well as on reperfusion efﬁcacy. After 1 year, mortality rate was determined by 
baseline multivessel coronary disease and patients’ age. ReMI was the most frequent 
cause of death during the whole follow-up time.
973-238 Minimising Door to Balloon Times and Day/Night 
Variation in Primary Percutaneous Coronary 
Angioplasty With Ambulance Triage, and Direct Transfer 
to the Cardiac Catheterisation Laboratory
Miles Dalby, Mohammed Al-Obaidi, Andrew Asherson, Robert Smith, Richard Grocott-
Mason, Molly Teoh, Andrew Mitcell, Mark Mason, Charles Ilsley, Hareﬁeld Hospital, 
London, United Kingdom, Hillingdon Hospital, London, United Kingdom
Background: Primary Percutaneous Coronary Intervention (PPCI) must be performed 
rapidly to realise the beneﬁts seen in clinical trials. Causes of delay include ECG review 
between the ambulance crew and centre, interhospital transfers, ER assessment, within 
hospital transfers and setting up the Cardiac Catheter Lab(CCL). Day/Night inequity of 
reperfusion times remains a problem.
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Methods: The service was developed for a catchment of 300,000 patients with 6 miles from 
PPCI centre-district hospital. Ambulance crews were empowered to diagnose Myocardial 
Infarction eligible for PPCI. The only communication was from ambulance control with 
an estimated time of arrival. The CCL team was mobilised immediately. The patient was 
transferred directly from the ambulance bay to the CCL without stops in any other clinical 
area. Assessment was carried out in the CCL, and the PPCI undertaken immediately.
Results: In nine months 145 patients presented and 116 underwent PPCI (80%). 81 
presented by direct ambulance transfer (DAT) and 64 by interhospital transfer (IHT). (All 
data medians and interquartile ranges). The excess time to reperfusion attributable to IHT 
vs DAT was 71mins. Total door to balloon (D-B) for IHT 97mins, 44%<90mins.
For DAT the time from the call to the PPCI centre to arrival was 10mins(10-14). The D-B 
times at the centre were: 08:00hrs-20:00hrs DAT: 27mins (23-34), IHT: 27mins(22-34) for 
20:00hrs-08:00hrs DAT: 32mins(22-40), IHT: 27mins(22-33). For DAT all patients were 
reperfused <90 mins, 95%<60mins and 63%<30mins from arrival. At 30 days, mortality 
was 0.5%(<75 years) and 16%(>75 years) and Death/Re-MI/Stroke (all ages) was 9%.
Conclusions: Patients can be transferred from ambulance directly to the CCL without 
delays. This is superior to IHT and saved approximately 70 minutes, bringing the door to 
balloon time to <90mins for all patients and <30 mins for most. With the correct protocols 
in place, D-B times of 30 minutes or less can be achieved in routine clinical practice even 
with very short notice periods, irrespective of time of day.
973-239 The SAMU Network Minimizes Treatment Delays for ST-
Elevation Myocardial Infarction: Insights From a Three-
Year Registry
Yves Lambert, Claude Lapandry, Patrick Sauval, Thierry Laperche, Jean Michel Juliard, 
Sophie Bataille, Xavier Mouranche, Jean Pierre Tresca, e-MUST Study Group, ARHIF, 
Paris, France
Background : Shortening total ischaemic time is essential for thrombolysis and also 
for PCI, but registries highlight prolonged reperfusion delays and accordingly a sizeable 
proportion of patients who never beneﬁt from such therapies. In the Paris area, pre-hospital 
medical teams of the SAMU network conducted a prospective, observational survey, the e-
MUST registry, to describe patterns of time to treatment for STEMI patients and to analyse 
the decision making process from onset of symptoms to reperfusion therapy .
Material and method : From january 2002 to december 2004, 5231 patients are enrolled. 
Different process of care interval times are studied : delay from onset of symptoms to 
seeking care, pain-to-drug (PTD), pain-to-needle (PTN) and pain-to-balloon (PTB) times, 
presentation of medical team to needle and to balloon times. The results of the three 
years are compared. Predicting factors for not beneﬁting from reperfusion therapy are 
also screened in the registry. Early major adverse cardiac events are investigated.
Results : The delay for seeking medical care is less than two hours for 63.5% of patients. 
The majority (89%) of patients is treated with either pre-hospital thrombolysis (PT) or PCI. 
The coronary reperfusion agent of choice is primary PCI for 55% of patients and PTB is 
less than 120 min for 15%. Median time from scene to balloon is 119 min while median 
time to needle is 82 min. PT is initiated within 120 min for 54.5% of patients and PTD 
is less than 180 min for 75% of patients. The ratio of patients who receive reperfusion 
therapy increases signiﬁcantly from 87.5% in 2002 to 91,5% in 2004 (p<0.005).The 
registry exhibits predicting factors for not beneﬁting from reperfusion therapy : age over 
75 (24% versus 7%), female (20% versus 8.5%) and prolonged delay from onset of 
symptoms. When the delay for seeking care is between 6 to 12 hours, 30% of patients 
never receive any reperfusion therapy.
Conclusion : The e-MUST registry highlights beneﬁcial effects of the french SAMU 
network for STEMI patients. The network contributes to increase the number of patients 
eligible for coronary reperfusion by early triage, and also, in minimizing treatment delays, 
close to benchmarks recommended by guidelines.
973-240 Temporal Trends in the Evaluation of Ejection Fraction in 
Patients Hospitalized With Acute Myocardial Infarction: 
Insights From the Worcester Heart Attack Study
Paul Santolucito, Dennis A. Tighe, Darlene Lessard, Robert J. Goldberg, University of 
Massachusetts Medical School, Worcester, MA
BACKGROUND: Determination of ejection fraction (EF) following acute myocardial 
infarction (AMI) is a powerful predictor of complications. Although recommended as a 
standard of care, trends in its evaluation are not well known. The purpose of this study 
was to evaluate trends in the evaluation of EF in a community sample of patients (pts) 
with AMI.
METHODS: Data from 12,760 pts hospitalized with validated AMI in 14 periods from 
1975 to 2003 in the Worcester Heart Attack Study were reviewed. We examined trends 
in EF evaluation and clinical and demographic factors associated with EF determination 
after AMI.
RESULTS: Changes in hospital evaluation of EF in pts with AMI are shown (ﬁgure). In 
the most recent study period (2001-2003), 27% of pts did not have an EF evaluation. Pts 
not undergoing EF evaluation were older, had shorter length of stay, and were more likely 
to have code status limitations compared to those having EF determinations. Pts not 
receiving EF evaluation were more likely to have a prior history of heart failure and MI, 
and to suffer an in-hospital AMI related death. They were less likely to experience other 
signiﬁcant in-hospital complications.
CONCLUSION: While the proportion of pts with AMI undergoing EF evaluation has 
increased over time, EF determination appears to have reached a plateau and many pts 
in recent years did not have their EF determined. Characteristics of pts not having EF 
evaluations differ from those having their EF determined. Further efforts to obtain EF in 
pts with AMI appear indicated.
973-241 Relationship Between Microvascular Injury and 
Degree of ST-Segment Elevation Before Percutaneous 
Coronary Intervention
Atsushi Yamamuro, Takashi Akasaka, Shuichiro Kaji, Koichi Tamita, Makoto Kinoshita, 
Minako Katayama, Shigefumi Morioka, Yasuki Kihara, Kobe General Hospital, Kobe, 
Japan, Wakayama Medical University, Wakayama, Japan
Background: Studies have suggested that the marked ST-segment elevation before 
percutaneous coronary intervention (PCI) in patients with acute myocardial infarction 
(AMI) was complicated by the microvascular dysfunction. We have demonstrated that 
the microvascular injury can be quantitatively assessed by the coronary ﬂow velocity 
(CFV) pattern using Doppler guidewires. The purpose of this study was to evaluate 
the association between the degree of the ST-segment elevation before PCI and the 
microvascular injury.
Methods: Consecutive 155 patients with ﬁrst-time anterior AMI were studied following 
emergent PCI (≤25% residual stenosis with TIMI ﬂow grade 2-3). The microvascular injury 
was evaluated on the basis of coronary ﬂow velocity patterns using Doppler guidewires. 
In accordance with our previous reports regarding the coronary ﬂow velocity pattern, we 
deﬁned the presence of microvascular dysfunction as a diastolic deceleration time of 
≤600 ms and the presence of systolic ﬂow reversal. We classiﬁed the patients according 
to the degree of ST-segment elevation before PCI into three categories: <4 mm (group 1), 
4-5 mm (group 2), 5 mm< (group 3).
Results: As for the relationship between the degree of ST-segment elevation before PCI 
and the severity of microvascular injury, higher the ST-segment elevation, higher the risk 
of microvascular dysfunction: 5/53 (9%) for group 1, 10/41 (24%) for group 2, and 28/61 
(46%) for group 3. The degree of ST-segment elevation before PCI was related to the 
diastolic deceleration time and peak systolic velocity: the higher ST-segment elevation, 
the shorter diastolic deceleration time (723 ±198 vs. 603±245 vs. 485±238 ms; p<0.05) 
and the lower the peak systolic velocity (11 ±23 vs. 3±23 vs. -12±30 cm/s; p<0.05).
Conclusions: The group having higher ST-segment elevation before PCI showed 
characteristic CFV patterns, with a shorter DDT and a lower peak systolic velocity. 
Therefore, even though PCI would be successfully performed, patients showing 
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974-242 Clinical Outcomes With AZD6140, an Oral Reversible 
ADP Receptor Antagonist, Compared With Clopidogrel 
in Patients With Acute Coronary Syndromes (ACS)
Christopher P. Cannon, Robert A. Harrington, Kenneth W. Mahaffey, Steen Husted, 
Robert F. Storey, Nick Sanders, Gary Peters, Hakan Emanuelsson, Brigham & Women’s 
Hospital, Boston, MA, AstraZeneca, Wilmington, DE
Background: AZD6140 is the ﬁrst oral reversible P2Y12 receptor antagonist and has 
greater and more consistent inhibition of platelet aggregation compared to clopidogrel. In 
this analysis of the DISPERSE2 study we evaluated clinical outcomes and their relation 
to PCI.
Methods: Patients with non-ST segment elevation ACS were randomized to AZD6140 90 
mg bid (AZD90), AZD6140 180 mg bid (AZD180) or clopidogrel 75 mg daily with a 300 mg 
loading dose (CLOP) for up to 12 weeks of treatment. Clinical outcomes (CV death, MI, 
stroke) were adjudicated centrally using modiﬁed TIMI deﬁnitions.
Results: The composite endpoint of CV death, MI and stroke occurred in 4.8% (16/334) 
AZD90, 3.0% (10/329) AZD180 and 4.9% (16/327) CLOP patients. MI occurred in 2.7%, 
(n=9), 2.1 % (n=7) and 4.3 % (n=14) patients, respectively. Due to the small number 
ACC_2006_4_Myocardial AA.indd   199 1/4/06   5:14:06 PM



















of events, differences were not statistically signiﬁcant (HR for MI for AZD180 vs CLOP 
0.62, 95% CI 0.28-1.37). Across all groups, 66% of patients had diagnostic coronary 
angiography, 42% PCI and 9 % CABG. 20% of the MIs were procedure related.
Conclusions: These encouraging data suggest that AZD6140, particularly the 180 mg 
dose, may be more effective than clopidogrel 75mg in preventing thrombotic events in 
patients with ACS both peri PCI and during medical treatment. These observations will 
need to be conﬁrmed in an appropriately powered clinical outcomes study. 
974-243 GRACE 6-Month Post-discharge Prediction Model 
(GRACE Score) Predicts 4-Year Mortality in Survivors 
With Acute-Coronary Syndromes
Eng W. Tang, Cheuk-Kit Wong, Peter Herbison, Dunedin School of Medicine, Dunedin, 
New Zealand, Dunedin hospital, Dunedin, New Zealand
Background: There is no validated model to predict mortality beyond 6-months post-
discharge for acute coronary syndrome (ACS).
Methods: On 1,143 consecutive patients with ACS in 2000-2002 (39% with ST-elevation 
AMI, 39% with non-ST-elevation AMI and 22% with unstable angina), the GRACE score 
was calculated for 1,057 hospital survivors. 
Results: The mortality was 7.5% during index admission, 12.1% at 6-months, 14.8% 
at 1-year, 18.7% at 2-years, 25.0% at 3-years and 39.2% at 4-years. The GRACE score 
predicted mortality at 6-month (c-statistic= 0.81), 1-year (c-statistic= 0.82), 2-year (c-
statistic= 0.81), 3-year (c-statistic= 0.81) and 4-year (c-statistic= 0.80). The model 
predicted mortality for all three subset of ACS at all time points, with c-statistic >0.75 
in all analyses. At 6-months, the predicted mortality correlated with actual mortality for 
each decile of risk.
Afterwards, a proportional increase in mortality was seen for each decile of risk. We 
construct a separate 3-year mortality model in these 1,057 patients and identiﬁed 
ten multivariate predictors of mortality (c-statistic= 0.89 for 6-month and 0.85 for 3-
year mortality). Seven of the ten factors were in the GRACE risk-model (age, history 
of coronary disease, heart failure, increased heart rate on admission, creatinine level, 
evidence of myonecrosis, not receiving percutanous coronary intervention).
Conclusions: The GRACE 6-month post-discharge model predicts long-term (up to 4-
years) survival in ACS patients.
974-244 Depression Is Not Associated With Long-Term Mortality 
in a Representative Patient Population With Myocardial 
Infarction
Kapil Parakh, Brett D. Thombs, Johns Hopkins Bayview Medical Center, Baltimore, MD
Background: Depression is common after myocardial infarction (MI). Many studies have 
shown that depression predicts early post-MI mortality, but the association of depression 
and longer-term mortality (i.e., beyond 3 years) has rarely been examined. 
Methods: Patients with acute MI admitted from July 1995 to December 1996 were 
interviewed 3 to 5 days after the index event. Depression was assessed using the Beck 
Depression Inventory (BDI) and Structured Clinical Interview for the Diagnostic and 
Statistical Manual, (non-patient version, SCID-NP). All-cause mortality was assessed in 
July 2005 using the Social Security Death Index and hospital databases. 
Results: Of 280 patients, 56 (20%) had a BDI > 10, a cutoff score indicating symptoms of 
at least mild-to-moderate depression and shown to predict early post-MI mortality. These 
patients had lower EF, longer hospitalizations, and lower perceived social support than 
patients with a BDI < 10. Of 279 patients with complete follow up, there were 68, 98, 
and 136 deaths at 3, 5, and 8 years, respectively, post-MI. Depression (either BDI > 10 
or major depression by SCID-NP) at baseline was not associated with higher mortality 
at any of these time points in unadjusted or multivariate Cox proportional hazards 
models. Compared to patients examined in the 3 prior studies of depression and longer-
term mortality after MI [Welin, et al., J Intern Med 2000; 247:629 (10 yr follow-up, 24% 
mortality); Pﬁffner, et al. J Cardiopulm Rehabil 2004; 24:87 (7 yr, 10% mortality); and 
Lesperance, et al. Circulation 2002; 105:1049 (5 yr, 18% mortality)], our patients (8-yr 
mortality 48.7%) were older (65 yr vs. all less than 65), were more often women (43% vs. 
0-32%), and had more comorbidities like hypertension (67% vs. 22-39%) and diabetes 
(36% vs. 9-16%). These higher risk patients more reﬂect “real world” practice outside a 
tertiary referral center. 
Conclusions: While our previous report on this cohort showed that depression predicts 
4-month mortality (Bush, et al. Am J Cardiol 2001; 88:337), this association is no 
longer present with longer-term follow-up, perhaps because of the effects of competing 
comorbidities in a high-risk patient population reﬂective of a community sample.
974-245 The Effects of AZD6140, the First Oral Reversible ADP 
Receptor Antagonist, Compared With Clopidogrel on 
Biochemical Markers in Patients With Acute Coronary 
Syndromes (ACS)
Steen Husted, Robert F. Storey, Robert A. Harrington, Nick Sanders, Gary Peters, 
Hakan Emanuelsson, Christopher P. Cannon, Aarhus University Hospital, Aarhus, 
Denmark, AstraZeneca, Wilmington, DE
Background: The P2Y12 receptor plays a major role in the release of soluble CD40 
ligand (sCD40L) and other pro-inﬂammatory responses of platelets. The DISPERSE2 
study compared different regimens of AZD6140 with clopidogrel in patients with non-ST 
elevation ACS to assess effects on biochemical markers of inﬂammation.
Methods: Patients with ACS were randomized to AZD6140 90 mg bid (AZD90), AZD6140 
180 mg bid (AZD180) or clopidogrel 300 mg loading dose then 75 mg daily (CLOP) for 
up to 12 weeks treatment. Half of the AZD6140 patients in each group received a 270 mg 
loading dose (AZD270). High sensitivity plasma cross-reacting protein (CRP), interleukin 
6 (IL-6), myeloperoxidase (MPO) and sCD40L were measured by a central laboratory at 
randomization, hospital discharge and week 4.
Results: Compared to baseline, mean CRP levels increased for all treatment groups at 
discharge and were lower than at randomization by week 4. Mean IL-6 levels did not rise 
post-admission but decreased by week 4. Mean MPO and sCD40L levels did not show 
clear changes over time or between treatment groups.
Conclusions: AZD6140 did not appear to inﬂuence any of these biochemical markers 
differentially compared to clopidogrel in patients with non-ST elevation ACS over 4 weeks. 
The clinical beneﬁt of P2Y12 inhibitors may be predominantly via antithrombotic rather 







BL DIS Wk 4 BL DIS Wk 4 BL DIS Wk 4
CRP mg/L 18.9 31.2 9.5 18.6 31.4 10.3 16.8 24.5 7.2
IL-6 ng/L 11.7 11.7 4.0 12.1 9.7 4.1 9.4 8.2 3.8
MPO ng/ml 325 259 280 357 277 285 311 298 257
sCD40L ng/ml 5093 4807 5362 5116 5025 5193 5036 4858 5111
BL = randomization DIS = discharge Wk 4 = Week 4 Treatment
 
974-246 Renin-Angiotensin System Inhibition Improves 
Outcomes in Acute Coronary Syndrome Patients With 
Chronic Kidney Disease and Preserved Left Ventricular 
Function
Reza Fazel, Brahmajee K. Nallamothu, Fadi Saab, David Armstrong, Jianming Fang, 
Eva Kline-Rogers, Bruce C. Rogers, Kim A. Eagle, James B. Froehlich, University of 
Michigan, Ann Arbor, MI, Emory University, Atlanta, GA
Background: Inhibition of the renin-angiotensin system improves outcomes in acute 
coronary syndrome (ACS) patients with chronic kidney disease (CKD) and left ventricular 
(LV) dysfunction, but its effects in those with CKD and preserved LV function are unknown. 
We hypothesized that the use of angiotensin-converting enzyme inhibitors (ACEI) or 
angiotensin receptor blockers (ARB) improves outcomes in ACS patients with CKD and 
preserved LV function.
Methods: We identiﬁed 518 consecutive ACS patients with CKD and preserved LV 
function admitted to the University of Michigan Hospital between May 1999 and April 
2004. We deﬁned CKD as GFR <60 ml/min/1.73m2 based on the Modiﬁcation of Diet in 
Renal Disease method. Preserved LV function was deﬁned as an ejection fraction >40%. 
Stepwise logistic regression modeling was used to determine the association between 6-
month mortality and ACEI/ARB use at discharge. Candidate variables for inclusion in the 
model (based on a P-value ≤0.05) included: ACEI/ARB use, age, gender, prior coronary 
disease, diabetes mellitus, Killip class, pulse and blood pressure at presentation, ACS 
type (unstable angina, myocardial infarction), revascularization during hospitalization, 
and use of evidence-based drugs (aspirin, beta-blocker, statin) at discharge.
Results: Overall, mean age of the study population was 64 years (+ 13), 77 (15%) 
were women, 149 (29%) had diabetes mellitus, 21 (4%) were dialysis-dependent, and 
mean GFR was 45 (+ 12) ml/min/1.73m2. 329 (63%) patients were discharged on an 
ACEI or ARB. Elderly patients (age>65 years) were less likely to receive ACEI/ARB at 
discharge (unadjusted odds ratio, 0.62; 95% CI, 0.43 - 0.88; P=0.008). After multivariable 
adjustment, ACEI/ARB use at discharge was associated with lower 6-month mortality 
(odds ratio, 0.36; 95% CI, 0.16 - 0.84; P=0.01). The ﬁnal model’s c-statistic was 0.86 and 
its goodness-of-ﬁt statistic was non-signiﬁcant (P>0.10) indicating reasonable ﬁt.
Conclusions: The use of ACEI or ARB at discharge is associated with lower 6-month 
mortality in ACS patients with CKD and preserved LV function. The low rate of ACEI/ARB 
use in these patients represents a missed opportunity to improve clinical outcomes.
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975-247 Acute Coronary Syndrome With Troponin Elevation But 
Non-Signiﬁcant Coronary Artery Disease: A Benign 
Condition?
Carlos T. Aguiar, Jorge S. Ferreira, Investigators Portuguese Registry of ACS, Hospital 
Santa Cruz, Carnaxide, Portugal
Background: Troponin (Tn) elevations in patients (pts) with non-ST-elevation acute 
coronary syndromes (NSTE-ACS) have been associated with a higher incidence of 
multivessel coronary artery disease (CAD), complex lesions, visible thrombus, and 
impaired myocardial perfusion. The clinical signiﬁcance of Tn elevation in pts subsequently 
found not to have angiographically signiﬁcant CAD has been a source of confusion. The 
purpose of this study is to evaluate the prevalence, characteristics, and early outcome of 
unselected pts with Tn-positive NSTE-ACS not showing signiﬁcant CAD on angiography.
Methods: Pts with NSTE-ACS enrolled in a nationwide prospective registry were eligible 
if their management included coronary angiography during hospitalization. We divided pts 
into 4 groups according to Tn status and presence of CAD. Study endpoint is in-hospital 
all-cause mortality.
Results: Study population consisted of 2116 pts, of whom 1809 presented signiﬁcant 
CAD (85.5%). Among the 1455 Tn-positive pts (68.8%), the 191 (13.1%) without 
CAD were signiﬁcantly younger, more often female, and less often had a history of 
hypercholesterolemia, prior myocardial infarction or peripheral arterial disease, and less 
often presented ST-depression on the initial ECG, compared to those with CAD. Dual 
antiplatelet therapy, beta-blockers, and ACE inhibitors were less often prescribed to Tn-
positive pts without CAD than to those with CAD. Overall in-hospital mortality was 1.3% 
(27 deaths). The rates of in-hospital mortality were 0.9% in Tn-negative pts without CAD, 
1.6% in Tn-positive pts without CAD, 0% in Tn-negative pts with CAD, and 1.8% in Tn-
positive pts with CAD (p=0.016). Tn elevation was an independent predictor of in-hospital 
mortality (adjusted HR 7.4; 95% CI, 1.0-55.0; p<0.05). There was no signiﬁcant interaction 
between Tn status and angiographic CAD for in-hospital mortality (p=0.92).
Conclusions: Elevated Tn in NSTE-ACS is associated with a higher risk for early death, 
even among pts who do not have signiﬁcant angiographic CAD. Further studies are 
required to clarify the mechanisms conferring this adverse prognosis, and to establish 
comprehensive guidelines for medical management.
975-248 Renal Insufﬁciency, Braunwald Class and Long-Term 
Outcomes in Patients Undergoing Coronary Artery 
Bypass Grafting for Acute Coronary Syndromes
Martin Holzmann, Niklas Hammar, Tobias Nordqvist, Torbjörn Ivert, Karolinska Institute, 
Stockholm, Sweden
Background Renal insufﬁciency (RI) and Braunwald class are predictors of short- and 
long-term outcomes in patients undergoing coronary artery bypass grafting (CABG). In 
patients with acute coronary syndromes (ACS) the association of RI and Braunwald class 
with long-term mortality and incident myocardial infarction post-CABG is less clear.
Methods All patients (n=973) without dialysis-dependent RI undergoing a ﬁrst isolated 
CABG for ACS during 1980-1995 who survived 30 days postoperatively were included. 
Creatinine clearance (Ccr) was calculated using the Cockroft-Gault formula and was 
related to incidence of myocardial infarction (MI), and all-cause mortality within 5 years. 
Braunwald class was used to classify patients according to severity of symptoms.
Results Normal renal function (Ccr ≥ 90 mL/min) was present in 254 (26%) patients. Mild 
(Ccr 60-90 mL/min), moderate (Ccr 30-60 mL/min) and severe (Ccr <30 mL/min) RI was 
present in 419 (43%), 264 (27%) and 15 (2%) patients, respectively. Seventy patients 
(25%) among those with Ccr < 60 mL/min were in Braunwald class IIIC compared to 50 
(20%) patients among those with normal renal function. There were 107 (11%) deaths 
and 110 (11%) fatal and non-fatal MI:s during follow-up. Among patients with Ccr < 60 
mL/min, 12 (18%), 31 (22%) and 20 (29%) died or had an MI within 5 years in Braunwald 
class IIB+IIC, IIIB and IIIC, respectively. After adjustment for potential confounders mild, 
moderate and severe RI all predicted all-cause mortality within 5 years post-CABG; 
hazard ratio (HR) 1.4, (95% conﬁdence interval (CI) 0.7-3.0), HR 3.1, (95% CI 1.4-7.1) 
and HR 11, (95% CI 3.7-34.2), respectively, compared to normal renal function. In patients 
with mild, moderate and severe RI there was an increase in long-term risk of incident MI; 
HR 1.9 (95% CI 1.0-3.4), HR 2.0, (95% CI 0.9-4.0) and HR 6.2 (2.0-19.2) respectively 
compared to normal renal function.
Conclusions Already mild and moderate renal insufﬁciency predicts all-cause mortality 
as well as incident MI within 5 years in patients undergoing CABG for ACS. Patients with 
moderate and severe RI have more severe symptoms and as symptoms get worse there 
is a higher risk of death or incident MI.
975-249 Prevalence of Tako-Tsubo Syndrome and Description of 
Partial and Circular Patterns
Rémy Pillière, NIcolas Mansencal, Joseph Thierry, Franck Digne, Pascal Lacombe, 
Olivier Dubourg, Hôpital Ambroise Paré, AP-HP, Boulogne, France
Background: Several studies have recently reported a new medical entity called Tako-
Tsubo (TT) cardiomyopathy. The aim of our study was to determine the prevalence and 
the features of this cardiomyopathy in a large population presenting with ACS.
Methods: Among 4268 pts refereed to our cath lab, we studied consecutive pts with 
suspicion of ACS over an 5-year study period. All included pts underwent a coronary 
arteriography and a left ventricular angiogram < 48 hours after the onset of the chest 
pain. Pts with no angiographic signiﬁcant coronary stenosis systematically underwent a 
coronary vasopasm provocation test. We deﬁned TT syndrome as described in previous 
study. Long-term follow-up was collected in all patients.
Results: Among the 1512 pts with a suspicion of ACS, only 10 pts presented a TT syndrome. 
The prevalence of TT syndrome in our population was 0.7%. Eight pts presented a typical 
pattern of TT syndrome Two pts presented a partial and circular pattern of TT syndrome: 1 
pt had an akinesia of the basal and mid segments of all walls and 1 pt had an akinesia of 
the mid segments of all walls. All pts had a recovery of wall motion abnormalities and LVEF 
was rapidly improved (Figure). No pts with TT syndrome died during FU.
Conclusion: The prevalence of TT syndrome in a population of ACS is 0.7 %. This study 
suggests that angiographic presentations of TT syndrome may be typical (as previously 
described) or partial and circular, and should be systematically recognized.
 
975-250 Atrial Fibrillation Is a Long-Term Predictor of Poor 
Outcome in Acute Myocardial Infarction
Anwar Tandar, Kent G. Meredith, Heidi Thomas, Tami L. Bair, Benjamin D. Horne, William 
H. Barry, Jeffrey L. Anderson, Joseph B. Muhlestein, LDS Hospital, University of Utah, 
Salt Lake City, UT
Background: Atrial ﬁbrillation (AF) occurs frequently during hospitalization with acute 
myocardial infarction (AMI), and has been reported to increase short-term mortality. AF 
related tachycardia is often associated with hemodynamic instability and may increase 
ischemic demand on the myocardium in the setting of AMI. Whether AF upon presentation 
for AMI also has an adverse effect on long-term outcomes is not known.
Methods: Patients (N=4,852) enrolled in the Intermountain Heart Collaborative 
Study Registry between 1993-2005 who presented with AMI were studied. Baseline 
characteristics, including the presence of AF upon AMI presentation were recorded and 
patients were followed for an average of 2.6±2.8 years for all-cause mortality, cardiac 
death, and coronary death. Patients were determined to have AF if it was present 
upon AMI presentation. Models were developed using univariate and multivariate Cox 
regression adjusting for standard risk factors to obtain a hazard ratio (HR) for all-cause 
mortality, cardiac death, and coronary death.
Results: AF was present in 660 (13.6%) patients (age=71±10, males=66.0%, 
diabetes=27.7%, hypertension=61.9%, hyperlipidemia=47.8%, smokers=27.1%, 
dead at follow-up=42.6%) and absent in 4192 (86.4%) (age=62±13, males=71.9%, 
diabetes=20.5%, hypertension=54.4%, hyperlipidemia=55.2%, smokers=27.1%, dead at 
follow-up=21.4%) (all baseline characteristics differed between groups [p<0.001]). AF was 
a signiﬁcant predictor of all-cause mortality in both univariate (HR=1.27, 95% CI: 1.11-
1.46, p=0.001) and multivariate analysis (HR=1.25, 95% CI: 1.09-1.44, p=0.002). This 
result remained for the prediction of cardiac death (HR=1.37, 95% CI 1.14-1.66, p=0.001) 
and coronary death (HR=1.33, 95% CI 1.09-1.62, p=0.005) in multivariate analysis.
Conclusion: AF in the setting of AMI continues to be a signiﬁcant predictor of poor 
outcomes even when evaluated long-term. Prospective clinical trials are needed to 
determine whether this high-risk group can beneﬁt from more aggressive reperfusion and 
anti-ischemic strategies in addition to risk factor reduction.
975-251 Long-Term Safety of Cholesterol Lowering Wth 
Pravastatin on Cancer Incidence in Patients With 
Coronary Heart Disease (CHD): The LIPID Trial 
Extension
John Simes, Adrienne Kirby, Helen Pater, David Hunt, Paul Glasziou, Harvey White, 
David Colquhoun, Peter Thompson, Wendy Hague, Tony Keech, Andrew Tonkin, for 
the LIPID Investigators, NHMRC Clinical Trials Centre, University of Sydney, Australia, 
National Heart Foundation, Melbourne, Australia
Background: Older epidemiological and randomised studies of cholesterol-lowering 
had raised safety concerns regarding an increased incidence of cancer, while recent 
observational studies of statin therapy raised the possibility of a reduced incidence of 
some cancer types. The effectiveness and safety of statin therapy in patients with CHD 
or at high risk for CHD has been clearly established in many randomized trials over 5 
years follow-up. However, there is little randomized evidence over a longer period, which 
is needed to assess plausible effects on new cancers.
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Methods/Results: The LIPID trial now has 11 years of follow-up. The main trial compared 
6 years of pravastatin treatment with placebo, in 9014 patients with prior CHD and average 
baseline total cholesterol 4.0-7.0 mmol/L (155-271 mg/dL). The LIPID cohort has been 
followed up since then for a further 5 years, with statin treatment recommended for all 
patients: 98% consented to extended follow-up and 84% in both randomized groups have 
taken statin treatment. Long-term safety data on cancer incidence were available for 8853 
patients, of whom 1454 had at least one cancer. Data were obtained by direct contact over 
8 years and from cancer registries for the full 11 years (currently 97% complete). 
Randomized group
Placebo (%) Pravastatin (%) Relative risk (95% CI) 
Main trial (6 years) n=4502 n=4512
Patients with cancer
Main Trial 9.4 8.9 0.95 (0.82-1.10)
Extended follow-up 7.0 7.0 1.01 (0.86-1.19)
Total (11 years) 16.3 16.0 0.97 (0.87-1.09)
Cancer deaths
Main trial 3.1 2.8 0.89 (0.70-1.13)
Extended follow-up 4.6 4.5 0.97 (0.78-1.19)
Total (11 years) 7.0 6.7 0.93 (0.80-1.09)
Patients with cancer (total)
Prostate 4.7 4.7 1.00 (0.82-1.22)
Colorectal 2.3 2.4 1.06 (0.80-1.39)
Other GI 0.8 0.6 0.67 (0.40-1.12)
Respiratory 2.3 2.1 0.91 (0.69-1.20)
Bladder / Kidney 1.5 1.8 1.19 (0.86-1.64)
Breast 0.5 0.4 0.86 (0.47-1.59)
Melanoma / Sarcoma 1.7 1.8 1.02 (0.75-1.40)
Hematological 1.5 1.1 0.71 (0.49-1.02)
Conclusion: Over the long-term of 11 years follow-up, patients originally assigned pravastatin, 
compared with placebo, had very similar rates of cancer overall and for major types. There 
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976-252 Does Revascularization of Chronic Total 
Occlusion(CTO) Contribute to Improve the Long-Term 
Prognosis?
Keisuke Hirano, Toshiya Muramatsu, Reiko Tsukahara, Yoshiaki Ito, Yoshiyuki Furuse, 
Kawasaki Social Insurance Hospital, Kawasaki, Japan
Background:In this study, we investigated the possible contribution of vascular patency of 
CTO to the improvement of cardiac function and long-term prognosis.
Methods:January 1996 and September 2005, we examined 1285 CTO lesions,
846 patients in this study. The subjects were divided into GroupP, which included patients 
who underwent a successful revascularization and did not develop re-occlusion in the 
remote phase(616 patients,68+/-11years) and GroupO, which included patients whose 
CTO was occluded in the remote phase(230patients,69+/-10years). The average follow 
up period was 770+/-602days. Predictors of cardiac deaths were analyzed employing by 
the Coxs proportional hazards model.
Results:The long-term survival rate was signiﬁcantly lower in GroupO(68%) than that in 
GroupP(94%). The value of LVEF was higher in GroupP than that in GroupO(p=0.05).
The survival rate was signiﬁcantly higher in EF>40%(94%) than that in EF<40%(71%). 
The patients without myocardial viability determined 201-Tl scintigraphy and ultrasound, 
the long term survival rate in the groupP was better than that of groupO(89% v.s.61%,p= 
0.01).Multivariate analysis revealed that occlusion, unimproved EF, high age(more than 
75year old), low EF(less than 40%), and unsuccessful cases, were signiﬁcant predictors 
of cardiac death.
Conclusions: vascular patency of CTO makes better and long-term prognosis, even in 
patients with no myocardial viability.
In the near Future, DES reduce the restenosis of stenting for CTO, and it is expected that 
it is important to raise the rateio of initial success.
976-253 The Impact of Complete Revascularization on Long-
Term Outcomes in Elderly Patients With Coronary 
Artery Disease Undergoing Percutaneous Coronary 
Intervention
Kenji Ando, Yoshimitsu Soga, Takashi Yamada, Shinichi Shirai, Koyu Sakai, Keita 
Odashiro, Masahiko Goya, Masashi Iwabuchi, Hiroyoshi Yokoi, Hitoshi Yasumoto, 
Hideyuki Nosaka, Masakiyo Nobuyoshi, Kokura Memorial Hospital, Kitakyushu, Japan
Background: Although elderly patients (pts) are associated with poor outcomes after 
percutaneous coronary intervention (PCI), a few data exist on importance of complete 
revascularization (CR) about long-term outcomes in elderly pts undergoing PCI.
Methods: From Sep. 1981 to July 1998, 9764 pts were underwent PCI for stable angina 
pectoris at our institution. Pts were divided into two groups: 1305 elderly pts those aged 
75 years or older and 8459 younger pts those aged less than 75 years. CR was deﬁned 
as successful PCI without residual coronary artery stenosis (>75%). Long-term clinical 
follow-up data were obtained by a review of the hospital records and telephone contacts.
Results: Elderly pts had similar procedure success rate (91.2% vs. 89.8%, p=NS), 
clinical success rate, deﬁned as procedural success without death/MI/CABG, (89.1% 
vs.88.7%, p=NS) and signiﬁcantly lower CR rate (57.8% vs.66.3%, p<0.0001) compared 
to younger pts. 6-year survival rate was signiﬁcantly higher in younger pts than elderly 
pts (87.6% vs. 69.4%, p<0.0001). CR improved signiﬁcantly survival rates in both groups 
(younger pts :CR(+)90.6% vs. CR(-)82.3%, p<0.0001. elderly pts :CR(+)76.4% vs. CR(-
)61.2%, p<0.0001) and was more effective in elderly pts than younger pts (absolute risk 
reduction: -15.2% vs. -8.3%).
Conclusion: Elderly pts had a lower CR rate and a higher mortality rate than younger 
pts. CR improved long-term mortality and more efforts for revascularization should be 
needed especially in elderly pts.
976-254 Five-Year Follow-Up of the Medicine, Angioplasty or 
Surgery Study (mass-ii): A Randomized Controlled 
Clinical Trial of 3 Therapeutic Strategies for Multivessel 
Coronary Artery Disease
Whady Hueb, Paulo R. Soares, Neuza Lopes, Bernard J. Gersh, Luiz A. Cesar, Eulogio 
E. Martinez, Sergio A. Oliveira, Jose A F Ramires, Heart Institute (InCor), Sao Paulo, 
Brazil, Mayo Clinic, Rochester, MN
Background Despite routine use of coronary artery bypass graft (CABG) and percutaneous 
coronary intervention (PCI), there is no conclusive evidence that either one is superior to 
medical therapy (MT) alone for the treatment of multivessel CAD. We sought to evaluate 
the relative efﬁcacies of the possible therapeutic strategies for patients with multivessel 
coronary artery disease (CAD), stable angina, and preserved ventricular function.
Methods The primary end point was deﬁned as cardiac mortality, Q-wave myocardial 
infarction (MI), or refractory angina requiring revascularization. All data were analyzed 
according to the intention-to-treat-principle.
Results A total of 611 patients were randomly assigned to either a CABG (n=203), PCI 
(n=205), or MT (n=203) group. 254 (42%) patients had double-vessel disease, and 357 
(58%) had triple-vessel disease. At least one internal thoracic artery was used for grafting 
in 92% and, at least, one stent was implanted in 72% of patients. The rates for ﬁve-year 
survival rates were 92.12% for CABG, 88.30% for PCI, and 87.69% for MT (P=0.631). 
After ﬁve-year follow-up, 24.13% of MT patients and 32.18% of PCI patients underwent 
additional interventions, compared with only3.40% of CABG patients. At ﬁve-year follow-
up,76% of the patients in the PCI group,69.58% in the CABG group, and 57.30 %in the 
MT group were free of angina (P<0.0001).None of the study patients in any treatments 
groups had refractory angina at ﬁve-year follow up; moreover, we observed a reduction in 
rates of positive tests at the end of study for all patients.
Conclusions All three therapeutic regimens yielded similar and relatively low rates of 
cardiac-related death. Medical therapy for multivessel CAD was associated with the same 
incidence of long-term events and rate of additional revascularizations, compared with 
PCI. In addition, CABG was superior to MT for eliminating anginal symptoms.
976-255 Long-Term Follow-Up Patients with ST-Segment 
Elevation Acute Myocardial Infarction Treated with 
Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent
Sunao Nakamura, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan Udayachalerm, Damras 
Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, Matsudo, Japan
Background: Previous clinical study utilizing Sirolimus-eluting stent (SES) and Paclitaxel-
eluting stent (PES) in simple coronary lesions demonstrated an impressive reduction in 
intimal hyperplasia and restenosis. However, clinical efﬁcacy of SES and PES in treating 
patients with ST-segment elevation myocardial infarction (STEMI) has not been validated. 
Methods: We assessed baseline clinical and angiographic characteristics, in-hospital 
and 12, 24-month major adverse cardiac events (MACE) in 1838 consecutive STEMI 
patients who received on SES, PES or bare metal stents (BMS) without cardiogenic shock 
undergoing emergent PCI. Results: The baseline clinical characteristics between 3 groups 
were similar. See table for the clinical results. Conclusion: Implantation of Sirolimus-eluting 
stent and Paclitaxel-eluting stent in STEMI patients is not associated with any risk of 
adverse in-hospital events, and reduced the need for repeat PCI at follow-up. 
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BMS (n=388) SES (n=843) PES (n=607) p
In-hospital Clinical success (%) 98.5 98.8 99.0 NS
Death (%) 1.0 0.8 1.0 NS
Stent thrombosis (%) 0.5 0 0 NS
12-month Death (%) 1.3 0.9 1.2 NS
Angiographic restenosis 
(%) 16.0 3.8* 3.3* 0.01
Repeat PCI (%) 10.8 3.0* 2.5* 0.01
24-month Death (%) 1.3 0.9 1.2 NS
Angiographic restenosis 
(%) 17.5 3.8* 3.3* 0.01
Repeat PCI (%) 11.9 3.0* 2.5* 0.01
 
976-256 Which Patients With Previous Bypass Surgery Beneﬁt 
Most From Repeat Revascularization?
Lawrence Liao, John H. Alexander, David F. Kong, Michael H. Sketch, Jr., Paul A. 
Pappas, Jing Zhou, Shu S. Lin, Linda K. Shaw, Kevin J. Anstrom, Daniel B. Mark, Duke 
Clinical Research Institute, Durham, NC
Background: Although many patients with ischemic heart disease have undergone prior 
coronary artery bypass grafting (CABG), there are limited outcomes data in this group to 
guide management.
Methods: We examined outcomes in 4890 prior-CABG patients (median age 64 years, 
69.6% male, 32.9% diabetic) who underwent diagnostic cardiac catheterization at our 
institution since 1986. We created a series of regression models for survival with each 
of three initial treatment strategies (medicine alone, percutaneous coronary intervention 
(PCI), and re-do CABG) in order to identify characteristics associated with better 10-year 
survival with each treatment.
Results: Within 30 days of catheterization, 2957 patients received medical therapy, 
1700 underwent PCI, and 233 underwent CABG. There were 1807 deaths during a 
mean follow-up of 5.8 years (median 4.8 years, maximum 19 years). After accounting 
for other variables and propensity for treatment, neither PCI (p = 0.25) nor CABG (p = 
0.23) were associated with better survival compared to medicine alone in the overall 
cohort. However, individual patients had better 10-year survival estimates with speciﬁc 
strategies: medical therapy was preferred in 39.4%, PCI in 38.5%, and CABG in 21.7%. 
Patients with diabetes, peripheral vascular disease or renal insufﬁciency were less likely 
to beneﬁt from revascularization (all p <0.001). Patients with lower ejection fraction or 
worse coronary (native or graft) disease were more likely to beneﬁt with revascularization 
(all p <0.001). Among revascularization patients, those with the most severe graft disease 
or heart failure were more likely to beneﬁt from CABG compared to PCI (both p <0.001).
Conclusions: Although overall survival in patients with prior CABG is similar after initial 
treatment with medical therapy, PCI or CABG, important sub-groups of patients were 
more likely to beneﬁt from revascularization. Targeting revascularization to these patients 
has the potential to improve patient outcomes.
976-257 Prevalence and Clinical Impact of Angiographic Stent 
Fracture and Stent Hinge Movement After Sirolimus-
eluting Stent (SES) Implantation in Complex PCI
Kazushige Kadota, Kazuaki Mitsudo, Katsumi Inoue, Tsuyoshi Goto, Satoki Fujii, 
Harumi Kato, Hiroyuki Yamamoto, Yasushi Fuku, Sou Takenaka, Akitoshi Hirono, 
Hiroyuki Tanaka, Masanao Taba, Atsushi Ikeda, Junpei Maekawa, Sachiko Maekawa, 
Seiji Habara, Yukinobu Nakamura, Tsuyoshi Miyaji, Chinatsu Yamada, Yoji Okamoto, 
Suguru Otsuru, Kurashiki Central Hospital, Kurashiki, Japan
Background: Stent fracture is reported to be related to in-stent restenosis after Sirolimus-
eluting stent (SES) implantation. PCI for more complex lesions such as very long lesions, 
in-stent restenosis (ISR) lesions, bending lesions, or lesions with overlapping stenting 
may increase the prevalence of stent fracture. We performed the systematic angiographic 
follow-up study and evaluated stent fracture and stent hinge movement, and clinical 
relevance in more complex lesions. 
Methods and Results: The study population comprised 431 patients (mean age 68.6 
years old) with 647 lesions (CTO; 64 lesions, ISR; 195 lesions, multiple stenting; 201 
lesions, bending lesion; 80 lesions, lesion longer than 30mm; 103 lesions), from which 
565 lesions were angiographicaly followed after 6-8 months and the follow-up rate was 
87.3%. Angiographic stent fracture was deﬁned as stent bending with obvious separation 
of stent struts. Angiographic stent hinge movement was deﬁned as movement of stent 
shaft at the bending point without separation of stent struts. Binary in-segment restenosis 
rate was 11.3 %. Stent fracture was observed in 2.3% i.e. 13 lesions, among which 9 
had hinge movement and 4 did not. Stent hinge movement without stent fracture was 
observed in 1.6% i.e. 9 lesions. Restenosis rate of stent fracture with hinge movement 
was 55.5%. There was no restenosis in stent fracture lesions without hinge movement. 
Five out of 9 hinge-movement lesions without stent fracture had restenosis. Prevalence 
of stent fracture and/ or stent hinge movement with restenosis was 1.8% i.e. 10 lesions 
(lesion site: proximal; 0, mid ; 3 , distal; 6 , SVG ostium; 1, overlapping stenting; 9 , ISR 
lesion; 3 , bending lesion; 2 ) in 10 patients, among which 2 patients had symptom and the 
other 8 had no symptom and 3 patients had target lesion revascularization with PCI. 
Conclusions: Angiographic stent fracture and hinge movement were not so rare 
phenomena after SES implantation for complex lesions. Stent hinge movement was more 
related to restenosis after SES implantation than stent fracture. These results suggested 
that dynamic mechanical stress might be a trigger of restenosis after SES implantation.
976-258 Minimally Invasive Direct Coronary Artery Bypass 
(midcab) Surgery Versus Bare-metal Stenting in 
Isolated Proximal LAD-Stenosis: 5-Year Follow-up
Holger Thiele, Stefan Oettel, Stephan Jacobs, Rainer Hambrecht, Peter Sick, Friedrich-
Wilhelm Mohr, Gerhard Schuler, Volkmar Falk, University of Leipzig - Heart Center, 
Leipzig, Germany
Background: Randomized trials comparing stenting to minimally invasive direct coronary 
artery bypass surgery in patients with isolated proximal left anterior descending (LAD) 
lesions have shown a signiﬁcantly higher reintervention rate for stenting and similar results 
for mortality and reinfarction at short-term follow-up. Long-term follow-data are sparse.
Methods and results: Patients with isolated proximal LAD stenosis were randomized 
either to surgery (n=110) or bare-metal stenting (n=110). At 5 year follow-up data were 
obtained with respect to the primary endpoint death, reinfarction or repeated target vessel 
revascularization. Clinical symptoms were assessed by the CCS-classiﬁcation. Follow-up 
information was completed for 216 patients (98.2%) and mean follow-up was 5.6±1.2 
years. With respect to mortality (surgery 12%, stenting 10%, p=0.54) and reinfarctions 
(surgery 7%; stenting 5%, p=0.46) there were no differences for both treatment strategies. 
The need for repeat target vessel revascularization was signiﬁcantly higher after stenting 
(32%) compared to surgery (10%; p<0.001). Clinical symptoms improved signiﬁcantly in 
both treatment groups in comparison to baseline, however, there was a favorable trend for 
surgery (stenting: CCS 2.6±0.9 to 0.5±0.8, p<0.001; surgery: 2.6±0.9 to 0.3±0.6; p<0.001, 
p=0.05 stenting vs. surgery).
Conclusions: At 5 year follow-up minimally invasive bypass surgery as well as bare-metal 
stenting show similar results for the endpoints mortality and reinfarctions. Nevertheless, 
the reintervention rate is higher after stenting and the relieve in clinical symptoms is 
slightly better following surgery.
976-259 Overlapping Sirolimus-Eluting Stents: Analysis From 
the Matrix Registry
Roxana Mehran, Michael Collins, Edward Krebs, Alexandra J. Lansky, George Dangas, Isaam 
Moussa, Giora Weisz, Eugenia Nikolsky, Manuela Negoita, Susheel Kodali, John Liuzzo, 
Ramez Sulaiman, Jeffrey W. Moses, Gregg W. Stone, Martin B. Leon, Columbia University 
Medical Center, New York, NY, Cardiovascular Research Foundation, New York, NY
Background. Lesions requiring multiple stents represent a challenging subset for 
treatment with PCI. Recent studies suggested a less favorable outcome in pts treated 
with overlapping paclitaxel-eluting stents. Impact of overlapping sirolimus-eluting stents 
(SES) on outcomes of pts undergoing PCI has not been reported.
Objective. Based on data from the ongoing prospective MATRIX registry designed to 
evaluate safety and efﬁcacy of SES in an unselected population, our study was aimed at 
assessing the outcomes of consecutive pts treated with overlapping SES.
Methods. Primary endpoint was target vessel failure (TVF) deﬁned as cardiac death, 
myocardial infarction (MI) or target vessel revascularization(TVR).
Results. A total of 139 pts (18.1%) were treated with overlapping stents (mean length 
of overlapping segment 3.5mm). One, 2 or 3 overlapping segments were present in 
122 (16.3%), 29 (3.9%) and 8 (1.1%) pts, respectively. Results were compared with pts 
treated with non-overlapping SES (Table). Patients with vs. without overlapping SES had 
longer lesion, higher incidence of impaired TIMI ﬂow, a trend towards higher rates of non-
Q wave MI and TVF in hospital and at 6 month. Iindependent predictors of TVF included 
lesion length (OR=1.04; p=0.01), diabetes (OR=2.86; p=0.01) and prior brachytherapy 
(OR=16.6; p=0.0003) but not overlapping stents.
Conclusions. The use of overlapping SES is associated with higher rates of TVF that are 











Lesion length, mean±SD (mm) 38.0±14.8 18.5±9.7 <0.0001
Reference vessel diameter, mean±SD 
(mm) 2.76±0.36 2.77±0.46 0.68
Baseline TIMI grade ﬂow ≤2 11.5% 6.0% 0.02
In-hospital events (%)
Cardiac death 0 0 -
MI 5.2% 2.0% 0.06
Q-wave 0 0 -
Non-Q wave 5.2% 2.0% 0.06
TVR 0 0.5% 1.0
TVF 5.2% 2.1% 0.07
Events at 6 months (%)
Cardiac death 0 0.7% 1.0
MI 6.0% 2.7% 0.08
TVR 3.4% 2.0% 0.31
TVF 9.5% 4.9% 0.07
Stent thrombosis 0 0.2% 1.0
 
976-260 The Safety and Outcome of the Multiple, Very Long 
Sirolimus-Eluting Stent Implantation in the the Real 
World Clinical Practice
Jong-Seon Park, Young-Jo Kim, Dong-Gu Shin, Bong-Sup Shim, Gu-Ru Hong, Jun-Ho 
Bae, Chang-Wook Nam, Seung-Ho Hur, Seong-Wook Han, Kee-Sik Kim, Yoon-Nyun 
Kim, Kwon-Bae Kim, Doo-Il Kim, Seong-Man Kim, Young-Woo Park, Dong-Soo Kim, 
Keimyung Univ. Hospital, Daegu, South Korea, Yeungnam University Hospital, Daegu, 
South Korea, Inje University Hospital, Busan, South Korea
Background: In the real world clinical practice, we often meet more complex and long 
lesions which increase restenosis and cardiovascular events than trial patients. The aim 
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of this study was to evaluate the clinical and angiographic outcome of the implantation of 
multiple, very long sirolimus-eluting stents (SES) in the real world clinical practice.
Methods: We implanted multiple, very long SES (>40 mm in total length) in 113 de novo 
lesions in 113 patients. The average length of the implanted stents as 58±14mm (41-112 
mm) and 2.2 stents were implanted in each lesion and the average stent diameter was 
3.0±0.3 mm. 
Results: Procedural and angiographic success were achieved in all patients. Non-Q 
wave MI (CK-MB≥3 times normal value) was developed in 13 patients (11.5 %). One 
patient had a late stent thrombosis 50 days after discharge (0.9 %). The major adverse 
cardiac events (MACE)-free survival was 93 % at 12 months. There were two sudden 
cardiac deaths and one non-cardiac death. One patient had a non Q-wave MI due to late 
stent thrombosis at 50 days after the procedure. A six months follow up angiography was 
performed on 76 patients (67 %) and angiographic in-stent restenosis was developed 
in 6 patients (9.2%). All of them were focal type in-stent restenosis and found at the 
overlapping segment or distal stents. 
Conclusions: In conclusion, very long lesion coverage with SES showed a favorable 
procedural and angiographic outcome. But, we have to consider the high risk of late stent 
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821-3 AZD6140 Yields Greater Inhibition of Platelet 
Aggregation Than Clopidogrel in Patients With Acute 
Coronary Syndromes Without Previous Clopidogrel 
Treatment
Robert F. Storey, Steen Husted, Robert A. Harrington, Stanley Heptinstall, Robert G. 
Wilcox, Paul A. Gurbel, Peer Grande, Nick Sanders, Gary Peters, Hakan Emanuelsson, 
Christopher P. Cannon, University of Shefﬁeld, Shefﬁeld, United Kingdom, Aarhus 
University Hospital, Aarhus, Denmark
Background: AZD6140 is the ﬁrst oral reversible P2Y12 receptor antagonist. The 
DISPERSE2 study compared different regimens of AZD6140 with clopidogrel in patients 
with non-ST elevation acute coronary syndromes (ACS) receiving ASA. We performed a 
substudy comparing the pharmacodynamic responses to the two agents.
Methods: ACS patients were randomized to AZD6140 90 mg bid, AZD6140 180 mg bid 
or clopidogrel 300 mg loading dose then 75 mg daily. Half the patients in each AZD6140 
group received AZD6140 270 mg loading dose. Patients had not received any recent 
clopidogrel therapy. All received ASA 75-100 mg daily. Platelet aggregation was measured 
using ADP 20 µM and optical aggregometry pre dose and at 2, 4, 8 and 12 h post dose. 
Further assessments were made at 4 weeks and a proportion continued medication for 
8 or 12 weeks with further assessments at these time points. Plasma levels of AZD6140 
were also assessed.
Results: 45 patients were studied. All AZD6140 doses showed more rapid onset of action 
and greater inhibition of platelet aggregation compared to clopidogrel (ﬁgure shows ﬁnal 
response to ADP). Plasma levels of AZD6140 peaked at 2 h. At 4, 8 and 12 weeks, both 
AZD6140 doses yielded consistently higher levels of inhibition of platelet aggregation 
compared to clopidogrel (4 weeks, 4 h post dose: clopidogrel 64 +/- 22%; AZD6140 90 
mg 79 +/- 22%; AZD6140 180 mg 95 +/- 8%).
Conclusion: AZD6140 yields more rapid, more complete and more consistent inhibition 
of platelet aggregation than clopidogrel in patients with ACS.
2:15 p.m.
821-4 AZD6140 Yields Additional Suppression of Platelet 
Aggregation in Patients With Acute Coronary 
Syndromes Previously Treated With Clopidogrel
Robert F. Storey, Robert A. Harrington, Steen Husted, Stanley Heptinstall, Robert G. 
Wilcox, Paul A. Gurbel, Peer Grande, Nick Sanders, Gary Peters, Hakan Emanuelsson, 
Christopher P. Cannon, University of Shefﬁeld, Shefﬁeld, United Kingdom, Duke 
University Medical Center, Durham, NC
Background: AZD6140 is the ﬁrst oral reversible P2Y12 receptor antagonist. The 
DISPERSE2 study compared different regimens of AZD6140 with clopidogrel in patients 
with non-ST elevation acute coronary syndromes (ACS) receiving aspirin. We performed 
a substudy assessing the effect of adding AZD6140 in patients already treated with 
clopidogrel.
Methods: ACS patients were randomized to AZD6140 90 mg bid, AZD6140 180 mg bid 
or clopidogrel 75 mg qd. Half the patients in each AZD6140 group received AZD6140 270 
mg loading dose. All patients received ASA 75-100 mg qd and all had previously received 
a loading regimen of clopidogrel during their hospital admission. Platelet aggregation (PA) 
was measured using ADP 20 µM and optical aggregometry pre dose and at 2, 4, 8 and 12 
h post dose. Plasma levels of AZD6140 were also assessed.
Results: 44 patients were studied. At 4 h after the initial dose there was no fall in PA 
in patients who continued clopidogrel whereas all AZD6140 groups showed marked 
suppression of PA (AZD6140 270 mg 43 +/- 22% pre dose, 2 +/- 4% post dose). Plasma 
levels of AZD6140 peaked at 2 h. The highest individual platelet aggregation response 
at 4 h was 66% in the clopidogrel group and 19% in all the AZD6140 groups combined 
despite a similar range of baseline PA values.
Conclusions: AZD6140 yields rapid additional suppression of PA in patients with ACS 
currently treated with clopidogrel and overcomes high levels of PA seen in some patients 
receiving clopidogrel.
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821-5 Fondaparinux Is Associated With Substantially 
Less Major Bleeding and Vascular Access Site 
Complications Compared With Enoxaparin in 
Patients With Acute Coronary Syndrome Undergoing 
Percutaneous Coronary Intervention: Insights from the 
OASIS 5 Trial
Shamir R. Mehta, Jean-Pierre Bassand, Christopher B. Granger, Petr Widimsky, 
Philippe Gabriel Steg, Hans-Jurgen Rupprecht, David P. Faxon, Rizwan Afzal, Susan 
Chrolavicius, Brandi Meeks, Keith A. A. Fox, Salim Yusuf, McMaster University and 
Hamilton Health Sciences, Hamilton, ON, Canada, Centre Hospitalier Universitaire Jean 
Minjoz, Besancon, France
Background: We investigated the efﬁcacy and safety of fondaparinux (fonda) in patients 
undergoing PCI in the OASIS 5 trial.
Methods: In OASIS 5, 20078 patients with ACS were randomized to subcutaneous (sc) 
fonda or enoxaparin (enox). During PCI, pts referred to the cath lab <6 h of last sc dose 
received no extra anticoagulation in the the enox group and 2.5mg fonda IV in the fonda 
group. Patients referred >6h of last sc dose received weight-adjusted UFH according to 
GP IIb/IIIa use in the enox group and fonda 2.5/5mg IV with/without GP IIb/IIIa in the 
fonda group.
Results: Efﬁcacy was similar between the groups, but there was a large reduction in 
major bleeds with fonda (table). The net clinical beneﬁt, as assessed by the composite 
of death, MI or major bleeding, was also signiﬁcantly lower in the fonda group. Fonda 
also reduced vascular access site complications, including pseudo-aneurysms and large 
hematomas. When PCI was performed <6 h of the last sc dose of enox (where no UFH 
was given by protocol), major bleeds were still reduced with fonda (3.5% vs 1.5%, HR 
0.58, P=0.003). There were no signiﬁcant differences between the groups in rates of 
abrupt closure (P=0.20) or threatened abrupt closure (P=0.31).
Conclusions: Fonda is associated with substantially lower rates of major bleeds and 
vascular access site complications with similar efﬁcacy to enox/UFH, resulting in greater 
net clinical beneﬁt. The reduction in bleeding was irrespective of concurrent UFH use 
during PCI. 
Events at 9 days in Patients Undergoing PCI During Study Treatment Period
Post PCI Events Enox Fonda HR (95% CI) P value
No. Rand. 3089 3118
Death/MI/Major Bleed 11.3 9.4 0.83 (0.72-0.97) 0.01
Major Bleeds 5.4 2.8 0.52 (0.40-0.67) <0.0001
Death 2.1 2.0 0.93 (0.66-1.31) 0.68
MI 5.5 5.8 1.06 (0.86-1.29) 0.60
Death/MI 6.9 7.2 1.05 (0.88-1.26) 0.58
Any vascular access site complication 8.1 3.3 0.40 (0.32-0.50) <<0.0001
Pseudo-aneurysm 1.6 1.0 0.63 (0.40-0.98) 0.039
Large Hematoma 4.4 1.6 0.35 (0.26-0.49) <<0.0001
2:45 p.m.
821-5 Beneﬁt of Early Statin Therapy During Acute Coronary 
Syndromes: A Meta-Analysis
Anthony A. Bavry, Girish Mood, P. Peter Borek, Dharam J. Kumbhani, Deepak L. Bhatt, 
Cleveland Clinic Foundation, Cleveland, OH, University of Pennsylvania, Philadelphia, PA
Background: Statins initiated early during acute coronary syndromes (ACS) have only 
recently been evaluated in clinical trials. Although a reduction in composite cardiac 
outcomes has been shown, the beneﬁt of early statin therapy on individual outcomes is 
unknown. Accordingly, we sought to evaluate the impact of early statin therapy initiated 
during an ACS on individual cardiac outcomes.
Methods: We conducted a meta-analysis on randomized trials where statin therapy was 
administered early during an ACS. Studies were included if patients were randomized 
early to aggressive statin therapy or more conservative statin therapy and outcome data 
were available. We calculated risk ratios (RR) and 95% conﬁdence intervals (CI) for all-
cause mortality, myocardial infarction (MI), stroke, revascularization, and unstable angina 
requiring admission.
Results: In all, there were 7 studies available for analysis (Prove-IT, A to Z, MIRACL, 
PTT, FLORIDA, L-CAD and PACT) that randomized 15,969 patients (aggressive=8,019 
and conservative=7,950). Clinical follow up ranged from 1 to 24 months. The average 
time from randomization until statin therapy was initiated ranged from 6 hours to less than 
10 days. The incidence of all-cause mortality was 3.1% versus 4.1% in the aggressive 
versus conservative arms, respectively (RR=0.76, 95%CI 0.64 to 0.89, p=0.001). The 
number needed to treat (NNT) to prevent 1 excess death was 100 patients. The incidence 
of recurrent MI was 5.9% and 6.2%, respectively (RR=0.95, 95%CI 0.84 to 1.07, p=0.38), 
while the incidence of stroke was 0.83% and 1.1%, respectively (RR=0.74, 95%CI 0.54 
to1.02, p=0.065). The incidence of unstable angina and the incidence of revascularization 
were also signiﬁcantly reduced in the aggressively treated arms, 5.7% versus 6.6% and 
10.4% versus 11.5%, respectively (RR=0.88, 95%CI 0.78 to 0.99, p=0.039 and RR=0.91, 
95%CI 0.84 to 0.99, p=0.029, respectively).
Conclusions: Aggressive statin therapy initiated early during an ACS results in a 
signiﬁcant survival beneﬁt with a favorable NNT to prevent each death. Furthermore, 
this approach signiﬁcantly reduces subsequent unstable angina and the need for 
revascularization. 
3:00 p.m.
821-6 Use of Percutaneous Coronary Intervention Versus 
Coronary Artery Bypass Surgery for Patients With 
Acute Coronary Syndromes and Multivessel Coronary 
Disease in the Drug-Eluting Stent Era: Data From the 
CRUSADE Quality Improvement Initiative
Prospero B. Gogo, Jr., Harold L. Dauerman, Jyotsna Mulgund, Manesh R. Patel, E. 
Magnus Ohman, W. Brian Gibler, Robert A. Harrington, Eric D. Peterson, Matthew T. 
Roe, University of Vermont College of Medicine, Burlington, VT, Duke Clinical Research 
Institute, Durham, NC
Background: Drug-eluting stents (DES) were approved by the FDA in April 2003. Yet 
the inﬂuence of these on the choice of revascularization for patients with acute coronary 
syndromes (ACS) has not been determined.
Methods: Using data from the CRUSADE Quality Improvement Initiative, we studied 
103,288 patients who presented with non-ST-segment elevation acute coronary syndromes 
(NSTE ACS) (ischemic ST/T wave changes and/or elevated cardiac biomarkers) at 365 
hospitals between January 2002 and June 2005.
Results: 82,924 NSTE ACS patients (80.3%) underwent cardiac catheterization during 
the index hospitalization. Of these, 25,068 patients (24.3%) had 3-vessel coronary 
disease (3VD). In the overall population, the use of revascularization increased 
signiﬁcantly over the study period (from 51.1% to 64.5%, p=0.001 for trend). Overall, the 
use of percutaneous coronary intervention (PCI) rose over time (from 38.3% to 52.5%, 
p<0.001) while the overall use of coronary artery bypass grafting (CABG) remained at 
13%. Interestingly, among patients with 3VD who underwent revascularization, the use 
of CABG actually fell (48.9% to 39.9%, p<0.001) while use of PCI rose (51.1% to 60.1%, 
p<0.001) (Figure).
Conclusions: The introduction of DES has increased utilization of PCI in patients with NSTE 
ACS. Even among those with 3VD, PCI has become the preferred strategy in community 
practice. These ﬁndings conﬁrm the need for further comparative trials of DES vs. CABG. 
3:15 p.m.
821-7 Early Invasive Versus Conservative Management in 
Non ST Elevation Acute Coronary Syndromes: A 
Metanalysis
Andrei Pop, Mohan R. Nandalur, Paul Vaitkus, University of Illinois at Chicago, Chicago, IL
Background: The recent publication of ICTUS questioned the beneﬁt of an early invasive 
approach for patients with non ST elevation Acute Coronary Syndrome (ACS). Our goal was 
to analyze all available data of routine invasive versus initially conservative approach in ACS.
Methods: We pooled all published randomized controlled clinical trials of early invasive 
versus conservative approach in ACS. We calculated a Mantel-Haenszel Odds Ratio and 
95% conﬁdence intervals. The endpoints were Death + Myocardial Infarction (MI), and 
Death at 6-12 months. We performed a subgroup analysis of trials from the stent era.
The following studies were analyzed: TIMI IIIb, VANQWISH, FRISC II, TACTICS TIMI 18, 
RITA, VINO, ICTUS. MATE was excluded as no 6-12 month data were reported.
Results: There were 7 studies enrolling 10,211 pts. The results (see ﬁgure) support an 
overall reduction of Death + MI, and Death for all studies and all stent studies.
Conclusions: Our meta-analysis supports the conclusion that an early invasive approach 
results in a reduction of morbidity and mortality in ACS patients. Despite the recent 
neutral results of ICTUS, the overall data support a beneﬁt of an early invasive approach, 
suggesting the possibility that ICTUS suffered from a beta error.
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829-3 Effect of Stem Cells on Left Ventricle Wall Thickness 
and Capillary Density in Pigs Following Myocardial 
Infarction
Nadine Matthias, Michael Schwarzer, Kai Pinkernell, Parwis Fotuhi, Eckhard Alt, Tulane 
University, New Orleans, LA
Background: Transplantation of adult autologous stem cells is considered a promising 
approach for cardiac regeneration after myocardial infarction (MI). The aim of this study 
was to determine the effect of adipose derived stem cells (ADSC) on vascular density and 
wall thickness of the left ventricle in pigs following MI.
Methods: MI was induced in 17 pigs (33±5 kg, ADSC animals n=8, control n=7) 
by occlusion of the mid LAD with an angioplasty balloon for three hours. In the same 
procedure stem cells were harvested from subcutaneous fat tissue and processed. 
After reperfusion a cell suspension containing the ADSC (1.5 million ADSC cells/kg 
body weight) or control solution was injected through the balloon. At 8 weeks animals 
were euthanized; the hearts were removed and sliced in 5 sections (apex to basis). The 
basal side of the left ventricle was used, while the right ventricle was excluded. The wall 
thickness was assessed in the infarct area, healthy myocardium and in two parts in the 
border zone, calculated by planimetrie and compared to each other.
Endothelial cells were stained for von-Willebrand factor. Capillaries with a diameter 
equal or below 10 µm in a perpendicular cut were counted in the border zone, healthy 
myocardium, and infarct area and then quantiﬁed.
Results: The wall in the infarct area was signiﬁcantly thicker for the ADSC group (5.9±2 
mm) compared to the control group (3.6±1.2 mm). The same signiﬁcant difference 
was seen in the border zone. The wall thickness was 11.2±2.2 mm in the ADSC group 
and 8.6±1.6 mm in the control group. The healthy myocardium showed no signiﬁcant 
differences. Capillary density (per 0.1mm2) in the border zone of the ADSC group 
(41.6±17.9) was signiﬁcantly increased (p<0.05) compared to the control group 
(32.9±12.6). The capillary density in the healthy myocardium and in the infarct area was 
not different in both groups.
Conclusions: This study shows a positive effect of ADSC on wall thickness and capillary 
density after MI. Our data suggest that subcutaneous adipose tissue exhibits a beneﬁcial 
effect on vascular density and remodeling and, therefore, might be a valuable alternative 
source of cells to improve cardiac regeneration after acute myocardial infarction.
7:15 a.m.
829-4 Genetically Modifying Marrow Stromal Stem Cells to 
Secrete Erythropoietin Enhances the Protective Effect 
of Cellular Therapy in the Infarcted Myocardium
Marc E. Jolicoeur, Ian Copland, Marc Antoine Gillis, Angelo Calderone, Jacques 
Galipeau, Anique Ducharme, Montreal Heart Institute, Montreal, PQ, Canada, Lady 
Davis Institute for Medical Research, Montreal, PQ, Canada
Background: The cardioprotective effect of exogenous stem cells is thought to originate 
from enhanced regional neovascularization mediated by sustained paracrine secretion of 
proangiogenic cytokines within infarct burdens. Erythropoietin (EPO) may be beneﬁcial 
to infarcted tissues by suppressing inﬂammation, inhibiting apoptosis, and enhancing 
angiogenesis. We sought to assess whether genetically engineered marrow stromal cells 
(MSC) used as a vehicle for EPO would enhance the cell-based therapeutic angiogenesis 
and further improve function recovery after myocardial infarction.
Methods: MSC from female C57Bl/6 mice were transduced with retroviral vectors 
expressing mouse Epo cDNA. MSCepo+ were shown to secrete Epo at a rate of 3-4 Units 
of Epo/106cells/24hrs. Ten minutes after myocardial infarction, C57Bl/6 female mice (10 
weeks old) were injected in the myocardium with either saline (n=9), 1.5 x106 MSCnull 
(n=9) or MSCepo+ (n=11). Echocardiogram and hematocrit (Ht) were performed at day 
1, 7 and 14. Invasive hemodynamic measurements were performed at day 14, before 
sacriﬁce. Infarct size was calculated using the ratio of infarcted/ total circumferences from 
transverse sections. Capillary density was assessed by counting endothelial cells in the 
infarct border zones following vWF staining.
Results: Baseline fractional shortening (FS) were similar in the 3 treatment groups. At 
day 14, the MSCepo+ group showed a signiﬁcantly improved FS when compared to the 
MSCnull and saline groups (29.7% ± 8.5 versus 19.9% ± 6.6 and 19.1% ± 7.4 respectively, 
p<0.05). Left ventricular function improvement was greater in MSCepo+ and MSCnull groups 
compared to the saline group (+dp/dt of 3839 mmHg ± 653, 3269mmHg ± 742, and 2725 
± 803, p<0.05). Capillary density was signiﬁcantly higher in the MSCepo+ and the MSCnull 
groups than in the saline control group (249/mm2 ± 57, 186/mm2 ± 58, and 146/mm2 ± 
57, p<0.05).
Conclusion: MSCs genetically modiﬁed to express EPO preserve myocardial function 
following acute infarction and increase vascular density in the infarct border zones. 
These changes are hematocrit-independent and likely arise from a local effect of Epo 
on myocardium.
7:30 a.m.
829-5 PET Imaging of Peripheral Stem Cell Homing After 
Intracoronary Transfer in Patients Following Acute 
Myocardial Infarction
Didier Blocklet, Michel Tougounz, Micheline Lambermont, Philippe Unger, Nicolas 
Preumont, Eric Stoupel, Jean-Paul Degaute, Michel Goldman, Serge Goldman, Guy 
Berkenboom, ERASME Hospital, ULB, Brussels, Belgium
Background: Several studies have shown marginal increase in left ventricular function in 
patients receiving autologus stem cells after acute ST-elevation myocardial infarction (MI). 
However, this improvement could be due to the recovery of viable myocardium induced by 
the reperfusion therapy. Therefore, we aimed to determine the homing of these stem cells 
after intracoronary (IC) transfer and to assess the feasibility of a peripheral approach for 
CD34+ isolation (rather bone marrow harvesting).
Methods: 6 (3 male, 3 female) patients (range age : 41 to 71 years) with a ﬁrst large 
anterior myocardial infarction (time to revascularization 25±11 hours, mean ± SD) and 
successful reperfusion ( 3 primary PTCA and 3 rescue PTCA) underwent cytapheresis 
(Cobe spectra) 9±3 days after the acute event. After selection with an Isolex 300i device, 
47.5 106±5.4 106 stem cells were available for the transplantation, encompassing 14.9 106 
± 3.58 106 CD34+ and 50% of them were labelled with FDG (18F-ﬂuorodeoxyglucose). 
Cell viability after radiolabelling was > 95%. The labelled cells were then combined with 
the non labelled cells and infused into the left anterior descending artery (2 proximal, 4 
middle) through the central lumen of an over-the-wire balloon catheter (placed at the stent 
level). Two hours after this IC transfer, all patients underwent a PET imaging study.
Results: PET detected 6±0.5 % of the injected activity in the infarcted area (mainly in the 
border zone). At 3 months, echocardiography revealed a slight increase in left ventricular 
ejection fraction from 56±7% to 60±7% (NS) and a signiﬁcant (P<.05) improvement in 
wall motion score index from 1.63±0.30 to 1.40±0.28. At 6 months, no adverse events 
occurred (no restenosis, no ventricular arrhythmias).
Conclusions: Transplantation of peripheral stem cells is feasible after an acute MI. FDG 
imaging detects homing in the infarcted area and at 6 months, the clinical outcome is 
favorable.
7:45 a.m.
829-6 Chronic Therapy With Erythropoietin, Even 
Administrated Late After Reperfusion, Induces 
Endothelial Progenitor Cells Mobilization and 
Myocardial Salvage in Post-mi Rats
Fabrice Prunier, Otmar Pﬁster, Federica del Monte, Roger Hajjar, Masssachusetts 
General Hospital, Boston, MA, Boston University School of Medicine, Boston, MA
Background: Erythropoietin (EPO) administration in high dose has been shown to 
reduce infarct size by preventing apoptosis when administrated before or immediately 
after myocardial ischemia.
Objective: We assessed the effects of chronic low dose EPO treatment after the acute 
phase of MI.
Methods and Results: Rats underwent 40 minutes of coronary occlusion followed by 
reperfusion or sham procedure. Rats were assigned to the following groups: darbepoetin-
alpha 0.75 µg/kg (MI+darb 0.75, n=12) or 1.5 µg/kg (MI+darb 1.5, n=12) or vehicle 
(MI+PBS, n=16) i.p. once a week from day 7 post-surgery; Sham-operated rats were 
divided in two groups: darb. 1.5 µg/kg (Sham+darb 1.5, n=4) or vehicle (Sham+PBS, 
n=6). After 8 weeks of treatment, animals underwent echocardiography, left ventricular 
pressure/volume measurements, peripheral blood endothelial progenitor cells count 
(EPCs), MI size and area at risk (AAR) assessment. AAR was similar among the 3 MI 
groups. Compared to MI+PBS, MI+darb 1.5 exhibited a reduction of MI/AAR ratio by 46%, 
p<0.05; signiﬁcantly reduced left ventricle dilatation and improved cardiac function (+16% 
fraction shortening, p<0.05; +30% +dp/dt, p<0.05, +147% maximum elastance, p<0.05). 
None of echographic or hemodynamic parameters were signiﬁcantly different between 
MI+PBS and MI+darb 0.75. EPCs were signiﬁcantly increased by 100% in MI+darb 1.5 
compared to MI+darb (p<0.05) but not in MI+darb 0.75.
Conclusion: Even administrated late after reperfusion, chronic EPO treatment reduces 
MI size and improves cardiac function. This positive effect is found only with dose able to 
mobilized endothelial progenitor cells.
8:00 a.m.
829-7 One Day Kinetics of Bone Marrow Mononuclear Cells 
in Acute and Chronic Myocardial Infarction: Transient 
Myocardial Homing or Persistent Engraftment After 
Intracoronary Injections in Human?
Martin Penicka, Otto Lang, Petr Widimsky, Petr Kobylka, Tomas Kozak, Tomas Vanek, 
Karol Curila, Petr Tousek, Third Medical School Charles University and University 
Hospital Kralovske Vinohrady, Prague, Czech Republic
Background: The efﬁcacy of intracoronary injection to deliver autologous bone marrow-
derived mononuclear cells (BMNCs) into the diseased human myocardium remains 
controversial. Therefore, we aimed to investigate the one-day kinetics of myocardial 
engraftment of BMNCs after intracoronary injection using 99mTc-d,l-hexamethylpropylene 
amine oxime (99mTc-HMPAO) nuclear imaging in patients with acute anterior myocardial 
infarction and chronic ischemic heart failure.
Methods: The study population consisted of 5 patients with the ﬁrst acute anterior 
myocardial infarction (age 58 ± 11yrs; ejection fraction range 33% to 45%) and 5 patients 
with chronic ischemic heart failure (age 50 ± 6yrs; NYHA III; ejection fraction range 28% 
to 34%). Bone marrow blood was aspirated from both iliac crests (range 24.2x108 to 
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57.0x108 BMNCs). Twenty % of BMNCs suspension was labeled with 700-1000 MBq 
99mTc-HMPAO. Nuclear imaging was performed at 2 and 20 hours after injections in the 
left anterior descending coronary artery.
Results: At 2 hours after BMNCs injections, myocardial homing was observed in all 
patients with acute myocardial infarction (range 1.31% to 5.10%) and in all but one 
patient with chronic ischemic heart failure (range 1.10% to 3.0%). At 20 hours, persistent 
myocardial engraftment (1.00%-1.34%) was noted only in 3 patients with acute myocardial 
infarction, while no activity remained in the myocardium in any patient with heart failure.
Conclusions: Homing of BMNC displays dynamic changes within ﬁrst 20 hours after 
intracoronary injections. Persistent myocardial engraftment was noted only in subset of 
patients with acute myocardial infarction, while none in patients with chronic ischemic 
heart failure.
8:15 a.m.
829-8 Final Results of the RECOVER G-CSF Randomized Trial 
in Patients With Large Myocardial Infarction
Stephen G. Ellis, Marc Penn, Brian Bolwell, Thomas Wang, Matthews Chacko, Kelly 
Brezina, Gerry McConnell, Eric Topol, Cleveland Clinic Foundation, Cleveland, OH
Based upon animal infarct model data suggesting a survival beneﬁt with G-CSF/SCF 
versus placebo, we initiated an FDA approved single center dose escalation phase 1 
randomized double-blind trial of G-CSF (5->10 ug/kg/day SQ x 5 days) versus placebo 
in patients reperfused hours after MI with baseline LVEF 20-39%. Patients reperfused < 
4 hrs. were excluded due to expected improvement in LV function. Patients reperfused > 
48 hrs. were excluded out of concern that maximum cell mobilization might occur too late 
for optimal homing/LV recovery. The primary safety endpoint was rupture free survival at 
30 days and the primary efﬁcacy endpoint change in LVEF over the same time frame. 
Secondary endpoints included CD 34 + CD 117 + cell mobilization in change in infarct wall 
thickness through 30 days. The last patient was enrolled September 16, 2005. Baseline 
demographics and initial stem cell mobilization data are shown. There were no deaths/MI’s 
through one year in the 5 ug/kg G-CSF group, CD 117 max in GCSF group was inversely 
related to age (p=.055). Primary endpoint data will be available for presentation.
These data, in conjunction with the completed FIRSTLINE and ongoing Rostock studies, 
will provide important data regarding this form of stem cell/cytokine mobilization to guide 
subsequent more deﬁnitive studies. 
Placebo (n = 6) G-CSF 5ug/kg (n=6)
G-CSF 10 ug/kg 
(n =6)
Age (years) 61 +/- 12 53+/- 5 60 + 10
Male (%) 100 100 83.3
Anterior MI (%) 66.7 66.7% 83.3
Time, MI-> PCI 15.0 +/- 19.8 hrs. 4.1 +/-3.7 hrs. 12.4 +/- 13.0 hrs.
Time, MI-> drug 31.7 + 7.7 hrs. 36+/- 9 hrs 38.2 +/- 5.3 hrs.
CD 34, base/max 3.3/5.3 3.5/35.3* 3.4/28.9
CD 117, base/max 2.1/5.3 2.6/34 .9* 2.4/25.5
LVEF, base/30 day Pending 37/41% Pending
Infarct wall thickness, base/30 
day Pending 9.1/9.0 mm Pending
*p < 0.01 vs. GCSF
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830-3 The Independent and Combined Risks of Diabetes and 
Non-Endstage Renal Impairment in Non ST-Segment 
Elevation Acute Coronary Syndromes
Shaheeda Ahmed, Christopher P. Cannon, Robert P. Giugliano, Amy Shui, Sabina A. 
Murphy, David A. Morrow, Elliott M. Antman, Eugene Braunwald, C. Michael Gibson, The 
TIMI Study Group, Cardiovascular Division, Brigham & Women’s Hospital, Boston, MA
Background: Diabetes (DM) and renal impairment (RI) are each associated with worse 
cardiovascular outcomes, but their combined impact in non ST-segment elevation acute 
coronary syndromes (NSTE-ACS) has not been well characterized.
Methods: Data were pooled from 13,140 patients in ﬁve NSTE-ACS TIMI trials (TIMI 11A 
and B, TIMI 12, OPUS-TIMI 16, and TACTICS-TIMI 18). Patients were divided based on DM 
status and degree of RI, deﬁned as none, mild, or moderate based on a baseline estimated 
glomerular ﬁltration rate (GFR, ml/min/1.73m2) of ≥ 90, 60-89 and 30-59 respectively.
Results: Patients with DM and moderate RI (n=609) were older, more often female 
and had more prior MI (p<0.01 for all) than all other subgroups. Compared to patients 
with no DM/RI (n=3,839), the risks of death, MI, and death/MI increased with advancing 
degrees of RI and were highest in those with DM and moderate RI (Table). The interaction 
terms for DM and RI (mild or moderate) in their association with MI and death/MI were 
signiﬁcant (p<0.01 for all). The risks of death and MI with moderate RI alone (and no DM) 
were also substantial and exceeded the risk with DM alone (and no RI).
Conclusions: While RI and DM are each associated with higher risks of death and MI, 
moderate RI alone confers a greater risk than DM alone. These two conditions appear to 
act synergistically to confer a particularly high-risk of events. Diabetes status and baseline 
GFR are two simple clinical parameters that can identify high risk NSTE-ACS patients.






















Death 1.3 (NS) 2.0 (<0.001) 3.0 (<0.001) 1.2 (NS) 2.4 (<0.001)
MI 0.7 (NS) 1.7 (<0.001) 2.5 (<0.001) 1.0 (NS) 1.4 (0.007)
Death/MI 0.9 (NS) 1.7 (<0.001) 2.4 (<0.001) 1.1 (NS) 1.7 (<0.001)
7:15 a.m.
830-4 Incidence and Not Timing of Death or Myocardial 
Infarction Differ According to Risk in Patients With Non-
ST Elevation Acute Coronary Syndromes: Implications 
for Long-Term Treatment and Follow-Up
Rajendra H. Mehta, Adam B. Greenbaum, Yuliya Lokhnygina, L. Kristin Newby, Frans 
Van de Werf, Paul W. Armstrong, Karen S. Pieper, Robert M. Califf, Christopher B. 
Granger, Robert A. Harrington, Duke Clinical Research Institute, Durham, NC, Henry 
Ford Health System, Detroit, MI
Background: Adverse events parallel the increasing risk proﬁle in patients (pts) with non-
ST elevation acute coronary syndromes (NSTEACS). However, the relationship between 
pts’ risk and the timing of these events is less clear.
Methods: We evaluated 25,417 NSTEACS pts from the GUSTO IIb, PURSUIT, 
PARAGON A and B trials to study whether pts’ clinical risk inﬂuences the timing of death 
and/or myocardial infarction (MI) during 6-month follow-up. The PURSUIT model for death 
was used to categorize pts into low, medium and high-risk groups.
Results: At 6 months, 3%, 4%, and 13% of pts died in low, medium and high-risk groups, 
respectively. However, the proportion of pts dying beyond 30 days were similar in the 3 groups 
(44%, 43%, and 41% of death, respectively, Figure). Similarly, whereas death/MI increased 
with higher risk (11%, 14% and 23%, respectively), the proportion of pts with this event 
beyond 30 days did not differ in the 3 strata (22%, 20%, and 25%, respectively). In fact, similar 
proportion of pts in 3 groups had these events at any given time during follow-up.
Conclusions: Our data suggest that while death and death/MI rates in NSTEACS pts are 
directly related to their risk, signiﬁcant and similar proportion in the low, medium and high-
risk groups continue to have subsequent events. Thus, our data caution against selective 
close follow-up of only high-risk pts and complacency for the low- or intermediate risk pts and 
support similar rigorous secondary prevention and follow-up strategies for all risk groups.
 
7:30 a.m.
830-5 Fasting Glucose Is a Powerful Independent Risk 
Factor for Long-Term Mortality in Patients With Acute 
Myocardial Infarction. A Prospective Study
Mahmoud Suleiman, Haim Hammerman, Michael Kapeliovich, Yoram Agmon, Monther 
Boulos, Walter Markiewicz, Doron Aronson, Rambam Health Campus, Haifa, Israel
Background: Stress hyperglycemia in patients with acute myocardial infarction (MI) has 
been associated with increased mortality. The majority of studies looked at the relationship 
between admission glucose and outcome, while the added prognostic importance 
of fasting glucose (FG) has not been prospectively explored. We studied whether an 
abnormal FG assessed early after an MI, is related to long-term prognosis.
Methods: We prospectively studied the relationship between FG and long-term mortality 
in 785 nondiabetic patients presenting with acute MI. FG was obtained >8 hours fast 
within 24 hours from admission. The patients were categorized into 3 groups: 1) FG in 
the normal range (<110 mg/dL, n=472 patients), 2) impaired fasting glucose (IFG; 110-
125 mg/dL, n=151 patients), and 3) FG in the diabetes range (DM; >=126 mg/dL, n=162 
patients). Cox proportional hazards analyses were performed to determine the relation 
between categories of FG and mortality adjusting for age, sex, baseline creatinine, 
hypertension, smoking, Killip class on admission, systolic blood pressure and heart rate 
on admission, anterior infarction, previous MI and reperfusion therapy.
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Results: The median follow up was 23 months (range 6 to 42 months). Mortality rates 
were 6.2%, 17.0% and 36.6% in patients with normal FG, IFG, and FG in the DM range, 
respectively. Compared to normal FG, the adjusted RR for mortality was 2.7 in patients 
with FG in the IFG range (95% CI 1.5-4.6, P = 0.0005) and 4.5 in patients with FG in the 
DM range (95% CI 2.8-7.3, P < 0.0001).
Conclusions: FG on admission is a powerful indicator of long-term prognosis in 
nondiabetic patients with acute MI. The risk for mortality increases markedly even with 
mild elevations of FG.
7:45 a.m.
830-6 The Incidence of Provoked Spasm Using Acetylcholine 
Predicts Adverse Outcomes After Acute Myocardial 
Infarction
Kohei Wakabayashi, Nobuyuki Shimizu, Youichi Takeyama, Showa University Fujigaoka 
Hospital, Yokohama, Japan
Background: Although the prognostic value of coronary endothelial dysfunction has been 
demonstrated, there is no report regarding the prognostic signiﬁcance of the incidence of 
provoked spasm on patients after AMI.
Methods and Results: From 1999-2004, we followed the ﬁrst 220 consecutive patients 
received spasm provocation tests using acetylcholine within 14 days of AMI. Coronary 
spasm was deﬁned as transient >99% luminal narrowing. All patients were divided into 
two groups, positive group ( n=160) and negative group ( n=60). Primary end point was 
the survival free of reinfarction, revascularization, ischemic stroke, or readmission ( for 
heart failure, arrhythmia, etc) at 6 months. The event-free survival at 6 months was 81.9% 
in the positive group and 98.2% in the negative group ( p=0.019). At long-term follow 
up (mean, 39 months), survival free of death, reinfarction, revascularization, ischemic 
stroke, or readmission was 55% and 71.7% ( p=0.025). By multivariate analysis, spasm 
provocation tests were signiﬁcant, independent predictors of a poor prognosis, even after 
adjustment for traditional cardiovascular risk factors.
Conclusions: Coronary endothelial vasodilator dysfunction predicts atherosclerotic 
disease progression, ischemic stroke, and cardiovascular event rates. The incidence of 
provoked spasm will be important prognostic signiﬁcance after AMI. Spasm provocation 
tests can provide prognostic tool in patients after AMI.
8:00 a.m.
830-7 Lipoprotein-Associated Phospholipase A2 
(LpPLA2) Measured 30 Days Post-Acute Coronary 
Syndrome Independently Predicts Risk of Long-
Term Cardiovascular Outcomes: A PROVE-IT TIMI-22 
Substudy
Michelle O’Donoghue, David A. Morrow, Marc S. Sabatine, Sabina A. Murphy, Carolyn 
McCabe, Christopher P. Cannon, Eugene Braunwald, Brigham and Women’s Hospital, 
Boston, MA
Background: LpPLA2 is an independent predictor of cardiovascular events in population-
based studies. The prognostic utility of LpPLA2 in patients with acute coronary syndromes 
(ACS) has not been established.
Methods: Plasma levels of LpPLA2 activity were measured in baseline (n=3648) and 30-day 
(n=3265) samples from PROVE-IT TIMI-22, which randomized patients to atorvastatin 80 mg 
or pravastatin 40 mg after ACS. The prespeciﬁed primary endpoint was death, MI, unstable 
angina (UA), revascularization (revasc) or stroke. Mean follow-up was 24 m. We used a Cox 
model to adjust for age, risk factors, index diagnosis, LDL, C-reactive protein and study drug.
Results: Early after ACS, LpPLA2 was not associated with the primary or component 
endpoints. In contrast, patients with elevated LpPLA2 at 30 d were signiﬁcantly more likely 
to suffer the primary endpoint (Figure A, P=0.002). After adjusting, LpPLA2 remained 
a signiﬁcant predictor of MI (5th vs 1st quintile adj HR 2.0, 95% CI 1.18-3.40), death or 
MI (HR 1.7, 95% CI 1.08-2.68) and the primary endpoint (HR 1.31, 95% CI 1.00-1.72). 
Mean LpPLA2 was lower at 30 d than at baseline (40.9 vs 35.7 nmol/min/ml, P<0.001). 
Treatment with atorvastatin was associated with a 20% reduction in LpPLA2, whereas 
LpPLA2 rose 4% with pravastatin (Figure B, P<0.001).
Conclusions: LpPLA2 levels 30 days post-ACS (but not immediately post-ACS) 
independently predict a higher risk of long-term cardiovascular outcomes. Intensive statin 
therapy lowered the level of LpPLA2 by 30 days.
8:15 a.m.
830-8 Myocardial Infarction Presenting With Atypical 
Symptoms: Does the Absence of Chest Pain Predict 
Poor Outcomes?
Sarah A. Ramer, Michael J. Love, Robbie L. Stewart, Jafna L. Cox, Queen Elizabeth II 
Health Sciences Centre, Halifax, NS, Canada
Background: Patients with acute myocardial infarction typically present with a chief 
complaint of chest pain. In those patients who present atypically, diagnosis may be 
more difﬁcult. The extent to which the presence or absence of chest pain impacts on 
subsequent management and outcome is largely unknown.
Methods: We accessed the Improving Cardiovascular Outcomes in Nova Scotia (ICONS) 
registry, which contains detailed clinical information on all consecutive patients admitted 
with acute coronary syndrome or congestive heart failure in the province of Nova Scotia 
from October of 1997 to the present date. There were 6212 consecutive patients listed 
in the ICONS registry with an admission diagnosis of acute myocardial infarction (AMI) 
between the years 2000 and 2002. Patients who presented with cardiac arrest or 
cardiogenic shock were excluded.
Results: Of the 6212 patients with AMI, 5960 met our inclusion criteria. Of these, 1369 
(23%) did not have chest pain on presentation. Compared to those with chest pain, 
patients presenting with other symptoms were older (75 vs. 66 median age), more likely 
to be female (47% vs. 34%), and had higher rates of diabetes (37% vs. 27%). Patients 
presenting without chest pain had both higher in-hospital mortality (19% vs. 7%, p<0.001), 
and higher 1-year mortality rates (35% vs. 14%, p<0.001). A multivariate analysis showed 
that the absence of chest pain was an independent predictor of one-year mortality (OR 
1.53, CI 1.06-2.19). Paradoxically, this higher risk group of patients had lower rates of 
evidence-based therapy prescribed at hospital discharge including beta blockers (82% 
vs. 91%), ASA (81% vs. 89%), and statins (46% vs. 62%). Patients who presented without 
chest pain also had lower rates of revascularization at one year (11% vs. 23% for PCI, 
10% vs. 15% for CABG).
Conclusions: Patients who present with AMI in the absence of chest pain have high-risk 
baseline characteristics, including advanced age and diabetes. These patients appear 
to receive sub-optimal treatment at hospital discharge, have fewer revascularization 
procedures and experience more than double the mortality at 1-year follow-up when 
compared with patients who present with chest pain.
ORAL CONTRIBUTIONS
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7:00 a.m.
836-3 Better Guideline Compliance With Medical Therapy 
Seen in Patients With Prior Coronary Revascularization: 
Results From the REduction of Atherothrombosis for 
Continued Health (REACH) Registry
Christopher P. Cannon, Benjamin A. Steinberg, P. Gabriel Steg, Deepak L. Bhatt, Gregg 
C. Fonarow, Uwe Zeymer, on behalf of the REACH Registry Investigators, Brigham & 
Women’s Hospital, Boston, MA
Background: The REACH Registry involves outpatients with documented 
atherothrombosis, and will assess their treatment and long-term outcomes. To evaluate 
current compliance with recommendations for medical therapy in coronary artery disease 
(CAD) patients, the relationship between prior revascularization and use of guideline-
recommended therapies was investigated.
Methods: From over 5,000 outpatient practices, in 44 countries worldwide, the baseline 
characteristics and medical therapy of 40,258 patients with documented CAD, (deﬁned as 
prior MI, PCI, CABG, or history of unstable angina or angina requiring medical therapy), 
were compared by prior revascularization was compared.
Results: Approximately 1/3 of patients had prior CABG, 1/3 prior PCI and 1/3 had no prior 
revascularization. Patients with prior CABG were older, and often male and diabetic. Prior 
PCI patients were youngest (Table 1). Guideline-recommended medical therapy use was 
signiﬁcantly higher in those with prior revascularization. Angiotensin-converting enzyme 
inhibitors (ACEI) and angiotensin receptor blockers (ARB) were used in similar ratios 
between treatment groups.
Conclusions: Prior revascularization appears to be associated with better use of 
guideline-recommended medical treatment. Whether treatment by cardiologists or greater 
awareness of CAD is a factor deserves further research. Use of guideline-recommended 
therapies, especially beta-blockers and statins, needs to increase. 
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Age (mean, years) 69.5 66.2 68.9 <0.0001
Female (%) 23.1 27.7 39.6 <0.0001
Diabetes (%) 37.3 30.4 33.6 <0.0001
Prior medical treatment
At least one antiplatelet (%) 86.3 91.3 79.5 <0.0001
Warfarin (%) 16.8 10.1 13.3 <0.0001
At least one antithrombotic (%) 95.0 96.0 88.0 <0.0001
Beta-blocker (%) 64.5 65.7 55.5 <0.0001
ACEI (%)
ARB (%)













Statin or other lipid-lowering agent 
(%) 86.2 86.5 70.4 <0.0001
7:15 a.m.
836-4 Self-reported Medication Adherence Predicts 
Cardiovascular Outcomes in Patients With Stable 
Coronary Disease: The Heart and Soul Study
Anil K. Gehi, Sadia Ali, Mary A. Whooley, Mount Sinai School of Medicine, New York, NY, 
University of California San Francisco, San Francisco, CA
Background: Non-adherence to cardiac treatment recommendations is associated with 
adverse cardiovascular (CV) events following myocardial infarction (MI). It is not known 
whether medication adherence predicts CV outcomes in patients with stable coronary 
heart disease (CHD), or whether this association is independent of traditional CV risk 
factors.
Methods: We assessed medication adherence in 1019 outpatients with stable CHD who 
were enrolled in the Heart and Soul study by asking, “In the past month, how often did you 
take your medications as the doctor prescribed?” Possible responses were: all of the time 
(100%), nearly all of the time (90%), most of the time (75%), about half the time (50%), 
or less than half the time (<50%). Non-adherence was deﬁned as taking medications as 
prescribed 75% of the time or less. CV events were deﬁned as CHD death, MI, or stroke 
during 3 years of follow-up. We examined the association of medication non-adherence 
with CV events using multivariate logistic regression, adjusting for potential confounding 
variables.
Results: Among non-adherent participants, 20% (17/84) had an adverse CV event, 
compared with 11% (105/935) of adherent participants (p=0.02). Medication non-
adherence remained associated with adverse CV events after adjusting for traditional 
CV risk factors (odds ratio (OR) 2.6, 95% conﬁdence interval (CI) 1.3-5.5; p=.009). 
The increased risk of CV events associated with non-adherence was greater than that 
associated with hypertension (OR 1.5, 95% CI 0.9-2.7; p=.13) or diabetes (OR 1.8, 95% 
CI 1.1-2.9; p=.02).
Conclusion: Medication non-adherence independently predicts adverse CV events in 
patients with stable CHD. The risk associated with non-adherence is greater than the risk 
associated with diabetes or hypertension. Medication adherence may be a critical target 
for improving cardiovascular outcomes in patients with stable CHD.
7:30 a.m.
836-5 Statin Use and Low-Density Lipoprotein Cholesterol 
Goals in 2004: How Are We Doing Applying National 
Cholesterol Education Program III Guidelines?
Benjamin A. Steinberg, Philip O’Hagan, Philip Chadwell, Graham Turner, Christopher 
P. Cannon, Brigham & Women’s Hospital, Boston, MA, TNS Healthcare, Epsom, United 
Kingdom
BACKGROUND: Following the NCEP recommendations, it has been unclear as to how 
many patients with indications for use of statins are taking them, and whether patients are 
reaching their low-density lipoprotein cholesterol (LDL-C) goals.
METHODS: CardioMonitor is a sample of 4,676 outpatients with cardiovascular disease 
(CVD) from 250 primary care physicians and 50 cardiologists, regionally representative. 
Extrapolation to the entire U.S. population was performed using weighting methodology 
based on each physician as representative of the physician population and each patient 
based on proportion of workload and frequency of consultation. Patients with CAD 
or equivalent and those with 2 or more risk factors were identiﬁed based on NCEP III 
guidelines. LDL-C levels and statin use were compared to NCEP III targets for each group.
RESULTS: This survey estimates approximately 67.2 million patients have CVD or CAD 
risk factors, and 35.1 million with CAD or equivalent. Although 60% were on a statin, 48% 
still had LDL-C levels greater than the NCEP III target, 100 mg/dL. Only 7.1% were on 
high-dose therapy (80 mg atorvastatin or simvastatin, ≥20 mg of rosuvastatin) (Table 1). 
Of the 26.4 million patients with 2 or more risk factors, 24% had LDL-C levels greater than 
the goal of 130 mg/dL, despite 33% already taking a statin.
CONCLUSION: In 2004, despite well-deﬁned goals, LDL-C levels remain substantially 
above the goal in the highest risk patients, and more aggressive treatment and dose 










On High-dose Statin: 
80 mg atorvastatin/
simvastatin, ≥20 mg 
rosuvastatin (%)
CAD 23.4 64.5 56.7 8.3
PAD 5.0 59.3 53.7 9.5
Cerebrovascular Disease 4.1 50.6 51.0 6.0
DM 15.8 54.8 50.8 6.0
Any >0 of the Above 35.1 59.6 52.3 7.1
7:45 a.m.
836-6 Older Patients Receive the Greatest Beneﬁt From the 
Initiation of Anti-hypertensive Agents in the Setting of 
Coronary Artery Disease and Normal Blood Pressure
Stephen J. Nicholls, Ilke Sipahi, Paul Schoenhagen, Paul Thompson, David Frid, 
Harry Shi, Kamlesh M. Thakker, E. Murat Tuzcu, Steven E. Nissen, Cleveland Clinic 
Foundation, Cleveland, OH, Pﬁzer Global Pharmaceuticals, New York, NY
Background: Increasing age is a predictor of clinical outcome in patients with coronary 
artery disease (CAD). A number of well-established therapies for secondary prevention 
are underutilized in these patients. Lowering of blood pressure in apparently normotensive 
patients with CAD has been reported to be beneﬁcial. This study assessed the impact of 
age on the clinical beneﬁt of this strategy.
Methods: 1991 patients with angiographically documented CAD and diastolic blood 
pressure <100 mmHg received amlodipine 10mg daily, enalapril 20mg daily or placebo 
for 24 months in the Comparison of Amlodipine versus Enalapril to Limit Occurences of 
Thrombosis (CAMELOT) study. The impact of baseline age greater or less than the mean 
(57.7 years) on the incidence of major adverse cardiac events (MACE) was assessed.
Results: In the older patients (n=980) the incidence of MACE compared with placebo 
was reduced by 40% (16 v 25%, p=0.004) by amlodipine and 23% (20 v 25%, p=0.12) by 
enalapril. This beneﬁt of amlodipine was driven by a 57% reduction in hospitalization for 
angina (6 v 13%, p=0.002). Nonsigniﬁcant reductions were also noted in hospitalization 
with enalapril by 20% (11 v 13%, p=0.33) and coronary revascularization with amlodipine 
by 33% (11 v 16%, p=0.07) and enalapril by 23% (12 v 16%, p=0.22). In younger patients 
(n=1011), however, amlodipine resulted in a nonsigniﬁcant reduction in MACE (18 
v 22%, p=0.18) while there was no clinical beneﬁt with enalapril (21 v 22%, p=0.90). 
Neither antihypertensive agent signiﬁcantly reduced the incidence of nonfatal myocardial 
infarction, regardless of age.
Conclusion: Lowering of blood pressure with amlodipine in apparently normotensive 
patients with CAD exerts its greatest clinical beneﬁt in older patients. Given the high 
incidence of CAD associated morbidity in the elderly, the current results suggest that 
such interventions can have a profound beneﬁt. This provides further evidence to support 
the need for aggressive treatment of hypertension in patients with established CAD, 
regardless of age.
8:00 a.m.
836-7 Long-Term Adherence to the ACC/AHA Class I Post-
Discharge Medications and Recommendations Using 
Multifaceted Medical Therapy in 2287 Patients With 
Established Coronary Heart Disease: Interim Data From 
the Clinical Outcomes Utilizing Revascularization and 
Aggressive Drug Evaluation (COURAGE) Trial
Marcin Dada, Robert A. O’Rourke, Koon K. Teo, Pamela M. Hartigan, Merril Knudtson, 
William Kostuk, David J. Maron, Paul Casperson, William S. Weintraub, William E. 
Boden, Hartford Hospital, Hartford, CT
Background: Despite scientiﬁc evidence from multiple randomized controlled trials 
(RCT) that individual secondary prevention interventions reduce morbidity and mortality, 
few studies have evaluated long-term intervention with multiple ACC/AHA recommended 
therapies in patients with established coronary heart disease (CHD). Our purpose was to 
compare adherence to comprehensive treatment guidelines at baseline and at 48-months 
of follow-up in patients with chronic CHD enrolled in the COURAGE trial.
Methods: COURAGE is a large multicenter North American RCT comparing 
percutaneous coronary intervention plus aggressive medical therapy versus aggressive 
medical therapy alone during a median 5 year follow-up. Medical therapy in both arms 
conforms with current ACC/AHA treatment guidelines and includes aspirin, clopidogrel, 
long-acting metoprolol and/or amlodipine, lisinopril, and simvastatin. Treatment targets 
include systolic (S) and diastolic (D) BP<130/85 mmHg, LDL-cholesterol 60-85 mg/dL, 
AHA step II diet, and exercise 5 times/week. Medical therapy and multiple risk factor 
intervention is protocol-driven and delivered by nurse case managers at each site.
Results: Compared to baseline rates of therapy, data at 48 months show improvement in 
the use of anti-platelet agents (91% vs 96%), beta blockers (73% vs 85%), antihypertensive 
agents (calcium blockers 31% vs 46%, ACE inhibitors 49% vs 64%, and angiotensin II 
receptor blockers 4% vs 13%), and statins (71% vs 96%). There was also substantial 
improvement in attaining follow-up treatment targets for LDL (25% vs 66%), SBP (40% 
vs 59%), DBP (82% vs 90%), AHA step II diet (53% vs 77%), and exercise (23% vs 39%) 
when compared to baseline data.
Conclusions:Increased adherence to ACC/AHA class I post-discharge medications 
and recommendations in the COURAGE trial is associated with improved multiple risk 
factor goal attainment, and provides a real-world model for this approach in patients with 
established CHD.
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836-8 African Americans With Chronic Angina: Risk Factors 
and Treatment Proﬁles Compared to Caucasians
George W. Vetrovec, Susan Meyhan, Jennifer Watson, Bernard Chaitman, Robert Cody, 
Nanette Wenger, VCU Medical Center, Richmond, VA, CV Therapeutics, Palo Alto, CA
Background: Management of patients with chronic angina (CA) remains a signiﬁcant 
clinical problem. In particular, contemporary patient (pt) demographics and treatment 
descriptions are limited, particularly comparing outcomes African Americans (AA).
Methods: To assess current CA pt proﬁles, we retrospectively surveyed 32 cardiology 
practices. A majority of practices were private, but 29% were academic and represented 
diverse US locations: 44% from the Midwest, 31% from the South and 12.5% each from 
the West and Northeast. Outpatient charts of pts with a diagnosis of angina seen at least 
yearly were randomly selected at each site. Local staff abstracted standardized data with 
oversight by a trained nurse who assured consistent data collection at all sites.
Results: Data were available for 1,957 pts (>35 yrs of age with 65% male) 92% of whom 
experienced at least one episode of angina a month. Of this population 489 (25%) were 
African American (AA). Mean age for AA was 63.0 + 12.8 (SD); for Caucasians (C) 
67.1+12.5 yrs. Risk factor comparisons for AA vs. C: HBP 81% vs. 68%, Diabetes 40 
vs. 30%, CHF 31 vs. 16%, COPD 11 vs. 13% demonstrating a higher overall risk proﬁle 
for AA. Conversely, Revascularization was less frequent for AA: 37.5 vs. 60.1 % (PCI 
- 38 vs. 42%; CABG - 16 vs. 32%) while AA tended to be on more chronic anti-anginal 
medications than C: 95.4 vs. 88.3%. Relative to symptoms, AA had more angina than C: 
95.9 vs. 89.6%. 
Conclusion: Data from this national chart review demonstrate that AA with chronic angina 
tend to be younger but have more angina, more risk factors and less revascularization 
compared to C, suggesting that AA patients warrant better treatment strategies.
POSTER SESSION
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994-215 The PPAR-α Activator, Fenoﬁbrate, Fails to Provide 
Myocardial Protection in Ischemia-reperfusion  
Injury in Pigs
Ya Xu, Li Lu, Clifford Greyson, Mona Rizeq, Karin Nunley, Michael R. Bristow, Carlin 
S. Long, Gregory G. Schwartz, VA Medical Center and University of Colorado Health 
Sciences Center, Denver, CO
Background: Peroxisome proliferator-activated receptor-alpha (PPAR-α) is expressed 
in myocardium. Rodent studies suggest that PPAR-α activation reduces myocardial 
ischemia-reperfusion (I/R) injury and infarct size; however, effects of PPAR-α activation 
in large animal models of myocardial I/R are unknown. We determined whether chronic 
treatment with the PPAR-α activator, fenoﬁbrate, affects myocardial I/R injury in pigs.
Methods: Domestic farm pigs (n=66) were assigned to treatment with fenoﬁbrate 50 
mg/kg/d orally or no treatment, with either a low fat diet (4% fat by weight) or a high fat diet 
(20% fat by weight). After 4 weeks of treatment, pigs underwent 90 min low-ﬂow regional 
myocardial ischemia and 120 min reperfusion under anesthetized open-chest conditions, 
resulting in myocardial stunning. Elevated levels of free fatty acids were maintained in 
the high fat group by infusion of triglyceride emulsion and heparin during the terminal 
experiment. An additional 21 pigs underwent 60 min no-ﬂow ischemia and 180 min 
reperfusion, resulting in myocardial infarction.
Results: Fenoﬁbric acid plasma concentration averaged 11 µg/ml, similar to the EC50 
for activation of PPAR-α in vitro and to maximal concentrations achieved in clinical use. 
Myocardial expression of PPAR-α mRNA was prominent, but unaffected by fenoﬁbrate 
treatment. Fenoﬁbrate treatment signiﬁcantly decreased arterial free fatty acid concentration 
and myocardial expression of interleukin-1β (p<0.01). However, in contrast to the beneﬁcial 
effects reported in rodent models, fenoﬁbrate had no effect on LV contractile function after 
low-ﬂow I/R or on infarct size after no-ﬂow I/R in this large animal model. Moreover, there 
was no effect of fenoﬁbrate treatment on myocardial substrate uptake, lipid accumulation, or 
expression of cytokines interleukin-6 or interferon-γ in either diet group.
Conclusions: Despite expression of PPAR-α in porcine myocardium, the PPAR-α 
activator fenoﬁbrate does not alter myocardial metabolic or contractile responses in I/R.
994-216 Pyrroloquinoline Quinone (PQQ) and/or Metoprolol 
Decrease Infarct Size and Improve Mitochondrial 
Function in a Rat Model of Ischemia/Reperfusion
Bo-Qing Zhu, Ursula Simonis, Hui-zhong Zhou, Luyi Li, John R. Teerlink, Joel S. 
Karliner, University of California, San Francisco, San Francisco, CA, San Francisco 
State University, San Francisco, CA
Background: Previous studies showed that PQQ is cardioprotective. In this study we 
asked: 1) Is metoprolol as effective as low dose PQQ in reducing infarct size and in 
preventing mitochondrial damage? 2) Are PQQ plus metoprolol additive in their effects? 
Methods: Intact male rats were subjected to 30 min of LAD occlusion and 2 hours of 
reperfusion with LV hemodynamic monitoring. Metoprolol (1mg/kg) and/or PQQ (3mg/
kg) were given by i.v. injection at the onset of reperfusion to mimic clinical treatment. 
After ischemia/reperfusion (I/R), we measured the respiratory control ratios (RCR) of 
intact mitochondria from anterior ischemic and posterior non-ischemic myocardium and 
malondialdehyde (MDA) concentrations as a maker for lipid peroxidation. 
Results: Metoprolol and/or PQQ reduced infarct size (infarct mass/risk area) and 
protected against ischemia-induced LV dysfunction after 1-2 hours of reperfusion, as 
evidenced by increased LV developed pressure and decreased LVEDP. Compared to 
I/R, metoprolol and/or PQQ decreased CK release and enhanced mitochondrial RCR 
in both ischemic and non-ischemic myocardium. Only PQQ alone decreased MDA in 
myocardium. 
Conclusions: Metoprolol and/or PQQ given at the onset of reperfusion are highly 
effective in reducing infarct size and improving cardiac function. PQQ/metoprolol 
combination therapy may further reduce infarct size. PQQ is superior to metoprolol in 
protecting mitochondria and in reducing lipid peroxidation.
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(497±141*) 3.0±1.7** 105±2** 4.5±0.5* 6.5±0.3 260±9 232±9
Sham




0 4.6±2.4* 99±6 9.2±0.4** 9.3±0.4** 61±12** 61±12**
Date are Mean±SEM. MP = Metoprolol. Change in CK = CK at end reperfusion minus baseline value. * P<0.05, ** 
P<0.01 vs. I/R (Ischemia/Reperfusion).
 
994-217 Stromal Cell-Derived Factor-1 Stimulates the Survival 
and Proliferation of Sca-1+ Mesenchymal Stem Cells 
Derived From Mouse Bone Marrow
Seung-Cheol Choi, Chi-Youn Park, Ji-Hyun Choi, Jihyun Yoon, Young-Hoon Kim, Wan-Joo 
Shim, Young-Moo Ro, Do-Sun Lim, Korea University Medical Center, Seoul, South Korea
Background: Stromal cell-derived factor-1 (SDF-1) and its CXCR4 receptor have been 
reported to play several roles in mobilization of bone marrow stem cells to the injured 
heart, cell migration and apoptosis in certain hematopoietic and neuronal cells. Here we 
show that SDF-1 promotes the survival and growth of MSCs derived from mouse bone 
marrow. 
Methods: MSCs isolated from bone marrow of ICR (6 to 8-wk-old) mice were cultured 
for 7 days in vitro to deplete hematopoietic lineage cells. Sca-1+ MSCs were puriﬁed 
by magnetic-activated cell sorting system and exposed to 0.2 mM H2O2 in the absence 
or presence of 100 ng/ml SDF-1. The phenotype characteristics and multipotentiality 
of Sca-1+ MSCs were analyzed. The cell viability was determined by the MTT assay. 
Cell proliferation was assayed by BrdU labeling, while Annexin V-binding positive cells 
undergoing early apoptotic process was detected by ﬂow tometry. 
Results: Flow cytometry assay indicated that 9.2% of Sca-1+ MSCs expressed CD45, and 
< 2.0% of the cells expressed CD34 and c-kit. Sca-1+ MSCs differentiated into adipocytes or 
osteocytes after treatment with speciﬁc induction medium for 3 weeks in vitro. Co-incubation 
with SDF-1 signiﬁcantly reduced the number of H2O2-induced annexin V-positive cells (8.9% 
in the control group vs. 9.2% in the SDF-1-treated group vs. 29.6% in the H2O2-treated 
group vs. 18.1% in the SDF-1+H2O2-treated group, p<0.05). BrdU labeling cell proliferation 
assay indicated that SDF-1 stimulated cell proliferation of H2O2-treated Sca-1
+MSCs at 48 h 
(Optical density: 0.59 ± 0.02 in the H2O2-treated group vs. 0.71 ± 0.02 in the SDF-1+H2O2-
treated group, p<0.05), and at 72 h (0.66 ± 0.01 in the H2O2-treated group vs. 0.79 ± 0.03 in 
the SDF-1+H2O2-treated group, p<0.05). MTT assay also showed that SDF-1 increased cell 
viability of Sca-1+ MSC during H2O2-induced apoptosis. 
Conclusions: These results showed that SDF-1/CXCR4 signaling has cytoprotective 
and anti-apoptotic effects against H2O2-induced MSC injury. The transplantation of MSCs 
expressing SDF-1 into infarcted myocardium will promote survival of transplanted MSCs 
as well as regeneration of host myocardium by inhibiting apoptotic process.
994-218 Mobilization of Bone Marrow Mesenchymal Stem Cells 
in Response to Myocardial Ischemia Depends on the 
Duration of the Coronary Occlusion and Reperfusion in 
Pig Myocardial Infarction Model
Silvia Charwat, Serdar Farhan, Johannes Matiasek, Noemi Pavo, Rita Garamvolgyi, 
Zsolt Petrasi, Akos Hevesi, Sabine Steiner-Boker, Christoph Kopp, Dietmar Glogar, 
Johann Wojta, Kurt Huber, Mariann Gyongyosi, Medical University of Vienna, Vienna, 
Austria, University of Kaposvar, Kaposvar, Hungary
Background. The aim of the present study was to investigate the effect of ischemic 
preconditioning on the mobilisation of BM haematopoietic and mesenchymal SCs in 
porcine coronary occlusion/reperfusion model.
Methods. Catheter-based coronary occlusion followed by reperfusion was performed in 17 
pigs (Group AMI). Preconditioning was obtained in 18 pigs (Group P) by 2 cycles of 5 min of 
balloon occlusion of LAD with 2 cycles of 5 min interval of reperfusion before the coronary 
occlusion (duration between 30 and 90 min) and reperfusion (duration between 30 and 60 
min). End-diastolic and end-systolic volumes calculated from the area-length method of 
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echocardiography served for the evaluation of the global left ventricular ejection fraction. 
Plasma levels of troponin I and myoglobin were measured after the end of the reperfusion 
by using ELISA kits. CD31+, CD 45+, CD90+, and CD44+ cells, as representatives of BM 
haematopoietic and mesenchymal SCs, were taken at baseline and at the end of ﬁnal 
reperfusion from venous blood and counted by whole blood ﬂow cytometry.
Results. The relative increase (ratio of post-ﬁnal reperfusion and baseline values) in 
haematopoietic SC concentration was observed in both groups (132+/-96% vs. 105+/-
38% in Groups AMI and P). Mobilization of mesenchymal SC was observed only in Group 
AMI but not in Group P (155+/-176% vs. 80+/-19%, p<0.05). A trend towards higher 
global ejection fraction (41±11% vs 35±10%), less troponin I (11.3±16.0 vs 24±45 ng/ml) 
and myoglobin (578±869 vs 1295±1643, ng/ml) was observed in Group P. The relative 
increase of the mesenchymal stem cells correlated positively linearly with the duration of 
the coronary occlusion+reperfuion (r=0.518, p=0.05) and troponin I (r=0.731, p<0.001) 
only in group AMI. The duration of coronary occlusion did not inﬂuence the mobilization 
of the BM SCs in group P.
Conclusions. Ischemic preconditioning attenuates the mobilization of mesenchymal BM 
SCs in porcine myocardial infarctus model. A direct link between the duration of the 
myocardial ischemia followed by reperfusion and the mobilisation of mesenchymal SCs 
after the infarction without preconditioning could be observed.
994-219 Myocyte Bag-1 Provides Endogenous Cardioprotection 
Following Relocation From the Cytoplasm to the 
Nuclei in the Rat Heart Exposed to in vivo Ischemia/
Reperfusion Injury
Paul Townsend, Dane Jeﬁc, John Abboud, Yassar Almanaseer, Mohamed Jabaren, 
Julius Gardin, Riyad Fares, Riccardo Raddino, Howard Rosman, Louis Saravolatz, 
Zuhair Allebban, Rowena Angeles, Joshua Martindale, Carol Chen-Scarabelli, 
Tiziano Scarabelli, St John Hospital/Wayne State University, Detroit, MI, University of 
Southhampton, Southhampton, United Kingdom
Background: BAG-1 is a family of proteins, which promotes cell survival and modulates 
chaperone activity, by interacting with a wide range of cellular targets. Aim of this study is 
to examine the level of protein expression and the subcellular distribution of BAG-1 in the 
rat heart exposed to in vivo ischemia(I)/reperfusion(R) injury.
Methods and Results: By immunohystochemistry, in rat tissue sections from control 
hearts, nuclear and cytoplasmic BAG-1 positive staining was observed in 50.2+/-3.7% 
of the total myocyte population; while 24.3+/-1.8% of cardiac cells showed exclusive 
BAG-1 cytoplasmic localization. Interestingly, in rat hearts exposed to 35 mins of regional 
I followed by 120 mins R, nuclear and cytoplasmic BAG-1 positive staining was seen 
contemporaneously in a small percentage of cardiac cells (11.7+/-3.1%). Conversely, 
compartmental distribution of myocyte BAG-1 was signiﬁcantly increased in the nuclear 
compartment (83.4+/-6.3%), and consensually reduced in the cytoplasm (15.1+/2.6%), 
suggesting that BAG-1 can actively relocate from the cytoplasm to the nuclei of cardiac 
cells undergoing I/R injury. Importantly, TUNEL positive staining, which was extended 
to 5.8+/-1.8% of the entire myocyte population, was never detected in cardiac cells 
exposed to I/R showing exclusive distribution of BAG-1 in the nuclear compartment, or 
combined nuclear/cytoplasmic BAG-1 staining. On the contrary, TUNEL positive labelling 
consistently colocalized with BAG-1 cytoplasmic staining in cardiac cells in which post-
ischemic expression of BAG-1was limited to the cytoplasm, suggesting that BAG-1 
relocation from the cytoplasm to the nuclei of cardiac cells exposed to I/R injury can 
provide myocyte with an intrinsic mechanism of cardioprotection.
Conclusions: In conclusion, we showed for the ﬁrst time in the intact rat that BAG-
1 relocates from the cytoplasm to the nuclei of cardiac cells exposed to I/R injury; in 
addition, we also provide ﬁrst evidence at the cellular level that this relocation represents 
a powerful mechanism of endogenous cardioprotection.
994-220 Delta Protein Kinase C Antagonist Given Systemically 
at Reperfusion is Cardioprotective
Luyi Li, Bo-qing Zhu, Leon Chen, Daria Mochly-Rosen, John R. Teerlink, Joel S. 
Karliner, University of California San Francisco, San Francisco, CA, Stanford University, 
Palo Alto, CA
Background: Epsilon protein kinase C (PKC)-selective activator peptide mimics 
ischemic preconditioning and a delta-PKC-selective inhibitor peptide (deltaV1-1) prevents 
reperfusion injury in isolated perfused rat and porcine heart, when given either by aortic 
injection or introcoronary infusion. We investigated the effect of a delta-PKC peptide 
inhibitor linked to the TAT peptide (KID-1, Kai Pharmaceuticals) on cardioprotection in an 
in vivo rat model of ischemia / reperfusion injury. 
Methods: Ischemia was induced by 30-min left anterior descending artery occlusion and 
followed by 2 hours of reperfusion. The delta-PKC antagonist was given intravenously 
via a femoral vein during the last 2 min of ischemia and the ﬁrst 2 min of reperfusion. 
Hemodynamics were continuously monitored via a catheter inserted into left ventricle 
(LV). Infarct size was measured using triphenyltetrazolium staining and expressed as a 
percentage of the total LV area at risk. 
Results: KID-1(4.8mg/kg) signiﬁcantly reduced infarct nsize (P<0.05), without systemic 
hemodynamic effects as measured by LV developed pressure and dP/dt. KID-1 also 
decreased creatine kinase (CK) release (p<0.05) and improved hemodynamic function. 
Conclusions: There are the ﬁrst data to show that a delta-PKC peptide antagonist given 
by peripheral injection at the time of reperfusion protects against injury in the intact blood-
reperfused rat heart.
Groups CK (U/L) Infarct size (%)
Open chest 2h reperfusion Fold-increase % AAR/LV %IS/LV %IS/AAR
Control




345±61 1158±288 3.8* 65.6±7.8 14.92±1.6* 22.92±3.1*
LV Developed Pressure (mmHg) LV dP/dt (mmHg/sec)
Baseline Occlusion 2h reperfusion Baseline Occlusion 2h reperfusion
Control




116.1±10.4 86.7±17.9 89.5±9.0 6891±1580 4035±1309 6450±1982
Value are mean±SD IS = infarct size AAR = area at risk * P<0.05 vs Control
 
994-221 Reduction of Nitrite to Nitric Oxide in Ischemic Heart 
Is Catalyzed by Distinct Blood-Borne and Tissue 
Elements
Patrick H. McNulty, Soﬁa Scott, Mark Kozak, Lisa A. Harach, Lawrence I. Sinoway, 
Jianhua Li, Penn State College of Medicine, Hershey, PA
Background: Nitric oxide (NO) protects hearts from ischemic injury by slowing 
mitochondrial permeability transition. Mechanisms which generate NO within ischemic 
myocardium are thus of interest. We hypothesized that one such mechanism is reduction 
of nitrite anion (NO2), and that NO2 reductases in both erythrocytes and the endothelium 
catalyze this reaction. 
Methods: Rat hearts were excised and ﬁnely minced either before (Sanguinous) 
or after (Asanguinous) perfusion to remove erythrocytes. Samples were incubated 
with 100 µM NO2 at various pO2 and pH, and NO2 reduction to NO measured by 
chemiluminescence. 
Results: As shown in the Table, deoxygenating Sanguinous samples increased the rate 
at which they reduced NO2 to NO by ~14-fold, whereas lowering pH to 5.0 or incubating 
with 100µM of the endothelial xanthine oxidoreductase (XOR) inhibitor allopurinol 
had little effect. In contrast, NO2 reduction by Asanguinous samples was slower and 
insensitive to oxygenation, but accelerated ~8-fold when pH was lowered to 5.0, and this 
was partly blocked by allopurinol. 
Conclusions: Both blood and tissue catalysts may reduce NO2 to NO within ischemic 
rat heart. The blood catalyst is likely hemoglobin, which becomes a NO2 reductase 
during hypoxia. Tissue catalysts include both endothelial XOR and allopurinol-insensitive 
enzymes, which become NO2 reductases during acidosis. These catalysts may be targets 
for novel treatments of myocardial ischemic injury. 












Sanguinous 5+5 85+35 * 97+60 * 70+36 * 6+15
Asanguinous -4+10 4+14 36+22 * 28+18 * + 0+11
* p<0.05 vs. Oxygenated; + p < 0.05 vs. without allopurinol
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995-222 Intravenous Nicorandil Immediately Before 
Percutaneous Coronary Intervention can Prevent Slow/
no-reﬂow Phenomenon
Yusuke Kawai, Yoshihisa Fujimoto, Kenichi Hisamatsu, kazuhiro Dan, Youko Ikeda, 
Satoshi Akagi, Naoto Tokunaga, Eiji Taguchi, Katsumasa Miyaji, Mitsuru Munemasa, 
Hiromi Matsubara, Hiroshi Mikouchi, National Hospital Organization Okayama Medical 
Center, Okayama, Japan
Background: It has been reported that slow/no-reﬂow phenomenon is a poor prognostic 
factor in percutaneous coronary intervention (PCI). Although slow/no-reﬂow phenomenon 
in acute myocardial infarction (AMI) can be improved by intracoronary administration of 
nicorandil, procedure for preventing the phenomenon in coronary artery disease including 
angina pectoris (AP) has not yet established.
Methods: Our preliminary study in 12 patients indicated that 6 mg of intravenous 
nicorandil signiﬁcantly increased coronary ﬂow compared with 1 mg and 3 mg of 
intravenous nicorandil, without lowering systemic blood pressure. Thus, 293 patients 
performed emergent (n=51) or elective (n=242) PCI were randomly assigned to receive 
intravenous administration of 6 mg nicorandil immediately before ballooning. The number 
of nicorandil group was 109 including 16 patients with AMI and 93 patients with AP, and 
that of control group was 184 including 35 patients with AMI and 149 patients with AP. 
Baseline characteristics including age, gender and atherosclerotic risk factors, and the 
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incidence of slow/no-reﬂow phenomenon were compared between two groups.
Results: 32 patients were complicated slow/no-reﬂow phenomenon during PCI. None of 
the baseline characteristics including atherosclerotic risk factors were related to slow/no-
reﬂow phenomenon. Incidence of postprocedural slow/no-reﬂow phenomenon (TIMI 0 to 
2) was signiﬁcantly lower in nicorandil group than control group (3 patients, 2.8% vs. 29 
patients, 15.8%; p<0.001). In patients with AMI, slow/no-reﬂow phenomenon occurred in 
0% of nicorandil group and in 31.4% (11 patients) of control group (p<0.05). In patients 
with AP, slow/no-reﬂow phenomenon occurred in 3.2% (3 patients) of nicorandil group 
and in 12.1% (18 patients) of control group (p<0.05).
Conclusions: Intravenous nicorandil immediately before PCI can prevent slow/no-reﬂow 
phenomenon not only in patients with AMI but also in patients with AP.
995-223 Can Greater Inhibition of Platelet Aggregation be 
Tolerated? Evaluation of the Bleeding Risk of AZD6140 
Compared with Clopidogrel (CLOP) in Patients with 
Acute Coronary Syndromes (ACS)
Hakan Emanuelsson, Kenneth W. Mahaffey, Robert A. Harrington, Steen Husted, 
Robert F. Storey, Nick Sanders, Gary Peters, Christopher P. Cannon, AstraZeneca R&D, 
Molndal, Sweden
Background: AZD6140 is the ﬁrst oral reversible P2Y12 receptor antagonist and has 
been shown to have greater and more consistent inhibition of platelet aggregation 
compared to CLOP. This analysis of the DISPERSE2 study assessed if this increased 
pharmacodynamic effect is associated with increased bleeding risk.
Methods: Non-ST segment elevation ACS patients were randomized to AZD6140 90mg 
bid (AZD90), AZD6140 180 mg bid (AZD180) or CLOP 300 mg loading dose if needed, 
then 75 mg daily for up to 12 weeks. Half of the patients in each AZD6140 group received 
a 270 mg loading dose (AZD270). The primary endpoint of major and minor bleeding 
events at week 4 was adjudicated centrally using modiﬁed CURE deﬁnitions. 
Results: See table for primary endpoint results. Across groups, 66 % of patients had 
diagnostic coronary angiography, 42% PCI and 9% CABG. There were no consistent 
differences in bleeding events between the AZD6140 doses and clopidogrel for subgroups 
based on sex, age (<65 vs >65 years), weight (<70 kg vs >70 kg), clopidogrel pretreatment 
or glycoprotein IIb/IIIa inhibitor use. The AZD270 loading dose was also well tolerated 
as evaluated by occurrence of bleeding and other adverse events over 48 hours after 
administration. Most of the major bleeding events observed were associated with CABG.
Conclusions: Major and minor bleeding events occurred at similar rates in all patient 
groups. This suggests that AZD6140 therapy is well tolerated across a broad range of 
patient characteristics and background therapies. 
Adjudicated Bleeds - Week 4
Category AZD90 (n=334) AZD180 (n=323) CLOP (n=327)
n % n % n %
Total 32 9.6 25 7.7 26 8.0
Major 23 6.9 16 5.0 22 6.7
Minor 9 2.7 12 3.7 4 1.2
Procedure related 18 5.4 12 3.7 19 5.8
 
995-224 Statins in Acute Coronary Syndrome: A Meta-analysis
Jahandar R. Saleh, Ramin Ebrahimi, Atman P. Shah, Nitin Wadhani, Edward J. Toggart, 
UCLA/West Los Angeles VA, Los Angeles, CA
Background: The use of statins in patients at risk of or with known coronary artery 
disease is well accepted and recommended based on ACC/AHA guidelines. The early 
and aggressive use of these agents, however in patients with acute coronary syndromes 
(ACS) is not well deﬁned. The purpose of this study was to deﬁne the efﬁcacy of early and 
aggressive use of statins in patients with ACS in the form of a pooled analysis.
Methods: A search of the medline, cochran database and proceedings of medical 
journals from 1994-2005 was conducted to include prospective randomized blinded trials 
in patients with ACS that tested early and aggressive use of statins in such patients. 
Patients had a follow-up of at least three months. Standard cardiovascular endpoints such 
as death, myocardial infarction (MI), ischemia and stroke were analyzed.
Results: Four trials, MIRACL (n=3086), TIMI 22 (n=4162), and A to Z (n=4497) and a study 
by Chang (n=119) totaling 11,864 patients ﬁt the above criteria and were included in the 
meta-analysis. The overall risk difference in the aggregate primary endpoint (death from 
any cause or MI or cardiac arrest or ischemia or stroke) is -2.96% (early aggressive minus 
conservative treatment) P value < 0.001, 95% conﬁdence interval for true risk difference 
(-4.24% to -1.48%) with relative risk reduction (RRR) of 15%. All cause mortality reported 
in 3 studies showed overall risk difference of -0.84% (early aggressive minus conservative 
treatment) P value =0.0184, 95% conﬁdence interval for true risk difference (-1.55% to 
-0.14%) with a RRR of 4%.
Conclusion: Based on the result of this pooled analysis, early and aggressive use of 
statins in patients with ACS results in signiﬁcant reduction in major cardiovascular 
endpoints and should be considered strongly in such patients.
995-225 Better Coronary Flow in Culprit Lesions With Deep 
Echo Attenuation Treated by Directional Coronary 
Atherectomy
Tsunekazu Kakuta, Shigeki Kimura, Taishi Yonetsu, Shingo Maeda, Asami Suzuki, 
Hideomi Fujiwara, Tsuchiura Kyodo Hospital, Tsuchiura, Japan
Background: Coronary artery lesions with deep echo attenuation in intracoronary 
ultrasound (ICUS) has been reported to be a risk factor for slow/no ﬂow phenomenon 
after PCI. We hypothesized that the removal of the echo attenuated atherosclerotic tissue 
by directional coronary atherectomy (DCA) before stenting may provide better coronary 
ﬂow after PCI compared with standard stenting.
Methods: To test this hypothesis, we compared TIMI ﬂow grade and corrected TIMI 
frame count (CTFC) between the two groups each of 30 matched lesions with deep echo 
attenuation in ICUS (DCA group : n=30; treated with DCA and stenting, nDCA group : 
n=30; treated with POBA and stenting). Deep echo attenuation was deﬁned as an ICUS 
appearance with attenuated echo signals without dense calciﬁcation. Lesion location, 
reference diameter, angiographic diameter stenosis, lesion length, age, gender, and the 
frequency of acute coronary sysndrome were matched between the two groups.
Results: There was no signiﬁcant difference in total cholesterol, LDL, frequency of 
current smoker, frequency of diabetes mellitus, and blood pressure between the two 
groups. CTFC in DCA group was 14 ± 5, and 24 ± 18 in nDCA group (p<0.01). There 
were 2 lesions of TIMI ﬂow grade less than 2 in DCA group (6.6%), whereas 10 lesions 
showed TIMI ﬂow grade less than 2 in nDCA group (33%) (p<0.05).
Conclusions: Removal of plaque with deep echo attenuation by DCA before stenting may 
reduce distal atheroembolism, resulting better outcome after PCI. Further prospective 
study is warranted.
995-226 Impact of Plaque Rupture on Myocardial Infarct Size in 
ST-Elevation Anterior Acute Myocardial Infarction
Ikuyoshi Kusama, Kiyoshi Hibi, Masami Kosuge, Naoki Nozawa, Hiroyuki Ozaki, Hideto 
Yano, Toshiaki Ebina, Shinichi Sumita, Masahiko Kanna, Kengo Tsukahara, Jun Okuda, 
Noriaki Iwahashi, Tatsuya Nakachi, Yoshio Tahara, Satoshi Umemura, Kazuo Kimura, 
Yokohama City University School of Medicine Cardiovascular Division, Yokohama, Japan
Background: Recent studies have indicated that stent thrombosis causes a large 
myocardial infarction with signiﬁcant decline in left ventricular (LV) function. Similarly, in 
the patients (pts) with acute myocardial infarction (AMI), some pts show large infarct size 
despite early reperfusion. To determine the predictive factors of infarct size variability, we 
investigated the association between infarct size and lesion morphology at the culprit 
lesion using intravascular ultrasound (IVUS).
Methods: A total of 91 anterior AMI pts with reperfusion within 6 hours of onset were 
enrolled and divided into 2 groups according to the presence or absence of plaque 
rupture deﬁned by preintervention IVUS: pts with rupture (Group R, n=54) and without 
rupture (Group N, n=37).
Results: Group R had a higher proportion of males (89 vs 68% p<0.05) and smokers (74 
vs 44% p<0.05), lower incidence of preinfarction angina (67 vs 87% p<0.05), and higher 
incidence of no-reﬂow phenomenon (33 vs 13% p=0.08) as well as lower myocardial 
blush grade (1.3 vs 2.3 p<0.05) following percutaneous coronary intervention. By IVUS 
analysis, Group R had a higher incidence of soft plaque (86 vs 65% p<0.05), positive 
remodeling (69 vs 37% p<0.05) and larger vessel area (18.0 vs 13.7mm2 p<0.01). Peak 
creatine kinase levels were higher (4707 vs 2309 IU/l p<0.01) and LV ejection fraction 
(LVEF) at discharge was lower (52 vs 64% p<0.01) in Group R. A multivariate logistic 
regression analysis revealed that the presence of plaque rupture and proximal lesion 
site were correlated with LVEF<50% at discharge (Odds ratio 5.5 and 7.1 both p<0.05, 
respectively). In the subgroup analysis in which only pts with reperfusion within 2 hours 
from onset were examined (n=39), the number of abnormal Q-waves on admission ECG 
was greater in Group R than in Group N (2.3 vs 1.1 p<0.05).
Conclusion: In pts with anterior AMI, plaque rupture at the culprit lesion was associated 
with vulnerable lesion morphology with greater no-reﬂow phenomenon and larger infarct 
size, suggesting that plaque embolism may play a major role in the progression of 
myocardial damage. Additionally, plaque rupture may cause rapid myocardial damage 
before reperfusion in super acute phase of AMI.
995-227 Platelet Aspirin Resistance in an ED Population With 
Suspected Acute Coronary Syndromes
W. Franklin Peacock, IV, Charles L. Emerman, Deepak Bhatt, The Cleveland Clinic, 
Cleveland, OH
Background: Platelet resistance to aspirin is reported as high as 30%, and some claim it 
may be overcome by increasing aspirin dosing to 325mg. The prevalence of Emergency 
Department (ED) aspirin resistance in suspected acute coronary syndromes (ACS) has 
never been described. Our purpose was to determine the prevalence of platelet aspirin 
resistance and the effect of 325 mg aspirin in this cohort.
Methods: We determined platelet aspirin resistance in a convenience sample of patients 
presenting to the ED. Eligible patients had at least 10 minutes of chest pain or an ischemic 
equivalent within 24 hours. Patients received 325 mg po aspirin, and after 2 hours blood 
was assessed for platelet function (Accumetrix, Inc, San Diego, CA), the results of which 
were blinded. Deﬁnitions: aspirin resistance (RES) as ≥ 550; positive troponin T (TnT) > 
0.1 ng/mL; signiﬁcant coronary lesion > 70% stenosis. A high risk composite was deﬁned 
as a 30 day revisit, positive cardiac catheterization (CC), or hospital length of stay (LOS) 
> 3 days.
Results: Of 200 enrolled patients, 50.5% were male, 50.0% black, and 46.5% white. 
TnT was (+) in 7.5% (15), CC was done in 10.5% (21), and 33.3% (7) had a signiﬁcant 
stenosis. Final diagnoses were non-cardiac in 83.4% (166), stable angina 8.0% (16), 
and unstable angina 8.5% (17). Overall, 6.5% (13) were RES. When stratiﬁed by RES, 
there was no statistical difference between cohorts in regards to gender (p=0.162), race 
(p=0.689), likelihood of CC (p=0.629), or ED disposition (p=0.058). The rate of high risk 
trended greater in RES patients than No RES [23.1% (3), vs 9.1% (17), (p=0.104)]. One 
month follow up found ED re-visits in 12.5% (1) of RES, vs 4.9% (8) of No RES, re-
hospitalization in 12.5% (1) of RES vs. 4.3% (7) of No RES (p>0.05). There was no LOS 
difference at index admission, but if re-hospitalized within 30 days, the mean LOS was 6.5 
days in the RES cohort, vs 3.2 days in the No RES (p<0.0001)
Conclusions: Even after 325 mg po aspirin, platelet resistance to aspirin is present 
in 6.5% of patients presenting to the emergency department with a suspected acute 
coronary syndrome. When present, aspirin resistance is associated with greater hospital 
resource utilization.
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995-228 Clopidogrel Attenuates the Complications Associated 
With Poor Early Reperfusion in Patients With STEMI 
Undergoing Lysis in the CLARITY-TIMI 28
Benjamin M. Scirica, Marc S. Sabatine, Christopher P. Cannon, Carolyn H. McCabe, 
Eugene Braunwald, Peter H. Stone, Brigham and Women’s Hospital, Boston, MA
Background: ST segment resolution (STRes) is an established marker of epicardial 
reperfusion. We sought to determine the clinical beneﬁts of clopidogrel on sustained 
STRes using continuous ECG (CECG) monitoring for the ﬁrst 48h of the CLARITY-TIMI 
28 trial, which compared clopidogrel v. placebo in STEMI pts receiving lytics. 
Methods: 164 pts had interpretable CECG recordings. STRes pattern was deﬁned as 
“simple” (uninterrupted, curvilinear decline in STRes from peak to asymptote) or “complex” 
(re-elevation of ST-seg >1.0 mm). Per protocol, all pts underwent angio at 2-8d. The 1° 
endpoint was an occluded infarct-related artery/death/MI pre-angiography. 
Results: Pts treated with clopidogrel had a trend towards increased odds of a simple 
STRes pattern compared to placebo (adjOR 1.52, 95%CI 0.78-2.94). Among pts with 
complex STRes, the rate of the 1° endpoint was lower with clopidogrel compared to the 
placebo (3.9% v. 31%, p=0.01) while there was no difference between clopidogrel and 
placebo among pts with simple STRes (14.8% v. 12.5%, p=0.98). 
Conclusion: Pts who received clopidogrel had a trend towards early sustained reperfusion 
by CECG. Among those pts with a complex STRes pattern, indicating interrupted 
reperfusion, treatment with clopidogrel signiﬁcantly improved clinical outcomes compared 
to placebo. Clopidogrel may favor early sustained reperfusion following lytics, while for 
those with evidence of impending re-occlusion, it may improve outcome by maintaining 
late artery patency.
995-229 Distal Embolism During Native Vessel and Vein Graft 
Coronary Intervention With a Vascular Protection 
Device: Predictors of High-Risk Lesions
Seif El-Jack, Pornratanarangsi Suwatchai, Peter N. Ruygrok, James T. Stewart, John 
A. Ormiston, Douglas S. Scott, Mark WI Webster, Green Lane Cardiovascular Service, 
Auckland City Hospital, Auckland, New Zealand
Background: Distal athero- and thrombo-embolism contributes to periprocedural myocardial 
necrosis during percutaneous coronary intervention (PCI). Embolism may be reduced by 
vascular protection devices. We hypothesised that angiographic variables predict lesions at 
increased risk for distal embolism, as assessed by debris retrieval from a distal ﬁlter.
Method: 194 consecutive patients undergoing native coronary (n=130) or vein graft 
(n=64) PCI using the BSC FilterWire® were enrolled. Clinical presentation was STEMI 
(38%), NSTEMI (32%), unstable angina (16%) and stable angina/inducible ischemia 
(13%). Debris was visually analyzed using a semi-quantitative grading score. Those with 
major debris, deﬁned as particles≥ 1mm diameter, were compared with those with no 
debris or debris <1mm, and related to clinical and angiographic (vessel location, vessel 
size, lesion length, lesion characteristics, vessel calciﬁcation, angiographic thrombus, 
TIMI ﬂow) variables.
Results: Major debris was retrieved in 55% of patients, more frequently from vein graft 
(69%) than native vessel lesions (48%, p=0.006). No clinical characteristics predicted 
major debris. In native vessel lesions the only signiﬁcant angiographic predictor of major 
debris was longer stent length (p=0.004) and in vein graft lesions stent length (p=0.003) 
and lesion complexity (p=0.05) were the predictors. Longer stent length was the only 
predictor of major debris in the population as a whole (p<0.001). Conclusion: Longer 
stent length, likely reﬂecting lesion length and plaque burden, is the strongest predictor 
of major distal embolism during PCI in both native vessel and vein graft lesions. Use of 
vascular protection devices should be considered during PCI of long lesions.
995-230 Drug-Eluting Stent Thrombosis: Real-World Incidence 
and Potential Predictors of Stent Thrombosis.
CheolWoong Yu, JiWon Jang, YoungJoo Lee, HyunCheol Cho, SeungHyung Ha, 
SangWon Park, SeungMook Jung, RakKyung Choi, SangSun Park, DalSoo Leem, 
SukKeun Hong, HeungGon Hwang, Sejong General Hospital, Bucheon, South Korea
Background: Stent thrombosis (ST) is a rare but devastating complication of coronary 
stent implantation. Concerns have been raised about higher rates of drug-eluting stent 
(DES) thrombosis due to delayed endothelialization and an unrestricted use of DES. The 
aim of this study was to evaluate the real-world incidence of angiographically conﬁrmed 
stent thrombosis and the potential risk factors of ST in an unrestricted population after 
DES implantation.
Methods: All 1436 patients who underwent successful DES implantation (sirolimus-
eluting, 928 patients [1365 stents] versus paclitaxel-eluting, 508 patients[827 stents]) at 
our institution between March 2003 and May 2005 were followed up prospectively after 
the procedure.
Results: During that period, 16 patients (1.11%) had stent thrombosis (10 [1.07%] with 
sirolimus and 6 [1.18%] with paclitaxel; P=0.07). Two patients had acute thrombosis 
(0.14%), 5 patients had subacute thrombosis (0.35%) and 9 patients had late thrombosis 
(0.63%). Among 9 late thrombosis cases, 5 patients developed ST respectively at 7, 13, 
15, 21, 22 months after procedure. Two of these 16 patients died (mortality rate, 12.5%) 
and twelve patients have presented with acute myocardial infarction (75%). Independent 
predictors of ST were chronic total occlusion (P=0.001), bifurcation lesion (P=0.11), 
premature antiplatelet therapy discontinuation (P=0.003), and stent length (P=0.017).
Conclusions: In this single-center experience, the incidence of angiographically 
conformed stent thrombosis after successful DES implantation was ≈ 1%. Chronic total 
occlusion, premature antiplatelet therapy discontinuation, bifurcation lesion, and stent 
length were identiﬁed as predictors of stent thrombosis. In the complex lesions such as 
chronic total occlusion and bifurcation lesions, stent thrombosis developed even after 
proper antiplatelet therapy was achieved.
995-231 Impact of Secondary Prevention Treatment With 
Atorvastatin, Simvastatin and Pravastatin After Acute 
Myocardial Infarction on One-Year Outcome in Current 
Clinical Practice: Results of Mitraplus
Anselm K. Gitt, Frederik Meiser, Rudolf Schiele, Harm Wienbergen, Frank Towae, 
Tobias Heer, Martin G. Gottwik, Jochen Senges, MITRAplus-Study-Group, Herzzentrum 
Ludwigshafen, Ludwigshafen, Germany
Background: Treatment with statins for secondary prevention reduces the risk of death 
and cardiovascular events. Recent trials found a superiority of high dosage atorvastatin 
over pravastatin for long-term outcome in selected patients (pts). Little is known about 
the impact of treatment with different statins on long-term outcome in pts after STEMI/
NSTEMI in clinical practice. Methods and 
Results: We analysed data of 13270 survivors of STEMI/NSTEMI in the MITRAplus 
registry. Pts without statin therapy at discharge had a signiﬁcantly increased 1-year-
mortality, even after adjustment for differences in baseline characteristics (OR 1.32, 
95%CI 1.22-1.40). After adjusting for age, gender, diabetes, acute reperfusion therapy, 
betablocker treatment and LV-EF<40% no signiﬁcant difference in death, nonfatal 
myocardial reinfarction and nonfatal stroke was found comparing pravastatin with 
atorvastatin (OR 1.02, 95%CI 0.83-1.25) and simvastatin with atorvastatin treatment (OR 
1.02, 95%CI 0.88-1.19). 
Conclusions: In consecutive patients surviving STEMI/NSTEMI in clinical practice, 
treatment with statins for secondary prevention was associated with a reduction in one-
year mortality. There was no difference in death, nonfatal reinfarction and nonfatal stroke 






n=3359 P value #
No Statin 
n=2908 P value *
Mean age 
(years) 65.1 66.4 65.3 0.02 72.4 <0.001
Female gender 
(%) 28.8 28.6 29.2 0.91 38.1 <0.001
Prior MI (%) 18.6 18.4 18.1 0.87 19.9 0.06
Diabetes (%) 25.2 25.1 25.3 0.99 31.1 <0.001
STEMI (%) 63.3 66.4 59.3 <0.001 59.0 <0.001
Aspirin (%) 92.4 92.0 91.3 0.26 90.0 <0.001
Betablocker (%) 91.0 90.4 90.2 0.54 71.4 <0.001
ACE inhibitor (%) 82.0 84.1 82.6 0.21 71.5 <0.001
1-Year-Mortality 
(%) 6.7 6.9 7.6 0.31 18.1 <0.01
Nonfatal 
reinfarction (%) 3.4 3.9 3.0 0.31 2.9 0.01
Nonfatal stroke 





10.6 11.1 11.2 0.69 21.6 <0.01
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996-232 Impact of High HDL Cholesterol on Hospital and 1-Year-
Mortality of Patients With Acute Myocardial Infarction: 
Results of the ACOS Registry
Frank Towae, Claus Juenger, Harm Wienbergen, Tobias Heer, Rudolph Schiele, Martin G. 
Gottwik, Jochen Senges, Anselm K. Gitt, MI Research Institute, Ludwigshafen, Germany
Background: Recent randomized clinical trials conﬁrmed that an intensive lipid lowering 
statin regimen with low low-density lipoprotein (LDL) cholesterol level provides greater 
protection agains major cardiovascular events. However, little is known about the inﬂuence 
of high-density lipoprotein (HDL) cholesterol on outcome of patients with myocardial 
infarction in clinical practice
Methods: From Jul 2000 to Nov 2002, 16567 consecutive patients (pts) with acute coronary 
ACC_2006_4_Myocardial AA.indd   213 1/4/06   5:14:13 PM



















syndromes were enrolled into the ACOS registry in Germany (155 hospitals). We evaluated 
the impact of HDL cholesterol on hospital and 1-year mortality in 10690 pts with STEMI or 
NSTEMI, in whom information on cholesterol levels were available. We compared patients 
with high HDL cholesterol (>50mg/dl for female and > 40 mg/dl for male) with those with low 
HDL cholesterol (< 50 mg/dl for female and < 40 mg/dl for male)
Results: Patients with had a lower prevalence of concomitant diseases.
Parameter Low HDL n=4534
High HDL
n=6147 p-value
Age [years], median 66.5 66.5 n.s
Female gender[%] 38.7 25.7 < 0.01
Prior MI [%] 19.8 17.6 < 0.01
Prior PCI/CABG 13.8 12.1 < 0.01
Diabetes [%] 33.3 21.6 < 0.01
Hypertension [%] 66.8 61.1 < 0.01
LDL Chol [mg/dl] 125 131 < 0.01
Hospital mortality [%] 6.1 4.7 < 0.01
1-year mortality [%] in pts discharged alive 9.9 6.9 < 0.01
After correction for baseline differences and LDL cholesterol levels, pts with high HDL had a 
signiﬁcant lower hospital (OR: 0.81, 0.68-0.96) and 1-year-mortality (OR 0.75, 0.63-0.88).
Conclusions:Independent on the level of LDL cholesterol, high HDL cholesterol levels 
were associated with a 19% better hospital and with a 25% better 1-year-mortality in 
patients with STEMI or NSTEMI in clinical practice.
996-233 Pretreatment With Simvastatin Reduces Myocardial No-
Reﬂow by Opening KAtp Channel
Jinglin Zhao, Yuejin Yang, Runlin Gao, Fuwai Heart Hospital, Beijing, People’s Republic 
of China
Background: Simvastatin, cholesterol lowering agent, can attenuate reperfusion injury 
after acute myocardial infarction and reperfusion. However, it remains unknown whether 
the simvastatin therapy can also reduce myocardial no-reﬂow for which suppression of 
adenosine triphosphate-sensitive K+ (KATP) channel opening during ischemia/reperfusion 
is an important mechanism. Therefore, this study was sought to assess the effect of 
simvastatin on myocardial no-reﬂow and explore the possible mechanism.
Methods: Coronary ligation area and the area of no-reﬂow were determined with both 
myocardial contrast echocardiography (MCE) in vivo and pathological means (Path) in 
thirty-two mini-swines randomized into 4 study groups: 8 in control, 8 in simvastatin-
pretreated (1mg/kg/d) for 3 days, 8 in simvastatin and glibenclamide (KATP channel 
blocker) -pretreated and 8 in sham-operated. Acute myocardial infarction and reperfusion 
model was created with three-hour occlusion of the left anterior descending coronary 
artery followed by one-hour reperfusion. The levels of SUR2, Kir6.1, and Kir6.2 in the 
reﬂow and no-reﬂow myocardium were quantiﬁed by western blotting.
Results: Compared with the control group, simvastatin signiﬁcantly improved ventricular 
function, increased coronary blood volumn from 50.6±3.1% to 74.3±3.2% the baseline 
after one hour of reperfusion (P<0.01), decreased area of no-reﬂow (MCE: from 78.5±4.5% 
to 33.4±4.9%, Path: from 82.3±1.9% to 35.2±5.4% of ligation area, P<0.01), reduced 
necrosis size from 98.5±1.3% to 83.4±4.9% of ligation area (P<0.05). Simvastatin also 
increased the levels of SUR2 and Kir6.2 in the reﬂow myocardium (P<0.05-0.01), but had 
no effect on the level of Kir6.1 (P>0.05). Combination of simvastatin and glibenclamide 
failed to signiﬁcantly modify area of no-reﬂow, necrosis size and the levels of SUR2, 
Kir6.1, and Kir6.2.
Conclusions: Simvastatin can reduce myocardial no-reﬂow after acute myocardial 
infarction and reperfusion. This beneﬁcial effect is due to its activation of KATP channel.
996-234 Early Initiation Of Low-Dose Atorvastatin Treatment 
After An Acute ST-Elevated Myocardial Infarction, 
Decreases Inﬂammatory Response And Stimulates 
Antithrombotic Mechanisms
Dimitris M. Tousoulis, Vasiliki Katsi, Charalambos Antoniades, Maria Kotsopoulou, 
Erini Bosinakou, Costas Tentolouris, Gerasimos Siasos, Christos Pitsavos, Marietta 
Charakida, Christodoulos Stefanadis, Athens University, Athens, Greece
Background: ST elevated myocardial infarction (STEMI) is accompanied by increased 
expression of interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-�), and soluble vascular 
cell adhesion molecule (sVCAM-1), as well as increased thrombogeneicity. Aggressive 
statins treatment reduces mortality in patients with STEMI, but the effect of low-dose 
atorvastatin on inﬂammation and thrombogeneicity during in these patients is unknown.
Methods. Twenty four patients with STEMI were randomly allocated into 2 groups to 
receive atorvastatin 10 mg/day (n=12, ATR) or no statin (n=12, controls) for 6 weeks 
after the incident. Serum IL-6, TNF-� and sVCAM-1, and plasma antithrombin III (ATIII) 
and proteins S (prtS) and C (prtC), were measured at baseline, the 1st and 6th week after 
admission.
Results: Baseline, levels of IL-6, TNF-�, sVCAM-1, ATIII, PrtS and PrtC were not 
signiﬁcantly different between ATR (7.7±0.7 pg/ml, 2.2±0.3 pg/ml, 455±43 ng/ml, 
79.3±4.0%, 92.1±5.6% and 94.2±5.3% respectively) and control group (6.09±1.01 pg/
ml, 2.45±0.29 pg/ml, 496±34 ng/ml, 68.6±3.1%, 92.1±7.8% and 89.2±4.9% respectively, 
p=NS for all). At the 1st week after admission, IL6 was slightly but not signiﬁcantly 
increased in both ATR (7.6±0.8pg/ml p=ns) and controls (6.82±1.02pg/ml p=ns), while 
it was decreased at 6 weeks only in ATR (4.7±0.8pg/ml p<0.05 vs baseline) but not in 
controls (4.18±1.38 p=ns). sVCAM-1 was increased at the 1st week in controls (552±40ng/
ml p<0.05 vs baseline) but not in ATR (438±24 ng/ml p=ns), although it returned to 
baseline in both controls (546±71ng/ml p=ns vs baseline) and ATR (445±56ng/ml p=ns 
vs baseline) at the 6th week. Although ATIII was increased at 6th week in controls (to 
78.9±2.2% p<0.05 vs baseline), it was almost doubled in ATR (157.7±7.66% p<0.01). 
Plasma PrtS and PrtC remained unaffected in both groups throughout the study period.
Conclusions. Low dose atorvastatin treatment decreases inﬂammatory process 
and induces antithrombotic mechanisms, during the ﬁrst 6 weeks after STEMI, in 
normocholesterolemic patients. These ﬁndings imply that even low-dose statin treatment 
may modify important pathways and affect the outcome of patients during the post-
infarction period.
996-235 Exploring the Relative Effects of Angiotensin 
Converting Enzyme Inhibitors of Varying Tissue Afﬁnity 
on C-Reactive Protein Following Acute Myocardial 
Infarction
James P. Tsikouris, Craig D. Cox, Jan Simoni, Ashwani Kumar, Ashish Sadhu, Miranda 
C. Peek, Gary E. Meyerrose, University of Pittsburgh School of Pharmacy, Pittsburgh, 
PA, Texas Tech University Health Sciences Center, Lubbock, TX
Background: Angiotensin converting enzyme (ACE) inhibitors vary in vascular tissue 
afﬁnity, as deﬁned by their propensity to penetrate vascular tissue and attenuate local 
renin angiotensin system (RAS) effects. Vascular inﬂammation is adversely inﬂuenced by 
the vascular RAS. The objective is to determine the relative effects of two ACE inhibitors 
of varying vascular tissue afﬁnity on a well-established marker of vascular inﬂammation, 
C-reactive protein (CRP), following acute myocardial infarction (MI). 
Methods: This randomized, open-label trial evaluated CRP levels in 60 patients that 
received 1 of 2 ACE inhibitors, quinapril (high tissue afﬁnity) or enalapril (low tissue 
afﬁnity), for 4 weeks. Treatment initiation began within 24 hours of acute MI onset. Dose 
titration was performed at set time points with predetermined equipotent target doses 
(quinapril 80 mg daily and enalapril 40 mg daily). Pretreatment and 4 week blood samples 
were analyzed for CRP (mg/dl) by immunoturbidometric method (values correspond as 
1:10 relative to certain clinical CRP assays that are commonly presented as mg/L). After 
evaluation for normality, data were analyzed using Mann-Whitney U and Wilcoxon signed 
rank when appropriate. All data are presented as mean ± SD, with p<0.05 signiﬁcant. 
Results: Pretreatment levels of CRP did not differ between enalapril and quinapril (1.15 
± 1.38 mg/dl vs. 1.05 ± 0.69 mg/dl, respectively, p=0.33). At 4 weeks mean CRP levels for 
enalapril and quinapril patients were 1.07 ± 1.79 mg/dl and 0.71 ± 0.20 mg/dl. Relative 
to baseline this represents a nonsigniﬁcant 7% reduction (p=0.41) and a signiﬁcant 32% 
reduction (p=0.005), respectively. Age, race, smoking history, hypertension, diabetes, 
body mass index, and post-treatment plasma ACE concentrations were very similar 
between groups. 
Conclusions: The CRP results indicate that after acute MI an ACE inhibitor with high 
vascular tissue afﬁnity may attenuate vascular inﬂammation to a greater extent than 
an ACE inhibitor of low tissue afﬁnity. Further investigation of the relative vascular anti-
inﬂammatory effects of agents within this class is warranted in a larger population and 
with longer treatment duration.
996-236 Sex Differences in the Efﬁcacy of Statins in Patients 
After Acute Myocardial Infarction
Igor Karp, Shunfu Chen, Louise Pilote, McGill University, Montreal, PQ, Canada, 
Montreal General Hospital, Montreal, PQ, Canada
Background. Statins have been shown to be effective for secondary prevention in post-
acute myocardial infarction (AMI) patients. However, even though most of the studies 
included patients of both sexes, women have been largely underrepresented. As a 
result, potential sex differences in the effectiveness of the use of statins have not been 
sufﬁciently studied.
Methods. We conducted a retrospective quasi-experimental study based on a medical 
administrative database in the province of Quebec, Canada. Patients discharged from 
hospital alive after their ﬁrst AMI-related hospital stay during the time period from 1997 
to 2003 were included. Patients who had been prescribed a statin within 90 days prior to 
the hospitalization were excluded from analysis. The active intervention group included 
patients who, at discharge, were prescribed a statin (atorvastatin, pravastatin, simvastatin, 
lovastatin, or ﬂuvastatin) at a dose equal to or higher than the statin-speciﬁc target, while 
the control group included patients who were not prescribed a statin at discharge. Both 
groups were followed for up to seven years. All-cause mortality served as the primary 
end-point outcome. Patients who at any point in time failed to maintain the initially-
assigned statin use or non-use regimen for 30 days or longer were censored. Multivariable 
proportional hazards regression analysis, including an interaction term between sex and 
statin use indicator variables, was used to estimate adjusted sex-speciﬁc hazard ratios 
associated with the use of statins.
Results. The study population included 33,872 patients (mean age=69 years). At 
discharge, the active intervention and control groups comprised 9,757 and 24,075 
patients, respectively. The overall all-cause death rates were 5.3 and 7.1 cases per 100 
person-years in the intervention and control groups, respectively. The adjusted hazard 
ratio for statin use versus non-use was 0.60 in men and 0.71 in women (p-value for the 
interaction term=0.0264).
Conclusions. The use of statins in post-AMI patients was associated with a statistically 
signiﬁcant reduction in all-cause mortality in both sexes. However, the reduction was more 
pronounced in men compared with women.
996-237 Does Impaired Fasting Glucose Inﬂuence Long Term 
Mortality After an Acute Myocardial Infarction? Data 
From the Rico Survey
Jean-Claude Beer, Gilles Dentan, Isabelle L’Huillier, Luc Janin-Maniﬁcat, Pierre Sicard, 
Yves Laurent, Luc Lorgis, Hamid Makki, Jean-Eric Wolf, Bruno Verges, Yves Cottin, 
on behalf of RICO survey working group, Service de Cardiologie, CHU, Dijon, France, 
Clinique de Fontaine-les-Dijon, Service de Cardiologie, Fontaine-les-Dijon, France
Background: Long term outcome after acute myocardial infarction (MI) has not yet been 
evaluated with regard to the new category of Impaired Fasting Glucose (IFG) deﬁned by 
the American Diabetes Association (ADA). Methods: 847 patients surviving after an acute 
MI from the RICO survey were included in the study. Patients were grouped according 
to ADA deﬁnitions: Diabetes Mellitus (DM) (FG ≥ 7 mmol/l or personal history of DM) ; 
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IFG (FG 6.1 to 7 mmol/l) ; NFG (normal FG < 6.1 mmol/L). The rate of cardiovascular 
death was determined at 1-year follow-up. Results: 337 (39.8 %) had DM, 118 (13.9 %) 
IFG and 392 (46.3 %) NFG. At follow-up, the cardiovascular mortality was 3 %, 8% and 
15 % respectively for NFG, IFG and diabetes mellitus (IFG vs NFG, P<0.05 and DM vs 
NFG, P <0.05). After adjustment for confounding factors (age, sex, anterior location, and 
LVEF), IFG and DM were strong independent predictor factor for 1-year cardiovascular 
mortality, respectively [RR (95%) : 1.67 (1.29-2.16), p<0.0001) and RR (95%) : 2.79 
(1.68-4.55), p<0.0001)].Conclusions: In patients surviving an MI, IFG and diabetes were 
highly prevalent and are associated with increased risk of cardiovascular death at long 
term follow-up. Diabetes screening, aggressive glycemic control during hospitalization, 
appropriately stringent follow-up, and risk factor modiﬁcation may provide opportunities to 
improve care in this group of patients. 
996-238 Predictive Value on Mortality of Stress Hyperglycaemia 
in Patients With Acute Myocardial Infarction
Francois Schiele, Katy Didier-Petit, Marie-France Seronde, Pierre Legalery, Nicolas 
Meneveau, Fiona Ecarnot, Jean-Pierre L. Bassand, University Hospital Jean Minjoz, 
Besancon, France
Background: In non diabetic patients at the early phase of myocardial infarction 
(MI), stress hyperglycaemia (SH), as deﬁned by elevated fasting plasma glucose 
concentrations, represents a major risk factor for mortality. To date, the predictive value 
of SH, taking into account risk score and use of guidelines-recommended treatments, is 
poorly documented.
Methods: A prospective observational study including all patients admitted with acute 
MI. Fasting plasma glucose levels 12 hours after admission, risk levels (using the Global 
Registry of Acute Coronary Events risk score), guidelines-recommended treatment use 
and one year mortality were recorded.
Results : 320 STEMI and 404 NSTEMI patients were included. The median glucose level 
was 126 mg/dl (6.9 mmol/l) [104-67], the median GRACE score was 147. The cut off 
value to deﬁne SH was determined at 138 mg/dl from a Receiver Operating Characteristic 
(ROC) curve. 175 (24%) patients had a pre-existing diagnosis of diabetes, and 154 (21%) 
non-diabetic patients were considered as having SH (SH+); the remaining 395 had no 
diabetes and no SH (SH-). The GRACE risk score was lower in the SH- group, but use 
of guidelines-recommended treatments was comparable in all three groups. At 1 year, 
there was a signiﬁcantly higher mortality rate in the SH+ group (18.8%) than in SH- 
group (6.1%), p <0.01. Mortality was comparable between the SH+ and diabetic groups 
(18.8 versus 16.6%, p=NS). The relation between glycemic status and 1 year mortality 
remained strong (SH+ vs SH-: OR= 3.3 [1.7-6.4] and diabetes vs SH-: OR = 3.1[1.6;5.8]) 
even after adjustment on the GRACE risk score (OR = 2.3 [1.7;2.9] per 10% increase) 
and on the treatment score (OR = 0.67 [0.60;0.76] per 10% increase). The use of a lower 
cut off value to deﬁne SH (115 mg/dl) changed the prevalence of SH, but not its predictive 
value on mortality.
Conclusions: In non-diabetic patients, the presence of SH indicates an increased risk 
of 1 year mortality, similar to that of diabetic patients. This predictive value on mortality 
remains strong after stratiﬁcation on risk score and treatment used.
996-239 Effects of Angiotensin-II Receptor Blockers on 
Coronary Atherosclerosis in Patients With Acute 
Myocardial Infarction Taking Angiotensin-Coverting-
Enzyme Inhibitors: An Intravascular Ultrasound (IVUS) 
Study
Hideto Yano, Kiyoshi Hibi, Kazuo Kimura, Naoki Nozawa, Hiroyuki Ozaki, Ikuyoshi 
Kusama, Masami Kosuge, Toshiaki Ebina, Tatsuya Nakachi, Noriaki Iwahashi, Jun 
Okuda, Kengo Tsukahara, Masahiko Kanna, Satoshi Umemura, Yokohama City 
University Medical Center, Yokohama, Japan
Background: The inhibition of renin-angiotensin-aldosterone system (RAS) by 
angiotensin-converting-enzyme inhibitors (ACE-I) reduce cardiovascular mortality and 
morbidity. Complete inhibition of RAS by dual blockade with angiotensin-II receptor 
blockers (ARB) and ACE-I is more effective antihypertensive strategy than ACE-I 
alone. However, whether the combination of ARB with ACE-I improve clinical outcome 
compared with ACE-I alone remain controversial. The aim of this IVUS study was to clarify 
whether complete inhibition of RAS have impact on the non-culprit intermediate coronary 
atherosclerosis.
Methods: A total of 76 patients with acute myocardial infarction (AMI) were randomly 
assigned to the valsartan (group V, target dose 80 mg daily 36 patients) or non-valsartan 
(group NV, 40 patients) groups. All patients received captopril (target dose 75 mg daily) 
and study drug after revascularization. The target plaque qualiﬁed for the IVUS study if 
it had not been inﬂuenced by any previous intervention, if the diameter of the stenosis 
was <50% on quantitative coronary angiography. The plaque had to be >10 mm apart 
from acute intervention site. IVUS interrogation was performed at acute phase and at 7- 
month follow up. The percent plaque volume changes (%∆PV), the percent lumen volume 
changes (%∆LV) and the percent vessel volume changes (%∆VV) were calculated.
Results: Culprit vessel, coronary risk factors, peak creatine kinase levels, lipid proﬁle, 
and high sensitive C-reactive protein levels were similar between the groups. Plasma 
aldsterone levels were lower (56 vs. 75pg/ml, p=0.02) and systolic blood pressure was 
lower (118 vs. 127mmHg, p=0.04) at follow up in group V compared with group NV. %∆LV 
(10.3 vs. -0.16%, p=0.03) and %∆VV (4.4 vs. -1.8%, p=0.02) were larger in group V, 
whereas %∆PV was similar between the groups (0.2 vs. -3.6%, p=0.2).
Conclusions: In patients with AMI, complete inhibition of RAS with ARB and ACE-I had 
impact on coronary artery enlargement without plaque progression compared with ACE-I 
alone. Improved coronary vascular tone in the combination group may confer additional 
cardiovascular protection, leading to the reduction of relevant cardiovascular events.
996-240 Renin-Angiotensin-Aldosterone System Antagonism 
Decreases the Incidence of Ventricular Dysrrhythmias 
Following Myocardial Infarction: Lessons From GUSTO-V
Michael J. Riley, Arman T. Askari, Kathy Wolski, Joan Booth, A. Michael Lincoff, Eric J. 
Topol, Cleveland Clinic Foundation, Cleveland, OH
Background: The beneﬁcial effects of renin-angiotensin-aldosterone system (RAAS) 
antagonism following an ischemic cardiovascular event are unequivocal and are thought 
to result from attenuation of remodeling imparted by these agents following myocardial 
infarction. Emerging preclinical data suggest that some of the beneﬁt of RAAS antagonism 
may result from a reduction in ventricular dysrrhythmia, but data from randomized clinical 
trials are lacking.
Methods: In GUSTO-V, 16,588 patients with acute ST-segment elevation myocardial 
infarction were randomized to receive standard-dose reteplase or half-dose reteplase 
in conjunction with full-dose abciximab bolus and 12-hour infusion. Data regarding 
baseline medications were collected for all patients. 6,528 (39.4%) patients were taking 
an angiotensin-converting-enzyme (ACE) inhibitor and/or angiotensin II-receptor blocker 
(ARB) at baseline (deﬁned as prior to randomization or within 24 hours post-randomization). 
The primary endpoint was the incidence of ventricular dysrrhythmia, i.e. ventricular 
ﬁbrillation (VF) or ventricular tachycardia (VT), during the index hospitalization.
Results: VT or VF occurred in 851 patients, 293 (4.5%) in the ACE-inhibitor/ARB group 
and 555 (5.5%) in those taking neither an ACE-inhibitor nor an ARB. A signiﬁcant 
association between ACE-inhibitor/ARB use at baseline and freedom from the primary 
endpoint was demonstrated (OR 0.65, 0.47-0.89, P=0.008). This signiﬁcant protective 
effect was seen even after adjustment for baseline antiarrhythmic and other medications 
and covariables independently related to the primary endpoint, including age, systolic 
blood pressure, history of congestive heart failure, and smoking status. Furthermore, the 
use of an ACE-inhibitor and/or ARB signiﬁcantly reduced VT/VF regardless of study-drug 
combination administered.
Conclusions: In patients presenting with acute myocardial infarction, RAAS antagonism 
with an ACE-inhibitor and/or ARB signiﬁcantly and independently reduces the incidence 
of VT or VF.
996-241 Blood Transfusion in Patients Undergoing Primary 
Percutaneous Coronary Intervention for Acute 
Myocardial Infarction: Analysis From the CADILLAC 
Trial
Eugenia Nikolsky, Roxana Mehran, Cindy L. Grines, Mark Turco, David A. Cox, Thomas 
Stuckey, Thomas Stuckey, Giulio Guagliumi, John J. Grifﬁn, Alexandra J. Lansky, 
Manuela Negoita, Dennis J. Mercado, Issam Moussa, Yingbo Na, Gregg W. Stone, 
Columbia University Medical Center, New York, NY, The Cardiovascular Research 
Foundation, New York, NY
Background: Whether blood transfusions are detrimental to pts undergoing percutaneous 
coronary intervention (PCI) is controversial. This issue has not been examined in pts with 
acute myocardial infarction (AMI) undergoing primary PCI. We therefore examined the 
outcomes of patients treated with blood transfusion in the CADILLAC trial.
Methods: Of 2,060 pts with AMI undergoing primary PCI, 82 (3.9%) received a blood 
transfusion not related to coronary bypass grafting during the index hospitalization. To 
control for differences in patient characteristics, a propensity score for transfusion was 
constructed and included in multivariate logistic regression analysis of death.
Results: Patients treated with blood transfusion were older, more frequently female, 
had higher prevalence of prior gastrointestinal bleeding, chronic renal insufﬁciency, 
triple-vessel disease, lower body mass index, and lower pre-procedure hematocrit (all 
P<0.03). Blood transfusion was associated with longer procedure time, more frequent 
use of abciximab, higher incidence of post-procedure TIMI ﬂow 0/1, and lower rates of 
procedural success (All P <0.04). Pts treated with blood transfusion had strikingly higher 
rates of death in-hospital (12.2% vs. 1.2%, P<0.0001), at 30-days (13.2% vs. 1.7%, 
P<0.0001) and at 1-year (25.2% vs. 3.4%, P<0.0001). After adjustment for potential 
confounders including propensity score for transfusion, blood transfusion was identiﬁed 
as independent predictor of death during the initial hospitalization (OR=12.3; P=0.0002), 
at 30-days (HR=7.11; P=0.0002) and at 1-year (HR=5.7; P<0.0001).
Conclusions: In patients undergoing primary PCI for AMI, blood transfusion is associated 
with markedly increased early and late mortality. Prospective randomized trial should 
further address the role of blood transfusion in outcomes of patients with AMI.
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997-242 Increased In-Hospital and Long-Term Morbidity and 
Mortality in Patients With Gastrointestinal Bleeding 
Following Percutaneous Coronary Intervention
Anuj R. Shah, Haris Athar, Igor Mamkin, Yaser Siraj, Michael Manolios, Rajeev 
Angampally, Jeff Matther, Roger Mennett, Jill Jarvis-Cloutier, Krista Maloney, Francis 
J. Kiernan, William E. Boden, Raymond G. McKay, University of Connecticut, Hartford 
Hospital, Hartford, CT
Background Use of adjunctive antiplatelet, anticoagulant and thrombolytic agents has 
increased the potential for gastrointestinal (GI) bleeding after percutaneous coronary 
intervention (PCI). We sought to analyze the impact of GI bleeding after elective or urgent 
PCI in a large, tertiary care center.
Methods We compared baseline clinical and angiographic characteristics and in-hospital 
and 9-month major adverse cardiac events in 3,982 consecutive patients who underwent 
PCI between 2002 and 2005, including 50 patients who developed GI bleeding after PCI. 
GI bleeding was deﬁned as frank upper or lower GI bleeding or melena that required 
discontinuation of antiplatelet or anticoagulation therapy, administration of protamine, or 
transfusion therapy.
Results Compared to patients without bleeding, patients who developed GI bleeding after 
PCI were older, more likely female, had more renal insufﬁciency and chronic lung disease, 
presented more commonly with ST-segment elevation myocardial infarction (STEMI) and 
non-STEMI, and had more extensive coronary atherosclerosis. There were no differences 
in peri-procedural medications, use of stenting or interventional success between the 
two groups.
Conclusions Patients with GI bleeding after elective or urgent PCI have worse in-hospital 
and long-term clinical outcomes.
In-hospital and long-term clinical outcomes
In-hospital outcomes GI bleeding n (%) No GI bleeding n (%) p
In-Hospital Mortality 3 (6.0%) 45 (1.1%) <0.01
Emergent Repeat PCI 2 (4.0%) 3 (0.1%) <0.01
Stroke 1 (2.0%) 5 (0.1%) <0.01
Contrast Nephropathy 8 (16.0%) 15 (0.4%) <0.01
Stent Thrombosis 1 (2.0%) 12 (0.3%) <0.04
Nine-Month outcomes
Mortality 8 (16.0%) 111 (2.9%) <0.01
Myocardial Infarction 3 (6.0%) 43 (1.1%) <0.01
 
997-243 Prediction of Adverse Clinical Outcomes in 
Unprotected Left Main Coronary Artery Stenting Using 
Risk Stratiﬁcation System of EuroSCORE
Seung-Jung Park, Young-Hak Kim, Jung-Min Ahn, Duk-Woo Park, Young-Hoon Jeong, 
Eui-Seock Hwang, Se-Whan Lee, Cheol Whan Lee, Myeong-Ki Hong, Jae-Joong Kim, 
Seong-Wook Park, Asan Medical Center, Seoul, South Korea
Background: This study aimed to evaluate predictors of serious adverse cardiac events 
including cardiac death or myocardial infarction (MI) after elective ULMCA stenting.
Methods: Between Jan 2000 and Mar 2005, 324 patients who had left ventricular ejection 
fraction (LVEF) ≥35% and ULMCA lesions underwent elective percutaneous interventions 
with bare metal stents (n=148) and drug-eluting stents (n=176). Analysis factors included 
clinical, angiographic, procedural and intravascular ultrasound (IVUS) parameters. The 
Euroscore and Parsonnet score are systemic risk parameters considering age, sex, and 
co-mobidities.
Results: During the follow-up period (30.5±15.9 months), 3 cardiac deaths (0.1%) and 
33 MIs (10.2%) occurred. By multivariate analysis, high Euroscore >6 (OR, 2.83; 95% CI 
1.19-6.73; p=0.019) and total stent length (OR, 1.23; 95% CI 1.05-1.44; p=0.010) were 
independent predictors of adverse outcomes.
Conclusions: A systemic risk stratiﬁcation system of the Euroscore is useful to predict 
serious adverse events after elective ULMCA stenting in patients with relatively preserved 
LV function.
Table. Univariate analysis 
Events (n=36) No events (n=288)
Age, yrs 61.6±11.4 58.5±12.0
Diabetes mellitus, % 16.4 25.7
Acute coronary syndrome, % 55.6 48.3
Euroscore * 3.6±2.1 2.8±2.2
Parsonnet score 10.1±5.6 8.8±5.1
Bifurcation location, % 66.7 55.2
LVEF, % 59.8±10.6 61.2±8.1
Reference diameter, mm 3.5±0.8 3.7±0.7
Use of drug-eluting stent, % 50.0 54.9
Multi-vessel intervention *, % 58.3 38.9
Total stent length *, mm 27.8±20.3 21.1±16.5
Vulnerable plaque †, % 36.0 33.8
* p<0.05, † Vulnerable plaque included lesions showing rupture, lipid core, ﬁssure and 
thrombus by IVUS
997-244 Prevalence of Metabolic Syndrome in Patients < 45 
Years Old With Acute Coronary Syndrome Presenting 
for Emergent Primary Percutaneous Intervention
Eugene H. Chung, Patrick J. Curran, Satish Sivasankaran, Manish S. Chauhan, David 
E. Gossman, Christopher T. Pyne, Thomas C. Piemonte, James Waters, Seth Bilazarian, 
Robert Rokowski, Nabila Riskala, Azadeh Shoraki, Richard W. Nesto, Lahey Clinic, 
Burlington, MA
Background:  The cardiovascular risk factor proﬁle of young people is changing as insulin 
resistance becomes more prevalent and occurs at an early age. We sought to determine 
the prevalence of the metabolic syndrome (METS) in patients 45 years or younger who 
presented with acute coronary syndrome (ACS) and underwent primary percutaneous 
coronary intervention.
Methods: We reviewed 223 consecutive patients between the ages of 18 and 45 who 
underwent cardiac catheterization for acute myocardial infarction at Lahey Clinic from June 
2001 through December 2004. METS was diagnosed by the presence of at least three of 
the ﬁve criteria deﬁned by NCEP III guidelines (modiﬁed by substituting BMI >28.8 kg/m2 for 
waist circumference). 162 patients had all ﬁve criteria for METS available for evaluation.
Results:  76 of 162 patients (47%) met at least 3 of the 5 criteria for METS (METS+). 16 
(21%) METS+ and 5 (6%) METS- patients had DM. The distribution of METS criteria in 
the 76 METS+ patients was as follows: 63 (83%) with an HDL <40 mg/dL; 57 (75%) with 
fasting glucose >110 mg/dl; 58 (76%) with BMI >28.8 kg/m2; 59 (78%) with triglycerides 
>150 mg/dl; and 47 (62%) satisfying the hypertension criterion. The 86 METS- patients 
had the following risk factor proﬁle: 39 (45%) with an HDL <40 mg/dl; 30 (35%) with fasting 
glucose >110 mg/dl; 21 (24%) with BMI >28.8 kg/m2; 12 (14%) with triglycerides >150 
mg/dl; and 15 (17%) satisfying the hypertension criterion. The prevalence of each criterion 
was signiﬁcantly higher (p< 0.05) in the METS+ group. Average Framingham Risk Scores 
were 7.0 and 5.0 for patients with and without METS, respectively. The prevalence of 
smoking, male gender, and positive family history were the same for both groups.
Conclusion: Metabolic syndrome is highly prevalent in young patients with ACS. 
Conventional means of risk assessment may not adequately identify young individuals 
at high risk for diabetes and cardiovascular disease. All criteria of METS are uniformly 
expressed in METS+ patients presenting with ACS. Admission hyperglycemia is a 
prominent feature of ACS presentation in METS+ patients.
997-245 Blood Type and the Age of the Red Cells Transfused 
Affects Mortality After Percutaneous Coronary 
Intervention
Peter S. Kim, Asma Authmany, Robert Saﬁan, A. Bradley Eisenbrey, Barbara O’Malley, 
Judy Boura, William O’Neill, William Beaumont Hospital, Royal Oak, MI
Introduction Acute blood loss anemia is a common complication after cardiac 
catheterization, leading to thousands of red cell transfusions each year. Recent studies 
indicate that red cell transfusion may have a detrimental effect on coronary patients. In 
addition, the characteristics of the red cells transfused may have an impact on mortality.
Methods This observational study assessed whether red cell characteristics, speciﬁcally 
storage age and blood type, was associated with increased one-year mortality. 
Retrospective chart review was conducted on all patients who received a red cell 
transfusion after percutaneous coronary intervention (PCI) between January 1995 and 
April 2003. A total of 743 patients were assessed. One year mortality data was gathered 
using our institution’s charts and the social security death registry. One-year survivors 
were compared to non-survivors.
Results Patients who died within one year had signiﬁcantly lower baseline renal function 
(CrCl 43 +/- 33 vs. 56 +/- 29; p < 0.0001), more diabetes (47% vs. 32%; p < 0.0001), and 
congestive heart failure (46% vs. 27%; p < 0.0001). In addition, non-survivors had more 
catheterization complications, including intubation (20% vs. 7%; p < 0.0001), shock (4.5% 
vs. 0.4%; p = 0.0001), and renal failure (19% vs. 6%; p < 0.0001). Non-survivors received 
signiﬁcantly older blood (17.4 +/- 7.7 days old vs. 15.9 +/- 8.0 days old; p = 0.0047). 
In addition, transfusion with type A and AB red cells was signiﬁcantly associated with 
increased one-year mortality compared with type O and B blood (45% vs. 62% vs. 34% 
vs. 19%, respectively; p < 0.0001). After step-down logistic regressions analysis, type A 
(OR 1.85; p = 0.014) and AB blood (OR 3.48; p = 0.0004) were found to be independent 
predictors of death at one year.
Conclusions Transfusion of type A and AB blood is independently associated with increased 
one-year mortality after percutaneous coronary intervention. The blood type and the age of 
the stored blood should be considered prior to red cell transfusion in coronary patients.
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998-246 Autonomic Markers as Predictors of Non-Fatal Acute 
Coronary Events After Myocardial Infarction
Juha S. Perkiomaki, Vesa Jokinen, Jari Tapanainen, Heikki V. Huikuri, University of Oulu, 
Oulu, Finland
Background: Autonomic markers, such as heart rate variability (HRV), heart rate 
turbulence (HRT) and baroreﬂex sensitivity (BRS) provide information on the risk of all-
cause mortality after an acute myocardial infarction (AMI), but their value in predicting 
non-fatal cardiac events is not well known.
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Methods: A consecutive series of 601 patients with an AMI underwent a 24-hour Holter 
recording, and assessment of BRS using phenylephrine test. Several parameters of HRV 
and HRT were determined.
Results: After up to 30 months of follow-up, 84 patients (14%) had a non-fatal acute 
coronary event. Among the studied variables, the short-term scaling exponent α1 
(p=0.002), power-law slope β (p=0.008), low-frequency component of HRV power 
spectrum (p<0.001), turbulence slope (p<0.001), and BRS (p<0.001) had the strongest 
association with the occurrence of non-fatal acute coronary events in univariate 
comparisons. After adjustment with relevant clinical variables (such as age, gender, 
ejection fraction, functional class, medication, diabetes) in the Cox proportional hazards 
model, α1 and β remained as statistically signiﬁcant predictors of non-fatal acute coronary 
events (HR=1.9 [1.2-3.1, 95% CIs, p=0.009] for α1 ≤ 1.025), (HR=1.9 [1.2-3.1, p=0.009] 
for β ≤ -1.507).
Conclusion: Several autonomic markers provide information on the risk of recurrent 
acute coronary events after an AMI. Altered fractal heart rate behavior seems to be the 
strongest independent predictor of such events.
998-247 Additional Ballooning Versus no Additional Ballooning 
After Drug-Eluting Stent Implantation in Routine 
Clinical Practice
Soon Yong Suh, Seung-Woon Rha, Hyun Hee Kim, Byoung Won Cheon, Jin Won 
Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, Cardiovascular Center, Korea 
University Guro Hospital, Seoul, South Korea
Background: Whether the additional ballooning using stent balloon or another semi or 
non compliant balloon after drug-eluting stent (DES) implantation is beneﬁcial or not is not 
clariﬁed yet. We sought the efﬁcacy of additional balloon strategy after DES implantation 
up to 6 months. 
Methods: The study population consisted of 343 patients (pts) who underwent standard 
PCI with DES.Clinical and angiographic parameters of 276 pts (male 188, mean age 62.2 
±10.4 years) with no additional balloon group were compared with those of 67 pts (male 
46, mean age 63.2 ±9.6 years) with additional balloon group. 
Results: Baseline clinical and procedural characteristics were similar between the two 
groups. At 6 months, binary restenosis was signiﬁcantly lower in the additional balloon 
group (1.5% vs 5.8%, p=0.04). Mean % restenosis was similar between two groups (31.0 
% vs. 30.1 %, p=NS ). Target lesion revascularization (TLR) is 3.3% vs 1.5%. Target 
vessel revascularization(TVR) is 4.7% vs 1.5%. Major adverse cardiac event (MACE) 
was signiﬁcantly lower in the additional balloon group (1.5 % vs. 7.6% in no additional 
balloon group, p=0.02).
Conclusions: Additional ballooning after DES implantation showed excellent angiographic 
and clinical outcomes including lower binary restenosis and MACE compared to those 
of the pts without additional ballooning. Additional ballooning just after DES implantation 
should be encouraged for better angiographic and clinical outcomes in contemporary PCI.
Table. Six month outcomes. 
Variables, N(%) Additional balloon(N=67) No additional balloon (N=276) p
Death 7(cardiac=3)(2.5%) 0(0%) 0.188
Q Myocardial infaction 2(0.7%) 0(0%) 0.485
TLR 9(3.3%) 1(1.5%) 0.44
TVR 13(4.7%) 1(1.5%) 0.232
MCACE 21(7.6%) 1(1.5%) 0.02
 
998-248 Primary Thrombosuction With Export Aspiration 
Catheter During Percutaneous Coronary Intervention 
in Acute Coronary Syndrome: Acute Results and In-
Hospital Outcomes
Gaurav Minocha, Praveer Agarwal, Sanjay Kumar Chugh, Mitu Anand Minocha, Atul 
Mathur, Suman Bhandari, Ashok Seth, Tarlochan Singh Kler, Escorts Heart Institute and 
Research Centre, New Delhi, India
Background: Percutaneous coronary intervention (PCI) for acute coronary syndrome 
(ACS) in lesions with a large thrombus load increases the procedural complication rate. 
Thrombus reduction with use of the Export aspiration catheter (EAC) has been reported 
in Primary PCI in ST elevation AMI (STEMI) only. This has not been described in the 
setting of the other Acute Coronary Syndromes (ACS) such as unstable angina (UA) and 
non ST Elevation myocardial infarction (NSTEMI). Objective of this study was to evaluate 
acute angiographic results, procedural safety and efﬁcacy of this technique in reducing 
thrombus burden in ACS.
Methods: The EAC a component of the Guard Wire Plus system, was originally 
developed for emboli containment in vein graft and peripheral interventions. An empty 
syringe attached to the EAC was used for thrombosuction before PCI in consecutive 
cases of ACS with visible angiographic thrombus (ﬁlling defects, contrast staining) unless 
the reference infarct - related artery diameter was less than 2 mm.
Results: EAC thrombosuction was performed successfully in 87 patients undergoing 
PCI (33STEMI, 30 UA, 24 NSTEMI) and gross thrombi were obtained from 46(52.8%) 
patients.Primary EAC aspiration was preferred and predilatation was required prior to 
EAC aspiration in 20.6% patients only. Thrombus load was completely removed in 57.4% 
patients with EAC aspiration alone. TIMI ﬂow improved following EAC aspiration alone in 
97.7% patients, with TIMI 3 ﬂow being restored in 73.5% patients After stenting, TIMI 3 
ﬂow was restored in 97.7% target vessels. There was transient slow ﬂow in 17 patients. 
In patients of STEMI, ST segment resolution >50% was observed in 81.8% patients. 
IIb/IIIa inhibitors were used in 68.9% patients and the mean procedural time was 45 ± 20 
minutes. There was no angiographic evidence of distal branch loss or vessel injury. No 
major procedural or in-hospital complication occurred in any patients.
Conclusions: Thrombosuction with EAC can be safely applied for thrombus reduction in 
treating ACS patients including UA, and both ST elevation as well as Non ST elevation 
AMI. Thrombosuction with EAC was associated with good acute angiographic result and 
no procedural complications.
998-249 Diabetes, Renal Function, and Cardiovascular Risk 
Following Myocardial Infarction: Lessons From 
The VALsartan In Acute myocardial iNfarcTion Trial 
(VALIANT)
Nagesh S. Anavekar, Scott D. Solomon, Aldo P. Maggioni, Yuri Belenkov, Jean-Lucien 
Rouleau, John J. V. McMurray, Eric J. Velazquez, Robert M. Califf, Marc A. Pfeffer, Baker 
Heart Institute, Melbourne, Australia, Brigham and Women’s Hospital, Boston, MA
Background. Diabetes is a common cause of renal dysfunction, an independent risk 
factor for cardiovascular (CV) disease. It is not clear if diabetes modiﬁes the relation 
between renal dysfunction and CV risk.
Methods. VALIANT randomized 14,703 patients with acute myocardial infarction (MI) 
complicated by heart failure (HF), left ventricular systolic dysfunction, or both. A total 
of 14,527 had creatinine measured at baseline. Glomerular ﬁltration rate (GFR) was 
estimated using the 4-component Modiﬁcation of Diet in Renal Disease equation. We 
used multivariable Cox proportional modeling to compare the relation between eGFR 
and composite CV outcome (CV death, recurrent MI, HF hospitalization, stroke, or 
resuscitated sudden death) in diabetics and non-diabetics.
Results. Mean eGFR was 66.8 ± 22.0 for diabetics (n=3358) and 71.2 ± 21.0 mL/
min/1.73 m2 for non-diabetics (n=11,169). Occurrence of CV composite was higher in 
diabetics (45.2% vs. 29.2%; P<0.001). Risk for CV events based on eGFR was similar in 
each group. Each reduction of eGFR by 10 units was associated with a hazard ratio of 
1.09 (95% conﬁdence interval [CI], 1.06-1.12) in diabetics and 1.08 (95% CI, 1.06-1.10) 
in non-diabetics for risk of the CV composite, independent of treatment assignment (P 
interaction 0.51).
Conclusions. Although diabetes is associated with higher risk for CV complications, this 
is not explained by renal dysfunction as non-diabetics and diabetics experience similar 
increases in CV risk with worsening renal function.
 
998-250 Chronic Obstructive Pulmonary Disease Is an 
Independent Predictor of Death in Patients With 
Myocardial Infarction: An Analysis of the VALsartan In 
Acute myocardial iNfarcTion Trial (VALIANT)
Aldo P. Maggioni, Zhen Huang, Karen S. Pieper, Scott D. Solomon, Rafael Diaz, Lars 
Kober, Eric J. Velazquez, John J. V. McMurray, Marc A. Pfeffer, Associazione Nazionale 
Medici Cardiologi Ospedalieri Research Center, Florence, Italy, Brigham and Women’s 
Hospital, Boston, MA
Background. By virtue of a shared etiology related to smoking, chronic obstructive 
pulmonary disease (COPD) is relatively common in patients with coronary heart disease. 
COPD may result in lower use of life-saving treatments such as beta blockers. The 
effect of COPD on treatment use and clinical outcome after myocardial infarction (MI) 
is unknown.
Methods. VALIANT randomized 14,703 patients with acute MI complicated by clinical 
or radiological signs of heart failure (HF), left ventricular systolic dysfunction (LVSD), 
or both. Patients were randomly assigned to receive captopril, valsartan, or both. The 
presence of COPD was recorded by the investigators at study entry. The relation between 
a history of COPD and 3-year all-cause death was determined by using multivariable Cox 
proportional modeling.
Results. COPD was reported in 1258 patients (8.6%). Patients with COPD were older, 
had more risk factors for coronary heart disease (such as diabetes), and more indicators 
of an adverse outcome than those without COPD (speciﬁcally signs/symptoms of HF). 
Beta-blocker treatment was prescribed less frequently in patients with COPD than 
in patients without (52% vs. 75%; P<0.0001). The 3-year mortality rate was 35.9% in 
patients with and 21.4% in patients without COPD (P<0.0001). Mortality was higher in 
patients with COPD than in those without COPD, regardless of beta-blocker prescription 
(P interaction=0.47). A non-cardiovascular cause of death was more frequent in patients 
with COPD than in those without (19.6% vs. 12.8%; P<0.0001). Multivariable analysis 
conﬁrmed that COPD is an independent predictor of 3-year all-cause mortality (hazard 
ratio [HR] 1.17; 95% conﬁdence interval [CI], 1.04-1.31; P=0.007) and cardiovascular 
death, MI, or HF (HR 1.14; 95% CI, 1.04-1.25; P=0.006).
Conclusions. COPD was independently associated with an approximate 17% increased 
risk of 3-year mortality in patients with LVSD, HF, or both after MI. Because of poor outcome 
and the difference in causes of death, more aggressive and/or speciﬁc treatments for (this 
high-risk subgroup of) patients with COPD should be investigated.
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999-251 Effects of Perindopril on Cardiac Events in 
Revascularized Coronary Artery Disease Patients
Maarten L. Simoons, Michel Bertrand, Willem J. Remme, Jaap W. Deckers, Roberto 
Ferrari, Kim Fox, Erasmus MC, Rotterdam, The Netherlands, Hopital Cardiologique, 
Lille, France
Background : The EUROPA trial has demonstrated that perindopril 8 mg once daily, an 
ACE inhibitor with high-tissue afﬁnity, signiﬁcantly decreased the risk of major cardiac 
events (cardio-vascular death, myocardial infarction and resuscitated cardiac arrest) by 
20% in patients with stable coronary heart disease (CAD) without apparent heart failure.
Aim: to assess the effect on cardiac events adding perindopril 8 mg once daily to standard 
therapy in the subgroup of EUROPA patients, with previous revascularization, and without 
previous myocardial infarction (MI). 
Methods: We conducted a subgroup analysis of the EUROPA study patients according to 
their revascularization and previous MI history. Among the 12,218 patients of EUROPA, 
we identiﬁed 6709 (54.9%) patients who had a previous revascularization. Approximately 
equal proportions had undergone PCI (3122) or CABG (3136). As well we identiﬁed 3047 
(24.9%) patients had not experienced a previous myocardial infarction.
Results: Out of the 6709 revascularized patients, 3340 were treated with perindopril (8 
mg per day), 3369 with placebo. Their baseline characteristics were similar to the whole 
EUROPA population in terms of demographics, medical history, physical examination 
(heart rate, blood pressure), and medications at screening. The mean patient age was 
60 years and 85 % were men.
The incidence of the composite endpoint CV death, MI and resuscitated cardiac arrest 
was of 6.6% in the perindopril group and 8.0% in the placebo group leading to a relative 
risk reduction (RRR) with perindopril of 17.3%, [95% CI: 1.3%;30.8%] p = 0.036. Incidence 
of myocardial infarction was of 4.6% for perindopril and 5.9% for placebo (RRR 23%, 
[95% CI: 4.9%;37.6%] p = 0.015).
In the 3047 revascularized patients without an history of MI, incidence of MI with 
perindopril was of 3.8% in the perindopril group as compared to 5.5% in the placebo 
group (RRR 31.7%, [95% CI: 4.4%;51.2%] p = 0.026).
Conclusion: Perindopril 8 mg daily is beneﬁcial for prevention of cardiac events in 
all stable CAD patients including those with previous revascularization and without 
previous MI.
999-252 Effect of Free Fatty Acid Inhibition on Silent and 
Symptomatic Myocardial Ischemia in Diabetic Patients 
with Coronary Artery Disease
Giuseppe M. Rosano, Mauricio Wajngarten, Cristiana Vitale, Otavio Gebara, Giuseppe 
Marazzi, Massimo Fini, Maurizio Volterrani, IRCCS San Raffaele, Roma, Italy, INCOR, 
Sao Paulo, Brazil
Background: Free fatty acid inhibition with Trimetazidine (TMZ) improves myocardial 
metabolism and myocardial ischemia in patients with coronary artery disease (CAD). 
Because of its effect on myocardial glucose utilization TMZ may represent a therapeutic 
option in diabetic patients with CAD. Methods: To evaluate whether the metabolic 
effect of TMZ may improve episodes of myocardial ischemia in diabetic patients with 
CAD we evaluated the effect of TMZ on 24 hour ambulatory ECG monitoring (AEM) in 
30 patients y (22 males and 8 females, mean (SE) age = 67±6.5 years) with NIDDM 
and ischemic cardiomyopathy. Patients were randomized to receive on top of standard 
therapy either TMZ (20 mg, tds) or Placebo (tds) and were evaluated at baseline and 
after 6 months. Results: Patients randomized to TMZ or Placebo were comparable 
regarding demographic data, distribution of CAD, and glicated haemoglobin levels. TMZ 
signiﬁcantly reduced the number of episodes of transient myocardial ischemia (-24% 
compared to baseline, p<0.01; -27% compared to placebo, p<0.01), and Total Ischemic 
Burden (-28% compared to baseline, p<0.01; -29% compared to placebo, p<0.01). TMZ 
also signiﬁcantly reduced the number of silent episodes of myocardial ischemia (-42% 
compared to baseline and -39% compared to placebo, p<0.01) and the time of silent 
myocardial ischemia/24 hours (-37% compared to baseline and -35% compared to 
placebo, p<0.01). No signiﬁcant changes in heart rate were detected between baseline, 
placebo and TMZ evaluations. Conclusions: In conclusion, TMZ is effective in reducing 
silent and symptomatic episodes of transient myocardial ischemia in diabetic patients with 
CAD on standard anti-anginal therapy.
999-253 Ranolazine Safety and Tolerability During Long Term 
Treatment of Stable Angina
Michael J. Koren, Michael Crager, Michael Sweeney, Jacksonville Center for Clinical 
Research, Jacksonville, FL, CV Therapeutics, Palo Alto, CA
Background: Ranolazine (Ran) is a novel agent shown to exert its anti-anginal effect 
without changes in blood pressure or heart rate in controlled, short-term exercise studies. 
Longer term (>3 months) Ran safety and tolerability have not been previously reported.
Methods: Subjects (n=746; mean age = 63.6 yrs) with exercise-limiting chronic angina 
who successfully completed one of two short-term (< 3 months), placebo-controlled 
treadmill studies [average baseline Duke Treadmill Score (DTS) = -14.4; range -30.0 to 
-7.5] participated in a Ran long-term open label study. Subjects initially received Ran 
500mg bid and were titrated to1,000mg bid. Age, sex, diabetes (DM), history of MI and 
CHF, and exercise duration were investigated as predictors of discontinuation due to 
adverse events (AEs) using Cox regression analyses. Mortality rates were compared with 
the DTS predicted mortality of up to 5.25% per year.
Results: Average subject follow-up on Ran was 2.96 (range 6 days to 6.6 yrs). All but one 
subject had at least 2 yrs follow-up unless death or discontinuation occurred before this 
time. There were 68 deaths [2.8% incidence per per patient year (PPY)] during follow-up 
including 15 sudden deaths (0.63% PPY) and 5 deaths (0.21% PPY) due to documented 
ventricular arrhythmias or cardiac arrest. No torsades de pointes was reported. Mean 
QTc interval (Fridericia corrected) was 419.9 msec (SE = 0.82) at baseline and 423.2 
msec (SE = 0.67) (P<0.001) during Ran therapy. Ten subjects developed QTc durations 
of >500 msec at some point and 72 subjects (9.7%) discontinued Ran due to AEs during 
the ﬁrst two yrs of follow-up. In Cox models, age >64 yrs (RR=2.32; P<0.001) and history 
of CHF (RR=0.55; P=0.030), but not male sex (RR=0.93; P=0.77), history of MI (RR=0.74; 
P=0.14), DM (RR=1.04; P=0.87) or below median exercise tolerance (RR=1.34; P=0.16), 
were signiﬁcant predictors of AE-associated study discontinuation.
Conclusions: Observed mortality rates during long-term Ran use did not exceed 
expectations in a high risk, angina-limited population. Most subjects tolerated at least 
two yrs of therapy. Drug intolerance occurred more commonly in older subjects and less 
commonly in those with a history of CHF.
999-254 Cost Beneﬁt Analysis of Treatment of Symptomatic 
Multivessel Coronary Disease With Preserved Left 
Ventricular Function. The Five-Year MASS II Report
Desiderio Favarato, Whady A. Hueb, Protasio Lemos Da Luz, Luiz A. M. César, Eulógio 
E. Martinez Filho, José A. F. Ramires, Sérgio A. Oliveira, Heart Institute (InCor), 
University of São Paulo Medical School, São Paulo, Brazil
Background: Treatment for patients with stable angina remains controversial. Surgical 
revascularization has been associated with greater symptom relief, and lesser necessity 
of further interventions.
Compare costs and efﬁciency of treatment regimens for CAD in symptomatic multivessel 
disease.
Methods: We studied 611 participants of MASS II (205 PTCA, 203 medical and 203 
CABG) . Incidence of cardiovascular death, acute myocardial infarction, PTCA or CABG, 
new catherizations and relief of angina, were assessed at 5 yrs.
The costs were based in ARTS I. Thus, PTCA US$ 6440.00, CABG US$ 10500.00; AMI 
US$ 2550.00, angiogram US$1900.00, and yearly medication cost of US$ 1200.00 for 
Medical treatment, and US$ 1.000.00 for PTCA and CABG. Cost efﬁciency analysis were 
carried by the event free-time and relief of angina.
Results: The ﬁve year incidence of death was 12.2% for PTCA, 12.8 for Medical and 5.4% 
for CABG (p= 0.023); AMI was 11.7% for PTCA, 9.4% fro medical and 4.9% in CABG 
(p=0.047); new angioplasty was performed in 37.6% for PTCA, 23.1% Medical, and 4.4% 
in CABG (p=0.00001); new angiograms 24.8% in PTCA, 17.8% Medical, and 5.4% in 
CABG (p=0.00001). Angina free frequency were 67.6% in PTCA, 55.1% in Medical, and 
74.3% in CABG group. Expected cost raised 41.4% in Medical, 18.7% in PTCA and 2.1% 
in CABG. The ﬁve years cost effectiveness analysis is shown in table.
Conclusion: CABG was the most cost-effective treatment for preventing events and 
relieving angina over 5 years.
Table
Expected Actual Event-free Event and Angina free
Medical 6,000.00 8,485.96 11,165.74 20,268.24
PTCA 11,440.00 13,573.90 18,852.64 27,882.90
CABG 15,650.00 15,975.37 18,153.93 24,443.34
 
999-255 Effect of Amlodipine on the Restenosis and Clinical 
Outcome in Patients With Coronary Artery Disease 
After Angioplasty : Results From the Cardiovascular 
Events Follow-Up Trial in Kokura (CAVEFT-Kokura)
Hiroyoshi Yokoi, Yoshimitsu Soga, Shinichi Shirai, Kenji Ando, Takashi Yamada, Koyu 
Sakai, Katsuhiro Kondo, Keita odashiro, Masashi Iwabuchi, Hitoshi Yasumoto, Hideyuki 
Nosaka, Masakiyo Nobuyoshi, Kokura Memorial Hospital, Kitakyushu, Japan
Background: CAMELOT Study showed that the administration of amlodipine to patients 
with coronary artery disease (CAD) resulted in reduced adverse cardio vascular events, 
especially repeat coronary revascularization.
Objective:To compare the effects of amlodipine versus placebo on restenosis and clinical 
outcome after Percutaneus coronary intervention (PCI).
Methods: In a prospective, double-blind design, 540 patients with 659 denovo lesions 
were randomized to receive 5-10mg of amlodipine or placebo. The primary angiographic 
endpoint was minimal lume diameter (MLD) at 6 month assessed by follow-up (FU) 
quantitative coronary angiography (QCA). Clinical end points were death, myocardial 
infarction, coronary bypass surgery and repeat any PCI at 12 months.
Results: Angioplasty was performed in all patients without complications ;461 patients 
(85%) had received coronary stent implantation. FU QCA was obtained in all patients. 
The MLD at FU was signiﬁcantly larger in the amlodipine group (1.49±0.52mm in the 
amlodipine group versus 1.40±0.51mm in the placebo group: p=0.041). The loss index 
was signiﬁcantly lower in the amlodipine group (0.50±0.66 in the amlodipine group 
versus 0.60±0.56 in the placebo group:p=0.035). The binary restenosis (deﬁned as >50% 
diameter stenosis at FU) rate was 21.8% in the amlodipine group versus 27.5% in the 
placebo group (p=0.09). The composite incidence of clinical events were occurred in 93 
patients (33%) in the amlodipine group versus 103 patients (39%) in the placebo group 
(p=0.14).
Conclusion: Administration of amlodipine resulted in reduced late lumen loss after PCI.
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999-256 Optimal Antiplatelet Therapy After DES Implantation in 
Patients Requiring Long-Term Anticoagulation
Annapoorna S. Kini, Jose Meller, Mary-Beth Duffy, Madhu S. Prattipati, Angelica M. Mares, 
Persis Bhandari, Sharad Kothari, Prakash Krishnan, Michael C. Kim, Pedro R. Moreno, 
Samin K. Sharma, Mount Sinai Medical Center/Cardiovascular Institute, New York, NY
Background:  The currently recommended daily dual antiplatelet therapy with Aspirin 
(A) + Plavix (P) after stenting in patients who require coumadin (C) is associated with 
increased incidence of bleeding (approx 15% at 1-year). In these patients, mono- (A or 
P) antiplatelet therapy may reduce the bleeding risk but not the risk of stent thrombosis 
(SAT), especially in the DES era. Since Plavix has a long half life (> 24 hrs), after 300-600 
mg loading dose, we proposed a modiﬁed antiplatelet strategy consisting of ASA 81 mg 
daily + Plavix 75 mg on alternate days, along with Coumadin adjusted to the target INR.
Methods and Results: We compared 30-day and 1-year incidence of bleeding, SAT and 
MACE in Coumadin requiring patients on dual antiplatelet therapy (A daily + P alternate 
days) with patients on monotherapy (A daily or P daily), after DES implantation from May 
2003 to Dec 2004. In-hospital and 30-day vascular complications, as well as GI bleeding 
up to 1-year were not different in the two groups.
Conclusion: Modiﬁed dual antiplatelet therapy with low dose daily ASA and alternate day 
Plavix for patients on Coumadin is safe compared to historic controls, with a trend towards 
lower stent thrombosis. Therefore, the optimal antiplatelet therapy for DES patients 
requiring long-term anticoagulation would be low-dose Aspirin with alternate day Plavix.
Results: 
Coumadin + ASA
and Plavix alternate 
days
n =179





TIMI major or minor bleeding 1.2 0.6 0.61
SAT 0.8 0.5 0.62
MACE 3.5 4.5 0.66
1-Year
TIMI major or minor bleeding 5.1 4.5 0.70
SAT 0.6 2.4 0.09
Death 4.5 6.4 0.48
 
999-257 Effects of Perindopril on Long-Term Clinical Outcome 
of Patients With Coronary Artery Disease and Left 
Ventricular Function
Michel E. Bertrand, Wilhelm J. Remme, Roberto Ferrari, Jab W. Deckers, Maarten I. 
Simoons, Kim M. Fox, Lille Heart Institute, Lille, France
Background: The EUROPA trial has demonstrated that perindopril, an ACE inhibitor with 
high-tissue afﬁnity, was able to signiﬁcantly decrease the risk of major cardiac events in 
patients (pts) with stable coronary heart disease (SCAD) without apparent heart failure
Aim: To assess the long-term clinical outcome of pts with SCAD and preserved left 
ventricular function (left ventricular ejection fraction (LVEF) > 40%).
Methods: A retrospective evaluation of LVEF was performed in the EUROPA study 
population. Among the 12,218 pts of EUROPA, we identiﬁed 7,096 (58%) pts who had 
LVEF measurement before randomization. Two groups of pts were studied: 6,878 (97 %) 
pts with LVEF > 40% (3,429 received 8 mg of perindopril and 3,449 received a placebo) 
and 218 pts (3%) with a LVEF 40%), there was a signiﬁcant relative risk reduction of 16 
% of the primary endpoint (a composite of cardiovascular death, non fatal myocardial 
infarction (MI) and resuscitated cardiac arrest) in the group treated with perindopril (8.3%) 
in comparison to the group treated with placebo (9.8%): Hazard ratio (HR) =0.84 [95% 
CI: 0.72-0.99] p=0.033). Similar results were obtained for the ﬁrst secondary endpoint 
(total mortality, non-fatal MI, hospital admission for unstable angina and cardiac arrest 
with successful resuscitation): HR=0.85 [95% CI: 0.76-0.96] p=0.008, for cardiovascular 
mortality and non fatal MI: HR=0.84 [95% CI: 0.72-0.99] p=0.036.
Similar beneﬁts were observed in pts with an LVEF > 40% and a history of previous MI 
and in pts with an LVEF < 40%.
Conclusions LVEF was documented in 58% of the EUROPA study population and only 
3% had an impaired LV function, conﬁrming that EUROPA pts did not have asymptomatic 
LV dysfunction. Results in pts with preserved LV function are consistent with those of the 
whole EUROPA study population and perindopril 8mg is beneﬁcial in all pts with stable 
coronary artery disease.
999-258 Outcome of Medical Management of Patients With 
Severe Multi Vesssel Coronary Artery Disease 
Unsuitable for Revascularization
Christiana O. Adesanya, Mohamed Osman, Sona Sharma, Anthony J. Pothoulakis, 
Carter G. Co, Sivakrishna Bhandaru, Department of Veterans Affairs Medical Center, 
Dayton, OH, Wright State University, Dayton, OH
Background: Medical management of patients with severe multi vessel coronary artery 
disease (CAD) unsuitable for revascularization consists of drug therapy and risk factor 
modiﬁcations. We studied retrospectively, the outcome of this approach.
Method: We examined the Computerized Patient Record System for all (1,838) patients 
who had coronary angiography at our Institution between 1999 and 2004. 108 patients 
had severe multi vessel CAD unsuitable for revascularization mainly due to poor target 
vessels. They received drug therapy including aspirin, beta blockers, ACE Inhibitors, 
statins and counseling for modiﬁcation of their risk factors. Primary endpoints were all-
cause and cardiac mortality. Secondary endpoints were angina, MI, heart failure (HF). 
Statistically signiﬁcant predictors were determined by Cox proportional hazard regression 
model (P<0.05).
Results: 104 men and 4 women were followed for 1-73 months (median 27). Mean 
age was 70.1 ± 9.0 years. Baseline ejection fraction (EF) was 37 ± 13%. Stable angina, 
unstable angina, MI, compensated and decompensated HF occurred in 43(39.8%), 
28(25.9%), 39(36.1%), 24(22.2%), and 30(27.8%) respectively. 34(31.5%) patients died, 
(11 of cardiac, 14 of non-cardiac, and 9 of unknown causes). All-cause mortality was 
associated with anemia (hemoglobin <10 gm), chronic kidney disease (GFR < 60 ml/
min), digoxin use, left ventricular dysfunction (EF <40%) {P<0.0001 respectively}, left 
main stenosis (P<0.0006). Log rank test analysis for cardiac deaths was signiﬁcant for 
anemia and digoxin use (P< 0.05). Simultaneous use of aspirin, beta blockers, ACE 
inhibitors, statins, control of hypertension (BP <140/90) and hyperlipidemia (LDL <100) 
were associated with decreased all-cause mortality (P <0.0001 respectively). BP<130/80 
was associated with decreased cardiac mortality (P <0.05)
Conclusion: In patients with severe multi vessel CAD unsuitable for revascularization, 
medical management is associated with decreased all-cause mortality. Anemia, chronic 
kidney disease, digoxin use, left ventricular dysfunction and left main stenosis are 
predictors of higher mortality.
999-259 Late Clinical Outcomes With Aspirin, Coumadin or Both 
After Acute Coronary Syndromes (Late Outcomes of 
the ASPECT-2 Trial)
Robert van Es, Ron van Domburg, Jaap Deckers, Jan Jonker, Diederick Grobbee, Freek 
Verheugt, Thoraxcentre, Erasmus MC, Rotterdam, The Netherlands, UMC, Nijmegen, 
The Netherlands
Background: Coumadin, in combination with aspirin or given alone was superior to 
aspirin alone in the secondary prevention of acute coronary syndromes in the ASPECT-2 
trial. The trial was terminated in 1999, after a mean follow-up of one year. The purpose 
of this observational study was to describe the late clinical outcome after a mean 
observation period of 7 years
Methods: Details of antithrombotic therapy, survival and cardiovascular events were obtained 
from the civil registry and from patient questionnaires. Mortality and MACE (ﬁrst occurence of 
death, myocardial infarction or stroke) were estimated by Kaplan-Meier curves.
Results: Follow-up information was obtained in 988 patients (99%). At follow-up 50 of 333 
patients allocated to aspirin, 40 of 323 patients allocated to coumadin ([INR] of 3.0-4.0) 
and 51 of 332 patients allocated to the combination of aspirin and coumadin ([INR] of 2.0-
2.5) were deceased. MACE occurred in 96, 87 and 91 patients respectively. Kaplan-Meier 
curves are shown in the ﬁgures. Cross-over rates from coumadin to aspirin was 72% and 
from combination therapy to aspirin was 77%.
Conclusions: Late clinical outcome showed a non-signiﬁcant reduction in mortality and 
MACE of coumadin compared to aspirin.The late treatment effect of coumadin may be 
reduced due to the high cross-over rate to aspirin.
ORAL CONTRIBUTIONS
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843-3 The Impact of the Deep Echo Attenuation on Coronary 
Flow After Percutaneous Coronary Intervention
Shigeki Kimura, Tsunekazu Kakuta, Taishi Yonetsu, Shingo Maeda, Asami Suzuki, 
Hideomi Fujiwara, Tsuchiura Kyodo Hospital, Tsuchiura, Japan
Background: The presence of deep echo attenuation (DEA) without dense calciﬁcation 
is sometimes detected by intravascular ultrasound (IVUS) in patients with coronary 
artery disease, which may be related with slow/no ﬂow phenomenon after percutaneous 
coronary intervention (PCI). 
Methods: Three hundred and ninety lesions in 364 consecutive patients, who underwent 
preintervention IVUS, were investigated. DEA was evaluated quantitatively by measuring 
plaque volumes with DEA (DEA-Vol). The impact of DEA and other characteristics by 
IVUS on coronary ﬂow after PCI were assessed by corrected TIMI frame count (CTFC) 
(30 frames/s). 
Results: Ninety-six lesions (24.6%) were excluded from the analysis due to uncrossability 
of IVUS catheter or heavy calciﬁcation of plaques. Thus, 115 lesions in patients with acute 
coronary syndrome (ACS) and 179 lesions in non-ACS were assessed in this study. Of 
these 294 lesions, DEA was observed in 117 (39.8%) lesions. The frequency of DEA was 
signiﬁcantly higher in ACS than in non-ACS (53.9% (62/115) in ACS vs. 30.7% (55/179) in 
non-ACS, p< 0.001) .The mean DEA-Vol in 117 lesions with DEA was 151.8 ± 234.1mm3, 
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and DEA-Vol was signiﬁcantly greater in ACS than in non-ACS (204.2 ± 294.6 vs. 92.8 
± 113.8mm3, p< 0.01). In the univariate analysis, CTFC analysis revealed signiﬁcantly 
poor coronary ﬂow after PCI in ACS patients (28.4 ± 35.7 in ACS vs. 19.4 ± 19.0 in 
non-ACS, p<0.05) , and in lesions with DEA (34.1 ± 39.6 in DEA (+) vs. 15.5 ± 7.1 in 
DEA(-), p<0.001), plaque distribution (25.0±32.0 in eccentric vs. 18.5 ± 10.8 in concentric 
lesions, p<0.05), and thrombus (33.6 ± 39.2 in thrombus (+) vs. 20.4 ± 22.8 in thrombus(-
), p<0.05). In 117 DEA (+) lesions, greater DEA-Vol group (DEA-vol > mean DEA volume) 
showed signiﬁcantly slower coronary ﬂow after PCI (CTFC: 57.8 ± 59.0 in greater DEA vs. 
27.3 ± 29.1 in smaller DEA, p<0.05). In the multivariate analysis, presence and volume of 
DEA remained signiﬁcant (P<0.001). 
Conclusions: The presence and the volume of DEA were signiﬁcantly correlated with 
procedural outcome after PCI, suggesting the relation between DEA and the existence of 
fragile plaque, which causes distal atherothrombosis.
9:15 a.m.
843-4 Microvascular Flow and Myocardial Perfusion After 
Acute MI Angioplasty in Anterior Versus Non-Anterior 
Infarcts: Results From the EMERALD Trial
Edwin A. Lee, George D. Dangas, Roxana Mehran, Eugenia Nikolsky, Alexandra J. Lansky, 
John Webb, David A. Cox, Bruce R. Brodie, Mansoor Qureshi, Anna Kalynych, Mark Turco, 
Heinz P. Schultheiss, Daniel Dulas, Barry D. Rutherford, David Antoniucci, Mitchell W. 
Krucoff, Raymond J. Gibbons, Denise Jones, Gregg W. Stone, Columbia University Medical 
Center, New York, NY, Cardiovascular Research Foundation, New York, NY
Background Percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) 
should aim not only for epicardial patency, but also myocardial perfusion and microvascular 
ﬂow. We assessed microvascular ﬂow, ST-segment resolution (STR) and infarct size by 
99mTc-Sestamibi (MIBI) in LAD vs. non-LAD infarcts in the EMERALD trial.
Methods 501 pts with AMI with symptoms less than 6 hrs and ≥ 2mm ST elevation or new 
LBBB were randomized to PCI with vs. without distal protection, had STR measurements 
since admission, and MIBI imaging within 1 month post-PCI.
Results The LAD group more frequently had baseline ST elevation, TIMI-2 ﬂow and Killip 
class≥2. The non-LAD group had more prior MI, multivessel disease, and higher baseline 
ejection fraction. Time from symptom onset to ER and ﬁrst balloon inﬂation were similar. 
Post PCI, pts in the non-LAD group had more TIMI-3 ﬂow, lower corrected TIMI frame 
counts, better myocardial perfusion (ﬁnal myocardial blush grade (MBG) 3), greater STR 
and smaller infarct size. By contrast, patients in the LAD group had slower post PCI TIMI 
ﬂow (ﬁnal TIMI 0-2) and decreased myocardial perfusion (ﬁnal MBG 0/1). There was a 
trend towards higher 6-month mortality in pts with LAD infarcts with no other signiﬁcant 
differences in clinical events (Table).
Conclusions Patients with LAD infarcts had more severe clinical presentation, and post-
PCI had lower grades of TIMI ﬂow, microvascular perfusion, and larger infarct size with a 
trend towards higher 6-month mortality. 
LAD 
(n=186) Non LAD (n=289) P value
Pre TIMI 3 18.8% 20.4% 0.72
Final TIMI 3 85.2% 94.4% 0.001
Final corrected TIMI frame count 24 18 <0.0001
Final MBG 3 40.1% 67.6% <0.0001
ST resolution >70% 35.1% 79.6% <0.0001
Infarct size Tc-99m (%LV) 25.8 ± 21.8 11.3 ± 13.7 <0.0001
30 day mortality (events) 2.8% (5) 2.1% (6) 0.67
30 day MACE (events) 7.7% (14) 6.0% (17) 0.49
6 month mortality (events) 5.5% (9) 2.1% (6) 0.09
6 month MACE (events) 13.5% (23) 8.9% (25) 0.17
9:30 a.m.
843-5 A Comparison of Upstream Versus Downstream 
Administration of Glycoprotein 2b/3a Blockers in 
Patients With Non ST-Elevation Acs Who Are All 
Scheduled for Early Invasive Therapy
Saman Rasoul, Menko Jan de Boer, Jan Paul Ottervanger, Jan Hoorntje, Kor Miedema, 
Jan Henk Dambrink, Marcel Gosselink, Harry Suryapranata, Arnoud W. van ‘t Hof, Isala 
Klinieken, Zwolle, The Netherlands
Background:Although many randomized controlled trials advocate the early initiation of 
glycoprotein2b/3a blockers in patients with non ST ACS, registry studies show that these 
agents are often reserved for downstream bail-out therapy only. This study combines the 
data from 2 randomized controlled trials, comparing routine upstream initiation of tiroﬁban 
in all patients versus bail-out use of tiroﬁban in selected patients only.
Methods:Inclusion criteria for both studies (ELISA-1 and 2) were unstable angina 
symptoms, classiﬁed as Braunwald class III, with either ST depression > 1 mm or a 
positive troponin T or CKmb. All patients were scheduled for coronary angiography. Bail 
out treatment was left at the discretion of the operator. The primary and secondary end 
point for both studies was enzymatic infarct size as assessed by the area uder the LDH 
release curve (LDHQ48) and initial TIMI ﬂow of the culprit lesion respectively.
Results: From August 2000 to December 2004, 273 patients were randomized to routine 
upstream therapy with tiroﬁban (10 microgr/kg bolus, 0.15 microgr/kg/min) (upstream 
group) and 275 patients to 2b/3a bail-out therapy only (bail-out group). No difference 
in baseline characteristics was present between the groups, apart from a shorter time 
to angiography in the bail-out group. In the bail-out group, tiroﬁban was given in 22% of 
patients. Patients in the upstream group more often had a patent culprit lesion (65.0 % 
(119/183) vs. 49.7%, (98/197), p=0.003) and a signiﬁcantly smaller enzymatic infarct size 
(median (25-75 perc): 125 (55-309) vs. 189 (68-504) IU/l, p=0.006) as compared to the 
bail-out group, after correction for time to angiography. There was a strong trend towards 
a better TIMI ﬂow after PCI (96% vs 91%, p=0.10) and a trend towards a lower incidence 
of death, re-MI, stroke or urgent TVR in the upstream group at 30 days follow-up (5.5% 
vs. 7.4%, p=0.38).
Conclusions: Early upstream therapy with tiroﬁban is associated with a better initial 
patency of the culprit lesion and a smaller enzymatic infarct size, as compared to patients 
in whom tiroﬁban is reserved for bail-out therapy only, in patients with non ST elevation 
ACS undergoing early invasive management.
9:45 a.m.
843-6 Discrimination of Human Coronary Thrombus Types by 
Optical Coherence Tomography in Vitro
Hiroshi Yabushita, Takahiro Hayashi, Masanori Matsuura, Takuro Ishise, Hajime 
Nakamura, Nobutaka Masunaga, Norio Nishioka, Kentaro Ohe, Kenji Yamaji, Toshikazu 
Tsujimoto, Atsuhiro Kurooka, Akio Kimura, Takaaki Chikugo, Hiroyuki Itou, Kinji 
Ishikawa, Kinki University School of Medicine, Osakasayama, Japan
Background: We have showed optical coherence tomography (OCT) has highly 
sensitivity and speciﬁcity for discriminating between different types of atherosclerotic 
plaques in vitro. To date, OCT imaging has not been investigated in sufﬁcient detail to 
assess its accuracy for discrimination of coronary thrombus types. The aim of this study 
was to establish OCT image criteria for discrimination of different types of thrombi.
Methods: OCT images of 53 aspirated fresh coronary samples obtained at acute 
myocardial infarction patients were correlated with both angioscopy and histology in vitro. 
OCT image criteria for three types of thrombus were formulated by analyzing a subset 
(n=8) of aspirated samples.
Results: OCT images of white thrombi on angioscopy were characterized by homogeneous, 
relative signal-rich segments without signal attenuation, consistent most likely with platelets 
and ﬁbrin by histology. OCT images of red thrombi were by homogeneous, signal-poor 
segments, consistent with red cells by histology. OCT images of yellow thrombi were by 
heterogeneous signal-rich segments with gradual attenuation, consistent with disrupted 
lipid-rich components by histology. Independent validation of these criteria by OCT reader 
for the remaining segments (n=45) demonstrated a sensitivity and speciﬁcity ranging of 
100% and 97% for white thrombus, 95% and 100% for red thrombus, and 89% and 97% for 
yellow thrombus, respectively (overall agreement, k = 0.93).
Conclusions: Additional OCT criteria are highly sensitive and speciﬁc for discriminating 
different types of coronary thrombi in vitro. The capability of OCT for accurately 
discrimination of plaque types including thrombi makes this technology suitable 
for evaluating plaque vulnerability, and will provide a basis for the interpretation of 
intracoronary OCT images obtained from patients.
10:00 a.m.
843-7 Randomized Comparison of Triple Versus Dual 
Antiplatelet Therapy After Drug Eluting Stent 
Implantation
Hyun-Sook Kim, Seung-Whan Lee, Jae-Hwan Lee, Jae-Hyeong Park, Kook-Min Kim, Jei 
Keon Chae, In-Whan Seong, Seung-Jung Park, Jae-Ki Ko, Seong-Wook Park, Chonbuk 
National University Hospital, Jeonju, South Korea, Sooncheonyang University Hospital, 
Bucheon, South Korea
Background: CREST study showed signiﬁcant decrease in the restenosis rate in the 
cilostazol group compared with the control group after bare-metal stenting. We performed 
a prospective randomized study to evaluate the effect of cilostazol after drug eluting 
stents (DES) on the top of aspirin and clopidogrel. 
Methods: From June 2004 to May 2005, 400 consecutive patients were randomized 
after DES stenting to receive a aspirin and clopidogrel plus cilostazol (group I, n=200) 
or aspirin and Clopidogrel (Group II, n=200) for 6 months. The primary end point was 
in-segment late loss at 6 months and the secondary end points included angiographic 
in-segment restenosis, major adverse cardiac events, stent thrombosis and side effect 
of antiplatelet agents.
Results: The baseline clinical and angiographic characteristics were similar between two 
groups(Table 1). One procedure-related death occurred in PES group. There were no other 
in-hospital events including acute myocardial infarction, target lesion revascularization, or 
stent thrombosis. During the follow-up, one patients was died in Group II. Both groups 
showed no difference of angiographic in-segment restenosis and late loss (Table 1). The 
6-month angiographic and clinical outcomes will be presented at the meeting.
Conclusions: This study showed no difference in the efﬁcacy between the triple and 
dual antiplatelet therapy on DES in coronary artery lesions. In other words, there was no 
statistically signiﬁcant synergistic effect of cilostazol on DES.
Group I Group II P value
Reference size (mm) 2.4 ± 0.36 2.6 ± 0.42 0.275
Lesion length (mm) 23.8 ± 12.5 20.9 ± 10.8 0.373
Total stent length (mm) 29.4 ± 11.2 26.7 ± 10.9 0.069
Pre MLD (mm) 0.60 ± 0.39 0.67 ± 0.38 0621
Post MLD (mm) 2.80 ± 0.37 2.86 ± 0.39 0.741
FU MLD (mm) 2.28±0.86 2.36±0.79 0.824
Late loss (mm) 0.30±0.49 0.52±0.72 0.370
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843-8 Early and Late Stent Thrombosis After Paclitaxel-
Eluting Stents: Analysis From the Integrated TAXUS 
Randomized Trial Program
Stephen G. Ellis, Antonio Colombo, Eberhard Grube, Jeffrey Popma, Joerg Koglin, Mary 
Russell, Gregg W. Stone, Cleveland Clinic Foundation, Cleveland, OH
Background: The incidence, timing and etiology of DES related stent thrombosis (ST) 
remains unclear.
Methods: We analyzed 2736 pts randomized to the slow-release TAXUS stent or bare 
metal stent in TAXUS II, IV and V. Follow-up is complete to 3y in TAXUS II and IV and 
1y in TAXUS V. Per protocol, clopidogrel was prescribed for 6m and ASA indeﬁnitely. 
ST (adjudicated by a blinded CEC) was deﬁned as angiographic evidence of complete 
occlusion, MI in the region of the treated vessel or sudden death <30d.
Results: Mean RVD = 2.73±.52 mm and stented length = 23.9±11.0 mm. Diabetes was 
present in 26%. Incidence of ST is shown below. Its timing ranged from 0 to 711 days. 
None of the 792 TAXUS pts followed to 3y had ST beyond 2y (95% CI 0% - 0.6%). 
MACE occurred in all 23 pts with ST, including death (26%), MI (78%) and TVR (70%). 
Of the 18 pts with ST ≤180d, 15 were on dual anti-platelet therapy (1 used clopidogrel 
inconsistently), 1 was on ASA only, 2 had both discontinued for surgery. Of the 5 pts with 
ST >180d, all were off clopidogrel (3 for >6mo), 1 was not taking ASA consistently, 1 was 
off both for surgery. 
BMS (n = 1367)
N (% [95% CI])
TAXUS (n = 1369)
N (% [95% CI]) p-value
Early (0-30 days) 7 (.51% [.23% - 1.10%]) 7 (.51% [.22% - 1.10%]) 1.00
Late:
(31-180 days) 2 (.15% [.03% - .59%]) 2 (.15% [.03% - .59%]) 1.00
(>180 days) 0 (.00% [.00% - .22%]) 5 (.37% [.14% - .90%]) 0.06
Total 9 (.66% [.32% - 1.29%]) 14 (1.02% [.58% - 1.76%]) 0.40
Conclusions: Through 6m, BMS and TAXUS appear equally susceptible to ST. ST after 
6m, though rare, may be slightly more common with TAXUS, and possibly related to 
absence of dual anti-platelet therapy. No late ST has thus far occurred after 2y, with 
longer-term follow-up in greater numbers of pts ongoing. Given the serious consequences 
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850-3 Skin Autoﬂuorescence Is Increased in Patients With 
Stable Coronary Artery Disease and Is Positively 
Associated With Serum Levels of Soluble Receptor for 
Advanced Glycation Endproducts
Douwe J. Mulder, Paul L. Van Haelst, Sascha Gross, Reindert Graaff, Andries J. Smit, 
Rijk O.B. Gans, Felix Zijlstra, University Medical Center Groningen, Groningen, The 
Netherlands
Background: Skin Autoﬂuorescence (AF) is a non-invasive marker for glycaemic and 
oxidative stress derived Advanced Glycation Endproducts (AGEs) in tissue. By interaction 
with their major cellular receptor (RAGE), AGEs have been demonstrated to enhance 
inﬂammation in atherosclerotic plaques. RAGE expression can be monitored by measuring 
serum levels of soluble RAGE (sRAGE). The aim of this study was to investigate whether 
skin AF is increased in patients with SCAD compared with healthy control subjects and to 
determine the relation of skin AF with sRAGE.
Methods: Skin AF was assessed in 63 patients with SCAD scheduled for elective CAG 
(mean age 64.8 ± 10.5 years; male: 76.2%; smoking: 26.8%; diabetes: 17.5%) and in 43 
healthy non-smoking and non-diabetic control subjects (mean age 39.7 ± 18.4 years; 
male: 38.3%). Patients with impaired renal function, heart failure, active inﬂammatory 
disease or a dark skin type were excluded. sRAGE was measured by ELISA, Quantikine, 
R&D systems. Skin AF was deﬁned as the average light intensity in the range of 420 - 600 
nm divided by average light intensity in the range of 300-420 nm (emission/excitation) and 
was measured on the lower arm, using a prototype of the current AGE-Reader.
Results: Skin AF was increased in the entire patient group as well as in non-diabetic 
patients compared with controls (2.22 and 2.14 vs. 1.67 * 10-2 AU; p < 0.001), even 
compared with a subgroup of controls with age > 40 years (2.22 vs.1.84 * 10-2 AU; p < 0.05). 
Additionally, skin AF was positively correlated with levels of sRAGE (adjusted r = 0.4; p < 
0.001), independently of age, sex, diabetes, kidney function, cholesterol and BMI.
Conclusions: Skin AF is increased in patients with SCAD and is positively correlated 
with serum levels of sRAGE. These data may contribute to further understanding of AGEs 
as mediators of atherosclerotic plaque formation.
11:15 a.m.
850-4 Comparative Evaluation of Postangioplasty Systemic 
Inﬂammatory and Oxidative Stress Response of 
Sirolimus-eluting and Bare Metal Stents
Mary E. Marketou, George E. Kochiadakis, Dragana Nikitovic, Dimitris Arfanakis, 
Emmanuel I. Skalidis, Nick E. Igoumenidis, Aikaterini Giaouzaki, Panos E. Vardas, 
Heraklion University Hospital, Heraklion, Greece
Background: Markers of systemic inﬂammation appear to be a risk factor of restenosis 
after percutaneous coronary intervention (PCI). We evaluated circulating levels of hs-CRP, 
IL-6 and lipid peroxides (LP) in patients undergoing elective implantation of sirolimus-
eluting stents (SES) compared to bare metal stents (BMS).
Methods: Fifty-two patients (35 male, aged 62 ± 11 years) with stable angina, lasting>6 
months who underwent elective single vessel PCI were randomized to SES (n=25) or 
BMS (n=27) implantation. Blood samples were taken before, 24 hours and 3 weeks after 
stent implantation in order to evaluate serum levels of hs-CRP, LP and IL-6.
Results: All procedures were successful. Baseline circulating biomarkers did not differ 
signiﬁcantly between the two groups (p=NS). At 24 hours after PCI, a similar increase 
of hs-CRP and IL-6 was noted in both groups. However, at 3-week follow-up period only 
SES group showed a signiﬁcant reduction compared to baseline. In addition, LP showed 
a signiﬁcant attenuation 3 weeks after PCI in the SES group, not noted in the US group 
(see Table 1).
Conclusions: SES implantation in stable angina favorably modiﬁes oxidative stress and 
inﬂammation response after PCI compared to BMS. These ﬁndings may have a key role 
in the promising SES results in the reduction of restenosis.
Table 1
SES BMS
before 24 hours 3 weeks before 24 hours 3 weeks
LP (µmol/L) 455±94 482±102 380±74* 409±120 443±156 435±122
hs-CRP (mg/dL) 1.03±0.4 1.97±0.4* 0.62±0.3* 0.9±0.5 1.88±0.4* 1.83±0.6*
IL-6 (pg/ml) 3.25±2.5 6.7±2.2* 1.5±1.7* 3.4±2.8 7.8±4.3* 3.6±3.2
*: p< 0.05 compared to baseline values
11:30 a.m.
850-5 Isolated Elevation in Troponin-T Following 
Percutaneous Coronary Intervention Is Associated With 
Higher Long-Term Mortality
Abhiram Prasad, Mandeep Singh, Amir Lerman, Ryan Lennon, David R. Holmes, 
Charanjit S. Rihal, Mayo Clinic, Rochester, MN
Background: Cardiac troponin T (cTnT) is a sensitive and speciﬁc marker of myonecrosis. 
There is little known about the incidence and prognostic signiﬁcance of an isolated 
elevation of cTnT without a rise in creatine kinase (CK)-MB following PCI.
Methods: We evaluated the outcomes of 1949 patients from the Mayo Clinic registry 
during the period of August 1, 2000, when routine measurements of cTnT were initiated 
for our PCI patients, through October 31, 2003 who had normal preprocedure cTnT and 
CK-MB, required non-emergency percutaneous coronary intervention (PCI), and had 
normal CK-MB following the procedure.
Results: An elevation in cTnT (cTnT+) was observed in 383 (19.6%) patients (median 
0.04 ng/ml; inner-quartile range 0.03-0.06 ng/ml). cTnT+ status was associated with 
adverse clinical and angiographic characteristics, and multivessel PCI. Over the 
median follow-up duration of 26-months, mortality (P<0.001) and the combined rate of 
death and myocardial infarction (p=0.004) were signiﬁcantly higher in cTnT+ patients. 
Estimated three-year survival for those with and without cTnT elevation was 86.9% vs 
93.2%, respectively. By multivariate analysis, an elevation in cTnT following PCI was an 
independent predictors of increased long-term mortality. A doubling in the post-PCI cTnT 
was associated with a partial hazard ratio of 1.20 (95% CI 1.02, 1.4; p=0.023).
Conclusions An isolated minor elevation in cTnT following PCI provides long-term 
prognostic information with regards to mortality and myocardial infarction. 
11:45 a.m.
850-6 Synergistic Effects of the Cholesteryl Ester Transfer 
Protein TaqIB, the Apolipoprotein E E2/E3/E4, and the 
Apolipoprotein C3 -482 C>T Polymorphisms on the 
Risk of Coronary Artery Disease
Axel Muendlein, Christoph H. Saely, Stefan Aczel, Thomas Marte, Fabian Schmid, 
Lorena Koch, Peter Langer, Philipp Rein, Guenter Hoeﬂe, Heinz Drexel, VIVIT Institute, 
Feldkirch, Austria, Academic Teaching Hospital Feldkirch, Feldkirch, Austria
Background: The genes encoding for cholesteryl ester transfer protein (CETP), 
apolipoprotein E (apoE), and apolipoprotein C3 (apoC3) play key roles in lipid metabolism. 
Their frequent variants CETP Taq1B B1>B2, APOE E3/E2/E4, and APOC3 -482 C>T are 
associated with atherogenic dyslipidemia and - in some studies - with the risk of coronary 
artery disease (CAD). A potential synergistic effect of these polymorphisms on the risk of 
CAD has not been investigated yet.
Methods: We analysed the CETP TaqIB, the APOE E3/E4/E2 and the APOC3 -482 C>T 
polymorphisms by 5’nuclease assay in 557 patients undergoing coronary angiography 
for the evaluation of established or suspected CAD. Signiﬁcant CAD was deﬁned as the 
presence of coronary stenoses with narrowings of at least 50%. 
Results: From our patients, 129 carried the APOE E4 allele, 278 the APOC3 -482T allele 
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and 196 the CETP B1B1 genotype. After multivariate adjustment, presence of the APOE 
E4 allele proved signiﬁcantly associated with an increased risk of signiﬁcant CAD (1.589 
[95% CI 1.013-2.491]; p = 0.044); the respective odds ratios associated with the APOC3 
-482T allele and the CETP B1B1 genotype were 1.170 [0.813-1.686]; p = 0.398 and 1.453 
[0.985-2.142]; p = 0.059, respectively. Importantly, the risk of signiﬁcant CAD was strongly 
increased in patients with more than one of the analysed genetic variants: adjusted odds 
ratios were 1.831 [1.113-3.013]; p = 0.017 for patients with both the APOE E4 allele and 
the CETP B1B1 genotype, 1.983 [1.017-3.868]; p = 0.045 for patients with both the APOE 
E4 and the APOC3 -482T alleles, 2.498 [1.474-4.231]; p = 0.001 for patients with both the 
CETP B1B1 genotype and the APOC3 -482T allele, and 4.491 [1.222-16.499]; p = 0.028 
for patients with all three variants.
Conclusions: There are strong synergistic effects of the CETP TaqIB, APOE E3/E4/E2 
and APOC3 -482 C>T polymorphisms on the risk of angiographically diagnosed CAD.
Noon
850-7 Prospective Evaluation of New and Old Criteria for the 
Metabolic Syndrome
Christoph H. Saely, Lorena Koch, Fabian Schmid, Thoms Marte, Stefan Aczel, Peter 
Langer, Guenter Hoeﬂe, Heinz Drexel, VIVIT Institute, Feldkirch, Austria, Academic 
Teaching Hospital Feldkirch, Feldkirch, Austria
Background: Recently, the International Diabetes Federation (IDF) has proposed 
new criteria for the deﬁnition of the metabolic syndrome. The aim of this study was to 
prospectively investigate the impact of the Adult Treatment Panel III (ATP-III) and IDF 
deﬁnitions of the metabolic syndrome on the incidence of vascular events.
Methods: In a prospective study of 750 coronary patients we recorded vascular events 
over 4 years.
Results: From our patients, 37.3% (n = 280) had the metabolic syndrome according to 
the ATP-III deﬁnition and 45.5% (n = 341) according to the IDF deﬁnition. Concordance 
between these deﬁnitions was moderate (Cohen-Kappa = 0.522; p <0.001). The 
metabolic syndrome as deﬁned by the ATP-III criteria signiﬁcantly predicted vascular 
events (adjusted hazard ratio = 1.719 [95% CI 1.243-2.376]; p = 0.001) but the metabolic 
syndrome as deﬁned by IDF criteria did not (adjusted hazard ratio = 1.247 [0.906-1.716]; 
p = 0.176) . Accordingly, event-free survival was signiﬁcantly lower among patients who 
fulﬁlled the ATP-III but not the IDF criteria than among those who met the IDF but not the 
ATP-III criteria (p = 0.012). The metabolic syndrome as deﬁned by ATP-III criteria remained 
signiﬁcantly predictive of vascular events after adjustment for type 2 diabetes, but not 
after additional adjustment for the metabolic syndrome components high triglycerides and 
low HDL cholesterol. These lipid traits in turn proved signiﬁcantly predictive of vascular 
events even after adjustment for the metabolic syndrome.
Conclusions: The ATP-III deﬁnition of the metabolic syndrome confers a signiﬁcantly 
higher risk of vascular events than the IDF deﬁnition. However, among angiographied 
coronary patients even the ATP-III deﬁnition of the metabolic syndrome does not provide 
prognostic information beyond its dyslipidemic features.
12:15 p.m.
850-8 Investigation of the Relation Between the New AHA/
CDC C-Reactive Protein Cutpoints and Cardiovascular 
Outcomes and Incident Diabetes in Patients With Stable 
Coronary Disease: A PEACE Substudy
Marc S. Sabatine, David A. Morrow, Kathleen A. Jablonski, Madeline M. Rice, Wayne 
Warnica, Michael J. Domanski, Judith Hsia, Bernard J. Gersh, Jean L. Rouleau, Nader 
Rifai, Paul M. Ridker, Marc A. Pfeffer, Eugene Braunwald, Brigham and Women’s 
Hospital, Boston, MA
Background: Elevated C-Reactive Protein (CRP) predicts cardiovascular (CV) outcomes 
in healthy individuals and in patients with acute coronary syndromes (ACS). The ability 
of CRP to predict outcomes in stable CAD and the utility of the new AHA/CDC CRP 
cutpoints remain relatively unexplored.
Methods: High-sensitivity CRP was measured in baseline samples in 3771 patients with 
stable CAD and preserved LV function in PEACE, a placebo-controlled trial of trandolapril. 
Patients were followed for a median of 4.8 years for CV outcomes and incident diabetes. 
Multivariable Cox regression was used to adjust for age, gender, BMI, traditional risk 
factors, renal function, treatment group and other cardiac medications.
Results: Patients were categorized using AHA/CDC CRP cutpoints: low (<1 mg/L), 
average (1-3), and high (>3). Baseline CRP >1 mg/L was an independent and signiﬁcant 
predictor of the composite of CV death, MI, or stroke (P<0.01), new heart failure (P<0.01), 
and new-onset diabetes (P<0.01) (Fig). The associations were similar regardless of prior 
MI, prior revascularization or treatment with trandolapril.
Conclusions: In stable CAD, an elevated CRP, even >1 mg/L, is a strong and 
independent predictor both of CV outcomes and new-onset diabetes. These data illustrate 
the important prognostic utility of CRP in apparently stable CAD, despite modern medical 
therapy and coronary revascularization, and highlight the need to ﬁnd novel strategies to 
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1018-221 Association of TIMI Risk Score and Extent of Coronary 
Artery Disease in Patients With ST-Elevation Myocardial 
Infarction: A CLARITY TIMI-28 Substudy
Michelle O’Donoghue, Marc S. Sabatine, Steven D. Wiviott, Sabina A. Murphy, Carolyn 
H. McCabe, Christopher P. Cannon, Eugene Braunwald, C. Michael Gibson, Brigham 
and Women’s Hospital, Boston, MA
Background: The TIMI Risk Score (TRS) for ST-elevation myocardial infarction (STEMI) 
is a simple bedside predictor of adverse outcomes. We hypothesized that this association 
may, in part, be due to the TRS being associated with the extent of underlying coronary 
artery disease (CAD), a relationship that has not been examined to date.
Methods: We calculated the TRS (using cardiac risk factors, weight, time to presentation, 
infarct location and physical exam signs) in 3283 patients enrolled in CLARITY-TIMI 28, 
a placebo-controlled trial of clopidogrel in addition to a ﬁbrinolytic in STEMI. Per protocol, 
routine angio was performed at 2-8 days. Vessel disease (VD) was deﬁned ≥ 50% stenosis 
in a major epicardial vessel as assessed by the investigator.
Results: A higher TRS was signiﬁcantly associated with 30-day death (Figure A, 
P<0.001), and the primary endpoint of occluded infarct-related artery on angio, death or 
MI prior to angio (P=0.002). The overall extent of CAD was: 45% 1VD, 30% 2VD, 18% 
3VD and 5% left main disease. A higher TRS was signiﬁcantly associated with a greater 
extent of CAD (Figure B, P<0.001) or left main disease (P<0.001), with more than a half 
of patients with a TRS ≥ 5 having multivessel or left main disease.
Conclusions: In a large cohort of patients with STEMI receiving a ﬁbrinolytic and routine 
angiography, the TRS is a powerful predictor of death and extent of CAD. Calculation of 
the TRS can help to identify patients at high risk of multivessel or left main disease.
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1018-222 Evaluation of the TIMI Risk Index in a Multi-continental 
Population of 19,103 Patients With STEMI in the 
ExTRACT-TIMI 25 Trial
David A. Morrow, Stephen D. Wiviott, Marc S. Sabatine, Robert P. Giugliano, Carolyn H. 
McCabe, Elliott M. Antman, Eugene Braunwald, TIMI Study Group, Brigham & Women’s 
Hospital, Boston, MA
The TIMI Risk Index is a simple risk index (heart rate x [Age/10]2/SBP) for bedside risk 
assessment of patients with ACS. The risk index was developed and validated in 14,114 
patients in InTIME II-TIMI 17, predominantly from North America and Western Europe 
and enrolled in 1997-98.
METHODS: To validate the risk index in a contemporary population with broad 
representation from Eastern Europe, Asia, Africa, and South America, we evaluated the 
risk index among 19,103 patients with STEMI treated with ﬁbrinolysis and enrolled in the 
ExTRACT-TIMI 25 Trial. Eligible patients were enrolled within 6 hours of symptom onset 
among 937sites in 49 countries between October 24, 2002 and October 1, 2005.
RESULTS: Using pre-speciﬁed risk categories, the TIMI Risk Index revealed a signiﬁcant 
graded increase in 30-day mortality with rising risk index(1.2 - 20.9.%, P<0.0001). The 
qualitative correlation between the predicted and observed mortality by risk index group 
was excellent (Figure-A). Stratiﬁcation by geographic region revealed a strong graded 
relationship with short-term mortality in all regions (Figure-B, p<0.0001 in each region).
CONCLUSIONS: A convenient risk index based upon age and vital signs remains an 
effective contemporary tool for risk assessment among patients with STEMI and performs 
well across multiple regions of the world.
1018-223 Fondaparinux Versus Enoxaparin in Patients With Acute 
Coronary Syndromes Without ST-Segment Elevation: 
Impact of Risk According to the GRACE Score
R. Peters, C. Joyner, M.G. Franzosi, J. Col, W. Boden, E. Paolasso, M. Flather, R. Afzal, 
S. Mehta, S. Yusuf, for the OASIS 5 study group, McMaster University, Hamilton, Canada
Background: The OASIS 5 trial (n=20,078) demonstrated that fondaparinux 2.5 mg OD 
was noninferior to enoxaparin 1 mg/kg BID, when used in addition to standard treatments 
in patients with non-ST-elevation acute coronary syndromes, while reducing the risk of 
bleeding by about 50%.
Methods: We performed a prospective stratiﬁed analysis in various risk groups according 
to the GRACE risk score. The primary composite outcome was cardiovascular death, 
myocardial infarction, or recurrent ischemia.
Results: The impact of fondaparinux versus enoxaparin on the rate of the primary 
outcome (at 9 days) was as follows: low-risk group (GRACE score <100), 5.2% vs 4.5% 
(hazard ratio, HR, 1.17; 95% conﬁdence interval [CI], 0.93-1.48;), intermediate-risk group 
(GRACE score 100-126), 5.2% vs 5.3% (HR 0.96; CI, 0.79-1.18), and high-risk group 
(GRACE >126), 7.2% vs 7.5% (HR, 0.96; CI, 0.81-1.15). For major bleeding at day 9: 
low-risk group: 1.1% vs 2.7% (HR 0.42, CI, 0.28-0.63), intermediate-risk group: 2.7% vs 
4.0% (HR 0.68, CI 0.53-0.88), high-risk group: 2.5% vs 5.4% (HR 0.45, CI, 0.35-0.58). 
At 180 days: primary outcome: low-risk group, 7.6% vs 8.2% (HR 0.93; CI, 0.77-1.11), 
intermediate-risk group, 10.3% vs 10.8% (HR 0.95; CI, 0.82-1.10), high-risk group, 19.1% 
vs 20.7% (HR 0.91; CI, 0.82-1.02). Major bleeding at 180 days: low-risk group: 2.2% vs 
3.8% (HR 0.57, CI, 0.42-0.77), intermediate-risk group: 4.8% vs 5.7% (HR 0.83, CI 0.67-
1.02), high-risk group: 5.3% vs 7.4% (HR 0.70, CI, 0.58-0.85). There was no evidence of 
statistical heterogeneity among the groups.
Mortality at 180 days increased as predicted by the GRACE score: 1.7%, 4.2%, 11.5% in 
the three risk groups. Mortality at 30 and 180 days was reduced with fondaparinux with 
no heterogeneity among the risk groups.
Conclusion: The beneﬁt of fondaparinux in the OASIS 5 trial is consistent in low, 
intermediate, and high risk patients with acute coronary syndromes, as stratiﬁed by the 
GRACE risk score, supporting its use in all patients with non-ST elevation acute coronary 
syndromes.
1018-224 Usefulness of a New Risk Score to Identify Patients 
With Non-ST-Segment Elevation Acute Coronary 
Syndromes Who Beneﬁt From an Invasive Treatment 
Strategy
Jose F. Santos, Carlos T. Aguiar, Jorge Ferreira, On Behalf of the Investigators for the 
PortugueseRegistry of Acute Coronary Syndromes, Sao Bernardo Hospital, Setúbal, 
Portugal, Santa Cruz Hospital, Carnaxide, Portugal
Background: In non-ST-segment elevation acute coronary syndromes (NSTE-ACS) an 
invasive strategy is increasingly pursued. Risk variables have different power in identifying 
beneﬁt from such a strategy.
Aim: Develop a risk score (Inv-Score) for patients (pts) with NSTE-ACS that combines risk 
stratiﬁcation and identiﬁcation of beneﬁt from an invasive strategy.
Methods: Studied 3240 pts with NSTE-ACS enrolled in a prospective registry from 01/01/02 
to 03/31/03. Independent predictors of in-hospital death or myocardial (re)infarction were 
identiﬁed. Characteristics related to a signiﬁcant beneﬁt of invasive strategy were selected 
to derive the Inv-Score (arithmetic sum of number of variables present). The score was 
subsequently validated in a cohort of 3876 pts enrolled in the same registry from 04/01/03 
to 07/31/05 and tested for its ability to predict in-hospital prognosis.
Results: Invasive strategy was an independent predictor of events in the test cohort 
(adjusted HR 0.61; 95%CI 0.43-0.86). Variables interacting with invasive strategy were 
age ≥65y, positive cardiac biomarkers and signs of heart failure at admission. The Inv-
Score predicted the speciﬁed endpoint in the validation cohort population (�2 trend 79.0, 
p<0.001). Figure. In pts with Inv-Score of 0/1 invasive strategy was not associated to a 
signiﬁcant reduction of events.
Conclusion: Inv-Score is a simple tool for risk stratiﬁcation and simultaneously identiﬁes 
pts who derive more beneﬁt from an invasive strategy.
1018-225 Thrombocytopenia Is Associated With Adverse 
Outcomes Following Treatment With Either Enoxaparin 
or Unfractionated Heparin in Patients Presenting With 
Acute Coronary Syndromes: A TIMI 11B Substudy
Robert W. Yeh, Stephen D. Wiviott, Robert P. Giugliano, David A. Morrow, James E. 
Bradner, Ik-Kyung Jang, C. Michael Gibson, Elliot M. Antman, Brigham and Women’s 
Hospital, Boston, MA, Massachusetts General Hospital, Boston, MA
Background: While enoxaparin has been shown to improve outcomes in non-ST 
elevation acute coronary syndromes (NSTE ACS), its effect on the development of 
thrombocytopenia in this population is controversial. We studied the incidence and 
clinical importance of thrombocytopenia in patients with NSTE ACS after treatment with 
enoxaparin (enox) or unfractionated heparin (UFH).
Methods: TIMI 11B compared enox to UFH in the management of patients presenting 
with NSTE ACS. Thrombocytopenia was deﬁned as a platelet count below 100,000 /mL 
or > 50% drop from baseline. Baseline features and clinical outcomes were compared for 
thrombocytopenic and non-thrombocytopenic patients.
Results: Thrombocytopenia developed in 118 (3.0%) of 3910 patients during the follow-
up period of 43 days. The incidence of thrombocytopenia was similar between enox 
and UFH groups (2.9% vs. 3.2%; p = NS). In patients treated with either enox or UFH, 
the development of thrombocytopenia was associated with more frequent subsequent 
death or MI at 43 days after multivariate adjustment (p<0.05 for each comparison). TIMI 
major bleeding was more common in thrombocytopenic patients regardless of treatment. 
(Figure)
Conclusions: In patients with NSTE ACS, the incidence of thrombocytopenia was similar 
when treated with enox or UFH, and those who developed thrombocytopenia had higher 
rates of death, MI, and major bleeding. Further study on the mechanisms of development 
of thrombocytopenia and its relationship to adverse outcomes is warranted.
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1018-226 Comparison of the TIMI and GRACE Risk Scores in 
the Canadian Acute Coronary Syndromes II Registry: 
Simpler Is Not Necessarily Better
Andrew T. Yan, Raymond T. Yan, Mary Tan, Kumar Sridhar, Marino Labinaz, Eric A. 
Cohen, David H. Fitchett, Anatoly Langer, Shaun G. Goodman, St. Michael’s Hospital, 
Toronto, ON, Canada, Canadian Heart Research Centre, Toronto, ON, Canada
Background: Accurate risk stratiﬁcation is important in the management of non-ST 
elevation (NSTE) acute coronary syndromes (ACS). Although several risk scores have 
been developed to help reﬁne clinical assessment, there are limited data on their 
comparative discriminatory performances across the broad spectrum of ACS.
Methods: The prospective Canadian ACS II Registry recruited less selected patients 
with NSTE ACS from 36 centres across Canada. The Global Registry of Acute Coronary 
Events (GRACE) and Thrombolysis in Myocardial Infarction (TIMI) risk scores were 
determined for 1603 patients. Clinical endpoints were all-cause mortality and the 
composite of death and non-fatal myocardial (re-)infarction [(re)MI] in hospital. Model 
discrimination was measured by the c-statistic and compared by the method according 
to Hanley and McNeil.
Results: Overall, the in-hospital rates of death and death/(re)MI were 1.9% and 6.5%, 
respectively. The median (interquartile range) GRACE and TIMI scores were 117 (96-145) 
and 3 (2-4), respectively. There was a moderate correlation between the 2 risk scores 
(Spearman’s rho=0.41, P<0.001). 
In-hospital outcome TIMI risk scorec-statistic*
GRACE risk score
c-statistic* P value for difference
Death 0.64 (0.54-0.74) 0.83 (0.77-0.90) <0.01
Death/ (re)MI 0.57 (0.51-0.63) 0.65 (0.59-0.71) <0.05
* (95% conﬁdence interval)
Conclusions: Across the wide range of NSTE ACS, the GRACE risk score demonstrated 
superior discrimination compared to the TIMI risk score in the prediction of both in-
hospital mortality and the composite endpoint of death/ (re)MI. However, both risk scores 
were of only moderate clinical utility in predicting death/(re-)MI.
1018-227 Modiﬁcation of a Simple Scoring System for Prediction 
of In-Hospital Mortality in Acute Coronary Syndromes: 
The Incremental Value of Cardiac Biomarkers in Risk 
Stratiﬁcation
Amit P. Amin, Sandeep Nathan, Patricia Vassallo, James E. Calvin, Rush University 
Medical Center, Chicago, IL
Background: The TIMI risk score (TRS) is a validated risk-stratiﬁcation tool in acute 
coronary syndromes (ACS). We previously reported the utility of the RUSH score (RS) 
[JAMA 1995;273:136-141) for mortality prediction. We sought to improve its predictive 
ability by adding troponin (cTnI) elevation to the score and compare the performance 
characteristics of the modiﬁed RUSH score (mRS) to the TRS and the unmodiﬁed RS.
Methods: The Registry of Acute Coronary Syndromes (TRACS) comprised 3,468 
consecutive ACS patients presenting to 9 hospitals. The TRS and RS were calculated per 
published methods. RS variables used in the mRS were: MI within ≤14 days, no β - blocker, 
ST depression, ongoing chest pain, diabetes mellitus and age ≥75 years. Whereas the RS 
used regression-based weighting, we simpliﬁed the score to the sum of variables present 
and incorporated the OR for mortality by cTnI elevation, adjusted for RS (OR 3.87, 95% CI 
2.39 - 6.26, p<0.001) as a multiplicative function. The resulting mRS was categorized as 
0-2, 3-4, 5-9, 10-14, ≥15 points. ROC analyses were performed to compare the AUC for the 
TRS, RS and mRS. The predictive ability of the mRS was estimated by logistic regression 
and a multivariate forced model incorporating therapy variables.
Results: Overall in-hospital mortality in TRACS was 3.38%(n=117). Mean TRS was 
3.62 ± 1.2. Mortality by mRS score groups was: 0-2: 1.15%, 3-4: 1.54%, 5-9: 5.41%, 
10-14: 9.09%, ≥15: 20%. The mRS showed high discriminant ability for predicting in-
hospital mortality with a likelihood ratio of 3.5 for mRS ≥10. AUC by ROC analysis was 
0.74 (95% CI 0.69-0.78), signiﬁcantly higher than that of the TRS [0.57 (95% CI 0.52-
0.62, p< 0.001)], or the RS [0.69 (95% CI 0.64-0.73, p= 0.01)]. By multivariate analyses, 
mRS independently predicted mortality (OR 1.94, 95% CI 1.63-2.32) after adjustment for 
therapy variables.
Conclusions: Inclusion of cTnI positivity and simpliﬁcation of the original RS yields a 
straightforward and accurate predictive tool to assess in-hospital mortality risk in ACS 
patients. The performance characteristics of the mRS appear to be superior to the RS 
and TRS in this capacity. This modiﬁed scheme needs to be validated in future ACS 
data sets.
1018-228 The TIMI Risk Index for Myocardial Infarction Predicts 
Post-MI LV Ejection Fraction: A CLARITY - TIMI 28 
Substudy
Stephen D. Wiviott, David A. Morrow, Michelle O’Donoghue, Marc S. Sabatine, Sabina A. 
Murphy, Christopher P. Cannon, Brigham and Women’s Hosptial, Boston, MA
Background: We have previously reported a simple risk index (heart rate x [Age/10]2/
SBP) predicts mortality in both clinical trials and unselected patients with STEMI. Left 
ventricular Ejection Fraction (EF) is one of the most powerful predictors of post-MI 
mortality, and is an important measure for clinical decision making.
Methods: We investigated the relationship between the TIMI Risk Index (TRI) on 
presentation and post-MI EF. CLARITY - TIMI 28 compared clopidogrel vs placebo in 
patients receiving ﬁbrinolysis for STEMI. 1,579 patients with a core-lab assessment of EF 
(ventriculogram) were divided into 5 pre-deﬁned risk groups.
Results: There was a stepwise decrement in EF with increasing risk index group; median 
EF by group ranged from 59% to 51% (ﬁgure, p trend < 0.001). Patients with higher TRI 
were signiﬁcantly more likely to have EF < 50, EF <40, or EF < 30 (p trend = <0.001 for 
each), ﬁgure. These ﬁndings were qualitatively consistent for patients with and without 
prior MI.
Conclusions: A simple risk index obtained from age and vital signs available on initial 
medical contact is associated with post-MI EF. This may help to target medical therapies, 
and explain, in part, the mechanism by the Risk Index is associated with mortality. 
1018-229 Elevated Levels of Neopterin Show a Positive 
Relationship With the Severity of Acute Coronary 
Syndromes
Kei Yunoki, Takahiko Naruko, Akira Itoh, Kazuo Haze, Nobuyuki Shirai, Hajime 
Yamashita, Shoichi Ehara, Chizuko Kitabayashi, Takehisa Suekane, Yoshimi Sugama, 
Yoshihiro Ikura, Masahiko Ohsawa, Makiko Ueda, Osaka City General Hospital, Osaka, 
Japan, Osaka City University Graduate School of Medicine, Osaka, Japan
Background : Previous studies have shown that inﬂammation and oxidative stress in 
coronary atherosclerotic lesions relate to rapidly progressive plaque destabilization. 
Neopterin, a byproduct of the guanosine triphosphate pathway, has been shown to be 
produced by activated monocytes /macrophages after stimulation by interferon �. There 
is a close relationship between the concentration of neopterin produced by these cells 
and their capacity to release hydrogen peroxide. To elucidate whether an increase in blood 
levels of neopterin could be involved, we measured plasma levels of neopterin in patients 
with acute myocardial infarction (AMI), unstable angina pectoris (UAP), and stable angina 
pectoris (SAP). Moreover, we immunohistochemically studied the presence of neopterin 
in coronary atherectomy specimens obtained from patients with SAP and UAP. Methods: 
Plasma neopterin levels were measured in 209 patients (AMI:69, UAP:73, SAP:67). In 
AMI patients, blood samples were obtained within 24 hours after onset. Blood samples 
were analyzed using by HPLC with ﬂuorimetric detection. In addition, 61 atherectomy 
specimens obtained from a different cohort of patients with SAP (n=28) and UAP (n=33) 
were studied immunohistochemically for neopterin. Results: Plasma neopterin levels in 
AMI patients were signiﬁcantly higher than in UAP patients (P< 0.001), or in SAP patients 
(p<0.0001) (AMI, 26.72±14.47nmol/l; UAP, 20.43±11.52 nmol/l; SAP, 13.27±2.76 nmol/
l). The percentage of macrophages and neopterin positive area was signiﬁcantly higher 
(P<0.0005) in UAP patients than in SAP patients. Conclusions: This study demonstrates 
that plasma neopterin levels show a signiﬁcant positive correlation with the severity of 
acute coronary syndromes and that the more severe lesions also contain a signiﬁcantly 
higher percentage of neoptrin-positive macrophages. These observations suggest that 
increased levels of neopterin relate to plaque instability in human coronary atherosclerotic 
lesions.
1018-230 Admission White Blood Cell Count and Plasma 
Glucose: A Simple and Useful Combination for 
Predicting In-Hospital Outcome After Acute Myocardial 
Infarction
Masaharu Ishihara, Sunao Kojima, Tomohiro Sakamoto, Yushiro Asada, Kazuo Kimura, 
Shunichi Miyazakai, Masakazu Yamagishi, Chuwa Tei, Hisatoyo Hiraoka, Masahiro 
Sonoda, Kazufumi Tsuchihashi, Nobuo Shimoyama, Takashi Honda, Yasuhiro Ogata, 
Hisao Ogawa, Hiroshima City Hospital, Hiroshima, Japan, Japanese Acute Coronary 
Syndrome Study (JACSS), Japan
Background: Admission white blood cell (WBC) count and plasma glucose (PG) have 
been demonstrated to be associated with adverse outcome after acute myocardial 
infarction (AMI). This study was undertaken to investigate the joint effect of WBC count 
and PG on predicting in-hospital outcome in patients with AMI.
Methods: Between 2001 and 2003, 3665 patients with AMI were enrolled into JACSS, a 
Japanese multi-center registry. Patients were stratiﬁed into tertiles (low, medium and high) 
based on WBC count and PG at the time of hospital admission.
Results: Patients with high WBC count had a 2.0-fold increase in in-hospital mortality as 
compared to those with low WBC count. Patients with high PG had a 2.7-fold increase in 
mortality as compared to those with low PG. When combination of different strata for each 
variable was analyzed, a stepwise increase in mortality was seen (Figure). Patients with 
high WBC and high PG had the highest risk: 4.8-fold increase in mortality as compared to 
those with low WBC count and low PG. Multivariate analysis was performed to assess the 
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predictor of mortality using WBC count and PG as continuous variables and showed that 
WBC count (OR 1.17 per 1000 /mm3 increase, 95%CI 1.11-1.24, p<0.001) and PG (OR 
1.06 per 1 mmol/L increase, 95%CI 1.03-1.10, p<0.001) were independently associated 
with in-hospital mortality.
Conclusions: These ﬁndings suggested that a simple combination of WBC count and PG 
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1019-231 Somatostatin Receptor Type 2 (SSTR2) Expression in 
Post-Infarction Myocardial Inﬂammatory Inﬁltrate
Antonio Abbate, Rossana Bussani, Elisa Ober, Elena Barresi, Manuela Schneider, 
Rishabh Sharma, Fabio Bassan, Gianfranco Sinagra, Alfonso Baldi, Filippo Crea, 
George W. Vetrovec, Virginia Commonwealth University, Richmond, VA, University of 
Trieste, Trieste
Background. The role of inﬂammation in the pathogenesis of acute coronary syndromes 
(ACS) is currently being elucidated. Aim of this study is to assess the prevalence of the 
type 2 somatostatin receptor (SSTR2) in activated lymphocytes in the inﬂammatory 
inﬁltrate present in the myocardium after acute myocardial infarction (AMI).
Methods. Thirty-six cases were studied at autopsy: 12 cases dying within 4 weeks after AMI 
(recent AMI), 12 subjects dying at least 4 months after AMI (healed AMI), and 12 control 
subjects without cardiac diseases. Light-microscopy was performed to measure the prevalence 
of SSTR2 in activated lymphocytes (CD3+/DR+) in remote and peri-infarct regions.
Results. SSTR2 expression was never found in control hearts. SSTR2 expression in T-
lymphocytes in recent AMI was found in the peri-infarct inﬂammatory inﬁltrate in all cases 
(100%) and in the remote myocardium in 75% of cases (median number of SSTR2+ T 
lymphocytes 126/mm2 and 42/mm2 in the peri-infarct and remote regions, respectively, 
P<0.001 vs controls, P<0.01 for peri-infarct vs remote regions). In cases of healed AMI, 
SSTR2+ T lymphocytes were found in all cases in the peri-infarct regions and in 25% of 
cases in the remote myocardium (median number of SSTR2+ T lymphocytes 42/mm2 and 
42/mm2 in the peri-infarct and remote regions, respectively, P<0.001 vs controls).
Conclusion. This study identiﬁes for the ﬁrst time the presence of SSTR2 in the widespread 
myocardial inﬁltrate after AMI, identifying a speciﬁc subpopulation of lymphocytes likely 
to be involved in the immune process linked to coronary instability. By use of octreotide, 
a somatostatin analogue, the presence of SSTR2 may have also important diagnostic, 
prognostic, and therapeutic implications.
1019-232 Secretory Phospholipase A2 type IIA Levels Are 
Increased in the Coronary Circulation of Patients With 
Acute Coronary Syndromes
Francesco Loffredo, Giovanni Cimmino, Lavinia Forte, Maria Spadera, Marianna Volpe, 
Irma Porchetta, Lucia Riegler, Giandomenico Iannaccone, Raffaele Calabro’, Paolo 
Golino, Second University of Naples, Naples, Italy
Background: Secretory phospholipase A2 type IIA (sPLA2-IIA) is an inﬂammatory 
enzyme that has been shown to correlate with cardiovascular events. However, little is 
known about its involvement in the pathophysiology of acute coronary syndromes (ACS). 
Thus, the aim of our study was to determine whether sPLA2-IIA is produced and released 
within the coronary circulation of patients with ACS.
Methods: Blood samples were simultaneously obtained from the aorta (Ao) and the 
coronary sinus (CS) of patients with normal coronary artery (CON, n=12), stable angina 
(SA, n=21), and ACS (n=24). To differentiate between the relative contribution of the 
culprit lesion and that of the entire coronary circulation, patients with both SA and ACS 
were divided into two subgroups according to location of the culprit lesion in the left (SA 
L, n=12; ACS L, n=14) or in the right coronary artery (SA R, n=9; ACS R, n=10), knowing 
that CS drains blood only from the left coronary artery. Plasma levels of sPLA2-IIA were 
measured using a high sensitivity EIA kit.
Results: sPLA2-IIA plasma levels were signiﬁcantly higher in the CS of patients with ACS 
and the culprit in the left coronary artery, while no difference was observed in all other 
groups (Figure, *=p<0.01 vs corresponding value in Ao).
Conclusions: These ﬁndings indicate that sPLA2-IIA is produced and released within the 
coronary circulation of patients with ACS at the level of the culprit lesion and establish a 
new biochemical link between this enzyme and the clinical occurrence of ACS. 
1019-233 Serum Amyloid A Is a Better Predictor of Clinical 
Outcome Than C-reactive Protein in Non-ST-Segment 
Elevation Acute Coronary Syndrome
Masami Kosuge, Kazuo Kimura, Toshiyuki Ebina, Kiyoshi Hibi, Naoki Nozawa, Ikuyoshi 
Kusama, Hideto Yano, Jyun Okuda, Noriaki Iwahashi, Tatsuya Nakaji, Hiroyuki Ozaki, 
Masahiko Kanna, Toshiyuki Ishikawa, Kengo Tsukahara, Satoshi Umemura, Yokohama 
City University Medical Center, Yokohama, Japan
Background: Inﬂammation could play an important part in pathogenesis in non-ST-
segment elevation acute coronary syndrome (NSTE-ACS). Elevated high-sensitive C-
reactive protein (hs-CRP) is associated with adverse outcomes in NSTE-ACS. However, 
serum amyloid A (SAA) has been reported to be more sensitive than CRP as a marker 
of inﬂammation. We evaluated the ability of SAA, in combinating with hs-CRP, to predict 
clinical outcome in patients with NSTE-ACS.
Methods: A total of 277 patients with NSTE-ACS were classiﬁed according to the 
presence or absence of elevated SAA >0.8 mg/dl (the upper limit of normal) or elevated 
hs-CRP >0.2 mg/dl (the upper limit of normal) on admission: group A, both no elevated 
SAA and no elevated hs-CRP (n=133); group B, no elevated SAA but elevated hs-CRP 
(n=30); group C, elevated SAA but no elevated hs-CRP (n=28); and group D, both elevated 
SAA and elevated hs-CRP (n=86).
Results: There were no differences in age, sex, previous infarction, multivessel disease 
or coronary risk factors excluding diabetes among the 4 groups. In groups A, B, C, and 
D, the proportion of diabetes was 23%, 53%, 46%, and 43% (p=0.001); positive troponin 
T was 36%, 33%, 54%, and 59% (p=0.003); ST-segment depression on admission was 
67%, 57%, 89%, and 73% (p=0.06); and major adverse cardiac event (MACE) including 
death, (re)infarction, or urgent target-vessel revascularization at 30 days was 8%, 3%, 
25%, and 23%, respectively (p=0.002). Multivariate analysis showed that as compared 
with group A, the odds ratios for MACE in groups B, C, and D were 0.50 (p=0.30), 1.95 
(p=0.038), and 1.86 (p=0.044), respectively. Among 153 patients with negative troponin 
T, the results were similar; in groups A, B, C, and D, 30-day MACE was 2%, 5%, 23%, 
and 26%, respectively (p<0.001), and multivariate analysis showed that as compared 
with group A, the odds ratios for MACE in groups B, C, and D were 1.07 (p=0.58), 2.03 
(p=0.029), and 1.96 (p=0.035), respectively.
Conclusions: Regardless of elevated hs-CRP, elevated SAA is associated with 30-day 
MACE in patients with NSTE-ACS, even among those with negative troponin T. Compared 
with hs-CRP, SAA is better related to 30-day MACE and could be of great utility for risk 
stratiﬁcation.
1019-234 Increased Plaque Heat Generation in Patients With 
Diabetes Mellitus and Acute Coronary Syndromes. An 
Increased Local Inﬂamamtory Actiation
Eleftherios Tsiamis, Konstantinos Toutouzas, Maria Drakopoulou, Virginia Markou, 
Manolis Vavouranakis, Aris Androulakis, Elli Stefanadis, Costas Tsiouﬁs, Christodoulos 
Stefanadis, Ippokratio Hospital, University of Athens, Athens, Greece
Background: Acute coronary syndromes (ACS) are related to increased inﬂammatory 
activation. Diabetes mellitus (DM) is a pro-inﬂammatory state. However, culprit plaques 
local inﬂammatory activation in patients (pts) with DM and ACS has not been extensively 
studied. Thermography detects local inﬂammatory involvement as heat generation. The 
aim of this study was to detect if culprit lesions of pts with DM and ACS have increased 
thermal heterogeneity compared to non-DM pts.
Methods: Among pts undergoing percutaneous coronary interventions, 45 with DM and 
63 non-DM, matched for age, statin-aspirin intake and angiographic stenosis(%) were 
enrolled. Pts were also stratiﬁed by the clinical syndrome, either ACS(n=43) or chronic 
stable angina(CSA, n=65). Coronary thermography (Medispes, ZWG, Switzerland) at all 
culprit lesions was performed and temperature difference (DT) between the atherosclerotic 
plaque and the proximal vessel wall was measured.
Results: Among pts with ACS thermal heterogeneity was increased in pts with DM (n=21) 
compared to non-DM (mean DT: 0.29±0.31ºC vs 0.15±0.21ºC, p=0.02), same as in the 
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CSA group (mean DT: 0.09±0.08ºC vs 0.05±0.04ºC, p=0.006) (Figure).
Conclusions: This study suggests that culprit lesions of pts with ACS and DM have 
increased thermal heterogeneity, compared to non-DM pts. Thus, a more aggressive 
strategy for plaque stabilization in pts with DM may be justiﬁed.
1019-235 RANTES Is an Independent Determinant of Outcome in 
Patients With Unstable Angina Pectoris
Adriaan O. Kraaijeveld, Wilco J. de Jager, Berent Prakken, Lex M. Nagelkerke, Ernst E. 
van der Wall, Theo J. van Berkel, Erik A. Biessen, J. Wouter Jukema, LACDR, Leiden, 
The Netherlands, LUMC, Leiden, The Netherlands
Background: Atherosclerosis and its consequences are driven by inﬂammatory 
mechanisms. Levels of a variety of chemokines, which play an important role in this 
process, are increased in atherosclerosis as well as in ischemic events and could well 
serve as biomarkers for clinical decision making and outcome. While over 50 chemokines 
have been described, identiﬁcation of relevant chemokines via proﬁling techniques could 
render novel biomarkers.
Methods: Blood samples were collected on admission from 54 patients (age 65.6±10.9 
years) with Braunwald class IIIB unstable angina pectoris and treated according to 
protocol. Despite medical treatment, 23 patients (43%) had refractory anginal symptoms 
and were referred for coronary angiography and subsequent revascularization therapy, 
while the other 31 non-refractory patients (57%) were stabilised on medical therapy 
alone. Various inﬂammatory markers were determined and differences in levels of 18 
chemokines were simultaneously investigated using a novel, highly sensitive multiplex 
bead assay and compared between the two groups.
Results: Fibrinogen (P=0.012) and erythrocyte sedimentation rate (ESR; P=0.02) 
were signiﬁcantly elevated in the refractory group. Interestingly, RANTES was the 
only signiﬁcantly elevated chemokine (32.7 vs. 23.2 ng/ml; P=0.018). In addition, no 
association could be identiﬁed between levels of ﬁbrinogen, ESR, C-reactive protein 
and RANTES. The odds ratio adjusted for age, sex, smoking behaviour, cholesterol level 
and statin treatment for occurrence of refractory angina for patients in highest quartile 
compared to the lowest quartile of RANTES was 14.6 (1.8-118.3; P=0.012). Furthermore, 
after 18 months follow-up baseline RANTES levels correlated with the need for future 
revascularization procedures (R=0.348; P=0.01).
Conclusions: In a well deﬁned cohort of patients suffering from severe unstable angina 
pectoris, we show that RANTES is a independent determinant for short as well as long 
term need for coronary angiography and revascularization procedures. Further prospective 
analysis is warranted for its application as a useful clinically applicable biomarker.
1019-236 Effects of Irbesartan and Perindopril on Endothelial 
Function and Inﬂammatory Process in Patients With 
Coronary Artery Disease and Stable Angina Pectoris
Pantelis Kourtelaris, Dimitris Tousoulis, Charalambos Antoniades, Carmen Vasiliadou, 
Gerasimos Siasos, Charalambos Vlachopoulos, Costas Toutouzas, George Latsios, 
Christos Pitsavos, Christodoulos Stefanadis, Athens University, Athens, Greece
Background: Endothelial dysfunction inﬂammation, play an important role in 
atherogenesis. The effect of ACE-inhibitors and angiotensin receptor blockers (ARB) on 
endothelial function and inﬂammation are unclear. We compared the effect of irbesartan 
or perindopril on endothelial function and levels of CRP and Fib in patients with stable 
angina (CAD).
Methods: In this study 60 patients with stable angina were enrolled. Twenty patients 
received irbesartan (75 mg/day), 20 received perindopril (2 mg/day) and 20 received no 
treatment for 4 weeks. Forearm blood ﬂow was measured using venous occlusion strain-
gauge plethysmography at baseline and after treatment. Endothelium dependent dilation 
(EDD) and endothelium independent dilation (EID) were expressed as the % change of 
ﬂow from baseline to the maximum ﬂow during reactive hyperemia or after sublingual 
nitroglycerin administration respectively. Wilcoxon rank test was used to compare the 
changes of each variable after treatment, in each study group.
Results: No signiﬁcant difference was observed in EDD and EID at baseline, between 
groups. EDD was improved in both perindopril and irbesartan-treated groups (from 40.6+/-
3.9 and 35.7+/-4.1 to 64.3+/-5.4 and 65.3+/-6.8% respectively, p<0.01 for both), while 
remained unaffected in controls (from 38.4+/-3.5 to 36.8+/-3.1% respectively, p=NS). EID 
remained unchanged in all groups. CRP serum level was decreased in both irbesartan 
(from 4.08+/-0.58 to 2.65+/-0.60 mg/l, p<0.05), and perindopril-treated group (from 5.0+/-
1.2 and to 2.18+/-0.44 mg/l, p<0.05). Fib levels were decreased in both irbesartan group 
(from 336+/- 16 to 286+/-22 mg/l, p<0.05) and perindopril groups (from 340+/-18 to 310+/-
18 p<0.05). Both CRP and Fib remained unchanged in the control group (from 3.5±0.79 
and 344±24 mg/L to 2.3±0.5 and 318±25 mg/L respectively, p=NS for all).
Conclusions: Both irbesartan and perindopril, improve endothelial function and decrease 
inﬂammatory process in patients with CAD and stable angina. These ﬁndings indicate that 
both angiotensin II receptor antagonists and ACE inhibitors exert their antiatherogenic 
effect by affecting inﬂammatory process in patients with stable angina.
1019-237 Similar Hospital Mortality for Diabetics With NSTEMI 
as for Non-diabetics With STEMI: Results of the Acos 
Registry
Anselm K. Gitt, Harm Wienbergen, Tobias Heer, Rudolf Schiele, Frank Towae, Martin 
G. Gottwik, Jochen Senges, ACOS-Study-Group, Herzzentrum Ludwigshafen, 
Ludwigshafen, Germany
Background: In 2000 a redeﬁnition of NSTEMI was published. Little is known about the 
impact of diabetes on treatment and outcome in NSTEMI as compared to STEMI.
Methods: Between Jul 2000 and Nov 2002, 16567 consecutive patients with acute 
coronary syndromes were enrolled in the ACOS registry in Germany (155 centers). We 
evaluated the impact of diabetes on hospital outcome after STEMI and NSTEMI.
Results: The prevalence of diabetes was 25% in STEMI and 31% in NSTEMI. Diabetics 
received acute reperfusion for STEMI (63.6% vs 75.7%, p<0.001) and acute PCI for 
NSTEMI (25.7% vs 34.7%, p<0.001) less often than non-diabetics. Diabetes was 
an independent determinant against acute reperfusion for STEMI (OR 0.73, 95% CI 
0.65-0.73) and against acute PCI in NSTEMI (OR 0.78, 95% CI 0.69-0.88). In STEMI 
and NSTEMI, diabetics received acute adjunctive treatment with ASA, clopidogrel, 
betablockers, ACE-inhibitors and statins less often than non-diabetics. Hospital mortality 
in diabetics was higher for both STEMI and NSTEMI as compared to non-diabetics 
(13.4% vs 8.0%, p<0.001 and 8.3% vs 4.6%, p<0.001 resp.). Diabetics with NSTEMI had 
similar hospital mortality as non-diabetics with STEMI (8.3% vs 8.0%, ns).
Conclusion: Diabetes had a similar impact on treatment and outcome of patients with 
NSTEMI and STEMI. Hospital and 1-year-mortality of NSTEMI was much higher in 
diabetics than in nondiabetics. Diabetics with NSTEMI had similar hospital mortality rates 
as non-diabetics with STEMI. 
1019-238 Genetic Polymorphism C242T on the NADPH Subunit 
p22-phox, Is Associated With Increased Risk for 
Myocardial Infarction and Endothelial Activation
Carmen Vasiliadou, Dimitris Tousoulis, Charalambos Antoniades, Marina Toutouza, 
Elli Stefanadi, Kyriakoula Marinou, Gerasimos Siasos, Athanasios Trikas, Gregory 
Vyssoulis, Christodoulos Stefanadis, Athens University, Athens, Greece
Background. Enzymatic production of free radicals plays a key role in atherogenesis. 
The p22 phox, a component of the NADH/NADPH oxidase in phagocytes and vascular 
smooth muscle cells, is essential for the production of reactive oxygen species. Evidence 
suggests that C/T polymorphism at position 242 of the p22 phox gene may affect its 
enzymatic activity. However, its role in the development of premature myocardial infarction 
(MI) as well as its ability to modify overall oxidative stress status and endothelial injury is 
unknown. We examined the effect of C242T polymorphism on p22 phox gene on the risk 
for MI, and on the variations of ox-LDL and sP-selectin.
Methods. The study population consisted of 197 patients with ﬁrst event of premature MI 
(aged 46.90±1.1 yrs old) and 204 age- and sex- matched controls. C242T polymorphism 
was detected by PCR, and levels of ox-LDL and P-selectin were determined by ELISA.
Results. The prevalence of the T allele was higher in MI patients (CC/CT/TT: 65/98/34) 
compared to controls (CC/CT/TT: 88/95/21, p<0.05). The risk for MI was higher in 
TT compared to CT+CC (1.818[95%CI:1.014-3.258] p=0.036), or compared to CC 
(2.192[95%CI:1.166-4.121] p=0.01). Carriers of the T allele (CT+TT) also had higher risk 
for premature MI (1.541[95%CI:1.026-2.312] p=0.023) compared to CC. Homozygosity 
for the T allele in the overall population was associated with higher levels of P-selectin 
(39.9±1.6ng/ml) compared to CT+CC (32.08±2.8ng/ml p<0.05). However, homozygosity 
for the T allele was associated with slightly but not signiﬁcantly higher levels of ox-LDL 
(83.9±7.09IU/L) compared to CT+CC (79.4±2.31 IU/L, p=NS)
Conclusions. Genetic polymorphism C242T on p22 phox, is associated with the 
development of premature MI, since the presence of 242T allele increases the risk for MI in 
young individuals. Furthermore, our ﬁndings suggest that although C242T polymorphism 
is associated with higher levels of P-selectin, it fails to predict plasma levels of ox-LDL, 
suggesting that it may exert its effect at a local level inside the vessel wall and not by 
modifying the overall oxidative stress status.
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1019-239 Plaque Characterization by Intravascular Ultrasound 
Virtual Histology Analysis in Diabetic Patients
Kenya Nasu, Etsuo Tsuchikane, Osamu Kato, Jean-Francois Surmely, Hiroshi Fujita, 
Yoshihiro Takeda, Tatsuya Itoh, Mariko Ehara, Yoshihisa Kinoshita, Mitsuyasu Terashima, 
Tetsuo Matsubara, Takahiko Suzuki, Toyohashi Heart Center, Toyohashi, Japan
Background: Background: Diabetes mellitus is one of the major risk factors for coronary 
artery disease. However, there is little data evaluating plaque morphology in diabetic 
patients.
Methods: Fifty-eight non-bifurcation signiﬁcant native coronary lesions (>75% stenosis 
by visual estimation) in 56 patients were imaged in vivo with a 20 MHz phased-array 
intravascular ultrasound (IVUS) catheter with motorized pull-back system at 0.5 mm/s. 
In vivo tissue histology sections were reconstructed by radiofrequency data analysis and 
evaluated from distal to proximal references of the target lesion. For each image, the 
percent of the different plaque components were analyzed. Then average of the value 
from all the image slices for one lesion was calculated. Patients were divided into two 
groups, a diabetic group (16 patients with 16 lesions) and a non-diabetic group (40 
patients with 42 lesions).
Results: Plaque composition was different between the two groups (Table) with more 
Dense Calcium (DM; 12.7% vs. non-DM; 8.4%, respectively, p = 0.0094), and Necrotic 
Core (DM; 15.6% vs. non-DM; 11.5%, respectively, p =0.01) in DM groups. Other plaque 
components as well as the percent plaque were similar between the two groups.
Conclusions: Compare to non-diabetic patients, coronary plaque compositions in 
diabetic patients showed an increased amount of Dense Calcium and Necrotic Core. This 
could possibly indicate an increased frequency of vulnerable plaque in diabetic patients.
Virtual Histology Analyses
Diabetics(n =16) Non-diabetics (n = 40) p value
Plaque area, % 53.9±13.4 52.6±12.8 NS
Fibrous area, % 56.9±10.2 62.0±13.4 NS
Fibro-fatty area, % 14.8±10.5 18.2±9.7 NS
Necrotic Core area, % 15.6±4.4 11.6±5.5 0.009
Dense Calcium area, % 12.7±5.0 8.4±5.7 0.01
 
1019-240 Patterns of Brain Natriuretic Peptide Utilization for 
Risk Stratiﬁcation of Patients With Non-ST-Segment 
Elevation Acute Coronary Syndromes
Matthew T. Roe, Sarah Milford-Beland, L. Kristin Newby, Adrian F. Hernandez, W. Frank 
Peacock, Francis M. Fesmire, Robert H. Christenson, J. Douglas Kirk, W. Brian Gibler, E. 
Magnus Ohman, Eric D. Peterson, Duke Clinical Research Institute, Durham, NC
Background: Elevated brain natriuretic peptide (BNP) levels are associated with a higher 
risk of mortality for patients (pts) with non-ST-segment elevation acute coronary syndromes 
(NSTE ACS), but the optimal use of BNP for risk stratiﬁcation remains unclear.
Methods: We analyzed BNP testing among pts with NSTE ACS (positive cardiac markers 
and/or ischemic ECG changes) from the CRUSADE Initiative at 312 U.S. hospitals from 
4/2003 to 12/2004. We evaluated pt features associated with BNP testing and the impact 
of BNP elevation on mortality.
Results: 5897 out of 30,324 pts (19.4%) had BNP levels tested. Patient features 
signiﬁcantly associated with BNP testing included signs of congestive heart failure (CHF) 
on presentation, prior CHF, older age, faster heart rate, higher body mass index, diabetes, 
prior bypass surgery, lower estimated creatinine clearance, and higher maximum troponin 
levels. Higher BNP levels were associated with an increase in the adjusted risk of in-
hospital mortality. However, the relative increase in mortality risk was greater in pts without 
signs of CHF vs those with signs of CHF, younger pts vs older pts, and nondiabetic pts 
vs diabetic pts (Table).
Conclusions: One ﬁfth of NSTE ACS pts had BNP levels analyzed during hospitalization, 
and these pts typically had high-risk clinical characteristics. However, the relative risk of 
mortality associated with elevated BNP was greater for pts without high-risk characteristics 
who were paradoxically less likely to undergo BNP testing. 
Adjusted Odds Ratios for Mortality by BNP Levels
BNP Levels Signs of CHF No Signs of CHF Age ≥65 Years Age <65 Years Diabetes No Diabetes
100-500 
ng/ml 1.88 2.89 1.87 6.75 2.47 3.08
500-1000 
ng/ml 2.16 6.20 3.03 6.71 3.31 4.98
1000-2500 
ng/ml 3.54 7.77 4.46 10.26 5.10 7.25
>2500 ng/ml 5.21 11.3 6.19 23.12 5.16 13.54
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1020-241 Human Umbilical Cord Blood Cells Improve Cardiac 
Function After Myocardial Infarction
Shin-Ichiro Yokoyama, Nihon University School of Medicine, Tokyo, Japan
Background; The ﬁeld of cell therapy for ischemic heart disease is a rapidly progressive 
as regenerative therapies. However, strategies of cell implantation into the infarcted 
myocardium have some limitations. UCB is an unlimited source of stem/progenitor 
cells that could be used for implantation into the injured heart. Because UCB contains 
an abundance of immature stem/progenitor cells and has been clinically used as an 
alternative to bone marrow transplantation. The aim of our study is to conﬁrm the potential 
of UCB as a new supplier of cells for myocardial repair. The use of UCB stem cells might 
be important to elderly and sick people whose autologous stem cells are not suitable. 
Method; As in vitro study, we cocultured human cord blood with the neonatal rat 
cardiomyocytes and investigated its cardiomyocyte speciﬁc markers (GATA4, Nkx2-5). 
As in vivo study, myocardial infarction was induced in the nude (F344/N) rats by ligation 
of the left coronary artery. Either 2x10(5) human UCB MNCs cells or equivalent cell-free 
medium was injected into the injured myocardium of the rats immediate after the induction 
of myocardial infarction. We performed their physiological and pathological assessment 4 
weeks after the implantation. We investigated the potential of human UCB cells to improve 
cardiac function following myocardial infarction. 
Result; In a co-culture system, double-positive (Nkx2-5 and HLA positive) cells were 
detected. In the pathological examination of in-vivo-study, double-positive (GATA4 and 
HLA positive) cells were observed in the heart of implantation rats. We also detected 
double-positive (vWF and HLA positive) cells. Immunoﬂuorescence staining for human 
CD34, CD45, and PECAM-1 also revealed as surviving cells in the myocardium. UCB 
cell transplantation signiﬁcantly improved ventricular function as compared to the control 
group. 
Conclusion; These ﬁndings suggest that CBMNCs include cells which can differentiate 
to cardiomyocytes as well as endothelial cells. Our ﬁndings suggest that transplanted 
human UCB cells survived and improved cardiac function following myocardial infarction. 
These results may show the usefulness of UCB cells for myocardial infarction.
1020-242 Absence of Clinical Hypotension with Eplerenone in 
Post-acute Myocardial Infarction Patients With Heart 
Failure and Left Ventricular Systolic Dysfunction: 
Results from EPHESUS
John Banas, Ramon Corbalan, Rajiv Patni, Henry Solomon, Robin Mukherjee, Bertram 
Pitt, Morristown Memorial Hospital, Morristown, NJ
Background: In EPHESUS, eplerenone (EPL) added to standard therapy with ACEI/
ARBs (87%) and β-blockers (75%) over mean 16-month follow-up signiﬁcantly improved 
outcomes in AMI patients with HF and LVSD. Due to the risk of hypotension in the 
immediate post-AMI period, the current analysis explores the effect of EPL on systolic 
blood pressure (SBP). 
Methods: Patients were randomized 3-14 days post-AMI to EPL (n=3319) or placebo 
(PBO; n=3313) plus standard therapy. Patients were stratiﬁed into quartiles by baseline 
SBP; mean change in SBP was calculated at 1 week post-randomization. The incidence 
of, and treatment discontinuations for, postural hypotension were summarized 48 hours 
and 7 days post-randomization, and at end of study. 
Results: In both treatment groups patients in the lowest SBP quartile demonstrated 
similar mean increases in SBP at week 1, whereas patients in the highest quartile had 
similar mean decreases (Table). In both treatment groups, the incidence of postural 
hypotension was extremely low at 48 hours and 7 days post-randomization (<0.1%) and 
at end of study (<1%), and there were no discontinuations due to postural hypotension. 
SBP increased from baseline to ﬁnal observation in both groups, with a smaller mean 
increase in the EPL group (3.2 vs 6.2 mm Hg, P<0.001). 
Conclusions: EPL added to standard therapy with ACEI/ARBs and β-blockers signiﬁcantly 
reduces mortality and morbidity in post-AMI patients with HF and LVSD without inducing 
hypotension in the early or late post-AMI period.
Quartile Drug Baseline n Baseline mean SBP (SD) Week 1Mean ∆ SBP (SD)
1 Placebo 1113 103 (6.2) 6.7 (13.0)
1 Eplerenone 1102 104 (6.3) 6.1 (13.8)
2 Placebo 743 118 (2.6) 0.5 (14.8)
2 Eplerenone 711 118 (2.6) 1.0 (13.9)
3 Placebo 486 128 (2.8) -4.2 (15.0)
3 Eplerenone 529 128 (2.7) -5.4 (14.5)
4 Placebo 659 147 (11.5) -16.2 (18.6)
4 Eplerenone 653 147 (11.6) -17.0 (18.1)
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1020-243 A Novel Enoxaparin Regime for ST-Elevation Myocardial 
Infarction Patients Undergoing Primary Purcutaneous 
Coronary Intervention: Intravenous but Not 
Subcutaneous Enoxaparin Achieves Adequate Anti-Xa 
Levels
Robert C. Welsh, Phil Gordon, Cynthia M. Westerhout, Christopher E. Buller, Blair J. 
O’Neill, PoKee Cheung, Paul W. Armstrong, University of Alberta, Edmonton, AB, Canada
Background: Whereas anticoagulation is essential to maximize the efﬁcacy and safety 
of primary PCI for STEMI the optimal dosing of enoxaparin (EN) in this setting is unclear. 
Accordingly, a sub-study of the Which Early ST elevation Therapy (WEST) study, explored 
a novel EN regime with systematic anti-Xa sampling.
Methods: High-risk STEMI patients randomized to primary PCI, received ASA, 
clopidogrel 300 mg and EN 1 mg/kg subcutaneous (SQ) at earliest point of care, including 
pre-hospital. Blinded anti-Xa blood samples were drawn prior and after primary PCI. An 
IV top up dose of EN (0.3-0.5 mg/kg) prior to PCI was encouraged. Data are presented as 
percentages, medians and IQR’s.
Results: Within the sub-study 30 randomized patients received primary PCI with 
abciximab used in 28/30. Demographics were: 54 years (49-65), male 83%, weight 84 kg 
(71-93), systolic BP 138 mmHg (114-159), and Killip class I 90%. The 1st anti-Xa level 55 
min. (45-76) post SQ EN was 0.28 U/ml (0.20-0.40), after which 83% (24/29) of patients 
were below suggested therapeutic levels (≥0.5 U/ml). 1st balloon inﬂation occurred 17 
min. later (12-26): IV EN top up was given 13 min. (7-21) prior to PCI in 22/30 pts. After 
completion of PCI & 40 min (30-50) after the 1st anti-Xa sample, the 2nd anti-Xa level was 
0.87 U/ml (0.61 - 1.00). An incremental dose-concentration relationship (r=0.71, p<0.001) 
was demonstrated after the 2nd anti-Xa sample i.e. no IV EN 0.41 (0.28-0.55, n=7), 3mg/
kg IV EN 0.80 (0.72-0.94, n=9), 4mg/kg IV EN 0.93 (0.74-1.20, n=4) and 5mg/kg IV EN 
0.99 (0.95-1.40, n=10). All patients that received an IV EN dose were therapeutic 0.96 
(0.80-1.08) but 5/7 without IV EN remained sub-therapeutic 0.41(0.28-0.55) p<0.01.
Conclusion: The majority of STEMI patients after a single dose of SQ EN (1mg/kg) have 
sub-therapeutic anti-Xa levels at 55 (1st anti-Xa, n=30) and 87 min (2nd anti-Xa, n=7) after 
administration. A strategy of IV EN top up (0.3-0.5mg/kg) effectively achieved adequate 
anti-Xa levels in all patients. This regime of SQ injection with in-lab IV top up provides a 
potentially attractive anti-thrombotic strategy facilitating early pre-hospital administration 
prior to primary PCI and deserves further systematic investigation.
1020-244 Percutaneous Coronary Intervention in Patients 
Receiving Only a Single Subcutaneous Dose of 
Enoxaparin: Results From the SYNERGY Trial
Glenn N. Levine, Yuliya Lokhnygina, Harvey D. White, Karen Chiswell, Neal S. Kleiman, 
Kenneth W. Mahaffey, Dietrich C. Gulba, Marc Cohen, Robert A. Harrington, John L. 
Petersen, Philip E. Aylward, James J. Ferguson, III, Robert M. Califf, Baylor College of 
Medicine, Houston, TX, Duke Clinical Research Institute, Durham, NC
Background: Prior to SYNERGY, supporting data for the use of subcutaneous enoxaparin 
(enox) in PCI were from observational studies of patients receiving multiple doses.
Methods: We examined time-dependent results following PCI in patients receiving one 
pre-procedural dose of subcutaneous enoxaparin with the endpoint of death or myocardial 
infarction (MI) at 30 days. We also conducted a time-matched analysis of patients who 
were randomly assigned to receive unfractionated heparin (UFH).
Results: Of the 120 patients randomly assigned to receive enox who received no 
prerandomization antithrombin therapy and underwent PCI within 12h of therapy, 110 
underwent PCI within 8h. Only 18 of these 110 patients received additional antithrombin. 
Per protocol, most of the patients (70%) undergoing PCI between 8h and 12h received 
additional antithrombin. There was no signiﬁcant difference in death/MI at 30 days 
between those randomized to enox (n=120) vs. those randomized to UFH (n=149) [13.3% 
vs. 10.1%, p=0.40] (Figure). In similar analysis of the larger cohort of patients who either 
received no prerandomization antithrombin or received the same drug that they were 
randomized to receive (enox n=204; UFH n=290), death/MI occurred in 10.3% and 9.3% 
of patients, respectively (p=0.72). In both analyses, most MIs occurred before PCI.
Conclusion: Though underpowered to make deﬁnitive conclusions, these data suggest 
that patients undergoing very early PCI have similar outcomes when treated with either 
enox or UFH.
 
1020-245 Preserved Epicardial Coronary Endothelial Function 
by Inhibition of δ Protein Kinase C in a Porcine Acute 
Myocardial Infarction Model
Hideaki Kaneda, Koichi Inagaki, Fumiaki Ikeno, Daria Mochly-Rosen, Stanford 
University, Stanford, CA, ShonanKamakura General Hospital, Kamakura, Japan
Background: Previous studies demonstrate impairment of endothelial-dependent 
vasodilation after ischemia/reperfusion (I/R). Though we have demonstrated that inhibition 
of δ protein kinase C (δPKC) at reperfusion reduces myocyte damage and improves 
cardiac function in a porcine acute myocardial infarction (AMI) model, impact of the 
selectiveδPKC inhibitor on epicardial coronary endothelial function remains unknown.
Methods: Either δPKC inhibitor (δV1-1, n=5) or saline (n=5) was infused into the left 
anterior descending artery at the last 1 minute of the 30-minute ischemia by balloon 
occlusion. In vivo responses to bradykinin (endothelium-dependent vasodilator) or 
nitroglycerin (endothelium-independent vasodilator) were analyzed at 24 h after I/R using 
intravascular ultrasound.
Results: In control pigs, endothelial-dependent vasodilation following bradykinin infusion 
in infarct-related epicardial coronary artery was impaired, whereas in δPKC inhibitor 
treated-pigs the endothelial-dependent vasodilation was preserved (Figure). Nitroglycerin 
infusion caused a similar vasodilatory responses in the both groups (Figure).
Conclusions: This is the ﬁrst demonstration that a δPKC inhibitor preserves vasodilator 
capacity in epicardial coronary arteries in an in vivo porcine AMI model. Because 
endothelial dysfunction correlates with worsen outcome in patients with AMI, this 
preserved endothelial function in epicardial coronary arteries might result in a better 
clinical outcome.
 
1020-246 Multi Pharmacy Is a Predictor of DES Stent Thrombosis
Paul Lee, Annapoorna S. Kini, Prakash Krishnan, Michael Farkouh, Angelica M. Mares, 
Michael C. Kim, Pedro R. Moreno, Samin K. Sharma, Mount Sinai Medical Center/ 
Cardiovascular Institute, New York, NY
Background: 
We hypothesized that the multiple drug use can lead to medication error, and thereby 
increase the risk for subacute stent thrombosis (SAT).
Methods and Results: We analyzed incidence and predictors of SAT post stenting. The 
procedural, in-hospital and follow-up events were obtained from a consecutive cohort of 
interventional patients from a large prospective database. In 13, 466 patients undergoing 
PCI with stenting, the number of drugs patient were taking correlated with the risk of stent 
thrombosis (p = 0.049, c-statistics = 0.56). Patient taking nine or more medication has a 
2.9 fold increase (CI 1.1, 7.2; p = 0.0003) of stent thrombosis compared to those patients 
taking less than nine medications (Table). In multivariate analysis and controlling for other 
previously described predictors of SAT in the non-DES era (visible thrombus, ACC/AHA 
Class B2/C, MI, LVEF, TIMI ﬂow after PTCA), the use of 9 ore more medications is the 
only predictor of SAT.
Conclusion: Poly-pharmacy is a predictor of stent thrombosis, independent of other 
major comorbities. Therefore, we postulate that a poly-pill strategy may decrease SAT by 
improving patients’ compliance. 
Number of drugs on discharge <5 5 to 8 9 or more
n 4631 8580 255
Subacute stent thrombosis (%, n) 0.41 (19) 0.62 (53) 1.57 (4)
 
1020-247 Unfractionated and Low-Molecular-Weight Heparin as 
Adjuncts to Thrombolysis in Aspirin-Treated Patients 
With ST-Elevation Acute Myocardial Infarction: A Meta-
Analysis of the Randomized Trials
Alexander GG Turpie, John W. Eikelboom, Daniel J. Quinlan, Shamir R. Mehta, Ian B. 
Menown, Salim Yusuf, McMaster University, Hamilton, ON, Canada
Background: There is uncertainty about the role of intravenous UFH and LMWH in 
patients with STEMI treated with aspirin and thrombolysis.
Methods: We performed a meta-analysis of the randomized trials to assess the effect of 
UFH and LMWH on reinfarction, death, stroke, and bleeding. 
Results: Fourteen trials involving a total of 25,280 patients were included (1239 
comparing intravenous UFH versus placebo or no heparin; 16,943 comparing LMWH 
versus placebo; and 7098 comparing LMWH versus intravenous UFH). Intravenous UFH 
during hospitalization did not reduce reinfarction (3·5% versus 3·3%; OR 1·08, 95% 
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CI: 0·58 to 1·99) or death (4·8% versus 4·6%; OR 1·04, 95% CI: 0·62 to 1·78) and did 
not increase major bleeding (4·2% versus 3·4%; OR 1·21, 95% CI: 0·67 to 2·18) but 
increased minor bleeding (19·6% versus 12·5%; OR 1·72, 95% CI: 1·22 to 2·43). During 
hospitalization/at 7 days, LMWH compared with placebo reduced the risk of reinfarction 
by about one-quarter (1·6% versus 2·2%; OR 0·72, 95% CI: 0·58 to 0·90, number needed 
to treat [NNT] = 167) and death by about 10% (7·8% versus 8·7%; OR 0·90, 95% CI: 0·80 
to 0·99, NNT = 111) but increased major bleeding (1·1% versus 0·4%; OR 2·70: 95% 
CI: 1·83 to 3·99, number needed to harm [NNH] = 143) and intracranial bleeding (0·3% 
versus 0·1%; OR 2·18, 95% CI: 1·07 to 4·52, NNH = 500). The reduction in death with 
LMWH remained evident at 30 days. LMWH compared with UFH during hospitalization/at 
7 days reduced reinfarction by about 45% (3·0% versus 5·2%; OR 0·57, 95% CI: 0·45 
to 0·73, NNT = 45), did not reduce death (4·8% versus 5·3%; OR 0·92, 95% CI: 0·74 to 
1·13) or increase major bleeding (3·3% versus 2·5%; OR 1·30, 95% CI: 0·98 to 1·72), but 
increased minor bleeding (22.8 vs 19.4%; OR 1·26, 95% CI: 1·12-1·43. The reduction in 
reinfarction remained evident at 30
Conclusion: In aspirin-treated patients with STEMI who are treated with thrombolysis, 
intravenous UFH has not been shown to prevent reinfarction or death. LMWH given for 
4-8 days compared with placebo reduces reinfarction by about one quarter and death by 
about 10% and when directly compared with UFH reduces reinfarction by almost one half. 
These data suggest that LMWH should be the preferred antithrombin in this setting.
1020-248 Is There Additional Beneﬁt of Intracoronary 
Transplantation of Autologous Peripheral Blood Stem 
Cell in Patients With Acute Myocardial Infarction?
Jin-Ho Choi, Il Rhee, Jinoh Choi, Wang-Soo Lee, Sang-Chol Lee, Hyeon-Cheol Gwon, 
Eun-Seok Jeon, Duk Kyung Kim, Sang Hoon Lee, YeonHyeon Choe, DaeWon Kim, 
Samsung Medical Center, Seoul, South Korea, Sungkyunkwan University School of 
Medicine, Seoul, South Korea
Background: Intracoronary infusion of autologous stem cells after acute myocardial 
infarction (AMI) may contribute to myocardial repair. We investigated whether patients 
with AMI treated by percutaneous coronary intervention (PCI) could beneﬁt from 
intracoronary infusion of autologous peripheral blood stem cells (PBSC), compared to 
standard PCI strategy.
Methods and Results: In this prospective nonrandomized open-labeled study, only 
patients with left anterior descending artery occlusion were enrolled to minimize bias 
related to the coronary artery anatomy. Ten patients who underwent successful PCI 
8.3±8.1 days after AMI and agreed to clinical trial received granulocyte-colony stimulating 
factor for 4 days. Then PBSC (2.0±0.7x10^9 mononuclear cells including 7.9±5.7x10^6 
CD34+ cells) were selectively infused into culprit coronary artery using transport 
catheter. To maximize myocardial localization of PBSC, proximal site of vessel was 
occluded by complaint balloon during cell infusion. After 6 month follow-up, left ventricular 
function evaluated by echocardiography and magnetic resonance imaging (MRI), and 
microvascular function evaluated by Doppler wire were improved in PBSC therapy group 
(left ventricular ejection fraction (LVEF); 37.2±7.5 vs 47.4±13.5% , p=0.027; coronary ﬂow 
reserve; 1.90±0.50 vs 2.84±0.79, p=0.004). There was no in-stent restenosis or major 
adverse clinical event. However, comparable improvement in left ventricular function 
was also shown in control groups who underwent elective PCI 8.4±7.0 days after AMI 
(N=31; LVEF; 41.9±8.0 vs 47.7±11.9%; p<0.001) or primary PCI (N=32; LVEF; 42.6±6.3 
vs 48.6±7.1%; p<0.001).
Conclusions: Our result shows that for patients with AMI and undergone PCI, additional 
intracoronary infusion of PBSC after AMI is safe and feasible, but may not lead to 
signiﬁcant difference of improvement in myocardial function compared to standard PCI 
strategy.
1020-249 Socioeconomic Differences in Use of Secondary 
Preventive Medication After Myocardial Infarction: A 
National Population-Based Study
Jeppe N. Rasmussen, Gunnar H. Gislason, Søren Rasmussen, Steen Z. Abildstrom, 
Lars Køber, Christian Torp-Pedersen, Mette Madsen, National Institute of Public Health, 
Copenhagen, Denmark
Background: We investigated differences between socioeconomic status (SES) and 
secondary preventive medication use after an myocardial infarction (MI) to increase 
knowledge of why the mortality is higher for low compared to high SES patients.
Methods: Data was linked from administrative registers. All Danish patients aged 30-64 
discharged alive after a ﬁrst MI in 1995-2002 were included (National Patient Register). 
Out-patient use of statins, beta-blockers and ACE-inhibitors (National Prescription 
Database) and individual income were determined.
By Cox-regression, adjusted for age, period, gender and comorbidity, 3 different outcomes 
were analysed for each drug: 1) time to ﬁrst prescription ﬁlling within 6 months from 
discharge, 2) time to more than 120 days between ﬁllings (indicating a pause) and 3) time 
to restart of treatment after a pause.
Results: 17,182 patients were identiﬁed (Table). Low income patients had a relative 
risk of initiating treatment of 0.81 (95% CI 0.76-0.86) for statin and 0.89 (0.89-0.93) for 
beta-blocker compared to high income. There was no signiﬁcant difference in risk of 
experiencing a pause or in restarting treatment after a pause according to income.
Conclusions: Despite high medicine reimbursement in Denmark, fewer patients with 
low than high SES initiated secondary preventive treatment. When initiated, treatment 
adherence did not differ between SES groups. It seems that improving treatment initiation 
for patients with low SES would be of long term beneﬁt.
1020-250 Increased In-Stent Neo-Intimal Hyperplasia after Stem 
Cell Mobilization by Granulocyte-Colony Stimulating 
Factor in Bare Stent, but Not in Drug-Eluting Stent in a 
Porcine Myocardial Infarct Model
Sang Yup Lim, Youngkeun Ahn, Yong Sook Kim, Myung Ho Jeong, Jeong Ha Kim, Sang 
Rok Lee, Kye Hun Kim, Il Seok Sohn, Ju Han Kim, Weon Kim, Jeong Gwan Cho, Jong 
Chun Park, Jung Chaee Kang, Chonnam National University Hospital, Gwangju, South 
Korea
Background: Using granulocyte-colony stimulating factor (G-CSF) itself and to mobilize 
stem cells has shown promise in infarcted heart. But, with the use of G-CSF, aggravation 
of in-stent restenosis (ISR) may occur and aggressive strategy to prevent ISR is needed. 
The purpose of this study was to elucidate the effects of G-CSF on ISR in a porcine model 
via comparison between bare and drug-eluting stents (DES). Methods: Bare stents (3.0 
x 18 mm) and DES (Cypher, 3.0 x 18 mm) were implanted in 40 porcine coronary arteries 
(bare stents, GroupI; bare stents with G-CSF, Group II; DES, GroupIII; DES with G-CSF, 
Group IV, n=10 in each group). G-CSF (10 µg/kg/day) was injected for 7 days from 24 
hour after stent implantation.
Results: Baseline white blood cell (WBC) and monocytes count were not signiﬁcantly 
different. After 7 days of G-CSF administration, WBC and monocyte counts were 
signiﬁcantly higher in Group II and IV than those in Group I and III (24,670±1,090 vs. 
7,950±1,520/mm3, 24,720±820 vs.7,510±1,020/mm3, each p<0.05, 2.51±0.34 vs. 
0.28±0.04 %, 2.49±0.25 vs. 0.24±0.05 %, each p<0.05). Area stenosis was 27.9±9.6 % 
in Group I and 76.7±12.0 % in Group II at 28 days (P<0.001). The ratio of inﬂammatory 
cells in the neointima was 6.5±1.7 % in GroupI and 10.1±6.3 % in Group II (P<0.001). No 
signiﬁcant differences were observed between Group III and IV. Phosphorylated signal 
transducers and activators of transcription (STAT)-3, STAT-3, and vascular endothelial 
growth factor (VEGF) were over-expressed in the neointima from Group II (vs. Group 
I, P<0.05). In porcine aortic smooth muscle cells, G-CSF increased the growth rate, 
migration, STAT-3 phosphorylation, and VEGF, which were suppressed by rapamycin 
and AG490, a STAT-3 inhibitor. Conclusions: The STAT-3 and VEGF are important in 
development of enhanced ISR by G-CSF in bare stents. DES could be a good strategy to 
prevent the G-CSF-stimulated proliferation and migration of smooth muscle cells which 
could be responsible for neointimal hyperplasia.
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1021-251 Are High-Risk Hypertensive Patients Prescribed 
Concomitant Statin Therapy? Prescription Patterns 
in Patients Initiating Antihypertensive Therapy in the 
United States
Richard H. Chapman, Allison A. Petrilla, Simon Tang, Lance Berman, Joshua S. Benner, 
ValueMedics Research, LLC, Falls Church, VA, Pﬁzer Inc., New York, NY
Background: The Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm 
(ASCOT-LLA), published April 2003, demonstrated that patients with hypertension 
and additional CHD risk factors receive signiﬁcant cardiovascular beneﬁt from statin 
(ST) therapy regardless of baseline LDL-C. We sought to document frequency of ST 
prescriptions in the 1st year after high-risk patients initiate antihypertensive (AH) 
medication, and to identify characteristics of patients receiving AH and ST therapies in a 
US managed care setting.
Methods: PharMetrics’ Patient-Centric Database was used to identify enrollees ≥25 years 
of age initiating AH treatment between September 2001 and February 2004. Cumulative 
probability of receiving ST therapy after AH initiation was examined for hypertensive patients 
with dyslipidemia, established CHD, diabetes, or no CHD but 3+ ASCOT CHD risk factors. 
Multivariate logistic regression was used to identify factors associated with receiving concomitant 
ST therapy, adjusting for demographic, clinical and health services use variables.
Results: There were 142,389 subjects who met inclusion criteria. Of the 43,825 (30.8%) 
who also had dyslipidemia, 17.3% were already on ST therapy, 29.4% were prescribed 
concomitant ST therapy in year 1, and 53.3% did not receive ST therapy during 1st year 
of AH therapy. These proportions were 11.5%, 30.9%, and 57.6%, respectively, for the 
14,647 (10.3%) hypertensive patients with established CHD; 11.6%, 27.4%, and 61.0% 
for the 17,567 (12.3%) with diabetes; and 17.1%, 29.1%, and 53.7% for the 15,701 
(11.0%) with no CHD but 3+ ASCOT risk factors. After adjusting for age, gender and other 
predictors, patients were more likely to receive ST therapy if they had dyslipidemia, CHD 
or CHD risk factors (including diabetes), or an initial AH prescription for a non-diuretic.
Conclusions: The majority of hypertensive patients with dyslipidemia, established CHD, 
diabetes or 3+ CHD risk factors do not ﬁll any ST prescriptions during 1st year of AH 
therapy. Although these proportions have likely improved since publication of ASCOT, 
increased attention to concomitant ST therapy could beneﬁt many hypertensive patients 
with additional CHD risk factors.
1021-252 Prevalence of Obstructive Lesions Detected by CT 
Coronary Angiography in Patients with Absent to 
Minimal Coronary Artery Calciﬁcation
Michael J. Gallagher, Gilbert L. Raff, James A. Goldstein, James Wegner, Judith Boura, 
Ajitha Raju, William W. O’Neill, William Beaumont Hospital, Royal Oak, MI
Background. Multi-slice CT coronary angiography (CTA) is able to detect non-calciﬁed 
coronary artery plaque. We sought to identify the prevalence and associated risk factors 
of obstructive lesions in low to intermediate risk patients with absent to minimal coronary 
artery calciﬁcation (CAC).
Methods. We prospectively evaluated 247 patients with suspected coronary artery 
disease (CAD). Exclusion criteria included positive cardiac biomarkers, ischemic ECG 
changes, or known CAD. All patients underwent 64-slice MSCT detection of CAC and 
CTA, and 98 (39.7%) underwent invasive coronary angiography.
Results. Absent (CAC=0) or minimal (CAC=1-10) coronary calciﬁcation was detected 
in 165 (66.8%) of 247 patients. In such patients, CTA revealed normal coronaries in 
129 (78.2%), mild to moderate disease (1-50% stenosis) in 19 (11.5%), and signiﬁcant 
disease (>50% stenosis) in 17 (10.3%) patients. Of the 17 patients with signiﬁcant CTA 
disease, 14 underwent cardiac catheterization. Nine of these patients had signiﬁcant CAD 
(>50% stenosis by QCA). We compared Framingham study risk factors in these 9 patients 
with the 129 patients with CAC ≤10 and normal CTA (Table). All 9 patients with obstructive 
CAD and absent/minimal CAC had ≥2 Framingham risk factors, and 5/9 patients had ≥3 
risk factors.
Conclusions. CTA evidence of obstructive disease was identiﬁed in 5.5% of low to 
intermediate risk patients with absent/minimal CAC. Importantly, all such patients had two 
or more Framingham study risk factors.
Characteristics of patients with absent/minimal coronary artery calciﬁcation
Normal CTA (n=129) Abnormal CTA (n=9) P Value
% of all pts with CAC<10 129/165 (78.2%) 9/165 (5.5%)
CAC = 0 115 6
CAC=1-10 14 3
CTA 50-75% stenosis 0 6
CTA >75%stenosis 0 3
Diabetes (no, %) 6 (4.7%) 4 (44%) 0.0015
Hypertension (no, %) 43 (33%) 3 (33%) 1.0
Hyperlipidemia (no, %) 31/114 (27%) 6 (67%) 0.021
Tobacco abuse (no, %) 23 (18%) 5 (56%) 0.017
1021-253 Association of Variant Alleles of Paraoxonase and 
Endothelial Nitric Oxide Synthase Genes With Early 
Onset of First Myocardial Infarction
Brian H. Morray, Ilan Goldenberg, Arthur J. Moss, Wojciech Zareba, James P. Corsetti, 
Charles E. Sparks, Daniel Ryan, Scott A. McNitt, Shirley W. Eberly, Jehu Mathew, 
University of Rochester, Rochester, NY
Background: In younger patients, the accumulative burden of traditional cardiovascular 
risk factors may not be as signiﬁcant as in an older population. Genetic risk factors 
have been suggested to play a role in the early development of coronary artery disease 
and myocardial infarction (MI). However, data regarding the association between 
polymorphisms in heart disease-related genes and the early onset of MI are limited.
Methods: The age of onset of ﬁrst MI was related to individual polymorphisms in each 
of 17 prespeciﬁed candidate genes in a cohort of 820 patients in whom a ﬁrst acute MI 
was identiﬁed in the Thrombogenic Factors and Recurrent Coronary Events (THROMBO) 
study.
Results: Of 17 originally deﬁned genes, high-risk alleles of paraoxonase (PON1: Q192R) 
and endothelial nitric oxide synthase (NOS3: E298D) exhibited signiﬁcant differences 
in their distribution between dichotomized age groups (quartile 1: ages ≤ 50 years; 
quartiles 2 to 4: ages > 50 years), with PON1 and NOS3 alleles having a signiﬁcantly 
higher frequency in patients in the lowest age quartile with adjusted odds ratio [OR]=1.83 
[p=0.001] and 1.78 [p=0.04], respectively. Multivariate regression analysis demonstrated 
that among patients in whom the PON1 and NOS3 high-risk polymorphisms were 
identiﬁed, the age of onset of ﬁrst MI was 2.8 [p=0.001] and 3.3 [p=0.03] years earlier, 
respectively, than patients with the respective wild-type genotype after adjustment for 
relevant clinical covariates.
Conclusions: In a cohort of patients with ﬁrst MI, variant alleles in the PON1 and NOS3 
genes were signiﬁcantly and independently associated with an earlier onset of acute 
coronary athero-thrombotic disease. This ﬁnding suggests that each polymorphism 
contributes to an accelerated development of coronary atherosclerosis.
1021-254 Long-Term Mortality and Changing Cause of Death in 
Patients With Acute Myocardial Infarction in New Jersey 
1986-1998
Alan C. Wilson, Yu-Hsuan Shao, Nora M. Cosgrove, Ronald S. Freudenberger, William 
J. Kostis, John B. Kostis, for the MIDAS Study Group, UMDNJ-Robert Wood Johnson 
Medical School, New Brunswick, NJ
Background: Although cardiovascular disease (CVD) remains the leading cause of 
death in the U.S., acute myocardial infarction (AMI) hospital case-fatality rates and CVD 
death rates have declined.
Methods: We used the statewide MIDAS database of 187,839 AMI hospital admissions in 
New Jersey from 1986-1998 to examine trends in long-term (5-year) mortality and cause 
of death following a ﬁrst AMI.
Results: The median age at ﬁrst AMI increased between 1986 and 1998 by 3 years in 
both men (64 to 67 years) and women (73 to 76 years). The 5 year CVD mortality rate for 
women decreased from 40% in patients with ﬁrst AMI in 1986 to 27% in those admitted in 
1998 (an average 2.7% per year) . The same trend was seen for men, from 29% to 18% 
(average 3.0% annual decrease). At the same time there was a steady increase in the 
non-CVD 5-year death rate in men and women from 7% to 11%, and from 8% to 15% 
respectively (Figure 1). The crude death rate from all causes within 5-years of a ﬁrst AMI 
is high but has decreased from 36% to 29% for men, and 48% to 41% for women
. 
Kaplan Meier (K-M) plots of survival stratiﬁed by cause of death (CVD vs non-CVD) after 
AMI for the same years indicated a more pronounced decrease in 5-year CVD mortality 
(especially among men), from 1986 to 1990 with less pronounced change therafter.
Conclusions:
Mortality after AMI remains high. Improvements in CVD treatment have reduced long-
term CVD mortality, however these improvements are partially offset by increasing 5-year 
mortality rates from non-CVD causes.
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1021-255 Natural History of Patients With Refractory Angina
Timothy D. Henry, Daniel Satran, Randall J. Johnson, Anil K. Poulose, Ian Augustin, 
Duana M. Walton, Rachel E. Olson, Karen L. Harvey, Alison Dummer, Teresa L. 
Streufert, Jay H. Traverse, Minneapolis Heart Institute Foundation, Minneapolis, MN, 
University of Minnesota, Minneapolis, MN
Background: An increasing number of patients have myocardial ischemia which is not 
amenable to standard revascularization techniques. These patients with refractory angina 
have been called “no option” patients and are believed to be at high risk for subsequent 
events. There is almost no data available regarding the natural history of an unselected 
cohort of these patients.
Methods: The OPTions In Myocardial Ischemic Syndrome Therapies (OPTIMIST) 
program at Abbott Northwestern Hospital (Minneapolis, MN) focuses on novel treatments 
for patients with refractory angina and collateral dependent ischemia who have high-risk 
features for coronary revascularization. The database currently includes comprehensive 
baseline characteristics, cardiovascular history and long term outcomes in 1066 patients 
with a median 3.5 year follow up.
Results: Cardiovascular history included hypertension (64.4%), diabetes (35.6%), 
hyperlipidemia (93.8%), current smokers (10.0%), former smokers (66.6%), CHF (30.8%), 
previous MI (75.1%), PCI (63.9%) and CABG (73.3%). During the 3.5 year follow-up, only 
126 patients (11.8%) died, 58 (5.4%) of cardiovascular causes including 18 MI, 13 CHF, 8 
sudden death arrhythmia, 8 periprocedural and 11 of natural causes associated with CAD. 
Despite being suboptimal candidates, 15.7% patients recieved revascularization (11.5% 
PCI and 4.1% CABG) and 357 (33.5%) patients underwent novel therapies including 
enhanced external counterpulsation (EECP) (16.2%), angiogenesis (protein, gene, stem 
cell) (12.9%), or transmyocardial laser revascularization (TMR) (3.2%).
Conclusions: Despite extensive coronary artery disease, patients with refractory angina 
have low long term mortality. Novel therapies for refractory angina should focus on 
relieving chest pain and improving quality of life.
1021-256 On-site PCI Versus PCI After Transfer in Rural Germany: 
Network Logistics for Patients With ST-Elevation 
Myocardial Infarction (STEMI)
Henrik Schneider, Frank Weber, Lydia Paranskaja, Christian Holzhausen, Huseiyn Ince, 
Michael Petzsch, Christoph A. Nienaber, for Drip & Ship Network Group, University of 
Rostock, Dept. Cardiology, Rostock, Germany
Background: Management of STEMI demands rapid and complete reﬂow to the infarct 
related artery (IRA). Primary PCI performed by an experienced operator is superior 
to thrombolytic therapy; however, few community hospitals in rural Germany offer PCI 
facilities.
Methods: In 2001 we founded a regional infarction network, using established ESC-
guidelines, comprising 1 interventional centre and 7 referring community hospitals without 
PCI facilities. Of 640 consecutive patients with STEMI, treated by primary PCI within the 
network 294 patients were transferred from a community hospital under pre-treatment 
of GP2b3a inhibitor (Transfer Group:TG), whereas 346 patients were admitted directly 
to PCI-centre (Centre group:CG). The interval from onset of symptoms to ﬁrst medical 
contact was 205 minutes in TG, and 195 minutes in CG (n.s.); 7.6% of the CG- and 
7.2% of the TG-patients were in cardiogenic shock (n.s.); 94.5% of patients completed 
12 month of follow-up.
Results: Median transportation to PCI took 54 minutes in TG. PCI of IRA was performed 
in 95.2% of TG- and 94.8% of CG-patients, 280 and 235 minutes after onset of 
symptoms (p<0.05). In addition, 95.9% of all patients received a GP2b3a inhibitor. With 
preinterventional application of GP2b3a inhibitor 22.3% of patients revealed TIMI-3 ﬂow 
of the IRA before PCI. After PCI normalized ﬂow to the IRA was documented at 87.6% 
in CG vs. 86.4% in TG (n.s.). There were no differences between groups with respect to 
infarct size (TG vs. CG: CK 2405 vs. 2395 U/l, CKMB 298 vs. 262 U/l), mortality (30 days: 
5.1 vs. 4.9%, 6 month: 7.1 vs. 6.9%, 12 month: 7.6 vs. 7.5%), NYHA (1,41 vs. 1.43) and 
LV-EF (0.41 vs. 0.43).
Conclusions: Transfer of patients with STEMI under pre-treatment of GP2b3a inhibitor in 
rural Germany using network logistics is feasible and safe. Regardless of transportation 
over 45 miles maximum and longer intervals from onset of symptoms to reperfusion, 
patients transferred from community hospitals to a PCI-centre have a 12 month outcome 
similar to patients admitted directly to a PCI-centre.
1021-257 Risk Score for Prediction of Major Bleeding After 
Percutaneous Coronary Intervention
Eugenia Nikolsky, Roxana Mehran, George Dangas, Martin B. Leon, Jeffrew W. 
Moses, Alexandra J. Lansky, Yingbo Na, A. Michael Lincoff, Gregg W. Stone, Columbia 
University Medical Center, New York, NY, the Cardiovascular Research Foundation, New 
York, NY
Background: Major bleeding is increasingly being recognized as an adverse prognostic 
factor after PCI. We therefore sought to develop and validate a risk score predictive of 
PCI related major bleeding.
Methods: The databases from two large, multicenter, randomized PCI trials were used 
for score development (the REPLACE II, n=6,010) and validation (the REPLACE I, 
n=1,056). Baseline clinical and procedural characteristics in the development dataset 
were considered as candidate univariate predictors of protocol deﬁned major bleeding. 
Multivariate logistic regression was used to identify independent predictors of major 
bleeding. Based on the odds ratio, independent risk factors were assigned a weighted 
integer, the sum of which comprised a total risk score.
Results: Ten variables were identiﬁed as independent correlates of major bleeding (age 
>73years, female gender, eGFR <60ml/min/1.73m2, anemia, administration of LMWH 
within 48hrs pre procedure, PCI duration >0.3hr [integer 1.5 for each], systolic blood 
pressure >150mm Hg, weight <70kg [1 for each], use of IIb/IIIa inhibitors [2] and IABP 
[9]). In the development set, risk of major bleeding varied from ~1% in low risk pts to 
~20% in high risk pts. The discriminatory power of this risk model was conﬁrmed in the 
validation dataset (Figure).
Conclusions: A simple risk score of baseline clinical and procedural variables is clinically 
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1022-215 Local Delivery of Evans Blue with Bare Metal Stent Can 
Prevents Restenosis as Same as Drug-eluting Stents
Yoshiharu Fujimori, Takashi Shiga, Kuniko Terasawa, Masayuki Yoshimura, Taichi 
Murayama, Masaaki Osegawa, Narita Redross Hospital, Narita, Japan
Background: Although drug-eluting stents(DES) signiﬁcantly prevent restenosis, there 
are several problems to be solved, such as delayed or no re-endothelization, and late 
thrombosis. We evaluated the effect of local delivery of Evans blue with bare metal 
stent(BMS) on preventing restenosis.
Methods: Study 1: We randomized 254 patients with AMI, who underwent successful 
primary stenting, to either local delivery of Evans blue group (n=128) or control group 
(n=124). In Evans blue group, we administered 20mg of Evans blue dye, using local drug 
delivery technique 3 weeks after the onset.
Study 2: we delivered Evans blue locally just after stenting in 40 patients with angina 
pectoris.
Results: Study 1: There were no differences in baseline characteristics, and coronary 
angiographic ﬁndings just after stenting and at 3-week follow-up between two groups. At 
seven-month follow-up, there was no signiﬁcant difference in reference vessel diameter 
between two groups. Minimal lumen diameter was signiﬁcantly larger in Evans blue 
group than in control group (2.44±0.77mm vs. 1.94±0.79mm, p<0.0001). Late loss was 
signiﬁcantly reduced in Evans blue group (0.63±0.68mm vs. 1.13±0.77mm, p<0.0001). 
Diameter stenosis was signiﬁcantly reduced in Evans blue group (21.3±21.2% vs. 
38.9±24.9%, p<0.0001). Restenosis rate was 8% in Evans blue group, signiﬁcantly lower 
than that in control group (25%, p<0.0001). There were no patients with subacute or late 
thrombosis.
Study 2: At six-month follow-up, restenosis rate was 7%. There were no patients with 
subacute or late thrombosis.
Conclusions: Local delivery of Evans blue with BMS can prevent restenosis as same as 
DES, without several problems accompanied with DES.
1022-216 Effect of Autologous Bone Marrow-derived 
Mononuclear Cell Injection on Myocardial Function and 
Perfusion in Patients With Refractory Angina Pectoris 
and Chronic Ischemia
Saskia L.M.A. Beeres, Jeroen J. Bax, Theodorus A.M. Kaandorp, Katja Zeppenfeld, 
Hildo J. Lamb, Petra Dibbets, Marcel P. Stokkel, Albert de Roos, Willem E. Fibbe, Ernst 
E. van der Wall, Martin J. Schalij, Douwe E. Atsma, Leiden University Medical Center, 
Leiden, The Netherlands
Background: Bone marrow cell transplantation is proposed as a novel therapeutic option 
for patients with coronary artery disease. This study investigated whether autologous 
bone marrow-derived mononuclear cell injection into ischemic myocardium of patients 
with severe angina pectoris could safely reduce anginal symptoms, improve myocardial 
perfusion and increase left ventricular (LV) function.
Methods: In 20 patients (63±10yrs, 16 male) with angina pectoris myocardial segments 
with stress-induced ischemia as assessed by technetium-99m tetrofosmin gated single 
photon emission computed tomography (SPECT) were injected with 30-100 million 
mononuclear cells. Anginal symptoms, Canadian Cardiovascular Society (CCS) class 
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and quality of life were assessed at 3 and 6 months follow-up. At baseline and 3-months 
follow-up, an exercise test, gated SPECT and magnetic resonance imaging (MRI) were 
performed to assess exercise capacity, myocardial perfusion and LV function.
Results: Intramyocardial injection of autologous bone marrow-derived mononuclear cells 
was safe. CCS class improved from 3.5±0.5 at baseline to 2.4±0.6 after 3 months (P<0.01) 
and to 2.4±0.6 after 6 months (P<0.01). Quality of life improved from 52.4±10.0% to 
71.2±9.6% at 3 months (P<0.01) to 72.7±14.6% at 6 months (P<0.01). Exercise capacity 
increased from 79.6±31.3% to 84.2±28.8% (P<0.05). MRI revealed an increased LV 
ejection fraction from 51±11% to 54±10% (P<0.01) and a reduced LV end-systolic volume 
from 97±50ml to 88±42ml (P<0.01). Wall motion score index improved from 0.36±0.32 to 
0.24±0.28 (P<0.01). The number of segments with stress-induced ischemia reduced from 
5.1±3.2 to 2.3±2.6 (P<0.01).
Conclusions: Autologous bone marrow-derived mononuclear cell injection in patients 
with ischemia is safe, reduces anginal symptoms, improves myocardial perfusion and 
increases LV function.
1022-217 Randomized Comparison of Sirolimus Versus Bare 
Metal Stent Implantation in Bifurcation Lesions
Henning Kelbæk, Leif Thuesen, Lene Kløvgaard, Erik Jørgensen, Lars Krusell, Kari 
Saunamäki, Gunnar V Jensen, Samir Aljabbari, Hans E Bøtker, Steffen Helqvist, 
Rigshospitalet, Copenhagen, Denmark
Background: Sirolimus eluting (SE) stents reduce the rate of restenosis compared with 
bare metal (BM) stents in simple coronary lesions. Whether this applies to bifurcations 
has not been investigated in randomized trials. Our purpose was to compare the clinical 
and angiographic outcome of patients with birfurcation lesions after SE and BM stent 
implantation. Methods: We randomized 125 patients with lesions located in coronary 
arteries involving a side branch > 1.75 mm to either SE or BM stents. Coronary 
angiograms at baseline and at 6 month follow up (FU) were analyzed by an independent 
core laboratory. Results: The demographic and baseline angiographic characteristics 
were similar in the 2 groups, the frequency of diabetes was 15%. Approximately 50% of 
the patients had a stent implanted in their side branch. Angiograms revealed strikingly 
larger minimal lumen diameters and less restenosis and late lumen loss in both main 
and side branches at 6 month FU after SE implantation (table). In addition, 12 month 
target lesion revascularization (TLR) and rate of major adverse cardiac events (MACE) 
were considerably improved in the SE group, whereas stent thrombosis occurred more 
frequently in the BM group. Conclusion: Implantation of SE is more safe compared with 
BM stents and markedly reduces restenosis and the occurrence of MACE in patients with 
bifurcation lesions. These results extend the indications for SE stent implantation from 
simple to more complex coronary artery disease. 
Angiographic and clinical outcome
Sirolimus Eluting 
Stent (n=68)















(mm) 2.79 2.22 2.93 2.20 NS NS
Baseline Diameter 
Stenosis (%) 64 40 68 40 NS NS
FU Late Lumen Loss 
(mm) 0.12 0.03 0.99 0.56 < 0.001 < 0.001
Binary Restenosis (%) 5 15 29 43 < 0.001 < 0.001
Death or Myocardial 
Infarction (%) 4.4 8.8 NS
TLR (%) 7.3 31.6 0.001
Any MACE (%) 10.3 33.3 0.002
Stent Thrombosis (%) 0 8.8 0.018
 
1022-218 Effect of Enhanced External Counterpulsation on 
Erectile Dysfunction in Patients With Medically 
Refractory Angina
William E. Lawson, John CK Hui, Elizabeth D. Kennard, Sheryl F. Kelsey, Ozlem Soran, 
Cardiology, State University of NY, Stony Brook, NY, University of Pittsburgh, Pittsburgh, PA
Background: Patients with medically refractory angina have multiple conditions 
associated with erectile dysfunction including: older age, advanced cardiovascular 
disease, diabetes, hypertension, a need for drugs affecting sexual function, moderate to 
severe physical impairment, and decreased psychosocial functioning. EECP decreases 
symptoms of myocardial ischemia, improves visceral blood ﬂow, increases nitric oxide and 
normalizes endothelial function, improves physical health and psychosocial functioning. 
This study determined the effect of EECP on sexual function in men with severe medically 
refractory angina.
Methods: Men with medically refractory angina enrolled in the International EECP 
Patient Registry completed the International Index of Erectile Function (IIEF) to assess 
erectile function before and after completing a course of EECP. Patients were assessed 
pre and post EECP for symptom status, medication use, adverse clinical events, and 
quality of life.
Results: A cohort of 120 men with a mean age of 65.0 ± 9.7 and duration of CAD of 
10.7 ± 8.9 years was enrolled. Men were high risk with 69% prior MI, 90% CABG or PCI, 
49% with 3 vessel CAD, and 86% were not candidates for further revascularization with 
CABG or PCI. Cardiovascular risk factors included: 71% hypertension, 83% hyperlipidemia, 
42% DM, 75% smoking. Medications included: BB [79 %], diuretics [40%], ACEI or ARB 
[58 %], CCB [38%], and nitrates [68%]. Functional status was low with mean DASI score 
of 16.6±14.8. Thirty-three percent of patients had seen a physician for sexual problems 
and 30% were using Viagra. After 35 hours of EECP anginal status improved in 89%, and 
functional status in 63%. A comparison of the IIEF scores pre and post EECP therapy, 
demonstrated a signiﬁcant improvement in erectile function from 10.0 ± 1.0 to 11.8 ± 1.0 
(p=0.003), intercourse satisfaction (4.2 ± 0.5 to 5.0 ± 0.5, p=0.009), and overall satisfaction 
(4.7 ± 0.3 to 5.3 ± 0.3, p=0.001). However there were no signiﬁcant changes in orgasmic 
function (4.2 ± 0.4 to 4.6 ± 0.4, p=0.19), and sexual desire (5.3 ± 0.2 to 5.5 ± 0.2).
Conclusions:The ﬁndings suggest that EECP therapy is associated with improvement in 
erectile function in men with refractory angina.
1022-219 Chronic Total Occlusion of Coroanry Artery Intervention 
Using the Novel Multidirectional Double Lumen 
Catheter
Tae Soo Kang, Yangsoo Jang, Young-Guk Ko, Donghoon Choi, Yonsei University College 
of Medicine, Seoul, South Korea, Yonsei University, Seoul, South Korea
Background: Failure of guidewire passage is the most common cause of procedural 
failure in chronic total occlusion(CTO). We have developed this novel supporting double 
lumen catheter(Multidirectional double lumen catheter(Ashai Intec Co. Ltd, Aichi, Japan) 
with arrow shaped tip allows for manipulation of two guidewires with the torquability and 
two wide bevels on the opposite side of catheter. It is designed to guide the second wire 
direction and angle into the true lumen, if the ﬁrst wire goes into false lumen. Another 
objects of this catheter is occlusion of side branch which take-off in occlusion level. 
Methods: We used this catheter in consecutive 19 patients(16 male, 57±8 years) with 
CTO and investigated procedural outcomes. Three diabetic patients were enrolled. 
Target lesion localized in LAD 68%, RCA 26% and LCx 6%. Mean lesion length was 
28.4±15.3mm. 
Results: Initial technically success rate(TIMI 3 distal ﬂow) was 84.7%.(16/19) In two 
pateits, failure of guidewire passage. In one patient, wire was not re-entered into the true 
lumen during subintimal coronary intervention. There was no peri-procedural complication 
including coronary perforation, acute myocardial infarction or subacute thrombosis after 
the procedure. 
Conclusions: Our preliminary result shows the multidirectional double lumen catheter 
may be a useful device for the treatment of CTO.
 
1022-220 The Impact of Enhanced External Counterpulsation 
Treatment on Emergency Room Visits and 
Hospitalizations
Ozlem Z. Soran, Elizabeth D. Kennard, Sherly F. Kelsey, University of Pittsburgh, 
Cardiovascular Institution, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA
Background: The improvements observed in symptoms and laboratory tests do not 
necessarily correlate with a reduction in emergency room (ER) visits and hospitalizations 
in patients with coronary artery disease (CAD) and left ventricular dysfunction (LVD). This 
study assesses the impact of Enhanced External Counterpulsation (EECP®) treatment, 
a non-invasive assisted circulatory device, on ER visits and hospitalization rates at six 
month follow up.
Methods:Two hundred thirty three patients with CAD and LVD have undergone 35-
hour course of EECP® for angina management. LVD was deﬁned as EF <= 40. Clinical 
outcomes, number of ER visits and hospitalizations within the six months prior to EECP® 
were compared with those at 6 month follow up. Statistical analysis was performed using 
paired t-tests and chi-square tests.
Results:Mean age was 69 years, 80% were male, 85%had prior MI, 56% had a history 
of congestive heart failure, 88% had prior PCI or CABG, 94% had multivessel disease. 
Mean EF was 30%. Cardiac risk factor prevalence was high. Forty two percent of patients 
had at least 1 ER visit and 63% had at least 1 hospitalization in 6 months prior to EECP®. 
At the completion of the treatment course at least 1 class angina reduction was observed 
in 71% of patients with a low major cardiovascular event rates (death/MI/CABG/PCI <4%). 
44% discontinued nitroglycerin use.
At 6 month follow up reduction in angina and nitro discontinuation was maintained. Ten 
percent had at least 1 ER visit and 19% had at least 1 hospitalization. The mean number 
of ER visits was reduced from 1.9 ±1.5 pre-EECP® to 0.17±0.94 at six months (p<0.001) 
and hospitalizations were reduced from 1.8±1.6 to 0.25±0.75(p<0.001).
Beta Blocker, calcium blocker, angiotensin-converting enzyme inhibitor, angiotensin 
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receptor blocker, antiplatelet and hypolipidemic medication use were similar at baseline 
and at 6 month follow up.
Conclusions:Despite the unfavorable risk proﬁle, CAD patients with LVD achieved a 
substantial reduction in angina with high event free survival rates. There was a signiﬁcant 
reduction in ER visits and hospitalization rates at 6 month follow up. EECP® may offer an 
effective treatment option for this group of patients.
1022-258 Five-Year Follow-Up in Patients With Endstage 
Coronary artery Disease After Treatment of Myocardial 
Ischemia With Cardiac Shock Wave
Achim Gutersohn, Guido Caspari, Raimund Erbel, West German Heart Center University 
of Duisburg Essen, Essen, Germany, Augusta Hospital, Duesseldorf, Germany
More sophisticated invasive and operative techniques in cardiovascular disease lead 
to an increasing number of patients with endstage CAD with no therapeutic options 
and refractory angina. An initial pilot study has proven acute positive effects on clinical 
symptoms. Here we present ﬁve year follow up data after cardiac shock wave therapy 
(CSWT).
Methods: CSWT was performed in 23 pts. with endstage CAD and proven ischemia using 
SPECT. R-Wave triggered shock waves were focused via in-line ultrasound on ischemic 
areas. About 3 x 150 impulses were applied three times per week repeating this after 3 
and 6 weeks. Shock wave were administered to ischemic areas using increasing energy 
ﬂuxes densities from 0.05 to 0,1 mJ/mm. Pts. were examined in SPECT before and after 
a 6 months. Also they were evaluated after 5 years.
Results: Pts. experienced no side effects. SPECT revealed a signiﬁcant increase in 
perfusion in treated myocardial areas in 60% of the patients whereas in non treated there 
was no perfusion increase. CCS class was reduced from initial 3.69 to 2.1 ; at 2.32 after 
5 years. Survival after 5 Years was 91.6 % .
Conclusion: We conclude that CSWT is a new, safe and efﬁcient non-invasive therapy 
for treating myocardial ischemia in CAD pts. which are ineligible for other interventions. 
In vitro and animal data prove that the mechanism of action is an increase of angiogenic 
factors like VEGF resulting in angiogenesis.
 
1022-259 Improved Effort Tolerance in Angina Patients With 
Enhanced External Counterpulsation Therapy Is 
Predominantly Due to Its Peripheral Training Effect
Sanjay Mittal, Anil Kumar Gothwal, P. Soni, P. Siddhu, S. Ramasamy, Ravi R. Kasliwal, 
N. Trehan, Escorts Heart Institute and Research Center, Delhi, India
Background: Effort tolerance is known to improve with Enhanced external counter 
pulsation (EECP) therapy in patients with chronic angina. The underlying mechanism of 
this improvement is still not clear.
Methods: Thirty four consecutive patients with chronic angina not amenable to 
revascularization procedures were subjected to 35 hours of EECP therapy. Prospectively 
they underwent clinical evaluation and symptom limited stress thallium (modiﬁed Bruce 
protocol) before and after therapy. The area as well as the percentage of inducible perfusion 
defects was semi quantitatively assessed in pre and post EECP thallium studies.
Results: Thirty two patients, mean age 59.78 + 8.78 yrs, 94% males with diffused coronary 
artery disease were studied. All patients showed symptomatic improvement with reduction 
in anginal episodes, increase in 6 minutes walk test and exercise duration. Although 53.6% 
patients showed reduction in ischemic area by at least 5% on stress thallium, there was 
neither signiﬁcant reduction in overall area of inducible ischemia, nor signiﬁcant change in 
the maximum cardiac load is achieved i.e. Rate Pressure Product (RPP).
Conclusions: Signiﬁcant clinical improvement is observed in chronic angina patients after 
EECP therapy. Stress thallium shows signiﬁcant improvement in exercise duration without 
appreciable change in cardiac load and maximum area of ischemia suggesting peripheral 
training effect as the predominant cause of symptomatic improvement in such patients
The baseline and post EECP
Pre EECP Post EECP P Value
Anginal episodes/ week 6.27 + 5.7 1.0+ 1.7 <0.001
Exercise Duration 355.5 + 191 sec 429+ 210 sec <0.001
6-Minute walk 743+ 372 feet 1181+ 393 feet <0.001
Area of ischemia 28.5 + 20.7 % 26.9 + 20.1 % <0.29
RPP 2.0+ 0.4 x 104 1.9 + 0.4 x 104 <0.14
1022-260 Extracorporeal Shock Wave for Therapy of Refractory 
Angina Pectoris: The Shock Trial
Jean-Paul Schmid, Mauro Capoferri, Tiziano Schepis, Patrick Siegrist, Verena 
Schroeder, Philippe A. Kaufmann, Otto M. Hess, Swiss Cardiovascular Center Bern, 
University Hospital, Bern, Switzerland, Nuclear Cardiology, Cardiovascular Center, 
University Hospital, Zurich, Switzerland
Background: Extracorporeal shock wave therapy (ESWT) has been shown to increase 
capillary density and regional myocardial blood ﬂow in animal experiments. In addition, 
non-enzymatic nitric oxide production and the up-regulation of vascular growth factor’s 
mRNA have been described. We hypothesized that ESWT in patients with chronic stable 
angina pectoris would relieve symptoms and ameliorate the ischemic threshold.
Methods: 15 patients (mean age 68 ± 8 years, 14 male) with chronic stable angina 
pectoris and evidence of inducible myocardial ischemia during MIBI-SPECT imaging 
were randomized into a treatment (n=8) and a placebo arm (n=7). 9 treatment sessions 
(9 to 12 spots of the ischemic myocardium with echocardiographic guidance; 50 shots/
spot at 0.09 mJ/mm2 vs placebo) were applied during a 3 month’s period. Medication was 
kept unchanged.
Results: In the treatment group, the ischemic threshold, determined during a 
cardiopulmonary exercise stress test, increased from 98 ± 27 to 115 ± 15 W (p=0.068), 
whereas in the placebo arm, the threshold did not change (88 ± 21 to 92 ± 30 W; 
p=0.893). The item “physical functioning” of the quality of life questionnaire SF-36 showed 
an amelioration from 61 ± 17 to 71 ± 16 (p=0.180) in the treatment group, but no change 
occurred in the placebo group (63 ± 24 to 62 ± 23). Neither arrhythmias, troponin rise nor 
other complications were observed during or after the treatment.
Conclusions: These preliminary data suggest, that ESWT improves symptoms and 
delays the ischemic threshold in patients with chronic stable angina pectoris.
ORAL CONTRIBUTIONS
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856-3 Vascular Endothelium Growth Factor-165 Gene Therapy 
Increases Left Ventricular Mass and Decreases Wall 
Thinning in Reperfused Myocardial Infarction
Mayra Guerrero, Krishna Athota, Jason Moy, Laxmi Mehta, Alberto Crottogini, Ruben 
Laguens, Peter Corry, Michael Borrelli, Joudy Boura, Ralph Gentry, Cindy Grines, Gilbert 
L. Raff, Charles Shanley, William O’Neill, William Beaumont Hospital, Royal Oak, MI
BACKGROUND: Vascular endothelial growth factor (VEGF) 165 has been found to promote 
cardiomyogenesis in chronic ischemia and non-reperfused myocardial infarction.
HYPOTHESIS: VEGF-165 induces angiogenesis and cardiomyogenesis in reperfused 
myocardial infarction resulting in decreased infarct size.
METHODS: 24 Yucatan minipigs underwent thoracotomy and a vascular clamp was placed 
in the left circumﬂex artery. Reperfusion was reestablished after 90 minutes of occlusion 
and VEGF-165 gene therapy or placebo was given. The viral vector Ad5-VEGF165 
consisted of a recombinant human adenovirus serotype 5, made replication deﬁcient 
by deletion of the E1A/E1B genes that were replaced by the human VEGF-165 gene. 
Two routes of administration were tested, intramyocardial (IM) injection and intracoronary 
(IC) infusion. The pigs were assigned to one of the following groups: IM Ad5-VEGF165 
(n=6), IM placebo (n=6), IC Ad5-VEGF165 (n=6) and IC placebo (n=6). The infarct size 
was quantiﬁed by contrast-enhanced magnetic resonance imaging (MRI) at 48 hrs and 
4 weeks post myocardial infarction and is reported as percentage of left ventricular (LV) 
mass. The percentage of LV wall thinning in the infarct area was measured. Triphenyl 
Tetrazolioum Chloride staining was used to validate MRI results.
RESULTS: The mean infarct size by MRI at 48 hrs post infarction was 13% ± 9% in 
placebo groups and 15% ± 8% in the VEGF groups (p=0.45). At 4 weeks, it decreased 
to 7% ± 8% in placebo groups and 8% ± 6% in VEGF groups (p=0.65). No signiﬁcant 
difference in reduction between groups (67% vs 58%, p=0.38). MRI was correlated with 
Tripheanyl Tetrazolium Chloride staining (Pearson’s correlation=0.87, p <0.0001). The 
mean LV mass at 48 hrs in placebo groups was 62 ± 12 gr and remained unchanged at 
4 weeks. Whereas the LV mass in VEGF groups increased from 55 ± 7 gr at 48 hrs to 60 
± 7 gr at 4 weeks (p=0.013). We found less wall thinning in VEGF groups 32% ± 15% vs 
48% ± 18% in placebo groups (p=0.032).
CONCLUSIONS: VEGF-165 gene therapy in reperfused myocardial infarction did not 
decreased infarct size but resulted in increased LV mass and decreased wall thinning. 
Whether this results in improved cardiac function is currently under investigation.
2:15 p.m.
856-4 Association of Transforming Growth Factor-β1 Gene 
Polymorphisms With Myocardial Infarction
Petra Hoppmann, Wolfgang Latz, Claudia Ganser, Marianne Eichinger, Albert Schömig, 
Adnan Kastrati, Werner Koch, Deutsches Herzzentrum, Munich, Germany
Background: Transforming growth factor-β1 (TGF-β1) is a multifunctional cytokine 
that exhibits vasculoprotective properties. Production and plasma levels of TGF-β1 are 
inﬂuenced by polymorphisms in the TGF-β1 gene (TGFB1). We investigated whether 
the -509C/T (rs1800469), 868T/C (rs1982073), 913G/C (rs1800471), and 11929C/T 
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(rs1800472) polymorphisms of TGFB1 are associated with myocardial infarction.
Methods: The study population consisted of 3657 patients with myocardial infarction (885 
women and 2772 men) and 1211 control individuals (598 women and 613 men) with 
angiographically normal coronary arteries and without signs or symptoms of myocardial 
infarction. Polymorphism-related genotypes were determined with TaqMan assays and 
haplotypes were estimated from the genotype data.
Results: The -509C/T polymorphism and -509C/868T/913G/11929C (CTGC) haplotype 
were associated with myocardial infarction in men, independently from other risk factors 
such as age, arterial hypertension, hypercholesterolemia, cigarette smoking and diabetes 
mellitus. Lower risks of myocardial infarction were observed among carriers of the -
509CC genotype (OR 0.49, 95% CI 0.27-0.87; P=0.01) and homozygous carriers of the 
CTGC haplotype (OR 0.61; 95% CI 0.38-0.98; P=0.04) as compared with noncarriers of 
this genotype or haplotype. None of the genotypes (P>0.37) or haplotypes (P>0.35) was 
related with myocardial infarction in women.
Conclusions: The positive association ﬁndings in this study suggest that TGFB1 is a 
susceptibility locus for myocardial infarction in men.
2:30 p.m.
856-5 Combined ANG-1 and VEGF Gene Transfer Enhances 
Perfusion and Improves Segmental Systolic Velocity in 
a Swine Chronic Myocardial Ischemic Model
Winston Shim, Chye Khoon Poh, Hwee Choo Ong, Shiqi Li, In Chin Song, Philip Wong, 
Seng Chye Chuah, National Heart Centre, Singapore, Singapore, National University of 
Singapore, Singapore, Singapore
Background: Therapeutic angiogenesis using vascular endothelial growth factor 
(VEGF) has been proposed as a therapeutic option for symptomatic patients that are 
refractory to conventional vascular interventions. However, recent clinical trials have 
revealed inadequacy of unilateral application of VEGF in relieving symptomatic ischemia. 
Combining angiopoietin-1 (ANG-1) and-2 (ANG-2), with VEGF may enhance the beneﬁts 
of therapeutic angiogenesis. Methods: Swine chronic myocardial ischemia was created 
by placing ameroid constrictor around the proximal left circumﬂex coronary (LCX) artery. 
Animals (n=6/group) were randomized to receive intramyocardial injection of AdVEGF, 
AdVEGF+AdANG-1, AdVEGF+AdANG-2 or control vector in the ischemic territory 4 
weeks after onset of ischemia. Perfusion index was determined by comparing regional 
blood ﬂow rates between ischemic LCX and non-ischemic LAD myocardial territories 
using ﬂuorescent microsphere technique 4 weeks after therapy. Stress echocardiography 
and tissue doppler imaging were performed for assessment of the systolic function.
Results: Four weeks post therapy, animals that received AdVEGF showed a higher, but 
statistically insigniﬁcant increased in perfusion (0.932 ± 0.08 vs 0.755 ± 0.05, p=0.1) 
compared to pre-treatment ischemic levels. In contrast, regional perfusion in animals that 
received combined therapy of AdVEGF+AdANG-1 was signiﬁcantly improved (0.965 ± 
0.05 vs 0.817 ± 0.07, p=0.037), but not in animals that received AdVEGF+AdANG-2 
(0.773 ± 0.09 vs 0.703 ± 0.09, p=0.059) or control vector (0.878 ± 0.13 vs 0.830 ± 0.11, 
p=0.568). The improved perfusion relieved ischemia, as evidence by enhanced segmental 
systolic velocity in the left ventricle (7.28 ± 0.48 cm/s vs 5.80 ± 0.45 cm/s, p=0.022) of 
AdVEGF+AdANG-1 group, but not other treatment groups.
Conclusions: Combining VEGF with ANG-1, but not ANG-2, increased regional perfusion 
and improved systolic function of left ventricle. These results reinforce the importance of 
coordinated regulation of angiogenic factors, and suggest ANG-1 as a key angiogenic 
partner in complementing VEGF function in improving therapeutic outcome for chronic 
myocardial ischemia.
2:45 p.m.
856-6 COMP-angiopoietin 1 Enhances the Engraftment of 
the Mobilized Peripheral Blood Stem Cells to Ischemic 
Tissue by Induction of Adhesion Molecules
Min-Seok Kim, Choon-Soo Lee, Tae-Yeon Kim, Jung-Won Suh, Hae-Young Lee, Jin 
Hur, Hyun-Jae Kang, Hyo-Soo Kim, Byung-Hee Oh, Young-Bae Park, Seoul National 
University College of Medicine, Seoul, South Korea
Background: A major limitation of intracoronary infusion of stem cells is the poor 
engraftment rate to ischemic tissue(less than 5%). We hypothesized that COMP-
Angiopoietin 1 would enhance the adhesion of the mobilized peripheral blood stem 
cells(PBSCs) to extracellular matrix(ECM) and to endothelial cells (ECs), leading to 
increased engraftment to ischemic tissue and enhancement of angiogenesis ultimately.
Methods and Results: (1)PBSCs mobilized by G-CSF and non-mobilized peripheral 
blood mononuclear cells(PBMC) were exposed to recombinant human angiopoietin-
1(COMP-Ang1) for 3 hours and evaluated the change of their adhesive capacity on 
mature EC monolayer and on an ECM, ﬁbronectin. COMP-Ang1-stimulated PBSCs 
showed increased adhesion to ECs and to ﬁbronectin, however no signiﬁcant changes 
were observed in PBMCs. (2)COMP-Ang1-stimulated PBSCs expressed more adhesion 
molecules(ICAM-1, αvβ5, and β2-integrin) in their surface in FACS analysis, whereas 
no signiﬁcant changes occurred in PBMCs. (3)The portions of Tie-2+ cells among in 
PBSCs and in PBMCs were assayed by FACS analysis. Then, to evaluate whether Tie-
2 receptor mediated pathway contributes COMP-Ang1-enhanced adhesion of PBSCs, 
Tie-2 proportion in adherent cells versus in total PBSCs were compared after COMP-
Ang1 treatment. The result was that adherent population contained twice as much Tie-2+ 
cells as total PBSCs(p<0.05). (4)In an athymic hind limb ischemia model, transplantation 
of the COMP-Ang1-stimulated PBSCs showed improved neovascularization at day 
21(perfusion ratio: 0.65±0.09 in COMP-Ang1-treated PBSCs, 0.27±0.12 in control 
PBSCs, n=8, p<0.05). The engraftment of cells into the ischemic tissue was assessed 
using CFSE-tagged mobilized PBSCs at day 7. The result showed that more PBSCs 
were engrafted into vascular structures in COMP-Ang1-stimulated group than in control 
group(n=8, p<0.05).
Conclusion: COMP-Angiopoietin 1 pretreatment increased adhesion molecules of 
PBSCs, leading to higher efﬁciency of engraftment rate into ischemic limb. The results 
of our study suggest that ‘priming’ of the mobilized PBSCs with COMP-Ang1 would be a 
promising strategy enhancing the efﬁcacy of stem cell therapy.
3:00 p.m.
856-7 Skeletal Myoblast Delivery of Angiopoietin-1 Versus 
Direct Adenoviral Angiopoietin-1 Injection
Lei Ye, Husnain Kh Haider, Shujia Jiang, Rusan Tan, Wee Chi Toh, Ruo Wen Ge, Peter 
K. Law, In Chin Song, Eugene KW Sim, National University of Singapore, Singapore, 
Singapore, University of Cincinnati, Cincinnati, OH
Background We hypothesized that angiogenic response and effcacy of angiopoietin-1 
(Ang-1) gene delivery in the infarcted myocardium would be inﬂuenced by the mode of 
delivery.
Methods Ang-1 was packaged into adenoviral vector (Ad-Ang-1) and used for either 
direct injection or transduction of skeletal myoblasts (SkM). Experimental myocardial 
infarction model was developed in 20 female pigs by coronary artery ligation. Three 
weeks later, the animals were grouped to receive intramyocardial injection of 5 ml DMEM 
alone (group 1 n=6), or containing 1x1010 PFU Ad-Ang-1 (group 2 n= 7), or 3x108 lac-
z labeled SkM transduced with Ad-Ang-1 (group 3 n=7). Animals were maintained on 
5mg /kg cyclosporine for 6 weeks. The animals were euthanized at 6 and 12 weeks post 
respective treatment and their heart tissue was processed for histological studies.
Results Extensive survival of the lac-z positive SkM was observed in pig heart up to 12 
weeks after cell transplantation. Blood vessel density (x100) by ﬂuorescent immunostaining 
for vWF-VIII and smooth muscle actin in group 3 increased from 42.25±3.82 and 34.73± 
2.52 at 6 weeks to 46.57±1.76 and 41.36 ±1.53 at 12 weeks as compared to group 1 
(16.0±0.91; 7.88± 0.52; p<0.01) and group 2 (30.63±2.11 p<0.01; 37.5± 2.04) at 6 weeks 
and (13.44±0.9; 7.00± 0.58; p<0.01) of group 1 and (37.43±2.77; 35.86± 2.79) of group 2 
at 12 weeks. Mature blood vessel index at was the highest in group 2 at 6 (98.5± 4.2%) and 
12 (96± 2.2%) weeks and followed by group 3 (85.26± 2.86%; 91.64± 7.96%). These were 
signiﬁcantly higher than those of group 1 (49.20± 4.7%; 52.08± 5.9%). The mean blood 
vessel diameter in group 2 and 3 at 6 weeks were signiﬁcantly smaller than those of group 
1 (11.72± 1.67 µm p<0.05). However, they increased to 10.9 ± 1.21 µm and 10.64± 1.14 µm 
at 12 weeks. Signiﬁcantly improved blood ﬂow was achieved by group 3 as compared with 
group 1 and group 2 at 6 weeks. Signiﬁcantly improved ejection fraction was only achieved 
in group 3 (49.22±5.92%, p=0.037) as compared with group 1 (36.84±3.02%).
Conclusion SkM mediated Ang-1 delivery is associated with better improved regional 
perfusion and heart function as compared with direct Ad-Ang-1 administration for 
cardiac repair.
3:15 p.m.
856-8 The Prognostic Value of Endoglin, a Marker of 
Neoangiogenesis, in Acute Myocardial Infarction
Ignacio Cruz, Javier Martin-Moreiras, Pedro Pabon, Alicia Barbero, Miguel Pericacho, 
Victor Ramirez, Pedro Luis Sanchez, Jose Miguel Lopez-Novoa, Candido Martin-
Luengo, Universitary Hospital of Salamanca., Salamanca, Spain
Background: Recently, efforts have focused on unraveling the molecular mechanisms 
that underlie postinfarction neovascularization. Therefore, the identiﬁcation of markers 
capable to reﬂect the formation of blood vessels should be desirable. Endoglin (CD105) 
is a proliferation-associated and ischemia and hypoxia-inducible protein, abundantly 
expressed in angiogenic endothelial cells, which has been studied by cancer researchers 
as a marker of tumor vascularization. The role of endoglin in myocardial infarction (MI) 
has not yet been explored.
Methods: Serum endoglin concentration was determined on arrival and 48 hours after 
the onset of symptoms in 100 patients (62% men, mean age:70±12 years) consecutively 
admitted for acute myocardial infarction. The control group comprised 32 healthy subjects 
who were sex and age matched (60% men, age: 69±13 years) to the patients. We tested 
the performance of endoglin on arrival, endoglin at 48 hours and endoglin differential 
(endoglin at 48 h minus endoglin on arrival) as predictors of short and long-term cardiac 
mortality
Results: Patients with acute myocardial infarction had lower endoglin levels on arrival 
compared to sex and aged-matched healthy subjects and these levels decreased 48 
hours later (on arrival: 4.2 ± 0.9 vs. healthy: 4.8 ± 0.8 ng/mL; p=0.003; on arrival 4.2 ± 0.9 
ng/mL vs 48 hours 3.6 ± 0.7 ng/mL; p<0.001). After adjustment for confounding factors, 
endoglin differential was the strongest independent marker of mortality at 30 day (odds 
ratio 2.78; 95% conﬁdence interval 1.25 to 5.94; p=0.012) and at one-year (odds ratio 
3.01; 95% conﬁdence interval 1.53 to 6.87; p=0.008) follow-up.
Conclusions: Endoglin differential reﬂecting endotelial dysfunction and impared 
angiogenesis is a new major short- and long-term predictor of mortality in patients with 
acute myocardial infarction.
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857-3 Adenosine Regulation With Acadesine Improves Two-
Year Survival After Reperfusion-Induced MI
Dennis T. Mangano, Ischemia Research and Education Foundation, San Bruno, CA
Background: No therapy exists which improves long-term survival after myocardial 
infarction following CABG surgery. Proclivity to hemorrhage effectively precludes acute 
administration of ﬁbrinolytic and most anti-thrombotic therapies, and impaired wound 
healing limits use of anti-inﬂammatory therapies. Because the autocoid adenosine 
mitigates the extent of ischemic injury in animal models, we questioned whether use of 
the adenosine-regulating-agent acadesine - by amplifying the natural adenosine response 
- would impact long-term survival following perioperative myocardial infarction.
Methods: At 54 institutions, 2,698 patients undergoing CABG were randomized 
(double-blind) to receive either acadesine (n=1,352; 0.1mg.kg-1min-1; 7 hours) or placebo 
(n=1,346), with myocardial infarction prospectively deﬁned as: (1) new Q-wave; and (2) 
CK-MB > 100ng.ml-1 (daily ECG; 14 serial CK-MB measures). Vital status and resource 
utilization was assessed over two years.
Results: Perioperative myocardial infarction (n=100) conferred a 4.2-fold increase in 
2-year mortality (P<0.001). However, acadesine treatment reduced that mortality by 
4.3-fold: from 27.8% (15/54; placebo) to 6.5% (3/46; acadesine) (P=0.006)_with the 
principal beneﬁt occurring over the ﬁrst 90 days following myocardial infarction (Figure). 
Multivariate analysis conﬁrmed these ﬁndings, with no other differences between the 
groups confounding this relationship.
Conclusions: Acadesine is effective for long-term secondary prevention for large, acute 
perioperative myocardial infarction, substantially reducing the risk of dying over the two 
years following infarction.
2:15 p.m.
857-4 A Phase 1/2 Trial of TG100-115, a Phosphatidylinositol-
3 Kinase Inhibitor, in Acute ST-Segment Elevation 
Myocardial Infarction Patients Treated by Percutaneous 
Coronary Intervention Indicates Acceptable Safety and 
Pharmacokinetics at the Initial Dose Level
David G. Rizik, Samin Sharma, Kenneth Kent, Ehtisham Mahmud, Ian Gilchrist, Jeffrey 
L. Anderson, Thomas Carlson, Raymond Gibbons, Raymond Kim, Anthony DeMaria, 
Jolene Shorr, David McClure, Charles Theuer, David Holmes, for the TG001-03 Study 
Group, Scottsdale Healthcare Hospital, Scottsdale, AZ
Background: TG100-115 is a new chemical entity designed to complement currently 
available treatments for STEMI by reducing the contribution of reperfusion injury to infarct 
size. TG100-115 inhibits phosphatidylinositol-3 kinase (PI3K), a key signaling element 
that mediates receptor-induced responses such as leukocyte and platelet activation, 
vascular permeability, and cardiomyocyte contractility. As such, the compound should 
reduce microvascular obstruction, leukocyte activation and platelet activation following 
ischemia. In agreement with these projections, TG100-115 reduces infarct size when 
delivered during the reperfusion period in animal models of myocardial infarction. The 
objective of this study is to determine the optimal dose of TG100-115 given intravenously 
following percutaneous coronary intervention (PCI) for ST segment elevation myocardial 
infarction (STEMI). 
Methods: Phase 1/2 ﬁrst-in-human, placebo-controlled, dose escalation trial in acute, 
ﬁrst-time STEMI patients undergoing PCI. Patients are randomized (4:1) to TG100-115 
or placebo and four doses are studied in sequence: 0.04, 0.02, 1 and 5 mg/kg. Safety is 
monitored in real time and prior to each planned dose escalation by a Data Monitoring 
Committee (DMC). Efﬁcacy measures include infarct size (assessed by cardiac magnetic 
resonance imaging (MRI) and SPECT) and ejection fraction (assessed by cardiac MRI 
and echocardiography). 
Results: Enrollment began in January, 2005 and 18 subjects (age range: 48 to 70) have 
been dosed at the 0.04 mg/kg dose level. The drug has been well tolerated and the DMC 
has authorized dosing at the 0.2 mg/kg level. Human PK parameters are similar to those 
predicted from pre-clinical models. Updated safety and PK results will be presented. 
Conclusions: A ﬁrst-in-human clinical trial of a new chemical entity that complements 
existing treatments for STEMI indicates acceptable safety at the initial dose level.
2:30 p.m.
857-5 Enoxaparin Dosing and Bleeding in Real World 
Practice: Results From CRUSADE
Nancy M. Allen LaPointe, Karen P. Alexander, Anita Y. Chen, Matthew T. Roe, Charles 
V. Pollack, Jr., E. Magnus Ohman, W. Brian Gibler, Eric D. Peterson, Duke Clinical 
Research Institute, Durham, NC
Background: The beneﬁt of enoxaparin in acute coronary syndromes (ACS) is well 
established, but questions remain regarding its bleeding risk. We investigated enoxaparin 
dosing and the association of excess dose with bleeding risk in a community-based ACS 
population.
Methods: Initial enoxaparin dose and administration frequency were available for 5,253 
pts in 296 hospitals participating in the CRUSADE Initiative (7/04-7/05). Recommended 
daily dose was calculated using weight and creatinine clearance (CrCl) according to the 
product labeling. Administered daily dose >10 mg above recommendation was considered 
excessive. Major bleeding was deﬁned as intracranial hemorrhage, transfusion, or drop 
in hematocrit by ≥12%.
Results: An excess dose of enoxaparin was given to 1,010 pts (19%), including 31% of 
pts aged ≥75 years and 70% of pts with CrCl <30. Pts with an excess dose were older 
(median age 77 vs 67 y), smaller (median BMI 26.2 vs 28.5), female (58.5% vs 36.8%), 
with more hypertension, diabetes, and heart failure (all p<0.001) than those without 
an excess dose. Excess dose was associated with a signiﬁcantly higher adjusted risk 
of transfusion and major bleeding than a non-excess dose in pts who did not undergo 
coronary artery bypass graft surgery (Figure).
Conclusion: An excessive dose of enoxaparin is common in practice, especially in high-
risk pts, and resulted in more bleeding and transfusions. Improved adherence to the 
recommended dose could substantially improve the safety proﬁle of enoxaparin. 
2:45 p.m.
857-6 Restoration of Platelet Function on Clopidogrel-Treated 
Subjects
Gemma Vilahur, Brian G. Choi, Mohammed U. Zafar, Valentin Fuster, Juan J. Badimon, 
Cardiovascular Institute, Mount Sinai School Medicine, New York, NY
Background: Clopidogrel (Clop) + Aspirin (ASA) is frequently used in ACS, but the anti-
platelet effect may preclude or delay surgery if required. We studied the possibility of 
restoring platelet function after Clop + ASA treatment.
Methods: We performed a cross-over randomized study of healthy subjects (n=10) given a 
loading dose of either 300 or 600 mg Clop + 324 mg ASA, followed by 75 mg Clop + 81 mg 
ASA daily for 2 days. Platelet function was assessed by light transmittance aggregometry 
(LTA) and ﬂow cytometry pre-treatment, 4h-, and 72h- post-load. Arachidonic acid (AA 1 
µM), ADP (5 and 10 µM), collagen (2 and 5 µg/ml), and TRAP (10 µM) served as agonists. 
By ﬂow cytometry we tested GPIIb/IIIa receptor exposure in the ADP-stimulated platelets. 
To restore platelet function, increasing amounts of pooled platelets (20, 40, 50, and 60% 




















AA (1µM) 70 ± 3.5 2 ± 0.1* 58 ± 1.6 60 ± 4.3
ADP (5µM) 59 ± 3.1 22 ± 3.0* 38 ± 3.5* 42 ± 4.3*
72h
AA(1µM) 70 ± 3.5 1 ± 0.3* 59 ± 3.4 59 ± 3.0
ADP (5µM) 59 ± 3.1 26 ± 3.7* 46 ± 4.5* 50 ± 3.2
*P<0.05 vs pre-treatment. Data is presented as % of maximal aggregation ± SE.
Similar results were found in the 300 mg arm and also for ADP 10 µM and collagen. ADP-
induced GPIIb/IIIa activation had a similar pattern to LTA.
Conclusion: 4h post-load, platelets could recover to all agonists except ADP with the 
equivalent of transfusing 40-50% of the patient’s platelet volume, which may be as few 
as 2 platelet pools (10 units); at 72h (24h after last dose), platelets could be fully restored 
with this transfusion equivalent. These results may facilitate the design of a proper clinical 
trial of pre-surgical transfusion of platelets in Clop-treated patients.
3:00 p.m.
857-7 Impact of Early Beta-Blocker Therapy for Acute 
Myocardial Infarction on In-Hospital Mortality
Robert D. Welch, Raymond E. Jackson, Sridevi R. Pitta, Phillip D. Levy, Lori S. Parsons, 
John G. Canto, Eric Peterson, Scott Compton, Robert J. Zalenski, Wayne State 
University School of Medicine, Detroit, MI, William Beaumont Hospital, Royal Oak, MI
Background: Recent data (COMMIT/CCS-2) suggested that early beta-blocker therapy 
for acute myocardial infarction (AMI) did not reduce in-hospital mortality and increased 
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the risk of cardiogenic shock. These ﬁndings question the method and timing of 
administration of beta-blockers. We compared in-hospital mortality among AMI patients 
treated with beta-blockers to those not treated early. 
Methods: Patients enrolled in the National Registry of Myocardial Infarction II & III were 
eligible. Included were those with ST-segment elevation and/or depression or LBBB. 
Excluded were patients with contraindications to beta-blocker therapy. A multivariate 
model was ﬁt to determine the odds (adjusted for baseline and treatment differences) of 
mortality for those treated with early (< 24 hours) IV + oral beta-blockers (IV-BB) or oral 
beta-blockers only (oral-BB) relative to no beta-blocker therapy. 
Results: 320,287 patients met the study criteria. The table details some patient 
characteristics and the proportion of deaths. Those treated with IV-BB did not experience 
a signiﬁcant decrease in the adjusted odds of mortality (odds ratio [OR] 1.01, 95% CI 
0.97-1.05; p=0.053). Early oral-BB therapy was associated with reduced mortality (OR 
0.63, 95% CI 0.61-0.65). 
Conclusions: Early treatment of ST-segment deviation AMI patients with IV-BB did not 
signiﬁcantly reduce in-hospital mortality. Further study is warranted to determine the 






Age (mean + SD) 63.5 + 13.9 68.0 + 14.1 70.1 + 13.9 <0.0001
Men 66.3% 60.9% 57.9% <0.0001
Hx MI 18.1% 25.3% 25.5% <0.0001
Hx CHF 6.3% 11.0% 18.4% <0.0001
Killip Class II on 
presentation 12.3% 16.4% 25.3% <0.0001
ST-segment elevation 81.4% 63.0% 61.1% <0.0001
Aspirin 91.9% 90.3% 78.5% <0.0001
Heparin 90.9% 80.2% 74.2% <0.0001
Mortality 6.1% 5.4% 11.4% <0.0001
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857-8 Incidence of, Predictors of, and Outcomes Related to 
Discontinuation of Thienopyridine Therapy at 1-Month 
After Coronary Stenting in AMI
John A. Spertus, Richard Kettelkamp, Clifton Vance, Philip G. Jones, John S. Rumsfeld, 
Eric D. Peterson, Richard G. Bach, Harlan M. Krumholz, David J. Cohen, Cardiovascular 
Outcomes Research Consortium, Kansas City, MO
Background: While drug eluting stents (DES) represent a revolutionary advance in 
percutaneous coronary intervention, they require prolonged adjuvant therapy with 
thienopyridines to minimize the risk of stent thrombosis. The rate and consequences of 
discontinuing thienopyridines after DES placement for an MI are unknown.
Methods: A prospective, 19-center registry of 500 DES-treated MI patients was analyzed 
to deﬁne the prevalence and predictors of thienopyridine discontinuation at 30 days. 
Rates of death and cardiac hospitalizations over the next 11 months were compared 
between adherent and non-adherent patients after adjusting for the propensity to be using 
thienopyridines at 1 month.
Results: 68 (13.6%) patients reported no longer taking thienopyridines 30 days after 
DES placement. These patients were older (64±13 vs. 60±12, p=0.03), less likely to have 
completed high school (73% vs. 89%, p<0.001), less likely to be married (56% vs. 71%, 
p=0.01) and were more likely to avoid healthcare due to cost (24% vs. 13%, p=0.02), to 
have had prior vascular disease (49% vs. 30%, p=0.003), lung disease (18% vs. 8%, 
p=0.02) and anemia at presentation (19% vs. 7%, p=0.001). They were less likely to 
have received discharge instructions about their medications (88% vs. 95%, p=0.05) or 
a cardiac rehabilitation referral (50% vs. 64%, p=0.03). Only limited education (<high 
school) was signiﬁcantly associated with discontinuing thienopyridines in the multivariable 
model (OR = 1.79, 95% CI=1.01-3.1; c-statistic for complete model = 0.71). Patients no 
longer taking thienopyridines died signiﬁcantly more often over the next 11 months (7.5% 
vs. 0.7%, p<0.0001; propensity-adjusted hazard ratio = 9.02; 95% CI = 1.34-60.6) and 
were more likely to be rehospitalized (23% vs. 14%, p=0.08; propensity-adjusted hazard 
= 1.53; 0.78-2.98).
Conclusions: Almost 1 in 7 MI patients who received a DES stopped taking 
thienopyridines within 30 days, but the ability to predict who would and would not continue 
therapy was limited. Because thienopyridine discontinuation was associated with 1-year 
post-MI mortality, strategies to improve adherence are urgently needed to optimize the 
outcomes of all DES-treated MI patients.
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